{
  "document": {
    "title": "Kenya National Clinical Guidelines for Management of Diabetes",
    "version": "2nd Edition 2018",
    "totalSections": 57,
    "totalTokens": 120679,
    "frontMatter": [
      {
        "id": "frontmatter-content-before-first-heading",
        "level": "section",
        "number": null,
        "title": "Content Before First Heading",
        "slug": "content-before-first-heading",
        "url": "/guidelines/content-before-first-heading",
        "tokenCount": 465,
        "content": "Republic of Kenya\n\n\n![MINISTRY OF HEALTH](images/picture_000_page_1.png)\n\n\nMINISTRY OF HEALTH\n\n\n![KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS](images/picture_001_page_1.png)\n\n\n**KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS**\n\n\n1 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS\n\n\n**KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS**\n\n\n**SECOND EDITION 2018**\n\n\nProduced by: The National Diabetes Prevention and Control Program\n\n\nDivision of Non-communicable Diseases Ministry of Health, Kenya\n\n\nFunded by: Ministry of Health, Kenya Diabetes Management and Information Centre and World Diabetes Foundation (WDF)\n\n\nAny part of this document may be freely reviewed quoted, reproduced or translated in full or in part so long as the source is acknowledged. It is not for sale or for use in commercial purposes.\n\n\nEnquiries regarding the Kenya National Clinical Guidelines for Management of Diabetes Mellitus should be addressed to:\n\n\nNational Diabetes Control Programme, Division of Non-communicable Diseases, Ministry of Public Health and Sanitation, P.O. Box 30016 - 00100 Nairobi, Kenya\n\n\n![DIVISION OF NON - COMMUNICABLE DISEASES](images/picture_002_page_2.png)\n\n\nDIVISION OF NON - COMMUNICABLE DISEASES\n\n\n![DIVISION OF NON - COMMUNICABLE DISEASES](images/picture_003_page_2.png)\n\n\n![KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS| 2](images/picture_004_page_2.png)\n\n\n![KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS| 2](images/picture_005_page_2.png)\n\n\nKENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS| 2\n\n\n3 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS\n\n\n",
        "startLine": 0,
        "endLine": 62,
        "introContent": null,
        "keywords": []
      },
      {
        "id": "frontmatter-table-of-content",
        "level": "h1",
        "number": null,
        "title": "TABLE OF CONTENT",
        "slug": "table-of-content",
        "url": "/guidelines/table-of-content",
        "tokenCount": 2077,
        "content": "# TABLE OF CONTENT\n\n\n| List of figures                                                   | List of figures                                                            | 6   |\n|-------------------------------------------------------------------|----------------------------------------------------------------------------|-----|\n| List of tables                                                    | List of tables                                                             | 7   |\n| Acronyms                                                          | Acronyms                                                                   | 9   |\n| FOREWORD                                                          | FOREWORD                                                                   | 10  |\n| PREFACE                                                           | PREFACE                                                                    | 12  |\n| ACKNOWLEDGEMENTS                                                  | ACKNOWLEDGEMENTS                                                           | 13  |\n| EXECUTIVE SUMMARY                                                 | EXECUTIVE SUMMARY                                                          | 14  |\n| CHAPTER ONE                                                       | CHAPTER ONE                                                                | 16  |\n| INTRODUCTIONTO DIABETES                                           | INTRODUCTIONTO DIABETES                                                    | 16  |\n| 1.1.                                                              | Definition                                                                 | 16  |\n| 1.2.                                                              | Pathophysiology                                                            | 16  |\n| 1.2.1.                                                            | Pathogenesis and pathophysiology of type 1 diabetes                        | 17  |\n| 1.2.2.                                                            | Pathogenesis and pathophysiology of type 2 diabetes                        | 18  |\n| 1.3.                                                              | Diagnosis of diabetes                                                      | 19  |\n|                                                                   | Signs and symptoms                                                         | 19  |\n| 1.4.                                                              | Classification of Diabetes Mellitus                                        | 22  |\n| 1.5.                                                              | Risk Factors                                                               | 24  |\n| 1.6.                                                              | Screening for Diabetes Mellitus type 2                                     | 24  |\n| CHAPTERTWO                                                        | CHAPTERTWO                                                                 |     |\n| MANAGEMENT OF DIABETES                                            | MANAGEMENT OF DIABETES                                                     | 27  |\n| 2.0                                                               | Introduction                                                               | 27  |\n| 2.1.                                                              | Management of Type 1 Diabetes                                              | 27  |\n| 2.1.1.                                                            | Insulin treatment                                                          | 30  |\n| 2.1.2.                                                            | Blood Glucose Monitoring                                                   | 40  |\n| 2.1.3.                                                            | Educating a child living with diabetes and his/her family                  | 42  |\n| 2.1.4.                                                            | Nutritional management in Children living with diabetes and his/her family | 42  |\n| 2.2.                                                              | Management of Type 2 Diabetes                                              | 43  |\n| 2.2.1.                                                            | Non-pharmacological management                                             | 46  |\n| 2.2.2                                                             | Pharmacological management                                                 | 60  |\n| 2.2.3                                                             | Blood Glucose Monitoring                                                   | 68  |\n| CHAPTERTHREE                                                      | CHAPTERTHREE                                                               | 75  |\n| MANAGEMENT OF COMPLICATIONS ANDCOMORBIDITIES IN DIABETES MELLITUS | MANAGEMENT OF COMPLICATIONS ANDCOMORBIDITIES IN DIABETES MELLITUS          | 75  |\n| 3.1.                                                              | Introduction                                                               | 75  |\n| 3.2                                                               | Acute Complications                                                        | 75  |\n| 3.2.1                                                             | Introduction                                                               | 75  |\n| 3.2.2                                                             | Diabetic Ketoacidosis (DKA)                                                | 75  |\n| 3.2.3.                                                            | Diabetic Hyperosmolar Hyperglycaemic State                                 | 81  |\n| 3.2.4.                                                            | Hypoglycemia                                                               | 81  |\n| 3.2.5.                                                            | Sick Day Management                                                        | 84  |\n| 3.3.                                                              | Chronic Complications of Diabetes                                          | 87  |\n| 3.3.1.                                                            | Macrovascular Complications                                                | 87  |\n| 3.3.2.                                                            | Chronic Microvascular Complications                                        | 93  |\n| 3.4                                                             | Co-Morbidities in Diabetes Mellitus                                        | 102 |\n| 3.4.1                                                             | Hypertension                                                               | 102 |\n| 3.4.2.                                                            | Mental Disorders in Diabetes                                               | 106 |\n| 3.4.3.                                                            | Lipids disorders in Diabetes                                               | 106 |\n\n\n![KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS| 4](images/picture_006_page_4.png)\n\n\n![KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS| 4](images/picture_007_page_5.png)\n\n\n![5 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS](images/picture_008_page_5.png)\n\n\n| CHAPTER FOUR                                                    | CHAPTER FOUR                                                    |   110 |\n|-----------------------------------------------------------------|-----------------------------------------------------------------|-------|\n| METABOLIC SYNDROME ANDOBESITY                                   | METABOLIC SYNDROME ANDOBESITY                                   |   110 |\n| 4.1.                                                            | Introduction                                                    |   110 |\n| 4.2.                                                            | Management of the metabolic syndrome                            |   110 |\n| 4.3.                                                            | Obesity                                                         |   111 |\n| 4.3.1.                                                          | Measurements for evaluation of obesity                          |   111 |\n| 4.3.2.                                                          | General principles of the management of obesity                 |   112 |\n| CHAPTER FIVE                                                    | CHAPTER FIVE                                                    |   114 |\n| MANAGEMENT OF DIABETES IN SPECIAL SITUATIONS                    | MANAGEMENT OF DIABETES IN SPECIAL SITUATIONS                    |   114 |\n| 5.1.                                                            | Diabetes in Pregnancy                                           |   114 |\n| 5.2                                                             | Management of diabetes during fasting                           |   115 |\n| 5.3                                                             | Diabetes in the Older AAdults                                   |   124 |\n| 5.4.                                                            | Management of Diabetes during Surgery                           |   125 |\n| 5.4.1.                                                          | Pre-Operative Management                                        |   127 |\n| 5.4.2.                                                          | Intraoperative management                                       |   128 |\n| 5.5.                                                            | Diabetes and HIV                                                |   129 |\n| 5.5.1.                                                          | Classification of HIV in patients with diabetes                 |   129 |\n| 5.5.2.                                                          | Risk factors for Diabetes in HIV patients                       |   129 |\n| 5.5.3.                                                          | Screening for diabetes in HIV patients                          |   130 |\n| 5.5.4.                                                          | Evaluation of a patient                                         |   130 |\n| 5.5.5.                                                          | Treatment of diabetes in HIV infected individuals               |   131 |\n| 5.6.                                                            | Diabetes andTB                                                  |   133 |\n| 5.6.1                                                           | Effects of diabetes onTB                                        |   133 |\n| 5.6.2                                                           | Effects ofTB on diabetes                                        |   133 |\n| 5.6.3                                                           | TB screening among diabetes patients                            |   134 |\n| CHAPTER SIX                                                     | CHAPTER SIX                                                     |   137 |\n| LIVINGWITH DIABETES                                             | LIVINGWITH DIABETES                                             |   137 |\n| 6.1.                                                            | Introduction                                                    |   137 |\n| 6.2.                                                            | Employment                                                      |   137 |\n| 6.3.                                                            | Driving, Flying and Operating Machines                          |   138 |\n| 6.4.                                                            | Insurance                                                       |   138 |\n| 6.5.                                                            | Sports, recreational and occupational exercise                  |   138 |\n| 6.6.                                                            | Diabetes and School                                             |   140 |\n| 6.7.                                                            | Caregiver and Family Support                                    |   140 |\n| CHAPTER SEVEN                                                   | CHAPTER SEVEN                                                   |   142 |\n| PREVENTION OF DIABETES                                          | PREVENTION OF DIABETES                                          |   142 |\n| 7.1.                                                            | Introduction                                                    |   142 |\n| 7.2.                                                            | Primordial Prevention                                           |   142 |\n| 7.3.                                                            | Primary Prevention                                              |   142 |\n| 7.4.                                                            | Secondary prevention                                            |   143 |\n| 7.5.                                                            | Tertiary Prevention                                             |   143 |\n| CHAPTER EIGHT                                                   | CHAPTER EIGHT                                                   |   145 |\n| ORGANIZATION OF DIABETES CARE                                   | ORGANIZATION OF DIABETES CARE                                   |   145 |\n| 8.1.                                                            | Introduction                                                    |   145 |\n| 8.2.                                                            | Leadership and governance                                       |   145 |\n| 8.3.                                                            | Requirements for a Diabetic Clinic                              |   159 |\n| References                                                      | References                                                      |   150 |\n| APPENDICES                                                      | APPENDICES                                                      |   152 |\n| ANNEX 1: CARDIOVASCULAR RISK STRATIFICATIONTOOL                 | ANNEX 1: CARDIOVASCULAR RISK STRATIFICATIONTOOL                 |   152 |\n| ANNEX 2: DIABETES FOOT CLINIC SCREENING,TREATMENT FORMV0.1      | ANNEX 2: DIABETES FOOT CLINIC SCREENING,TREATMENT FORMV0.1      |   153 |\n| ANNEX 3: EXAMPLE OF A 7 POINTTESTING PROFILE CHARTED FOR 3 DAYS | ANNEX 3: EXAMPLE OF A 7 POINTTESTING PROFILE CHARTED FOR 3 DAYS |   154 |\n\n\n",
        "startLine": 63,
        "endLine": 177,
        "introContent": null,
        "sections": null
      },
      {
        "id": "frontmatter-list-of-figures",
        "level": "h1",
        "number": null,
        "title": "LIST OF FIGURES",
        "slug": "list-of-figures",
        "url": "/guidelines/list-of-figures",
        "tokenCount": 670,
        "content": "# LIST OF FIGURES\n\n\n| Figure 1: Normal glucose homeostasis                                                                                                                   |   16 |\n|--------------------------------------------------------------------------------------------------------------------------------------------------------|------|\n| Figure 2: Glucose homeostasis in diabetes mellitus                                                                                                     |   17 |\n| Figure 3: Natural History of type 2 diabetes                                                                                                           |   18 |\n| Figure 4: Diagnostic cascade for type 2 diabetes                                                                                                       |   21 |\n| Figure 5: Injection technique using an insulin syringe                                                                                                 |   35 |\n| Figure 6: Injection Technique using the insulin pen                                                                                                    |   36 |\n| Figure 7: Structure of an insulin Pen Device and how to use it                                                                                         |   37 |\n| Figure 8: Adult insulin injection sites                                                                                                                |   38 |\n| Figure 9: Recommended sites for injection in children                                                                                                  |   39 |\n| Figure 10: Plate Model                                                                                                                                 |   51 |\n| Figure 11: Handy portion guide                                                                                                                         |   52 |\n| Figure 12: An illustration of low and high glycemic index food                                                                                         |   52 |\n| Figure 13: Medical management of Type 2 Diabetes Based on HbA1c levels                                                                                 |   60 |\n| Figure 14: Risks and benefits of glucose-lowering agents (excluding insulin)                                                                           |   63 |\n| Figure 15: Initiating Insulin Therapy in Type 2 diabetes                                                                                               |   64 |\n| Figure 16: Initiating pharmacotherapy in type 2 diabetes                                                                                               |   65 |\n| Figure 17: Self-Monitoring of Blood Glucose as a component of diabetes education                                                                       |   68 |\n| Figure 18: Algorithm for blood glucose self-monitoring in patients with type 2                                                                         |   69 |\n| Figure 19: Guidance on Self-Monitoring of Blood Glucose for people living with diabetes                                                                |   70 |\n| Figure 21: Management of DKA                                                                                                                           |   79 |\n| Figure 22: Howto perform an ankle-branchial index                                                                                                      |   91 |\n| Figure 23: Diabetic Foot Screening                                                                                                                     |   99 |\n| Figure 24: Performing a monofilament test for foot sensation in diabetes                                                                               |   99 |\n| Figure 25: Management of diabetic foot ulcers                                                                                                          |  100 |\n| Figure 26: Management of erectile dysfunction in men living with diabetes                                                                              |  101 |\n| Figure 27: Algorithm for the management of hypertension in patients with diabetes mellitus                                                             |  104 |\n| Figure 28: Management of hypertension in patients with diabetes in the Primary Care setting                                                            |  105 |\n| Figure 29: Algorithm for screening people living with diabetes forTB                                                                                   |  134 |\n| Figure 30: Stratification of total CV risk based on SBP and DBP and prevalence of Risk factors asymptomatic OD, diabetes, CKD stage or symptomatic CVD |  152 |\n| Figure 31: Appropriate footwear for persons living with diabetes                                                                                       |  153 |\n| Figure 32: Example of a 7 point testing profile charted for 3 days                                                                                     |  154 |\n\n\n",
        "startLine": 178,
        "endLine": 214,
        "introContent": null,
        "sections": null
      },
      {
        "id": "frontmatter-list-of-tables",
        "level": "h1",
        "number": null,
        "title": "LIST OF TABLES",
        "slug": "list-of-tables",
        "url": "/guidelines/list-of-tables",
        "tokenCount": 1093,
        "content": "# LIST OF TABLES\n\n\n| Table 1: Signs and Symptoms of Diabetes                                                                                                  |   19 |\n|------------------------------------------------------------------------------------------------------------------------------------------|------|\n| Table 2: Diagnostic criteria for Diabetes and pre-diabetes                                                                               |   20 |\n| Table 3: The main types of Diabetes                                                                                                      |   22 |\n| Table 4: Differences in type 1 and type 2 diabetes at diagnosis (clinical presentation, patient characteristics and pathogenesis)        |   23 |\n| Table 5: Modifiable and Non-Modifiable Risk factors for type 2 Diabetes                                                                  |   24 |\n| Table 6: Screening criteria for Diabetes                                                                                                 |   25 |\n| Table 7: Patient assessment at initial and follow-up visits                                                                              |   28 |\n| Table 8: Types of Insulin, mode of action and administration of Insulin                                                                  |   31 |\n| Table 9: Example of administration of short- and long-acting insulin as multiple daily injections                                        |   32 |\n| Table 10: Example of administration of Short and Intermediate-acting Insulin as multiple daily injections. as multiple daily injections. |   33 |\n| Table 11: Example of administration of Short acting, Intermediate-acting and pre-mixed Insulin                                           |   34 |\n| Table 12: RecommendedTarget Blood Glucose Levels and HbA1c                                                                               |   40 |\n| Table 13: Interpretation of Blood Glucose Level (BGL)                                                                                    |   41 |\n| Table 14: Clinical Assessment for initial and follow-up visits for Type 2 Diabetes                                                       |   43 |\n| Table 15: Structured diabetes education outline                                                                                          |   47 |\n| Table 16: Dietary Recommendations in Management of Type 2 Diabetes                                                                       |   49 |\n| Table 17: Examples of low and high glycemic index foods                                                                                  |   53 |\n| Table 18: Food groups and recommended servings per each food group                                                                       |   54 |\n| Table 19: Aerobic exercise recommended for individuals with type 2 diabetes                                                              |   57 |\n| Table 20: Resistance exercise recommended for individuals with type 2 diabetes                                                           |   58 |\n| Table 21: Oral glucose lowering agents, dosage, side effects and Contraindications                                                       |   62 |\n| Table 22: Adjusting dose of premixed insulin in adults with type 2                                                                       |   66 |\n| Table 23: Barriers to insulin therapy                                                                                                    |   67 |\n| Table 24: Examples of Self-Monitoring of Blood Glucose (SMBG) testing pro les                                                            |   72 |\n| Table 25: Targets for HbA1c, fasting plasma glucose and postprandial glucose in different patient types                                  |   73 |\n| Table 26: Fluid maintenance and replacement based on body weight and assumption of 10% dehydration in DKA                                |   80 |\n| Table 27: Management of hypoglycaemia                                                                                                    |   83 |\n| Table 28: Minimum amounts of fluid for oral rehydration                                                                                  |   85 |\n| Table 29: Guidelines for supplemental regular insulin                                                                                    |   85 |\n| Table 30: CVD risk factors and targets for type 2 diabetes                                                                               |   87 |\n\n\n| Table 31: Interpretation of ankle-brachial index (ABI) values                                                                                            |   92 |\n|----------------------------------------------------------------------------------------------------------------------------------------------------------|------|\n| Table 31: Frequency of screening for diabetic nephropathy based on status of kidney function                                                             |   98 |\n| Table 32: Frequency of screening for diabetic nephropathy                                                                                                |   94 |\n| Table 33: Principles of management of hypertension by level of severity                                                                                  |  103 |\n| Table 34: Desired level of lipids in patients with diabetes (LDL targets in the absence of CKD and CVD, DMin patients < 40 years, duration of <10 years) |  106 |\n| Table 35: Lipid Targets for secondary prevention (people with history of cardiovascular event)                                                           |  107 |\n| Table 36: Definition of overweight and obesity per age category                                                                                          |  111 |\n| Table 37: Classification of BMI                                                                                                                          |  112 |\n| Table 38: Diagnostic criteria for diabetes in pregnancy and gestational diabetes mellitus                                                                |  114 |\n| Table 39: Effects of diabetes on the mother and fetus or newborn                                                                                         |  120 |\n| Table 40: Risk categories of patients with diabetes with regards to fasting                                                                              |  121 |\n| Table 41: Summary of advice to Fasting patients with Type 2 diabetes                                                                                     |  123 |\n| Table 42: Management of a patient with diabetes during surgery                                                                                           |  128 |\n| Table 43: Classification of drug classes by metabolic profile                                                                                            |  130 |\n| Table 44: First line anti -TB regimen                                                                                                                    |  134 |\n| Table 45: Insulin adjustment before exercise                                                                                                             |  139 |\n| Table 46: Personnel and services offered per healthcare tier                                                                                             |  147 |\n| Table 47: List of Technical Working Group Members - Clinical Guidelines                                                                                  |  154 |\n\n\n",
        "startLine": 215,
        "endLine": 271,
        "introContent": null,
        "sections": null
      },
      {
        "id": "frontmatter-acronyms",
        "level": "h1",
        "number": null,
        "title": "ACRONYMS",
        "slug": "acronyms",
        "url": "/guidelines/acronyms",
        "tokenCount": 480,
        "content": "# ACRONYMS\n\n\nABI\n\n\nAnkle-Brachial Index\n\n\nACEI\n\n\nAngiotensin Converting Enzyme Inhibitors\n\n\nADA\n\n\nAmerican Diabetes Association\n\n\nAHT\n\n\nAnti-Hypertensive Therapy\n\n\nAKUH\n\n\nAgha Khan University Hospital\n\n\nANC\n\n\nAntenatal Care\n\n\nARB\n\n\nAngiotensin Receptor Blockers\n\n\nBMI\n\n\nBasal Metabolic Rate\n\n\nBGLs\n\n\nBlood Glucose Levels\n\n\nBP\n\n\nBlood Pressure\n\n\nCABG\n\n\nCoronary Artery Bypass Graft\n\n\nCF\n\n\nCorrection factor\n\n\nCRP\n\n\nC-reactive protein\n\n\nDCC\n\n\nDiabetes Comprehensive Care\n\n\nDKA\n\n\nDiabetes Ketoacidosis\n\n\nDMI\n\n\nDiabetes Management and Information Centre\n\n\nDNCD\n\n\nDivision of Non-communicable Diseases\n\n\nECG\n\n\nElectrocardiograph\n\n\nFBG\n\n\nFasting Blood Glucose\n\n\nFFA\n\n\nFree fatty acids\n\n\nGDM\n\n\nGestation Diabetes Mellitus\n\n\nGFR\n\n\nGlomerular Filtration Rate\n\n\nHAART\n\n\nHighly Active Anti-Retroviral Treatment\n\n\nHIV\n\n\nHuman Immunodeficiency Virus\n\n\nHHS\n\n\nHyperglycemic Hyperosmolar State\n\n\nHDL\n\n\nHigh Density Lipoproteins\n\n\nHGT\n\n\nHourly Glucose Test\n\n\nIDF\n\n\nInternational Diabetes Federation\n\n\nIFG\n\n\nImpaired Fasting Glucose\n\n\nIHD\n\n\nIschaemic heart disease\n\n\nIU\n\n\nInternational Units\n\n\nKNH\n\n\nKenyatta National Hospital\n\n\nLADA\n\n\nLatent Autoimmune Diabetes in Adults\n\n\nMSF\n\n\nMédecins Sans Frontières\n\n\nLDL\n\n\nLow Density Lipoproteins\n\n\nMDI\n\n\nMultiple Daily Injections\n\n\nMTRH\n\n\nMoi Teaching and Referral Hospital\n\n\nMUAC\n\n\nMid Upper Arm Circumference\n\n\nNIDDM\n\n\nNon-Insulin-Dependent Diabetes Mellitus\n\n\nNPH\n\n\nNeutral-Protamine-Hagedorn\n\n\nOGLA\n\n\nOral Glucose Lowering Agents\n\n\nOGTT\n\n\nOral Glucose Tolerance Test\n\n\nRBG\n\n\nRandom Blood Glucose\n\n\nSMBG\n\n\nSelf-Monitoring of Blood Glucose\n\n\nTB\n\n\nTuberculosis\n\n\nTSH\n\n\nThyroid Stimulating Hormone\n\n\nWC\n\n\nWaist Circumference\n\n\nWDF\n\n\nWorld Diabetes Foundation\n\n\nWHO\n\n\nWorld Health Organization\n\n\nWHR\n\n\nWaist Hip Ratio\n\n\n",
        "startLine": 272,
        "endLine": 574,
        "introContent": null,
        "sections": null
      },
      {
        "id": "frontmatter-foreword",
        "level": "h1",
        "number": null,
        "title": "FOREWORD",
        "slug": "foreword",
        "url": "/guidelines/foreword",
        "tokenCount": 860,
        "content": "# FOREWORD\n\n\nThe prevalence of chronic Non-Communicable Diseases (NCDs) such as Diabetes, Cardiovascular Diseases and Cancers has been on the rise in Kenya in the recent past. This has been occasioned by changes in the social and demographic situation in the country. The life expectancy in Kenya is improving, as the country develops rapidly. This has resulted in people living longer and at the same time adopting lifestyles that have negative impact on their health. This increase in diabetes and other NCDs has given rise to a double burden of communicable and non-communicable diseases in Kenya.\n\n\nDiabetes and other NCDs are now a threat to national development as they often result in long standing illness and complications that can be very costly to treat and progressively drain the strength and resources of individuals, families and communities rendering them unproductive and poor.\n\n\nIn response to this crisis, the Ministry of Health prioritized prevention and management of diabetes and other NCDs in the Kenya Health Policy 2012 - 2030. Furthermore, the Ministry of Health in collaboration with Non-Governmental Organizations, Regional and International Diabetes support bodies spearheaded the development of the National Clinical Guidelines for the Management of Diabetes Mellitus to provide a standardized approach of managing Diabetes in the country.\n\n\nPrevention and control of Diabetes and other NCDs is a key pillar to the attainment of Universal Health Coverage (UHC). These guidelines will standardize clinical practice that will ensure universal access to interventions addressing Diabetes and its complications. It also forms a part of the UHC delivery support documents and will contribute to the achievement of its overall aim.\n\n\nThe  guidelines  also  reaffirm  Kenya's  commitment  to  the  Declaration  of  Astana  on strengthening  the  Primary  Health  Care  (PHC)  systems  as  an  essential  step  towards achieving UHC. The guidelines are also informed by the commitments on Sustainable Development Goals (SDGs) as they intend to contribute to the general wellbeing of the individual  patients,  their  families  and  communities  towards  productivity  and  shared prosperity.\n\n\nThe National Clinical Guidelines for the Management of Diabetes Mellitus has effectively provided for high standard of care for Diabetes with clear consideration of management interventions and technologies that are easily accessible and available for Kenyans. To this end, the guidelines align with the National drive to ensure UHC is attained.\n\n\nA Technical Working Group (TWG) was established under the auspices of the Division of Non-Communicable Diseases (DNCD) to develop these guidelines that are based on up to date and evidence-based management of Diabetes Mellitus. These guidelines are a synthesis of information drawn from an extensive review of local and international knowledge and experiences.\n\n\nIn their development, the TWG adopted a Primary Health Care (PHC) approach as this is the most effective way to sustainably integrate Diabetes and other NCDs in the care continuum. PHC enables every person, everywhere to exercise their fundamental right to health. The guidelines will ensure essential Diabetes services ranging from awareness, early diagnosis, timely referral, regularly monitoring, health and risk factor education at the community level and palliative care are accessed at every level of care.\n\n\nThese guidelines are suitable for use by all health workers and health institutions from both the public and private sectors in the country. They provide clear directions on what needs to be done for people living with Diabetes and provide a guide on the continuum of care required throughout the life course of the individuals living with the disease.\n\n\nAs a Ministry, we appreciate that the task of managing complex NCDs like Diabetes cannot be left to the Government alone. It is in this regard that we embraced a broad partnership  base  to  tap  on  the  know-how  from  the  public,  private,  academia, pharmaceutical, patients' groups and other non-state actors in the developing of these guidelines.\n\n\nI  highly  recommend the use of the guidelines by all health care providers across the health sector as a reference document when managing Diabetes and its related complications.\n\n\n![………………………………](images/picture_009_page_11.png)\n\n\n………………………………\n\n\n………………………………\n\n\nSicily K. Kariuki (Mrs.), EGH Cabinet Secretary Ministry of Health\n\n\n",
        "startLine": 575,
        "endLine": 622,
        "introContent": null,
        "sections": null
      },
      {
        "id": "frontmatter-preface",
        "level": "h1",
        "number": null,
        "title": "PREFACE",
        "slug": "preface",
        "url": "/guidelines/preface",
        "tokenCount": 458,
        "content": "# PREFACE\n\n\nNon-communicable diseases (NCDs) are the leading causes of morbidity and mortality globally causing more deaths than all other causes combined, and they strike hardest at the world's low and middle-income populations. In Kenya NCD accounts for more than 50% of total hospital admissions and over 55% of hospital deaths. It is in this regard that the Ministry of Health and partners have developed this strategic document to serve as a comprehensive guide to addressing this emerging epidemic.\n\n\nAs a que from the Global Action Plan on NCDs and as a follow-up to the 3 UN High level meetings on NCDs, this guidelines are meant to build the capacity of Primary Health Care workers on the prevention, diagnosis and control of diabetes across the entire continuum of care.\n\n\nThe  hall  mark  of  diabetes  is  long  term  complications  like  foot,  cardiovascular,  eye, nerve and renal complications that are driven by poor glycemic control. This is a grim reality  considering  that  and  among  those  previously  diagnosed  with  diabetes  and were currently on treatment only 7% had achieved control.  This guideline will provide a standardized and harmonized road map towards improving prevention, screening, diagnosis and care of people with diabetes. It also promotes patient empowerment and recognizes the patients as a major stakeholder in diabetes care.\n\n\nThis guidelines are in themselves the minimum standard of care and act as a benchmark on quality and rights of access for the patients. They are however incremental in nature as the capacity of our health system varies greatly across the country and some county facilities may not have what is envisaged in this guidelines. In this regard, these guidelines should go hand in hand with capacity building and system strengthening and reform across the national and county health levels.\n\n\nWe are committed to ensuring that this guideline is implemented and adopted to the fullest in order to improve the lives of our population and provide the appropriate care to those living with diabetes\n\n\nDr. Rashid Abdi Aman, BPharm., PhD Chief Administrative Secretary Ministry of Health\n\n\n![KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS| 12](images/picture_010_page_12.png)\n\n\n",
        "startLine": 623,
        "endLine": 646,
        "introContent": null,
        "sections": null
      },
      {
        "id": "frontmatter-acknowledgements",
        "level": "h1",
        "number": null,
        "title": "ACKNOWLEDGEMENTS",
        "slug": "acknowledgements",
        "url": "/guidelines/acknowledgements",
        "tokenCount": 477,
        "content": "# ACKNOWLEDGEMENTS\n\n\nThe National Clinical Guidelines for the Management of Diabetes Mellitus was prepared with the active participation of diabetes experts from the Ministry of Health, teaching institutions, Non-Governmental Organizations, private sector and teaching hospitals in Kenya. The Guidelines are based on the clinical guidelines for management of diabetes in Sub Saharan Africa developed by the International Diabetes Federation (IDF) Africa region whom we owe thanks for allowing us to use the materials.\n\n\nThe participation of the following individuals and organization is gratefully appreciated, Dr. Eva Njenga (diabetologist and endocrinologist), Dr. Nancy Ngugi, (diabetologist and endocrinologist, KNH), Dr. Jemima Kamano (Physician MTRH), Dr. Nancy Kunyiha (diabetologist and endocrinologist, AKUH) and Mrs. Eva Muchemi (CEO Kenya Diabetes Management and Information Centre (DMI Centre). We however acknowledge everyone who was involved in the development, review and editing this guideline, your contribution to this process will forever be indebted.\n\n\nThe funding for  the  process  was  provided  by  the World  Diabetes  Foundation  (WDF) through the National Diabetes Comprehensive Care Project, Sanofi Aventis, Novo Nordisk, AstraZeneca and Novartis. The process received a lot of technical support from the Kenya Diabetes Management and Information Centre (DMI), Diabetes Kenya (DK), The diabetes study group, MSF Belgium, the University of Nairobi, Moi Teaching and Referral Hospital and Kenyatta National Hospital. Dr. Joyce N. Nato of the World Health Organization, Kenya Country Office provided technical advice to the drafting team.\n\n\nThe development of the guidelines was carried out under the auspices of the Division of Non-communicable Diseases. I would like to gratefully acknowledged the contribution and  leadership of dr. Joseph Kibachio and his staff especially Mr. Zachary Ndegwa, Dr. Martin Mwangi, Dr. Loise Nyanjau, Mrs. Scholastica Mwende, Dr. Oren Ombiro and Dr. Grace Kariuki.\n\n\n![.........................................................](images/picture_011_page_13.png)\n\n\n.........................................................\n\n\nDr. Kioko Jackson K , OGW, MBS Director of Medical Services Ministry of Health\n\n\n",
        "startLine": 647,
        "endLine": 670,
        "introContent": null,
        "sections": null
      },
      {
        "id": "frontmatter-executive-summary",
        "level": "h1",
        "number": null,
        "title": "EXECUTIVE SUMMARY",
        "slug": "executive-summary",
        "url": "/guidelines/executive-summary",
        "tokenCount": 862,
        "content": "# EXECUTIVE SUMMARY\n\n\nDiabetes is an increasing problem throughout the world and is a major contributor to the growing burden of chronic disease, especially in developing countries. It is associated with significant morbidity and decreased life expectancy due to its complications, which include heart disease, stroke, amputation, blindness and kidney failure. Diabetes reduces quality of life, especially in people with complications. The complications of undetected and untreated diabetes are serious and cause great human suffering and disability, and have huge socio - economic costs resulting from premature morbidity and mortality It is also associated with increased psychosocial problems including depression and anxiety.\n\n\nThe key risk factors for diabetes-obesity, physical inactivity, and unhealthy diets-require interventions to change unhealthy lifestyles. These changes are most likely to occur with implementation of a coordinated range of interventions to encourage individuals to maintain a healthy weight, participate in daily physical activity, and consume a healthy diet. Diabetes education is central to implementing such changes. It is more effective when provided through multiple methods and sites, such as schools, workplaces, mass media, and health centers. Educational messages are also more effective if they are reinforced by action and behavior change techniques and approaches.\n\n\nDiabetes care is a lifelong responsibility that requires people living with the disease to change many habits, such as what they eat, when they exercise and how frequently they visit a health care provider. They may need to take daily medications or insulin to keep their blood glucose levels in check. Having diabetes means that one has to adjust his lifestyle at work and at home. But these changes don't mean one won't be able to succeed at work or enjoy a healthy and fulfilling life. People living with diabetes have equal rights with those without the condition and should be protected from all forms of discrimination.\n\n\nDiabetes, being a complex disorder, necessitates a systematic approach in the organization of care. In order to achieve this, there are several elements that needs to be addressed. These includes: a well-trained and dedicated personnel, management and referral protocols &amp; algorithms, continuous supply of essential medicines and technologies, a registry of all patients in care in order to facilitate recall for non-attendance and for specific aspects of regular care and annual review charts that are useful for follow up of clinical and biochemical measurements.\n\n\nUnfortunately, the practice of diabetes care is still far from being organized and uniform across all levels. This guideline is an essential component of achieving quality diabetes care for all people with the condition. It provides recommendations of standards of care, and  use  evidence-based  interventions  to  achieve  those  standards,  in  order  to  guide healthcare professionals, people affected by diabetes, policy-makers and administrators.\n\n\nIn order to improve and standardize diabetes management, the implementation of this guideline is very critical. This calls for wide dissemination of the guideline, its introduction and acceptance into all health facilities whether public, private for no-profit or private for profit. Its  application will provide all the relevant information that will guide future revisions of the guidelines to suit the national needs for diabetes management.\n\n\n**The purpose of these Guidelines is to:**\n\n\n- i. Provide simple and practical ways to assess persons living with diabetes and make the right diagnosis and provide the best treatment and care.\n- ii. Assist health care providers to identify locally appropriate and sustainable ways of improving diabetes management.\n- iii. Mainstream diabetes management into the health care system and strengthen self-care management.\n\n\nThe guideline contents is organized in 8 chapters, that comprise of: introduction to Diabetes; management of diabetes; management of complications and comorbidities; metabolic syndrome and obesity; management of diabetes in special situations; living with diabetes; prevention of diabetes and organization of diabetes care.\n\n\nKnowthedabeteswaming signs\n\n\nIshara na dalili za maradhi ya kisukari:\n\n\nEndapojumlayaidadyak aslma7%zid\n\n\nkivangchakoc sukagukos)\n\n\nkweyedamunezaa maradhiyakisukanl\n\n\nHEALTHYEATING\n\n\nCHAPTER ONE\n\n\nKENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS| 16\n\n\nHYPOGLYCEMIA\n\n\nTREATMENTE\n\n\nHYPOGLYCEMIA\n\n\n",
        "startLine": 671,
        "endLine": 735,
        "introContent": null,
        "sections": null
      },
      {
        "id": "frontmatter-references",
        "level": "h1",
        "number": null,
        "title": "REFERENCES",
        "slug": "references",
        "url": "/guidelines/references",
        "tokenCount": 1593,
        "content": "# REFERENCES\n\n\n1. Ministry of Health. Kenya National Clinical Guidelines for Management of Diabetes Mellitus, 2010\n2. International Diabetes Federation. Pocketbook for Management of Diabetes in Childhood and Adolescence in Under-Resourced Countries, 2nd Edition, 2017.\n3. Kelly D, Hamilton JKL, Riddell MC. Blood glucose levels and performance in a sports camp for adolescents with a basal bolus insulin regimen (ultra-Lente-lis pro) in children with type 1 diabetes mellitus: A field study. Diabetes Care, 2001:24:4: 625-630\n4. Robertson K, Riddell MC, Guinhouya BC, Adolfsson P, Hanas R. ISPAD Clinical Practice Consensus Guidelines 2014 Compendium. Exercise in children and adolescents with diabetes. Pediatric Diabetes 2014: 15 (Suppl. 20): 203-223.\n5. Canadian Diabetes Association. Guidelines for the Care of Students Living with Diabetes at School, 2014.\n6. American Diabetes Association. (2017). Standards of Medical care in diabetes 2017. The Journal of Clinical and Applied Research and Education, 40(January), 1-142. http://doi.org/10.2337/dc16-S003\n7. Amod, A., Ascott-Evans, B. H., Berg, G. I., Blom, D. J., Brown, S. L., Carrihill, M. M., … Young, M. (2012). The 2012 SEMDSA Guideline for the Management of Type 2  Diabetes (Revised). Journal of Endocrinology, Metabolism and Diabetes of South Africa, 17(2), S1-S95.\n8. FDRE-MoH. (2016). Guidelines on Clinical and Programmatic Management of Major Non-Communicable Diseases, 33-51.\n9. Guide, F., &amp; Eating, H. (1999). Nutritional Management of Diabetes, 2-3.\n10. Guidelines, N. (1985). Nutrition guidelines. Nutrition &amp; Food Science, 85(3), 6-7. http://doi.org/10.1108/eb059063\n11. Last, J. M. (2008). A Dictionary of Epidemiology. International Journal of Epidemiology (Vol. 15). http://doi.org/10.1093/ije/15.2.277\n12. NICE. (2015a). Diabetes (type 1 and type 2) in children and young people: diagnosis and management, (August), 1-92.\n13. NICE. (2015b). T ype 2 diabetes in adults : management, (December), 1-57. Retrieved from https://www.nice.org.uk/guidance/ng28/resources/type-2diabetes-in-adults-management-1837338615493\n14. Pathways, N., &amp; Pathways, N. (2011). Hyperglycaemia in acute coronary syndromes: management, (October).\n15. Pathways, N., &amp; Pathways, N. (2016a). Brain cancers overview, (March).\n16. Pathways, N., &amp; Pathways, N. (2016b). Foot care for people with diabetes overview, (January).\n17. Pathways, N., &amp; Pathways, N. (2016c). Preventing type 2 diabetes overview, (November).\n\n\n18. Pathways, N., &amp; Pathways, N. (2016d). T Type 1 diabetes in adults o ype 1 diabetes in adults overview, (December), 1-7. Retrieved from http://pathways. nice.org.uk/pathways/type-1-diabetes-in-adults\n19. Rosenbloom,  a L. (1994). Diabetes in childhood and adolescence. Pediatric Annals, 23(6), 282-283. http://doi.org/10.1097/00007611-193212000-00026\n20. Vorster, H. H., Badham, J. B., &amp; Venter, C. S. (2013). Food-Based Dietary Guidelines for South Africa. South African Journal of Clinical Nutrition, 26(3), 5-12.\n21. Wolever, T., Barbeau, M., Charron, S., &amp; Harrigan, K. (1999). Guidelines for the nutritional management of diabetes mellitus in the new millennium: a position statement by the Canadian Diabetes Association. Can J Diabetes Care, 23(3), 56-69.  Retrieved from http://scholar.google.com/scholar?hl=en&amp;btnG=Search&amp;q= intitle:Guidelines+for+the+Nutritional+Management+of+Diabetes+ Mellitus+in+the+New+Millennium#0\n22. American Diabetes Association, 2017; Amod et al., 2012; EXCHANGE, 2007; FDRE-MoH, 2016; Guide &amp; Eating, 1999; Guidelines, 1985; NICE, 2015a, 2015a, 2015b; Pathways &amp; Pathways, 2016a, 2016b, 2016c, 2016d, 2011; Rosenbloom, 1994; Vorster, Badham, &amp; Venter, 2013; Wolever, Barbeau, Charron, &amp; Harrigan, 1999)\n23. https://www.niddk.nih.gov/health-information/diabetes/overview/diet-eating-physi cal-activity/carbohydrate-counting\n24. https://www.heart.org/HEARTORG/Conditions/More/MetabolicSyndrome/About-Met abolic-Syndrome\\_UCM\\_301920\\_Article.jsp\n25. EXCHANGE, G. (2007). Republic of Kenya. HeinOnline, (May). Retrieved from http://hei nonlinebackup.com/hol-cgi bin/get\\_pdf.cgi?handle=hein.ustreaties/kav08963&amp; section=1\n26. Hod M, Kapur A, Sacks DA, Hadar E, Agarwal M, Renzo GC Di, et al. The International Federation of Gynecology and Obstetrics (FIGO) Initiative on gestational diabetes mellitus: A pragmatic guide for diagnosis, management, and care#. Int J Gynecol Obstet [Internet]. [cited 2018 Oct 23];131:S173-211. Availablefrom: https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1016/ S0020-7292%2815%2930033-3%4010.1002/%28ISSN%291879-3479.Supplements\n27. International Association of Diabetes and Pregnancy Study Groups Consensus Panel IA of D and PSGC, Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, et al. Inter national association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care [Internet]. 2010 Mar 1 [cited 2018 Oct 23];33(3):676-82. Available from: http://www.ncbi.nlm.nih. gov/pubmed/20190296\n\n\n",
        "startLine": 5120,
        "endLine": 5153,
        "introContent": null,
        "sections": null
      },
      {
        "id": "frontmatter-appendices",
        "level": "h1",
        "number": null,
        "title": "APPENDICES",
        "slug": "appendices",
        "url": "/guidelines/appendices",
        "tokenCount": 1489,
        "content": "# APPENDICES\n\n\n**ANNEX 1: CARDIOVASCULAR RISK STRATIFICATION TOOL**\n\n\n![BP=blood pressure;CKD=chronickidney disease;CV=cardiovascular;CVD=cardiovascular disease;DBP=diastolicblood pressure; HT=hypertension:OD=organ damage:RF=riskfactor;SBP=systolicblood pressure.](images/picture_053_page_153.png)\n\n\n| Otherriskfactors, asymptomaticorgandamage ordisease   | Pre-HTN SBP130-139 orDBP85-89   | Stage1HTN SBP140-159 orDBP90-99   | Stage2HTN SBP160-179 orDBP100-109   | Stage3HTN SBP2180 orDBP≥110   |\n|-------------------------------------------------------|---------------------------------|-----------------------------------|-------------------------------------|-------------------------------|\n| No otherRF                                            |                                 | Lowrisk                           | Moderaterisk                        | Highrisk                      |\n| 1-2RF                                                 | Lowrisk                         | Moderaterisk                      | Moderateto highrisk                 | Highrisk                      |\n| ≥3RF                                                  | Lowto moderaterisk              | Moderateto highrisk               | Highrisk                            | High.risk                     |\n| OD,CKDstage3ordiabetes                                | Moderateto highrisk             | Highrisk                          | Highrisk                            | Highto veryhighrisk           |\n| SymptomaticCVD,CKDstage≥4or diabeteswithOD/RFs        | Veryhighrisk                    | Very highrisk                     | Very highrisk                       | Very highrisk                 |\n\n\nBP=blood pressure;CKD=chronickidney disease;CV=cardiovascular;CVD=cardiovascular disease;DBP=diastolicblood pressure; HT=hypertension:OD=organ damage:RF=riskfactor;SBP=systolicblood pressure.\n\n\nRisk\tfactors(RF)\t\tinclude:\tsmoking,\tage\t(men\t&gt;55\tyrs,\twomen\t&lt;65\tyears),\tdyslipidaemia,\tmale\tsex, obesity, central adiposity, family history of premature CVD( men &lt;55 years, women &lt;65 years) and impaired glucose tolerance)\n\n\nFigure 30: Stratification of total CV risk based on SBP and DBP and prevalence of Risk factors, asymptomatic OD, diabetes, CKD stage or symptomatic CVD\n\n\nAdapted from the ESH/ESC Guidelines for the management of arterial hypertension, 2013\n\n\n**ANNEX2: APPROPRIATE FOOT WARE FOR PEOPLE LIVING WITH DIABETES**\n\n\nFigure 31: Appropriate Footwear for persons living with diabetes\n\n\n![KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS| 154](images/picture_054_page_154.png)\n\n\n**ANNEX 3: EXAMPLE OF 7 POINT TESTING PROFILE CHARTERED FOR 3 DAYS**\n\n\nFigure 32: Example of a charted for 3 days 7-point testing profile\n\n\n![Source: Roche Accu-Chek®](images/picture_055_page_155.png)\n\n\nSource: Roche Accu-Chek®\n\n\nTable 47: List of Technical Working Group Members - Clinical Guidelines\n\n\n| Name                   | Organization             |\n|------------------------|--------------------------|\n| Dr. Joseph Kibachio    | MOH-DNCD                 |\n| Zachary Ndegwa         | MOH-DNCD                 |\n| Dr. Gladwell Gathecha  | MOH- DNCD                |\n| Scholastica Owondo     | MOH-DNCD                 |\n| Dr. Martin Mwangi      | MOH-DNCD/ FELTP          |\n| Samuel Kiogora         | MOH-CHS                  |\n| Peris Mbugua           | MOH-DNCD                 |\n| Dr. Loise Nyanjau      | MOHDNCD                  |\n| Dr. Ephantus Maree     | MOH-DNCD                 |\n| Dr. Grace Kariuki      | MOH-DNCD/FELTP           |\n| Dr. Oren Ombiro        | MOH-DNCD/FELTP           |\n| Eva Muchemi            | DMI Centre               |\n| Eric Omondi            | DMI Centre               |\n| Dr. Catherine Karekezi | DMI centre               |\n| Anne Gathura           | Nairobi County           |\n| Dr. Claris Ambale      | Machakos County          |\n| Dr. Bernadine Lusweti  | Thika level 5            |\n| Dr. Eva Njenga         | Diabetologist            |\n| James Katama           | CHAK HQ                  |\n| Dr. Nancy Kunyiha      | Diabetologist/AKUH       |\n| Dr. Nancy Ngugi        | Diabetologist/KNH        |\n| Isaac Miruka           | KNH                      |\n| Irene Kamau            | KNH                      |\n| Dr. Paul Laigong       | KNH                      |\n| Dr. Jemimah Kamano     | MTRH/AMPATH              |\n| Dr. Nicholas Kirui     | MTRH/AMPATH              |\n| Jackline Kerubo        | MTRH                     |\n| James Nduati           | Public Health Specialist |\n| Dr. Joyce Mbogo        | Pediatrician             |\n| Beatrice Gachambi      | MSF                      |\n| Dr. Yvonne Nzomukunda  | MSF                      |\n| Lili-Marie Wangari     | MSF                      |\n| Dr. Evelyn Mwania      | Novartis                 |\n| Dr. Ningala Kinyua     | BD                       |\n| Lilly Kamande          | Roche                    |\n| Karim Mounir           | Boehringer Ingelheim     |\n\n\nCanon\n\n\n157 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS\n\n\n![157 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS](images/picture_056_page_158.png)\n\n\n![Ministry of Health](images/picture_057_page_158.png)\n\n\n![Ministry of Health](images/picture_058_page_158.png)\n\n\nMinistry of Health\n\n\n![Supported By:](images/picture_059_page_158.png)\n\n\nSupported By:\n\n\n![Supported By:](images/picture_060_page_158.png)\n\n\n![Supported By:](images/picture_061_page_158.png)\n\n\n![KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS| 158](images/picture_062_page_158.png)\n\n\n![KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS| 158](images/picture_063_page_158.png)\n\n\nKENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS| 158",
        "startLine": 5154,
        "endLine": 5284,
        "introContent": null,
        "sections": null
      }
    ],
    "chapters": [
      {
        "id": "chapter-1",
        "level": "h1",
        "number": "1",
        "title": "CHAPTER ONE: INTRODUCTION TO DIABETES",
        "slug": "chapter-one-introduction-to-diabetes",
        "url": "/guidelines/chapter-one-introduction-to-diabetes",
        "tokenCount": 3149,
        "summary": null,
        "content": "# CHAPTER ONE: INTRODUCTION TO DIABETES\n\n\n## 1.1. Definition\n\n\nDiabetes mellitus is a chronic metabolic disorder characterized by sustained elevated blood glucose (hyperglycemia) resulting from defects in insulin secretion, action or both. Diabetes, if not well controlled leads to serious complications, resulting in multiple diseases or disorders that affect multiple body organs resulting to increased morbidity and premature death.\n\n\n## 1.2. Pathophysiology\n\n\nIn  people that are healthy (not living with diabetes), the pancreas secretes digestive enzymes and the hormones insulin and glucagon into the bloodstream to control the amount of glucose in the body. The release of insulin into the blood lowers the level of blood glucose by allowing glucose to enter the body cells, where it is metabolized leading to normal blood glucose levels. If blood glucose levels get too low, the pancreas secretes glucagon to stimulate the release of glucose from the liver, thus raising the levels of blood glucose to normal. This process is explained in figure 1.\n\n\nFigure 1: Glucose homeostasis in diabetes mellitus\n\n\n![17 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS](images/picture_012_page_17.png)\n\n\nSource: Adapted from IDF Education Modules, 2011\n\n\nWhen this normal body process is affected, as it happens in children and young adults due to pancreatic islet B cell destruction predominantly by an autoimmune process or from insulin resistance or insufficient insulin secretion, diabetes sets in. The process of glucose homeostasis in diabetes mellitus is explained as it happens in adults or obese children and adolescents in figure 2.\n\n\nFigure 2: Glucose homeostasis in diabetes mellitus\n\n\n![1.2.1.  Pathogenesis and pathophysiology of type 1 diabetes](images/picture_013_page_18.png)\n\n\nSource: Adapted from IDF Education Modules, 2011\n\n\n### 1.2.1. Pathogenesis and pathophysiology of type 1 diabetes\n\n\nType 1 diabetes mellitus is a chronic autoimmune disease associated with selective destruction of insulin-producing pancreatic β-cells leading to deficiency in insulin secretion. Deficiency in insulin leads to: -\n\n\n- i. Increased hepatic glycogenolysis and impaired non-hepatic glucose utilization (in skeletal and adipose tissue) leading to elevated plasma glucose levels\n- ii. When the capacity of the kidneys to reabsorb glucose is surpassed, glucosuria ensues (glucose loss via urine). Glucosuria leads to: -\n- osmotic\tdiuresis\tleading\tto\twater\tand\telectrolyte\tloss\t(polyuria)\n- increased\tthirst\t(polydipsia)\n- caloric\tloss\tleading\tto\tincreased\tappetite\tand\tfood\tintake\t(polyphagia)\n- iii. Uncontrolled lipolysis leads to elevated levels of free fatty acids (FFA) in the plasma. Oxidation of these FFAs leads to generation of ketone bodies\n- iv. Increased proteolysis with weight loss\n\n\n### 1.2.2. Pathogenesis and pathophysiology of type 2 diabetes\n\n\nThe pathogenesis of type 2 diabetes mellitus is characterized by:\n\n\n- Impaired\tinsulin\tsecretion:\tan\tislet\tcell\tdysfunction\tin\twhich\tthe reciprocal relationship between the glucagon-secreting alpha cell and the insulin-secreting beta cell is lost, leading to reduced insulin production in response to increased blood glucose. However, individuals with Type 2 diabetes have detectable levels of circulating insulin, unlike patients with Type 1 diabetes.\n- Peripheral\tinsulin\tresistance:\tleads\tto\tdecreased\tglucose\ttransport\tinto muscle cells, elevated hepatic glucose production, and increased breakdown of fat.\n\n\nFigure 3: Natural History of type 2 diabetes\n\n\n![Source: IDF education modules 2011 (Adapted from Ramlo-Halsted BA,](images/picture_014_page_19.png)\n\n\nSource: IDF education modules 2011 (Adapted from Ramlo-Halsted BA,\n\n\nEdelman SV. Prim Care, 1999; 26:771-789\n\n\n## 1.3. Diagnosis of diabetes\n\n\n**Signs and symptoms**\n\n\nMany of the signs and symptoms of diabetes are often missed or treated as common ailments. Patients with type 2 diabetes may present with established chronic complications of diabetes which need to be looked out for in the history and examination.\n\n\nTable 1: Signs and Symptoms of Diabetes\n\n\n| More Common                                         | Less Common            | Severe (Diabetic ketoacidosis)              |\n|-----------------------------------------------------|------------------------|---------------------------------------------|\n| Weight loss                                         | Excessive hunger       | Frequent vomiting and acute abdominal pain  |\n| Polyuria - in younger children bedwetting is common | Blurred vision         | Acetone smell on breath                     |\n| Excessive thirst                                    | Mood changes           | Dehydration with continuing polyuria        |\n| Tiredness/fatigue                                   | Skin infections        | Decreased level of consciousness            |\n|                                                     | Oral or vaginal thrush | Kussmaul respiration (deep, rapid, sighing) |\n|                                                     | Abdominal pain         | Coma Shock                                  |\n\n\nSource: 2012 SEMDSA Guidelines for the Management of Type 2 Diabetes\n\n\nDiabetes may be diagnosed based on plasma glucose criteria, either the fasting plasma glucose (FPG) or the 2-hour plasma glucose (2-h PG) value after a 75-g oral glucose tolerance test (OGTT), glycosylated hemoglobin (HbA1c) criteria.\n\n\nTable 2: Diagnostic criteria for Diabetes and pre-diabetes\n\n\n| Test                                                       | Intermediate hyperg ycaemia     | Diabetes                |\n|------------------------------------------------------------|---------------------------------|-------------------------|\n| Fasting glucose                                            | 6.1-7.0 mmol/L (100-125 mg/dL)  | 7.0 mmol/L (126 mg/dL)  |\n| OR 2-hour glucose following ingestion of 75-g glucose load | 7.8-11.0 mmol/L (140-199 mg/dL) | 11.1 mmol/L (200 mg/dL) |\n| OR random plasma glucose in symptomatic patient            |                                 | (200 mg/dL)             |\n| OR HbA1c                                                   |                                 |                         |\n\n\nFasting is defined as no caloric intake for at least 8 hours.\n\n\nThe HbA1c test should be performed in a laboratory using a method that is NGSP-certified and standardized to the Diabetes Control and Complications Trial assay.\n\n\nThe 2-hour postprandial glucose test should be performed using a glucose load containing the equivalent of 75-g anhydrous glucose dissolved in water.\n\n\nSource: IDF Clinical practice recommendations for managing type 2 diabetes in primary care, 2017\n\n\n**Diagnostic cascade for Type 2 Diabetes**\n\n\nFigure 4: Diagnostic cascade for type 2 diabetes\n\n\n![KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS| 22](images/picture_015_page_22.png)\n\n\nSource: TB/DM Bidirectional screening and treatment charts, MOH, 2018\n\n\n## 1.4. Classification of Diabetes Mellitus\n\n\nThe classification of diabetes has been revised by the WHO and is based on aetiology (table 4).\n\n\nTable 3: The main types of Diabetes\n\n\n\n\n| Type                         | Characteristics                                                                                                                                                                                                                                                                                                                                                                            |\n|------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Type 1 diabetes              | Most commonly results from autoimmune destruction of the pancreatic beta cells leading to absolute insulin deficiency. Insulin is required for survival. May present from 6 months of age but usually presents in childhood, adolescence and young adults. Occasionally Type 1 Diabetes may present at a later age and this is referred to as Latent Autoimmune Diabetes in Adults (LADA). |\n| Type 2 diabetes:             | Characteriz ed by progressive loss of b-cell insulin secretion frequently on the background of insulin resistance. It is the most common type of diabetes. More common among adults but is increasingly being diagnosed in a younger population due to overweight/obesity. Many patients with Type 2 diabetes are asymptomatic.                                                            |\n| estational diabetes mel itus | Diabetes diagnosed in the second or third trimester in a woman who was previously not known to have diabetes. It is often asymptomatic, and has to be screened for. Associated with poor pregnancy outcomes, especially if unrecogniz ed and untreated. It usually resolves after delivery.                                                                                                |\n| Other types of Diabetes      | These are less common and include genetic disorders, infections, and diseases of the exocrine pancreas (pancreatitis, Ca pancreas), endocrinopathies (thyrotoxicosis, Cushing's syndrome, acromegaly,) o as a result of drugs (corticosteroids. anti-psychotics, HAART)                                                                                                                    |\n\n\nTable 4: Differences in type 1 and type 2 diabetes at diagnosis (clinical presentation, patient characteristics and pathogenesis)\n\n\n| Characteristic                       | Type 1                                                  | Type 2                                                                                                                                                                                        |\n|--------------------------------------|---------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Onset                                | Sudden, acute or sub-acute                              | Slow, insidious onset, progressive disease. Patient could be undiagnosed for years.                                                                                                           |\n| Age                                  | Usually < 30-35 years                                   | Older patients > 35 years*                                                                                                                                                                    |\n| Typical symptoms                     | Moderate to severe symptoms of diabetes present         | Person often asymptomatic because of slow onset of the disease; asymptomatic glucosuria present                                                                                               |\n| Weight                               | Lean, often rapid weight loss be- fore diagnosis        | Normal to overweight at diagnosis                                                                                                                                                             |\n| Insulin secretion                    | Insulin deficient, needs insulin treatment at diagnosis | Initially inadequate insulin secretion, with pro- gressive deficiency over time                                                                                                               |\n| Chronic complica- tions at diagnosis | Not common                                              | Common because of late diagnosis.                                                                                                                                                             |\n| Insulin resistance                   | Absent                                                  | Present                                                                                                                                                                                       |\n| Ketosis                              | Yes, often diagnosed in Ketoaci- dosis                  | Not as common as in type 1                                                                                                                                                                    |\n| C peptide levels                     | Very low or absent                                      | Normal or reduced                                                                                                                                                                             |\n| Immune markers                       | Autoimmune disease: anti-GAD, ICA, 1A-2                 | Absence of auto-immune markers                                                                                                                                                                |\n| Heredity                             | Less common                                             | More common                                                                                                                                                                                   |\n| Metabolic syndrome                   | Absent                                                  | Present; a cluster of cardiovascular disease risk factors often present, e.g. hypertension, dyslip- idaemia, abdominal obesity, insulin resistance, microalbuminuria, and hypercoagulability. |\n| Treatment                            | Insulin therapy                                         | Initially: lifestyle changes +/- oral glucose low- ering agents, +/- Insulin                                                                                                                  |\n| Acute complica- tions                | DKA Hypoglycemia- associated with treatment             | HHS May get DKA Hypoglycemia: Associated with treatment                                                                                                                                       |\n| Chronic complica- tions of Diabetes  | More prone to micro-vascular complications              | High risk for macro-vascular diabetes: compli- cations; also develops micro-vascular compli- cations as disease progresses.                                                                   |\n\n\n* Consider Type 2 DM in obese younger patients with elevated sugars that do not present like Type 1 DM\n\n\nSource: Kenya National Diabetes Educators Manual, 2010\n\n\n## 1.5. Risk Factors\n\n\nIn view of the significant rise in the prevalence of diabetes in Kenya, its well-recognized morbidity, premature mortality, increasing health costs and awareness of its risk factors is an important step towards its control and prevention. The risk factors for type 2 diabetes are categorized into modifiable and non-modifiable as shown in the table 1 below. Type 2 diabetes is also found in obese children. Risk factors for type 1 Diabetes are not clearly known.\n\n\nTable 5: Modifiable and Non-Modifiable Risk factors for type 2 Diabetes\n\n\n| Modifiable                                                                     | Non-Modifiable                                               |\n|--------------------------------------------------------------------------------|--------------------------------------------------------------|\n| Overweight and Obesity                                                         | Age (>40 yrs.)                                               |\n| Physical inactivity                                                            | First degree relative with diabetes/genetic predispo- sition |\n| Unhealthy diets- high in refined sugars, fats and low in fruits and vegetables | Polycystic Ovarian Syndrome (PCOS)                           |\n| Impaired glucose tolerance /Impaired fasting glycaemia                         | Previous gestational diabetes or large babies (>4 kg)        |\n| Dyslipidaemia                                                                  | African and Asian                                            |\n| Alcohol abuse and tobacco use                                                  |                                                              |\n| Hypertension                                                                   |                                                              |\n\n\n## 1.6. Screening for Diabetes Mellitus type 2\n\n\nConsidering  the  insidious  nature  of  diabetes  symptoms,  misdiagnosis  and  the  poor health seeking behaviour of the population, screening and early diagnosis are crucial to reducing morbidity and mortality related to Diabetes.\n\n\n**Who to screen:**\n\n\nScreening should be considered:\n\n\n1. For all individuals with any risk factors\n2. Across all populations using the relevant cut-offs\n\n\nTable 6: Screening criteria for Diabetes\n\n\n|   Sno. | Population group/Risk                                                                                      | Parameters                                                                                        |\n|--------|------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|\n|      1 | Overweight or obese (adults and children)                                                                  | BMI ≥25                                                                                           |\n|      2 | First-degree relative with diabetes                                                                        |                                                                                                   |\n|      3 | Women previously diagnosed with GDMor delivered a baby weighing > 4 kg                                     |                                                                                                   |\n|      4 | History of Cardiovascular disease                                                                          |                                                                                                   |\n|      5 | Hypertension                                                                                               | Blood pressure ≥ 140/90 mmHg or on thera- py for hypertension                                     |\n|      6 | Blood lipids ● HDL ● Triglyceride ● LDL                                                                    | <35 mg/dL (0.90 mmol/L) >250 mg/dL (>2.82 mmol/L) < 100 mg/dL (<2.59 mmol/L)                      |\n|      7 | Women with polycystic ovary syndrome                                                                       |                                                                                                   |\n|      8 | Physical inactivity                                                                                        | <150 minutes of moderate activity per week                                                        |\n|      9 | Other clinical conditions associated with insu- lin resistance (e.g. severe obesity, acanthosis nigricans) |                                                                                                   |\n|     10 | Unhealthy diets                                                                                            | Foods low in fibre content, foods high in refined sugar, low consumption of fruits and vegetables |\n\n\nIf screening results are normal, testing should be repeated annually, with consideration of risk status.\n\n\nSource: American Diabetes Association. Classification and diagnosis of diabetes, 2017\n\n\nCHAPTER TWO\n\n\nOPHTHALMOLOGY\n\n\n27 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS\n\n\nCONSILTA\n\n\n",
        "startLine": 736,
        "endLine": 989,
        "introContent": null,
        "sections": [
          {
            "id": "section-1-1",
            "level": "h2",
            "number": "1.1",
            "title": "1.1. Definition",
            "slug": "11-definition",
            "url": "/guidelines/chapter-one-introduction-to-diabetes/11-definition",
            "parentId": "chapter-1",
            "breadcrumb": [
              "CHAPTER ONE: INTRODUCTION TO DIABETES",
              "1.1. Definition"
            ],
            "tokenCount": 71,
            "content": "## 1.1. Definition\n\n\nDiabetes mellitus is a chronic metabolic disorder characterized by sustained elevated blood glucose (hyperglycemia) resulting from defects in insulin secretion, action or both. Diabetes, if not well controlled leads to serious complications, resulting in multiple diseases or disorders that affect multiple body organs resulting to increased morbidity and premature death.\n\n\n",
            "startLine": 739,
            "endLine": 744,
            "introContent": null,
            "keywords": [],
            "subsections": null
          },
          {
            "id": "section-1-2",
            "level": "h2",
            "number": "1.2",
            "title": "1.2. Pathophysiology",
            "slug": "12-pathophysiology",
            "url": "/guidelines/chapter-one-introduction-to-diabetes/12-pathophysiology",
            "parentId": "chapter-1",
            "breadcrumb": [
              "CHAPTER ONE: INTRODUCTION TO DIABETES",
              "1.2. Pathophysiology"
            ],
            "tokenCount": 784,
            "content": "## 1.2. Pathophysiology\n\n\nIn  people that are healthy (not living with diabetes), the pancreas secretes digestive enzymes and the hormones insulin and glucagon into the bloodstream to control the amount of glucose in the body. The release of insulin into the blood lowers the level of blood glucose by allowing glucose to enter the body cells, where it is metabolized leading to normal blood glucose levels. If blood glucose levels get too low, the pancreas secretes glucagon to stimulate the release of glucose from the liver, thus raising the levels of blood glucose to normal. This process is explained in figure 1.\n\n\nFigure 1: Glucose homeostasis in diabetes mellitus\n\n\n![17 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS](images/picture_012_page_17.png)\n\n\nSource: Adapted from IDF Education Modules, 2011\n\n\nWhen this normal body process is affected, as it happens in children and young adults due to pancreatic islet B cell destruction predominantly by an autoimmune process or from insulin resistance or insufficient insulin secretion, diabetes sets in. The process of glucose homeostasis in diabetes mellitus is explained as it happens in adults or obese children and adolescents in figure 2.\n\n\nFigure 2: Glucose homeostasis in diabetes mellitus\n\n\n![1.2.1.  Pathogenesis and pathophysiology of type 1 diabetes](images/picture_013_page_18.png)\n\n\nSource: Adapted from IDF Education Modules, 2011\n\n\n### 1.2.1. Pathogenesis and pathophysiology of type 1 diabetes\n\n\nType 1 diabetes mellitus is a chronic autoimmune disease associated with selective destruction of insulin-producing pancreatic β-cells leading to deficiency in insulin secretion. Deficiency in insulin leads to: -\n\n\n- i. Increased hepatic glycogenolysis and impaired non-hepatic glucose utilization (in skeletal and adipose tissue) leading to elevated plasma glucose levels\n- ii. When the capacity of the kidneys to reabsorb glucose is surpassed, glucosuria ensues (glucose loss via urine). Glucosuria leads to: -\n- osmotic\tdiuresis\tleading\tto\twater\tand\telectrolyte\tloss\t(polyuria)\n- increased\tthirst\t(polydipsia)\n- caloric\tloss\tleading\tto\tincreased\tappetite\tand\tfood\tintake\t(polyphagia)\n- iii. Uncontrolled lipolysis leads to elevated levels of free fatty acids (FFA) in the plasma. Oxidation of these FFAs leads to generation of ketone bodies\n- iv. Increased proteolysis with weight loss\n\n\n### 1.2.2. Pathogenesis and pathophysiology of type 2 diabetes\n\n\nThe pathogenesis of type 2 diabetes mellitus is characterized by:\n\n\n- Impaired\tinsulin\tsecretion:\tan\tislet\tcell\tdysfunction\tin\twhich\tthe reciprocal relationship between the glucagon-secreting alpha cell and the insulin-secreting beta cell is lost, leading to reduced insulin production in response to increased blood glucose. However, individuals with Type 2 diabetes have detectable levels of circulating insulin, unlike patients with Type 1 diabetes.\n- Peripheral\tinsulin\tresistance:\tleads\tto\tdecreased\tglucose\ttransport\tinto muscle cells, elevated hepatic glucose production, and increased breakdown of fat.\n\n\nFigure 3: Natural History of type 2 diabetes\n\n\n![Source: IDF education modules 2011 (Adapted from Ramlo-Halsted BA,](images/picture_014_page_19.png)\n\n\nSource: IDF education modules 2011 (Adapted from Ramlo-Halsted BA,\n\n\nEdelman SV. Prim Care, 1999; 26:771-789\n\n\n",
            "startLine": 745,
            "endLine": 808,
            "introContent": {
              "content": "In  people that are healthy (not living with diabetes), the pancreas secretes digestive enzymes and the hormones insulin and glucagon into the bloodstream to control the amount of glucose in the body. The release of insulin into the blood lowers the level of blood glucose by allowing glucose to enter the body cells, where it is metabolized leading to normal blood glucose levels. If blood glucose levels get too low, the pancreas secretes glucagon to stimulate the release of glucose from the liver, thus raising the levels of blood glucose to normal. This process is explained in figure 1.\n\n\nFigure 1: Glucose homeostasis in diabetes mellitus\n\n\n![17 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS](images/picture_012_page_17.png)\n\n\nSource: Adapted from IDF Education Modules, 2011\n\n\nWhen this normal body process is affected, as it happens in children and young adults due to pancreatic islet B cell destruction predominantly by an autoimmune process or from insulin resistance or insufficient insulin secretion, diabetes sets in. The process of glucose homeostasis in diabetes mellitus is explained as it happens in adults or obese children and adolescents in figure 2.\n\n\nFigure 2: Glucose homeostasis in diabetes mellitus\n\n\n![1.2.1.  Pathogenesis and pathophysiology of type 1 diabetes](images/picture_013_page_18.png)\n\n\nSource: Adapted from IDF Education Modules, 2011",
              "tokenCount": 305,
              "startLine": 746,
              "endLine": 771
            },
            "keywords": [],
            "subsections": [
              {
                "id": "subsection-1-2-1",
                "level": "h3",
                "number": "1.2.1",
                "title": "1.2.1. Pathogenesis and pathophysiology of type 1 diabetes",
                "slug": "121-pathogenesis-and-pathophysiology-of-type-1-diabetes",
                "url": "/guidelines/12-pathophysiology/121-pathogenesis-and-pathophysiology-of-type-1-diabetes",
                "parentId": "section-1-2",
                "breadcrumb": [
                  "CHAPTER ONE: INTRODUCTION TO DIABETES",
                  "1.2. Pathophysiology",
                  "1.2.1. Pathogenesis and pathophysiology of type 1 diabetes"
                ],
                "tokenCount": 238,
                "content": "### 1.2.1. Pathogenesis and pathophysiology of type 1 diabetes\n\n\nType 1 diabetes mellitus is a chronic autoimmune disease associated with selective destruction of insulin-producing pancreatic β-cells leading to deficiency in insulin secretion. Deficiency in insulin leads to: -\n\n\n- i. Increased hepatic glycogenolysis and impaired non-hepatic glucose utilization (in skeletal and adipose tissue) leading to elevated plasma glucose levels\n- ii. When the capacity of the kidneys to reabsorb glucose is surpassed, glucosuria ensues (glucose loss via urine). Glucosuria leads to: -\n- osmotic\tdiuresis\tleading\tto\twater\tand\telectrolyte\tloss\t(polyuria)\n- increased\tthirst\t(polydipsia)\n- caloric\tloss\tleading\tto\tincreased\tappetite\tand\tfood\tintake\t(polyphagia)\n- iii. Uncontrolled lipolysis leads to elevated levels of free fatty acids (FFA) in the plasma. Oxidation of these FFAs leads to generation of ketone bodies\n- iv. Increased proteolysis with weight loss\n\n\n",
                "startLine": 772,
                "endLine": 786,
                "introContent": null,
                "keywords": [],
                "subsections": null
              },
              {
                "id": "subsection-1-2-2",
                "level": "h3",
                "number": "1.2.2",
                "title": "1.2.2. Pathogenesis and pathophysiology of type 2 diabetes",
                "slug": "122-pathogenesis-and-pathophysiology-of-type-2-diabetes",
                "url": "/guidelines/12-pathophysiology/122-pathogenesis-and-pathophysiology-of-type-2-diabetes",
                "parentId": "section-1-2",
                "breadcrumb": [
                  "CHAPTER ONE: INTRODUCTION TO DIABETES",
                  "1.2. Pathophysiology",
                  "1.2.2. Pathogenesis and pathophysiology of type 2 diabetes"
                ],
                "tokenCount": 230,
                "content": "### 1.2.2. Pathogenesis and pathophysiology of type 2 diabetes\n\n\nThe pathogenesis of type 2 diabetes mellitus is characterized by:\n\n\n- Impaired\tinsulin\tsecretion:\tan\tislet\tcell\tdysfunction\tin\twhich\tthe reciprocal relationship between the glucagon-secreting alpha cell and the insulin-secreting beta cell is lost, leading to reduced insulin production in response to increased blood glucose. However, individuals with Type 2 diabetes have detectable levels of circulating insulin, unlike patients with Type 1 diabetes.\n- Peripheral\tinsulin\tresistance:\tleads\tto\tdecreased\tglucose\ttransport\tinto muscle cells, elevated hepatic glucose production, and increased breakdown of fat.\n\n\nFigure 3: Natural History of type 2 diabetes\n\n\n![Source: IDF education modules 2011 (Adapted from Ramlo-Halsted BA,](images/picture_014_page_19.png)\n\n\nSource: IDF education modules 2011 (Adapted from Ramlo-Halsted BA,\n\n\nEdelman SV. Prim Care, 1999; 26:771-789\n\n\n",
                "startLine": 787,
                "endLine": 808,
                "introContent": null,
                "keywords": [],
                "subsections": null
              }
            ]
          },
          {
            "id": "section-1-3",
            "level": "h2",
            "number": "1.3",
            "title": "1.3. Diagnosis of diabetes",
            "slug": "13-diagnosis-of-diabetes",
            "url": "/guidelines/chapter-one-introduction-to-diabetes/13-diagnosis-of-diabetes",
            "parentId": "chapter-1",
            "breadcrumb": [
              "CHAPTER ONE: INTRODUCTION TO DIABETES",
              "1.3. Diagnosis of diabetes"
            ],
            "tokenCount": 645,
            "content": "## 1.3. Diagnosis of diabetes\n\n\n**Signs and symptoms**\n\n\nMany of the signs and symptoms of diabetes are often missed or treated as common ailments. Patients with type 2 diabetes may present with established chronic complications of diabetes which need to be looked out for in the history and examination.\n\n\nTable 1: Signs and Symptoms of Diabetes\n\n\n| More Common                                         | Less Common            | Severe (Diabetic ketoacidosis)              |\n|-----------------------------------------------------|------------------------|---------------------------------------------|\n| Weight loss                                         | Excessive hunger       | Frequent vomiting and acute abdominal pain  |\n| Polyuria - in younger children bedwetting is common | Blurred vision         | Acetone smell on breath                     |\n| Excessive thirst                                    | Mood changes           | Dehydration with continuing polyuria        |\n| Tiredness/fatigue                                   | Skin infections        | Decreased level of consciousness            |\n|                                                     | Oral or vaginal thrush | Kussmaul respiration (deep, rapid, sighing) |\n|                                                     | Abdominal pain         | Coma Shock                                  |\n\n\nSource: 2012 SEMDSA Guidelines for the Management of Type 2 Diabetes\n\n\nDiabetes may be diagnosed based on plasma glucose criteria, either the fasting plasma glucose (FPG) or the 2-hour plasma glucose (2-h PG) value after a 75-g oral glucose tolerance test (OGTT), glycosylated hemoglobin (HbA1c) criteria.\n\n\nTable 2: Diagnostic criteria for Diabetes and pre-diabetes\n\n\n| Test                                                       | Intermediate hyperg ycaemia     | Diabetes                |\n|------------------------------------------------------------|---------------------------------|-------------------------|\n| Fasting glucose                                            | 6.1-7.0 mmol/L (100-125 mg/dL)  | 7.0 mmol/L (126 mg/dL)  |\n| OR 2-hour glucose following ingestion of 75-g glucose load | 7.8-11.0 mmol/L (140-199 mg/dL) | 11.1 mmol/L (200 mg/dL) |\n| OR random plasma glucose in symptomatic patient            |                                 | (200 mg/dL)             |\n| OR HbA1c                                                   |                                 |                         |\n\n\nFasting is defined as no caloric intake for at least 8 hours.\n\n\nThe HbA1c test should be performed in a laboratory using a method that is NGSP-certified and standardized to the Diabetes Control and Complications Trial assay.\n\n\nThe 2-hour postprandial glucose test should be performed using a glucose load containing the equivalent of 75-g anhydrous glucose dissolved in water.\n\n\nSource: IDF Clinical practice recommendations for managing type 2 diabetes in primary care, 2017\n\n\n**Diagnostic cascade for Type 2 Diabetes**\n\n\nFigure 4: Diagnostic cascade for type 2 diabetes\n\n\n![KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS| 22](images/picture_015_page_22.png)\n\n\nSource: TB/DM Bidirectional screening and treatment charts, MOH, 2018\n\n\n",
            "startLine": 809,
            "endLine": 871,
            "introContent": null,
            "keywords": [],
            "subsections": null
          },
          {
            "id": "section-1-4",
            "level": "h2",
            "number": "1.4",
            "title": "1.4. Classification of Diabetes Mellitus",
            "slug": "14-classification-of-diabetes-mellitus",
            "url": "/guidelines/chapter-one-introduction-to-diabetes/14-classification-of-diabetes-mellitus",
            "parentId": "chapter-1",
            "breadcrumb": [
              "CHAPTER ONE: INTRODUCTION TO DIABETES",
              "1.4. Classification of Diabetes Mellitus"
            ],
            "tokenCount": 904,
            "content": "## 1.4. Classification of Diabetes Mellitus\n\n\nThe classification of diabetes has been revised by the WHO and is based on aetiology (table 4).\n\n\nTable 3: The main types of Diabetes\n\n\n\n\n| Type                         | Characteristics                                                                                                                                                                                                                                                                                                                                                                            |\n|------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Type 1 diabetes              | Most commonly results from autoimmune destruction of the pancreatic beta cells leading to absolute insulin deficiency. Insulin is required for survival. May present from 6 months of age but usually presents in childhood, adolescence and young adults. Occasionally Type 1 Diabetes may present at a later age and this is referred to as Latent Autoimmune Diabetes in Adults (LADA). |\n| Type 2 diabetes:             | Characteriz ed by progressive loss of b-cell insulin secretion frequently on the background of insulin resistance. It is the most common type of diabetes. More common among adults but is increasingly being diagnosed in a younger population due to overweight/obesity. Many patients with Type 2 diabetes are asymptomatic.                                                            |\n| estational diabetes mel itus | Diabetes diagnosed in the second or third trimester in a woman who was previously not known to have diabetes. It is often asymptomatic, and has to be screened for. Associated with poor pregnancy outcomes, especially if unrecogniz ed and untreated. It usually resolves after delivery.                                                                                                |\n| Other types of Diabetes      | These are less common and include genetic disorders, infections, and diseases of the exocrine pancreas (pancreatitis, Ca pancreas), endocrinopathies (thyrotoxicosis, Cushing's syndrome, acromegaly,) o as a result of drugs (corticosteroids. anti-psychotics, HAART)                                                                                                                    |\n\n\nTable 4: Differences in type 1 and type 2 diabetes at diagnosis (clinical presentation, patient characteristics and pathogenesis)\n\n\n| Characteristic                       | Type 1                                                  | Type 2                                                                                                                                                                                        |\n|--------------------------------------|---------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Onset                                | Sudden, acute or sub-acute                              | Slow, insidious onset, progressive disease. Patient could be undiagnosed for years.                                                                                                           |\n| Age                                  | Usually < 30-35 years                                   | Older patients > 35 years*                                                                                                                                                                    |\n| Typical symptoms                     | Moderate to severe symptoms of diabetes present         | Person often asymptomatic because of slow onset of the disease; asymptomatic glucosuria present                                                                                               |\n| Weight                               | Lean, often rapid weight loss be- fore diagnosis        | Normal to overweight at diagnosis                                                                                                                                                             |\n| Insulin secretion                    | Insulin deficient, needs insulin treatment at diagnosis | Initially inadequate insulin secretion, with pro- gressive deficiency over time                                                                                                               |\n| Chronic complica- tions at diagnosis | Not common                                              | Common because of late diagnosis.                                                                                                                                                             |\n| Insulin resistance                   | Absent                                                  | Present                                                                                                                                                                                       |\n| Ketosis                              | Yes, often diagnosed in Ketoaci- dosis                  | Not as common as in type 1                                                                                                                                                                    |\n| C peptide levels                     | Very low or absent                                      | Normal or reduced                                                                                                                                                                             |\n| Immune markers                       | Autoimmune disease: anti-GAD, ICA, 1A-2                 | Absence of auto-immune markers                                                                                                                                                                |\n| Heredity                             | Less common                                             | More common                                                                                                                                                                                   |\n| Metabolic syndrome                   | Absent                                                  | Present; a cluster of cardiovascular disease risk factors often present, e.g. hypertension, dyslip- idaemia, abdominal obesity, insulin resistance, microalbuminuria, and hypercoagulability. |\n| Treatment                            | Insulin therapy                                         | Initially: lifestyle changes +/- oral glucose low- ering agents, +/- Insulin                                                                                                                  |\n| Acute complica- tions                | DKA Hypoglycemia- associated with treatment             | HHS May get DKA Hypoglycemia: Associated with treatment                                                                                                                                       |\n| Chronic complica- tions of Diabetes  | More prone to micro-vascular complications              | High risk for macro-vascular diabetes: compli- cations; also develops micro-vascular compli- cations as disease progresses.                                                                   |\n\n\n* Consider Type 2 DM in obese younger patients with elevated sugars that do not present like Type 1 DM\n\n\nSource: Kenya National Diabetes Educators Manual, 2010\n\n\n",
            "startLine": 872,
            "endLine": 918,
            "introContent": null,
            "keywords": [],
            "subsections": null
          },
          {
            "id": "section-1-5",
            "level": "h2",
            "number": "1.5",
            "title": "1.5. Risk Factors",
            "slug": "15-risk-factors",
            "url": "/guidelines/chapter-one-introduction-to-diabetes/15-risk-factors",
            "parentId": "chapter-1",
            "breadcrumb": [
              "CHAPTER ONE: INTRODUCTION TO DIABETES",
              "1.5. Risk Factors"
            ],
            "tokenCount": 260,
            "content": "## 1.5. Risk Factors\n\n\nIn view of the significant rise in the prevalence of diabetes in Kenya, its well-recognized morbidity, premature mortality, increasing health costs and awareness of its risk factors is an important step towards its control and prevention. The risk factors for type 2 diabetes are categorized into modifiable and non-modifiable as shown in the table 1 below. Type 2 diabetes is also found in obese children. Risk factors for type 1 Diabetes are not clearly known.\n\n\nTable 5: Modifiable and Non-Modifiable Risk factors for type 2 Diabetes\n\n\n| Modifiable                                                                     | Non-Modifiable                                               |\n|--------------------------------------------------------------------------------|--------------------------------------------------------------|\n| Overweight and Obesity                                                         | Age (>40 yrs.)                                               |\n| Physical inactivity                                                            | First degree relative with diabetes/genetic predispo- sition |\n| Unhealthy diets- high in refined sugars, fats and low in fruits and vegetables | Polycystic Ovarian Syndrome (PCOS)                           |\n| Impaired glucose tolerance /Impaired fasting glycaemia                         | Previous gestational diabetes or large babies (>4 kg)        |\n| Dyslipidaemia                                                                  | African and Asian                                            |\n| Alcohol abuse and tobacco use                                                  |                                                              |\n| Hypertension                                                                   |                                                              |\n\n\n",
            "startLine": 919,
            "endLine": 938,
            "introContent": null,
            "keywords": [],
            "subsections": null
          },
          {
            "id": "section-1-6",
            "level": "h2",
            "number": "1.6",
            "title": "1.6. Screening for Diabetes Mellitus type 2",
            "slug": "16-screening-for-diabetes-mellitus-type-2",
            "url": "/guidelines/chapter-one-introduction-to-diabetes/16-screening-for-diabetes-mellitus-type-2",
            "parentId": "chapter-1",
            "breadcrumb": [
              "CHAPTER ONE: INTRODUCTION TO DIABETES",
              "1.6. Screening for Diabetes Mellitus type 2"
            ],
            "tokenCount": 473,
            "content": "## 1.6. Screening for Diabetes Mellitus type 2\n\n\nConsidering  the  insidious  nature  of  diabetes  symptoms,  misdiagnosis  and  the  poor health seeking behaviour of the population, screening and early diagnosis are crucial to reducing morbidity and mortality related to Diabetes.\n\n\n**Who to screen:**\n\n\nScreening should be considered:\n\n\n1. For all individuals with any risk factors\n2. Across all populations using the relevant cut-offs\n\n\nTable 6: Screening criteria for Diabetes\n\n\n|   Sno. | Population group/Risk                                                                                      | Parameters                                                                                        |\n|--------|------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|\n|      1 | Overweight or obese (adults and children)                                                                  | BMI ≥25                                                                                           |\n|      2 | First-degree relative with diabetes                                                                        |                                                                                                   |\n|      3 | Women previously diagnosed with GDMor delivered a baby weighing > 4 kg                                     |                                                                                                   |\n|      4 | History of Cardiovascular disease                                                                          |                                                                                                   |\n|      5 | Hypertension                                                                                               | Blood pressure ≥ 140/90 mmHg or on thera- py for hypertension                                     |\n|      6 | Blood lipids ● HDL ● Triglyceride ● LDL                                                                    | <35 mg/dL (0.90 mmol/L) >250 mg/dL (>2.82 mmol/L) < 100 mg/dL (<2.59 mmol/L)                      |\n|      7 | Women with polycystic ovary syndrome                                                                       |                                                                                                   |\n|      8 | Physical inactivity                                                                                        | <150 minutes of moderate activity per week                                                        |\n|      9 | Other clinical conditions associated with insu- lin resistance (e.g. severe obesity, acanthosis nigricans) |                                                                                                   |\n|     10 | Unhealthy diets                                                                                            | Foods low in fibre content, foods high in refined sugar, low consumption of fruits and vegetables |\n\n\nIf screening results are normal, testing should be repeated annually, with consideration of risk status.\n\n\nSource: American Diabetes Association. Classification and diagnosis of diabetes, 2017\n\n\nCHAPTER TWO\n\n\nOPHTHALMOLOGY\n\n\n27 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS\n\n\nCONSILTA\n\n\n",
            "startLine": 939,
            "endLine": 989,
            "introContent": null,
            "keywords": [],
            "subsections": null
          }
        ]
      },
      {
        "id": "chapter-2",
        "level": "h1",
        "number": "2",
        "title": "CHAPTER TWO: MANAGEMENT OF DIABETES",
        "slug": "chapter-two-management-of-diabetes",
        "url": "/guidelines/chapter-two-management-of-diabetes",
        "tokenCount": 22369,
        "summary": null,
        "content": "# CHAPTER TWO: MANAGEMENT OF DIABETES\n\n\n## 2.0. Introduction\n\n\nThe overall goal of diabetes management is to improve the quality of life and productivity of people living with diabetes, control comorbidities, and prevent complications by:\n\n\n- Early\tdiagnosis\n- Treatment\tto\ttarget\n- Regular\tscreening\tfor\tcomplications\tand\tcomorbid\tconditions\n- Education\ton\tdiabetes\tand\tcomplications,\tself-care\tand\tdiet\n- Community\tawareness\ton\tdiabetes\n- Establishing\tdiabetes\tcomprehensive\tcentres\tserved\tby\ta functional referral system\n- Having\ta\tmotivated,\tpassionate\tand\twell-educated\tdiabetes management team\n- Provision\tof\tessential\tcommodities\tand\ttechnologies\n\n\n## 2.1. Management of Type 1 Diabetes\n\n\nAll children and adolescents with type 1 diabetes require insulin. Poorly controlled type 1 diabetes increases the risk of stunted growth and diabetes complications, including diabetic ketoacidosis.\n\n\nComprehensive Type 1 diabetes management includes:\n\n\n- a) Insulin treatment\n- b) Blood glucose monitoring\n- c) HbA1c monitoring\n- d) Nutritional management and physical activity\n- e) Diabetes education\n6. f ) Rules for sick days\n- g) Psychosocial support\n8. A thorough clinical assessment of a patient with type 1 diabetes is recommended\n\n\nbefore initiating any therapy and during ongoing therapy.\n\n\nTable 7: Patient assessment at initial and follow-up visits\n\n\n|                                                                              | Initial visit   | Three- to six-monthly visits   | Annual visit   |\n|------------------------------------------------------------------------------|-----------------|--------------------------------|----------------|\n| History                                                                      |                 |                                |                |\n| Symptoms of hyperglycaemia, and duration of symptoms*                        | X               | X                              | X              |\n| Hypoglycaemic symptoms**                                                     |                 | X                              | X              |\n| Relevant family history                                                      | X               |                                |                |\n| Other risk factors (e.g. low or high birthweight)                            | X               |                                |                |\n| Relevant medical history                                                     |                 |                                |                |\n| - Co-morbid conditions (autoimmune diseases e.g. Thyroid)                    | X               |                                | X              |\n| - Symptoms of complications: visual, infection, foot, edema and palpitations | X               | X                              | X              |\n| Drugs                                                                        |                 |                                |                |\n| - Current (Side-effects and adherence)                                       | X               | X                              | X              |\n| - Allergies                                                                  | X               |                                | X              |\n| Hypoglycaemic symptoms**                                                     | X               | X                              | X              |\n| Vaccinations                                                                 |                 |                                |                |\n| - KEPI (date)                                                                | X               | X                              | X              |\n| - Influenza (date)                                                           | X               |                                | X              |\n| - Pneumococcal***                                                            | X               |                                |                |\n| Lifestyle                                                                    |                 |                                |                |\n| - Weight /height                                                             | X               |                                | X              |\n| - Physical activity                                                          | X               |                                | X              |\n| - Eating pattern and food availability                                       | X               | X                              | X              |\n| - Teenagers: Alcohol and drug use, tobac- co use                             | X               | X                              | X              |\n| - Sexual activity                                                            | X               | X                              | X              |\n| Psychosocial support                                                         |                 |                                |                |\n| - Family, school and the community support                                   | X               |                                | X              |\n| - Depression, anxiety and other mental disorders                             | X               | X                              | X              |\n| Education                                                                    |                 |                                |                |\n| - Level of education and school perfor- mance                                | X               | X                              | X              |\n| - Absenteeism per term                                                       | X               | X                              | X              |\n| - Family and community support (Parent                                       | X               |                                | X              |\n| Home monitoring of blood glucose (glucometer and strips; chart)              | X               | X                              | X              |\n| Physical examination                                                         |                 |                                |                |\n| Weight                                                                       | X               | X                              | X              |\n\n\n| Height                                                                             | Height                                                                                     | X   | X   | X   |\n|------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|-----|-----|-----|\n| Body mass index (BMI) for age and sex                                              | Body mass index (BMI) for age and sex                                                      | X   | X   | X   |\n| Mid upper arm circumference (MUAC)                                                 | Mid upper arm circumference (MUAC)                                                         | X   | X   | X   |\n| Tanner pubertal staging                                                            | Tanner pubertal staging                                                                    | X   | X   | X   |\n| Blood pressure (mmHg)                                                              | Blood pressure (mmHg)                                                                      | X   | X   | X   |\n| Injection sites assessment                                                         | Injection sites assessment                                                                 | X   | X   | X   |\n| Oral cavity                                                                        | Oral cavity                                                                                |     |     |     |\n| -                                                                                  | Dental caries                                                                              | X   |     | X   |\n| -                                                                                  | Gum disease                                                                                | X   |     | X   |\n| Eyes                                                                               | Eyes                                                                                       |     |     |     |\n| -                                                                                  | Visual acuity                                                                              | X   |     | X   |\n| -                                                                                  | Direct fundoscopy (dilated pupils), indi- rect fundoscopy, or fundus photographs           | X   |     | Xa  |\n| Special investigations                                                             | Special investigations                                                                     |     |     |     |\n| Blood tests                                                                        | Blood tests                                                                                |     |     |     |\n| -                                                                                  | Glucose                                                                                    | X   | X   | X   |\n| -                                                                                  | HbA1c                                                                                      |     |     |     |\n| -                                                                                  | (Six-monthly if at target, otherwise three- monthly. Also, whenever treatment is adjusted) | X   | X   | X   |\n| -                                                                                  | TSH                                                                                        | X   |     | X   |\n| -                                                                                  | Lipids: Total cholesterol, HDLcholester- ol, LDLcholesterol, triglycerides                 |     |     | X   |\n| -                                                                                  | Creatinine, and calculate estimated GFR                                                    |     |     | X   |\n| -                                                                                  | Potassium                                                                                  |     |     | X   |\n| -                                                                                  | HIV                                                                                        | X   |     | X   |\n| Urine                                                                              | Urine                                                                                      |     |     |     |\n| -                                                                                  | Glucose                                                                                    | X   |     | X   |\n| -                                                                                  | Ketones                                                                                    | X   |     | X   |\n| -                                                                                  | Protein (current g/lines albumin/creati- nine ratio)                                       |     |     | X   |\n| Other important tasks                                                              | Other important tasks                                                                      |     |     |     |\n| Education: Self-management and lifestyle ad- justment, including smoking cessation | Education: Self-management and lifestyle ad- justment, including smoking cessation         | X   | X   | X   |\n| Setting goals                                                                      | Setting goals                                                                              | X   | X   | X   |\n| Family planning for teenagers and preconception counselling                        | Family planning for teenagers and preconception counselling                                | X   |     | X   |\n| Medication revision/adjustment                                                     | Medication revision/adjustment                                                             | X   | X   | X   |\n\n\n\n\na Int erval for ret inop at y  sc reening c an b e inc reased t o onc e every 2 y ears if t h e last  2 ex am inat ions w ere norm al; m ore frequent ex am inat ions are required in t h e p resenc e of ab norm alit ies.\n\n\n\n\n* y m om of h y p erg ly aem ia inc lude p oly dip sia,  h eadac es,  b lurred vision,  p oly uria,  fat ig ue/ b ody  m alaise,  w eig t  loss ** S y m om s/ sig ns of H y p og ly em iaS ak iness,  nervousness or anx iet y ,  sw eat ing c ills and c lam y  ex rem it ies,  irrit onfusion,  inc luding delirium t ac y c ardia,  lig eadedness or diz z iness,  h ung er and nausea,  b lurred/ im aired vision,  t ing ling or num ness in t h e lip s or t ong ue,  h eadac es,  w eak ness or fat ig ue,  m ood c ang es,  lac of c oordinat ion,  nig ares or c ry ing out  during sleep ,  seiz ures,  loss of c onsc iousness\n\n\n\n\n6\n\n\n4\n\n\n\n\n*** neum oc oc al vac ine sh ould b e adm inist ered onc e. R evac inat ion is rec om ended for individuals &gt; y r. if vac inat ed &gt; y rs. ag o,  or p at ient s w it renal disease,  asp lenia and im unoc om rom ised st at es\n\n\nab\n\n\n5\n\n\n\n\n,\n\n\n\n\n,\n\n\n\n\nilit y ,\n\n\n### 2.1.1. Insulin treatment\n\n\n**Types of Insulin**\n\n\n**There are two broad categories of insulin: -**\n\n\n**1. Human Insulin- comes in three forms:**\n\n\n- Short-acting\t(regular/soluble)\tinsulin\n- Intermediate-acting\tinsulin-\te.g.\tNeutral\tprotamine\tHagedorn (NPH) insulin, Humulin N, Insulatard,\n- Pre-mix\tshort-acting\t(regular)\tand\tintermediate-acting\t(NPH) insulins - usually in the combination 70/30 (Mixtard, Humulin), Humulin 50/50\n\n\n**2. Analogue insulin**\n\n\n**Examples are:**\n\n\n- Rapid-acting\t-\te.g.\tHumalog,\tNovo\trapid,\tApidra\n- Long-acting\t-\te.g.\tLevemir,\tLantus\n- Pre-mix\t-\te.g.\tHumalog\t75/25,\tNoVo\tmix\t70/30\n\n\n**The two most common regimens used are:**\n\n\n- i.   Basal bolus regimen (the preferred option) - with short or rapid acting insulin given with main meals (usually three times per day) and intermediate-acting or long-acting insulin given once or twice daily (evening, or morning and evening).\n- ii.   Twice-daily insulin using pre-mixed insulin or short acting and NPH\n\n\nTable 8: Types of Insulin, mode of action and administration of Insulin\n\n\n| Insulin type           | Common Brand Names                                                                     | Onset of Action   | Peak of action       | Duration of action   | When to give              |\n|------------------------|----------------------------------------------------------------------------------------|-------------------|----------------------|----------------------|---------------------------|\n| Rapid acting           | Insulin lispro (Humalog), In- sulin glulisine (Apidra) and Insulin aspart (NoVo Rapid) | 15-30 minutes     | 1-2 hours            | 3-5 hours            | immediately prior to meal |\n| Short acting (soluble) | Actrapid, Hu- mulin R                                                                  | 30-60 minutes     | 2-4 hours            | 5-8 hours            | 30 minutes prior to meal  |\n| Intermediate acting    | NPH, Humulin N, Insulatard                                                             | 2-4 hours         | 4-10 hours           | 12-24 hours          | 30 minutes prior to meal  |\n| Long-acting            | Insulin detemir (Levemir)                                                              | 1-2 hours         | 6-12 hours           | 20-24 hours          | once or twice daily       |\n| Long-acting            | Insulin glargine (Lan- tus)                                                            | 2-4 hours         | relatively peak-less | 24 hours or less     | once daily                |\n| Mixed                  | Humulin 70/30 or Mixtard 70/30 Humalog 75/25                                           | 30 minutes        | 4-12 hours           | 8-24 hours           | 30 minutes prior to meal  |\n\n\n**Insulin requirements**\n\n\n- Pre-pubertal\tchildren\t(outside\tthe\tpartial\tremission\tphase)\tusually require 0.5-1.0 IU/kg/day.\n- During\tpuberty,\trequirements\tmay\trise\tsubstantially\tabove\t1\tand even up to 2 U/kg/day.\n- The\t''correct''\tdose\tof\tinsulin\tis\tthat\twhich\tachieves\tthe\tbest\tattainable glycaemic control for an individual child or adolescent, without causing obvious Hypoglycemia, and resulting in normal growth and development.\n\n\n**Initiating therapy in a child who is not in DKA**\n\n\nDuring insulin initiation, calculate a total daily dose of 0.5-0.75 U/kg/day. This can be given using either of the following regimens:\n\n\n- a. Basal bolus regimen\n- b. Twice-daily injections\n- C. Basal Bolus Regimen - also called Multiple Daily Injections (MDI). This is the preferred option.\n\n\n**This regimen can be given using two combinations**\n\n\n- Short-acting\tand\tlong-acting\tinsulin\tanalogues\n- Short-acting\tand\tintermediate-acting\tinsulin\tanalogues\n- i. Short-acting and long-acting insulin analogues If short-acting (soluble)/rapid acting and long-acting analogue insulins are used, give:\n- 60%\tof\tthe\ttotal\tdaily\tdose\tas\tshort-acting\t(soluble)\tinsulin\t(divided\tup between 3-4 pre-meal boluses)\n- 40%\tof\tthe\ttotal\tdaily\tdose\tas\ta\tsingle\tevening\tinjection\tof\tlong-acting analogue insulin. (Sometimes this dose does not last for 24 hours and then can be split into two doses - morning and evening).\n\n\n**Exampl e:**\n\n\nFor a 4 2-kg chil d who is started on 0 .5 U kg / day, the total daily dose is 21 units.\n\n\n/\n\n\nTable 9: Example of administration of short- and long-acting insulin as multiple daily injections\n\n\n|                  | Short-acting   | Long-acting   |\n|------------------|----------------|---------------|\n| Before breakfast | 4 Units        |               |\n| Before lunch     | 4 Units        |               |\n| Before dinner    | 4 Units        | 9 Units       |\n\n\n(rounded off to the nearest whole number).\n\n\nPre-meal doses can be adjusted depending on the size and frequency of the patient meals\n\n\n**ii. Short-acting and intermediate-acting insulin analogues**\n\n\nIf short-acting (soluble) and intermediate-acting insulin is used, give:\n\n\n- 70%\tof\tthe\ttotal\tdaily\tdose\tas\tshort-acting\t(soluble)\tinsulin (divided up between 3-4 pre-meal boluses)\n- 30%\tof\tthe\ttotal\tdaily\tdose\tas\ta\tsingle\tevening\tinjection\tof intermediate-acting insulin\n\n\n**Example:**\n\n\nFor a 42-kg child who is started on 0.5 U/kg/day , the total daily dose is 21 Units.\n\n\nTable 10: Example of administration of Short and Intermediate-acting Insulin as multiple daily injections. as multiple daily injections.\n\n\n|                  | Short-acting (soluble insulin) Intermediate-acting (NPH)   |         |\n|------------------|------------------------------------------------------------|---------|\n| Before breakfast | 5 Units                                                    |         |\n| Before lunch     | 5 Units                                                    |         |\n| Before dinner    | 5 Units                                                    | 6 Units |\n\n\n(rounded off to the nearest whole number)\n\n\nPre-meal doses can be adjusted depending on the size and frequency of the patient meals\n\n\nNB: In circumstances where meals are skipped or food is not available, Give the intermediate- acting insulin and skip the short acting insulin until the food is available. Do NOT completely stop insulin administration. Subsequently, doses can be adjusted daily according to blood glucose levels.\n\n\n**b. Twice daily injections**\n\n\nA starting point is to give two-thirds of the total daily insulin in the morning before breakfast and one-third before the evening meal. This may be given as pre-mixed insulin or short acting and intermediate acting insulin separately.\n\n\n**Example:**\n\n\nFor a 42-kg child who is started on 0.5 U/kg/day, the total daily dose is 21 Units. Two-thirds of this dose (14 units) is given in the morning (before breakfast), and one-third of the dose (7 units) before the evening meal. At each injection, 1/3 is short acting and 2/3 is intermediate-acting.\n\n\nTable 11: Example of administration of Short acting, Intermediate-acting and pre-mixed Insulin\n\n\n| Before breakfast    | Short-acting 5 Units   | Intermediate-acting 9 Units   | Pre-mixed insulin 14 Units   |\n|---------------------|------------------------|-------------------------------|------------------------------|\n| Before evening meal | 2 Units                | 5 Units                       | 7 Units                      |\n\n\n(rounded off to the nearest whole number)\n\n\n**It is important to note that:**\n\n\n- i. Insulin requirements can decrease for a time during the 'honeymoon period'  before rising again.\n- ii. The total daily dose required will generally increase as the child grows, and once puberty ensues a higher dose per kg per day is often needed.\n\n\nDuring  periods  of  regular  change  in  consumption  of  food  (e.g.  Ramadan)  the  total amount of insulin should not be reduced but redistributed according to the amount and timing of carbohydrate intake. However, if the total calorie intake is reduced during Ramadan, the daily amount of bolus insulin for meals usually needs to be reduced, for example to two-thirds or three-quarters of the usual dose.\n\n\n**Insulin injection techniques**\n\n\nProper injection technique is vital to ensure insulin is administered in the subcutaneous tissue. It is important to avoid intramuscular insulin injections.\n\n\nWhen starting the patient on insulin, the healthcare provider needs to ensure that the patient understands each of these essential topics\n\n\n- a. The Injection regimen\n\n\nOnce daily, twice daily or basal bolus\n\n\n**b. Choice of devices used**\n\n\n- o insulin vial and syringes or\n- o pen device\n\n\n**Howtoinject insulinwith a syringe**\n\n\n![Washyourhands.](images/picture_016_page_36.png)\n\n\n![Washyourhands.](images/picture_017_page_36.png)\n\n\nWashyourhands.\n\n\nCheckthe Insulin for lumps,crystals or discoloring.\n\n\nGentlyrollcloudy Insulin betweenyour handsuntil it is unitormly cloudy.\n\n\nNever shake Insulin.\n\n\nWipethetopofthe insulinvialwithaclean cloth/swab\n\n\n![Pull the plungerdown to letunitsof alr into the syringe.](images/picture_018_page_36.png)\n\n\nPull the plungerdown to letunitsof alr into the syringe.\n\n\nThe unitsofalr should equal the units of insulin that you plan to inject.\n\n\n![The unitsofalr should equal the units of insulin that you plan to inject.](images/picture_019_page_36.png)\n\n\n![The unitsofalr should equal the units of insulin that you plan to inject.](images/picture_020_page_36.png)\n\n\n![Figure 22](images/picture_021_page_36.png)\n\n\n![Figure 23](images/picture_022_page_36.png)\n\n\n![Figure 24](images/picture_023_page_36.png)\n\n\n![Push the alrinto the Insulinbottle.](images/picture_024_page_36.png)\n\n\n![Push the alrinto the Insulinbottle.](images/picture_025_page_36.png)\n\n\nPush the alrinto the Insulinbottle.\n\n\nLeave theneedle Inthe bottle.\n\n\nTurn theInsulinbottleand syringeupside down.\n\n\nBesure theneedleIsIn the Insulin,notIn theair space inside thebottle.\n\n\nPull theplungerdown to get\\_units of insulin into the syringe.\n\n\nFigure 5: Injection technique using an insulin syringe (Source: Optimizing Injection Technique in Diabetes Management Recommendations for Best Practice in Injection Technique, FIT guidelines South Africa, 1st edition)\n\n\nLookforairbubblesinthe syringe.lf there are alr bubbles,push the Insulin backIntothebottleand start againfrom step5.\n\n\nWhenyouhavetherlght Insulinunitswithnoalr bubbles,pull the syringe outof thebottle.\n\n\nClean theinjectionsite using a clean swab/cloth andletthesitedrybefore injecting\n\n\nPlnch up the area of skin thatyou wiped\n\n\nHold the syringe like a pencll.Besure the needle does nottouchanything.\n\n\nPush theneedle Into the pinchedskin ata90degree angle.Pushthe plunger to Inject the Insulin.\n\n\nRelease the pinch,thenpull the syringe needleout of your skin.\n\n\nlfyounotice a drop of blood,pressafingeronthe Injectionspot forafew seconds.\n\n\nPlace the used syringe Into a sharps container.\n\n\nDonotreuse the syringe\n\n\n**Partsofaninsulinsyringe**\n\n\n![How to inject](images/picture_026_page_37.png)\n\n\n**How to inject**\n\n\nWipe thetopof theinsulin bottle.Arrange your supplles.Washyour hands. To expose theplunger, twist thewhiteplungercap then pullit off.\n\n\nPull theinsulin syringe plunger down;align the thinblacklineofthe plunger(closest to the needle)withthedesired numberof units on the insulin syringe.You needair in theinsulin syringe equal to theamountof insulinyou willtake.\n\n\nPullthe plunger down slowly. Alignthethinblacklineofthe plunger(closest to the needle)withthedesired number of unitsonthe insulin syringe.\n\n\nHold the insulin syringe like apencil.Pinch upyour skin andpush the needle quickly through the skin at 90'(straight in)to the skin surface.Push the insulin in\n\n\n10\n\n\n8\n\n\n11\n\n\nIfyou aretaking cloudy insulin,rollthebottle betweenyour hands until it isuniformly cloudy.To avoid theformationofairbubbles, donot shake thebottleof insulin.\n\n\nHold theinsulin syringe like apencil.Push the needle straightthrough the center of therubbertopof the insulinbottleandpush the plunger down completely.\n\n\nIf airbubbles appear in theinsulin syringe,inject theinsulin backinto the vial.Thenredrawtheinsulin following steps6and7.\n\n\nDo notrecap used needles. Use the needle once and dispose ofit properly.\n\n\nFigure 6: Injection Technique using the insulin pen (Source: Optimizing Injection Technique in Diabetes Management Recommendations for Best Practice in Injection Technique, FIT guidelines South Africa, 1 st edition)\n\n\n![To expose theneedle,twist theorange needle shield then pull it straightoff. being carefulnotto bend the needleor let the needle touch anything.](images/picture_027_page_37.png)\n\n\nTo expose theneedle,twist theorange needle shield then pull it straightoff. being carefulnotto bend the needleor let the needle touch anything.\n\n\nLeave theneedle inthe insulinbottle.Carefullyturn thebottle and theinsulin syringeupside down sothe bottle is on top.\n\n\nConfirm thedoseiscorrect, and thencleana small area of skin.Letit dry completely before injecting.\n\n\n**Pen device**\n\n\nFigure7:  Structure of an Insulin Pen Device and how to use it.\n\n\n![c. Proper injection techniques](images/picture_028_page_38.png)\n\n\n**c. Proper injection techniques**\n\n\nDemonstrate the injection technique to the patient and the caregiver/family and have the patient repeat back before they leave.\n\n\n- -Injection sites: These are the abdomen, thighs, buttocks and upper arm. Injection sites should be clean disinfection of injection site is usually not required outside the hospital settings. Patients should never inject into sites of lipohypertrophy, inflammation or other lesions. (Refer to figure 14)\n- -Sites rotation is important to avoid lipohypertrophy. Patients should be given an easy to follow rotation scheme from the beginning of therapy which should be reviewed annually.\n- -Injection at a 900 angle unless the patient is very thin\n- -Use of lifted skin folds: A correct skin fold is made by lifting the skin with the thumb and index finger. Refer to figure 6 and 7)\n\n\n**Insulin injection sites for adults**\n\n\nFigure 8: Adult Insulin Injection Sites\n\n\n![39 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS](images/picture_029_page_39.png)\n\n\nFigure9: Recommended sites for injection in children\n\n\n![(Source: Optimizing Injection Technique in Diabetes Management Recommendations for Best Practice in Injection Technique, FIT guidelines South Africa, 1st edition)](images/picture_030_page_40.png)\n\n\n(Source: Optimizing Injection Technique in Diabetes Management Recommendations for Best Practice in Injection Technique, FIT guidelines South Africa, 1st edition)\n\n\n**d. Injection complications and how to avoid them (lipohypertrophy)**\n\n\n- e. Optimal needle length - use of shorter needles which are less traumatic to the patient and help in insulin adherence.\n\n\nShorter needles also reduce the incidence of intramuscular injections which can lead to more rapid insulin absorption and hypoglycemia\n\n\n- -Children: 6 mm for the insulin syringes and 4 - 6 mm in pen device\n- -Adults: 4 mm to 8 mm\n\n\n**f. Safe disposal of used sharps**\n\n\nCorrect disposal procedure of used insulin syringes/needles should be taught to the patient (storing in sealed containers and brought to the hospital for proper disposal). Sharps should NEVER be placed directly in household or public trash.\n\n\n**Insulin storage**\n\n\n- i. Insulin vials should be stored at 4-8 °C in a refrigerator where available or in some other method of cooler. In hot climates where refrigeration is not available, cooling jars, earthenware pot, and charcoal pot will help to preserve insulin activity.\n- ii. If using PEN device, insulin can be kept at room temperature for 28 days iii. Insulin must NEVER be frozen.\n- iv. Direct sunlight or extreme heat (in hot climates or in a vehicle) damages insulin.\n- v. Patients should not use insulins that have changed in appearance (clumping, frosting, precipitation, or discolouration).\n- vi. Once opened, an insulin vial should be discarded after 4 weeks.\n\n\n### 2.1.2. Blood Glucose Monitoring\n\n\nBlood glucose monitoring is essential in the safe management of childhood and adolescent diabetes to help prevent acute and chronic complications, and educate and empower the child and family. Every patient must have a glucometer and blood glucose test strips\n\n\nPatterns of blood glucose levels are generally more useful than single blood glucose readings. In case of scarce blood glucose testing strips, structured(point) testing for 2-3 consecutive day's pre-and post-meal will be better than staggered testing (Table 20).\n\n\nIf strips are readily available, a blood glucose test should regularly be done before each meal and at bedtime, prior to and following exercise.\n\n\nExercise, physical activity or play may result in low BGLs during or immediately after exercise, or a delayed hypoglycaemic effect many hours later (up to 16 hours). All blood glucose reading should be recorded in a diary or book indicating the date and time.\n\n\nTable 12: Recommended Target Blood Glucose Levels and HbA1c\n\n\n| Measurement       | Recommended level   |\n|-------------------|---------------------|\n| Pre-meal glucose  | 4.0 -7.0 mmol/L     |\n| Post-meal glucose | 5.0 -10.0 mmol/L    |\n| Bedtime glucose   | 6.0 - 10.0 mmol/L   |\n| 3 a.m. glucose    | 5.0-8.0 mmol/L      |\n| HbA1c             | <7.5%               |\n\n\nGlycaemic targets can relaxed accordingly to protect against hypoglycaemia if regular SMBG is not available\n\n\nTable 13: Interpretation of Blood Glucose Level (BGL)\n\n\n| Blood Glucose Level (BGL)                                        | Interpretation                                                               |\n|------------------------------------------------------------------|------------------------------------------------------------------------------|\n| Pre-meal BGLis always high                                       | Preceding dose of intermediate or long-act- ing insulin is insufficient      |\n| Pre-meal BGLis always low                                        | Previous dose of intermediate or long-acting insulin is too high             |\n| Pre-meal BGLis some- times very high and at other times very low | Either insulin, food or exercise are not con- sistent and should be reviewed |\n| BGL2 hours after the meal is too high                            | The meal dose of short-acting (regular) insu- lin was too low                |\n| BGL2 hours' post-meal is too low                                 | The previous meal dose of short-acting (reg- ular) insulin was too high      |\n\n\nNOTE: It is important to note that the level of blood glucose can rise in the early morning (dawn phenomenon). Therefore, care should be taken if increasing the evening intermediate/long-acting dose as hypoglycemia can occur in the middle of the night and this can be dangerous.\n\n\n**Correction Factor: How to Lower Pre-Meal Hyperglycemia**\n\n\nA constant correction factor (CF) is used to calculate insulin sensitivity factor (ISF) for everyone depending on the type of insulin used.\n\n\nThe insulin sensitivity factor is a number that gives the level of glucose change expected per unit of insulin increase or decrease.\n\n\n**The CF/TDD=ISF**\n\n\n1 unit of insulin causes a change of glucose level equivalent to the calculated ISF.\n\n\n### 2.1.3. Educating a child living with diabetes and his/her family\n\n\nA child living with diabetes and the family should be educated on the following aspects of diabetes management:\n\n\n- Insulin\tsecretion,\taction,\tand\tphysiology\n- Insulin\tinjections,\ttypes,\tabsorption,\taction\tprofiles,\tvariability\tand adjustments\n- Nutrition\t-\tfood\tplans;\tqualitative\tand\tquantitative\tadvice\ton\tintake\tof carbohydrate, fat, proteins, and fibre; coping with special events and eating out;\tgrowth\tand\tweight\tgain;\t'diabetic\tfoods';\tsweeteners\tand\tdrinks, prevention of disordered eating\n- Monitoring\t(glucose,\tketone),\tincluding\tglycated\themoglobin\tand\tagreed glucose targets\n- Hypoglycemia\tand\tits\tprevention,\trecognition\tand\tmanagement\tincluding use of glucagon\n- Hyperglycemia\tprevention,\trecognition\tand\tmanagement\n- Sick\tday\tmanagement:\tketosis,\tand\tprevention\tof\tketoacidosis\n- Problem-solving\tand\tadjustments\tto\ttreatment\tin\teveryday\tlife,\tmotivation\tand coping with unexpected glucose fluctuations\n- Goal\tsetting\n- Micro-\tand\tmacrovascular\tcomplications\tand\ttheir\tprevention,\tand\tthe\tneed for regular assessment\n- Exercise,\tholiday\tplanning,\tand\ttravel,\tincluding\teducational\tholidays\tand\tcamps\n- Smoking,\talcohol,\tand\tdrugs\n- Diabetes\tin\tschools\n- Sexuality,\tcontraception,\tpregnancy,\tand\tchildbirth\n\n\n### 2.1.4. Nutritional management in Children living with diabetes and his/her family\n\n\n- Children\tliving\twith\tdiabetes\tneed\ta\thealthy\tdiet\twith\tfood\tin\tamounts\tand proportions appropriate to the age and stage of growth (use the healthy plate model)\n- Nutritional\tcounselling\tshould\tbe\tadapted\tto\tcultural,\tethnic\tand\tfamily traditions as well as the cognitive and psychosocial needs of the individual child\n- Match\tthe\tdose,\ttype\tand\tregimen\tof\tinsulin\tto\tthe\tamount\tand\ttiming\tof\tfood\n- Include\ta\thealthy\tsnack\tbetween\tthe\tmain\tmeals,\tbefore,\tduring\tand\tafter exercise\n- Nutritional\tadvice\tshould\taddress\tfood\tavailability/food\tinsecurity,\tdiet,\tfood\tin take and physical activity patterns\n- Excessive\trestriction\tof\tcarbohydrate\tintake\tto\tlower\tblood\tglucose\tlevels should  be avoided\n- Sugary\tsoft\tdrinks\tor\tfoods\twith\thigh\tlevels\tof\tsaturated\tfat\tshould\tbe\tavoided.\n- Prevention\tand\tmanagement\tof\thypoglycemia,\tparticularly\tbefore,\tduring\tand after exercise should be addressed\n- Education\tshould\tinclude\tpreventing\thypoglycemia\n\n\n- Ideally\tthere\tshould\tbe\tan\texperienced\tdietitian\tin\tthe\tdiabetes\tteam\twho ought  to have individualized sessions with the child and the family/ caregiver\n- Unexpected\tweight\tloss\tmay\tbe\ta\tsign\tof\t(1)\tillness\te.g.\tinfections,\tcoeliac disease etc., (2) insulin omission, or (3) an eating disorder\n- Growth\tmonitoring\tshould\tbe\tdone\tuntil\tthe\tage\tof\t18\tyears\n\n\n## 2.2. Management of Type 2 Diabetes\n\n\nThe successful establishment of the diabetes health-care team and its supportive infrastructure is critical for the achievement of management goals. This includes provision of education for health-care professionals and for people living with diabetes.\n\n\nA thorough clinical assessment of a patient with type 2 diabetes is recommended before initiating any therapy and during ongoing therapy.\n\n\nTable 14: Clinical Assessment for initial and follow-up visits for Type 2 Diabetes\n\n\n|                                                                                                                                                                   | Initial visit                                                 | Three- to six-monthly visits                                  | Annual visit                                                  |\n|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|\n| History                                                                                                                                                           |                                                               |                                                               |                                                               |\n| Symptoms of hyperglycaemia* and duration of symptoms                                                                                                              | X                                                             | X                                                             | X                                                             |\n| Hypoglycaemic** symptoms                                                                                                                                          | X                                                             | X                                                             | X                                                             |\n| Relevant family history                                                                                                                                           | X                                                             |                                                               |                                                               |\n| Other risk factors (e.g. gestational diabetes, PCOS, hypertension)                                                                                                | X                                                             | X                                                             | X                                                             |\n| Relevant medical history (includingTB infection and exposure)                                                                                                     | Relevant medical history (includingTB infection and exposure) | Relevant medical history (includingTB infection and exposure) | Relevant medical history (includingTB infection and exposure) |\n| - Co-morbid conditions                                                                                                                                            | X                                                             |                                                               | X                                                             |\n| - Symptoms of complications: Cardiovas- cular, neurological, bladder function, sexual function (i.e. erectile dysfunction or low libido), feet, visual, infection | X                                                             | X                                                             | X                                                             |\n| Drugs                                                                                                                                                             |                                                               |                                                               |                                                               |\n| - Side effects                                                                                                                                                    |                                                               | X                                                             | X                                                             |\n| - Adherence                                                                                                                                                       |                                                               | X                                                             | X                                                             |\n| - Allergies                                                                                                                                                       | X                                                             | X                                                             | X                                                             |\n| Vaccinations                                                                                                                                                      |                                                               |                                                               |                                                               |\n| - Pneumococcal (date)                                                                                                                                             | X                                                             |                                                               | X                                                             |\n| - Influenza (date)                                                                                                                                                | X                                                             |                                                               | X                                                             |\n| Lifestyle                                                                                                                                                         |                                                               |                                                               |                                                               |\n| - Weight                                                                                                                                                          | X                                                             | X                                                             | X                                                             |\n| - Physical activity/sedentary lifestyle                                                                                                                           | X                                                             | X                                                             | X                                                             |\n\n\n| -                                                      | Eating pattern                                                                                     | X   | X   | X   |\n|--------------------------------------------------------|----------------------------------------------------------------------------------------------------|-----|-----|-----|\n| -                                                      | Smoking                                                                                            | X   | X   | X   |\n| -                                                      | Drug abuse                                                                                         | X   | X   | X   |\n| -                                                      | Alcohol                                                                                            | X   | X   | X   |\n| Psychosocial support                                   | Psychosocial support                                                                               |     |     |     |\n| -                                                      | Occupation                                                                                         | X   |     | X   |\n| -                                                      | Family and community support (sup- port groups)                                                    | X   |     | X   |\n| -                                                      | Depression, anxiety and other mental disorders                                                     | X   | X   | X   |\n| Home monitoring of blood glucose (glucom-              | Home monitoring of blood glucose (glucom-                                                          | X   | X   | X   |\n| Physical examination                                   | Physical examination                                                                               |     |     |     |\n| Weight                                                 | Weight                                                                                             | X   | X   | X   |\n| Height                                                 | Height                                                                                             | X   | X   | X   |\n| Body mass index (BMI) (kg/m 2 )                        | Body mass index (BMI) (kg/m 2 )                                                                    | X   | X   | X   |\n| Waist circumference (cm)                               | Waist circumference (cm)                                                                           | X   | X   | X   |\n| Heart rate and rhythm                                  | Heart rate and rhythm                                                                              | X   | X   | X   |\n| Blood pressure in mmHg(both systolic and diastolic BP) | Blood pressure in mmHg(both systolic and diastolic BP)                                             | X   | X   | X   |\n| Injection sites, if appropriate                        | Injection sites, if appropriate                                                                    | X   | X   | X   |\n| Feet                                                   | Feet                                                                                               |     |     |     |\n| -                                                      | Inspection: Ulcers, soft tissue, deformi- ties, Footwear                                           | X   | X   | X   |\n| -                                                      | Monofilament assessment                                                                            | X   |     | X   |\n| -                                                      | Vibration sense using tuning fork, or pinprick sensation                                           | X   |     | X   |\n| -                                                      | Ankle jerk                                                                                         | X   |     | X   |\n| -                                                      | Foot pulses                                                                                        | X   |     | X   |\n| Oral cavity                                            | Oral cavity                                                                                        |     |     |     |\n| -                                                      | Dental caries                                                                                      | X   |     | X   |\n| -                                                      | Gumdisease                                                                                         | X   |     | X   |\n| Eyes                                                   | Eyes                                                                                               |     |     |     |\n| -                                                      | Visual acuity                                                                                      | X   |     | X   |\n| -                                                      | Direct fundoscopy (dilated pupils), indirect fundoscopy, or fundus photo- graphs                   | X   |     | X a |\n| Systemic examination                                   | Systemic examination                                                                               |     |     |     |\n| Cardiovascular system examination                      | Cardiovascular system examination                                                                  | X   |     | X   |\n| Special investigations                                 | Special investigations                                                                             |     |     |     |\n| Blood tests                                            | Blood tests                                                                                        |     |     |     |\n| -                                                      | Glucose                                                                                            | X   | X   | X   |\n| -                                                      | HbA1c (Six-monthly if at target, otherwise three- monthly. Also, whenever treat- ment is adjusted) | X   | X   | X   |\n\n\n| - Lipids: Total cholesterol, HDL cholester-                                                                                                                                | X   |    | X   |\n|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----|-----|\n| - Creatinine, and calculate estimated GFR                                                                                                                                  | X   |    | X   |\n| - Potassium                                                                                                                                                                | X   |    | X   |\n| - TSH                                                                                                                                                                      | X   |    | X   |\n| - HIV                                                                                                                                                                      | X   |    | X   |\n| Urine                                                                                                                                                                      |     |    |     |\n| - Glucose                                                                                                                                                                  | X   |    | X   |\n| - Protein                                                                                                                                                                  |     |    |     |\n| - Ketones                                                                                                                                                                  | X   |    | X   |\n| - Leucocytes                                                                                                                                                               | X   |    | X   |\n| Urine microalbuminuria                                                                                                                                                     | X   |    | X   |\n| Uric acid                                                                                                                                                                  | X   |    | X   |\n| Full Hemogram                                                                                                                                                              | X   |    | X   |\n| Liver Function Tests (ALT, AST, ALP)                                                                                                                                       | X   |    | X   |\n| Urine microalbuminuria                                                                                                                                                     | X   |    | X   |\n| Uric acid                                                                                                                                                                  | X   |    | X   |\n| Full Hemogram                                                                                                                                                              | X   |    | X   |\n| Liver Function Tests (ALT, AST, ALP)                                                                                                                                       | X   |    | X   |\n| ECG                                                                                                                                                                        | X   |    | X   |\n| Cancer screening (Pap smear, breast, PSA)                                                                                                                                  | X   |    | X   |\n| Cancer screening (Pap smear, breast, PSA)                                                                                                                                  | X   |    | X   |\n| Other important tasks                                                                                                                                                      |     |    |     |\n| Education: Self-management and lifestyle adjustment, including tobacco cessation, alcohol cessation, Hypoglycemia avoidance and treatment, nutrition and physical activity | X   | X  | X   |\n| Setting goals                                                                                                                                                              | X   | X  | X   |\n| Preconception counselling and family planning                                                                                                                              |     | X  | X   |\n| Medication revision/adjustment                                                                                                                                             | X   | X  | X   |\n| Immunizations                                                                                                                                                              | X   |    | X   |\n\n\n\n\na Int erval for ret inop at y  sc reening c an b e inc reased t o onc e every 2 y ears if t h e last  2 ex am inat ions w ere norm al; m ore frequent  ex am inat ions are required in t h e p resenc e of ab norm alit ies.\n\n\n* y m om of h y p erg ly aem ia inc lude p oly dip sia,  h eadac es,  b lurred vision,  p oly uria,  fat ig ue/ b ody  m alaise,  w eig\n\n\n\n\n,\n\n\n\n\nt  loss\n\n\n** S y m om s/ sig ns of H y p og ly em iaN ervousness or anx iet y ,  sw eat ing c ills and c lam y  ex rem it ies,  irrit ab ilit y ,  c onfusion,  inc luding delirium ac y c ardia,  lig eadedness or diz z iness,  h ung er and nausea,  b lurred/ im aired vision,  t ing ling or num ness in t h e lip s or t ong ue,  h eadac es,  w eak ness or fat ig ue,  m ood c ang es,  lac of c oordinat ion,  nig ares or c ry ing out  during sleep ,  seiz ures,  loss of c onsc iousness. -p oly y st ic ovarian sy ndrom e\n\n\n\n\n-\n\n\n,\n\n\n**Management of Type 2 diabetes entails the following components:**\n\n\n- i. Treatment of hyperglycemia\n- ii. Treatment of hypertension and dyslipidemia\n- iii. Prevention and treatment of micro-vascular complications\n- iv. Prevention and treatment of macro-vascular complications\n- v. Prevention and treatment of non-vascular complications\n\n\n**Treatment of hyperglycemia**\n\n\nTreatment of hyperglycaemia in type 2 diabetes consist of the following;\n\n\n**a. Non -pharmacological**\n\n\n- i. Education\n- ii. Diet\n- iii. Physical activity\n- iv. Blood glucose monitoring\n\n\n**b. Pharmacological**\n\n\n- i. Oral glucose lowering agents (oral hypoglycaemic agents)\n- ii. Insulin\n- iii. Combination Therapies - e.g. Oral glucose lowering agents and insulin\n- iv. Non-insulin injectable glucose lowering agents (GLP-1 agonists)\n\n\n### 2.2.1. Non-pharmacological management\n\n\nThis is the cornerstone in achieving diabetes control. It includes diabetes education, medical nutrition therapy, physical activity and self-monitoring of blood glucose.\n\n\n**Diabetes Education**\n\n\nDiabetes education to the diabetic patient and the family is important in ensuring good glycemic control and prevention of diabetic complications. The diabetes education is a continuous process in the patients' follow up\n\n\n**Principles of diabetes education**\n\n\n- An\tevidence-based,\tstructured\teducation\tprogramme\tshould\tbe\toffered\tto\tall patients at the time of diagnosis, and consolidated at regular intervals thereafter. The aim is to promote patient self-management\n- Diabetes\teducation\tis\ta\tcontinuous\tprocess\tand\tdifferent\ttopics\tshould\tbe covered at separate sessions to ensure a proper understanding of the issues\n- The\tprogramme\tshould\tbe\tpresented\tby\teducators\twho\thave\tbeen appropriately trained\n- Diabetes\tself-management\teducation\t(DSME)\tshould\tbe\tindividualized. Small-group education is the most cost-effective option but individual education sessions should also be utilized where necessary\n- Educators\tshould\tensure\tthat\tactive\tlearning\tis\ttaking\tplace\n- Psychological\tand\temotional\tassessment\tis\tneeded\tat\tregular\tintervals\n- A\tregular\taudit\tof\tthe\tprogramme\tand\tits\teffect\ton\toutcomes\tis\tadvised\n\n\nTable 15:  Structured diabetes education outline\n\n\n| Visits                          | Education to be conducted during the diabetes clinic visit                                                                                                                                                                                                                                                                  |\n|---------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Visit 1                         | • Support system • Overview of Diabetes • Blood glucose monitoring • Nutrition • Physical Activity • Self-Glucose Monitoring                                                                                                                                                                                                |\n| Visit 2                         | • Hypoglycaemia • Hyperglycaemia • Sick Days • Mindful eating • Dining Out • Physical Activity                                                                                                                                                                                                                              |\n| Visit 3                         | • Stress and diabetes • Natural changes of diabetes • Blood pressure control • Heart health • Tobacco use • Eating for better health • Physical Activity                                                                                                                                                                    |\n| Visit 4                         | • Diabetes and alcohol • Diabetes changes over time • Problem-solving: glucose results • Complications: preventing and delaying • Foot care • Sleep habits                                                                                                                                                                  |\n| Visit 5                         | • Pregnancy: preparing, managing diabetes during pregnancy and appropriate postnatal care • Psychosocial issues, stress management and coping skills • What is the role of alternative medicine: How to make informed choices about their use of traditional and alternative medicine, potential harm and drug interactions |\n| Educating the elderly patients: | • Assess knowledge and understanding of diabetes • Evaluate ability to learn and apply new self-care skills • Asses nutrition and physical activity • Address poly-pharmacy and co-morbidities • Assess for cognitive dysfunction, depression and physical disability                                                       |\n\n\n**Dietary Management of Type 2 Diabetes Mellitus**\n\n\nDietary modification is one of the cornerstones of diabetes management. It is based on the principle of healthy eating in the context of socio-economic, cultural and psychological influences of food choices.\n\n\n**Principles of dietary management of Type 2 diabetes mellitus**\n\n\nAll members of the diabetes-care team must have knowledge about nutrition to be able to educate people living with diabetes with the support of a nutritionist. Dietary counseling is best given by a dietitian or nutritionist.\n\n\n**The following are principles of dietary management:**\n\n\n- To\tachieve\tideal/desired\tweight,\tan\tappropriate\tdiet\tand\texercise\tregimen should be agreed upon between the nutritionist and the patient/care giver\n- Three\tmain\tmeals\tshould\tbe\teaten\tin\ta\tday,\tand\tbinge\teating\tshould\tbe\tavoided\n- The\tdiet\tshould\tbe\tindividualized,\tbased\ton\ttraditional\teating\tpatterns,\tBMI, comorbid conditions; and should be palatable and affordable\n- Animal\tfat,\tsalt,\tdiet\tdrinks,\tsweeteners\tand\tfoods\tmarketed\tas\t'diabetic\tfoods' should be avoided\n- Tailoring\tthe\tnutritional\tintervention,\tso\tthat\tthere\tis\ta\tcareful\tmatch\tof\tboth\ta meal-planning approach and educational materials with the patient needs, and so that there is still some allowance for flexibility\n- Foods\tand\tdrinks\trich\tin\trefined\tsugars\t(simple\tsugars)\tshould\tbe\tavoided\n- Eating\tplans\tshould\tbe\thigher\tin\tcomplex\tcarbohydrates\t(starches)\tand\tfibre content\n- Vegetables\tand\tlimited\tnumbers\tof\tfruits\tshould\tbe\tencouraged\n- Food\tquantities\tshould\tbe\tmeasured\tin\tvolumes\tusing\tavailable\thousehold items, such as cups, or be countable, such as number of fruits or slices of yam or bread\n- Alcohol\tshould\tbe\tavoided\n- Sweeteners\tare\tnot\tessential\tand\tshould\tbe\tavoided\tas\tmuch\tas\tpossible\n- Drinking\tof\twater\tthroughout\tthe\tday\tshould\tbe\tencouraged\t(average\t8 glasses  of 250 mls each)\n\n\n**Table 16: Dietary Recommendations in Management of Type 2 Diabetes**\n\n\n**A. Follow a healthy, balanced eating plan**\n\n\n- Eat a variety of fresh fruit and vegetables every day, but avoid fruit juices\n- At least half of the grain intake must be from whole grain products\n- Use a variety of meat alternatives, including pulses, beans and other legumes\n- Consume white meat at least twice per week\n- Limit the intake of processed and fast foods\n- Increase the intake of water to meet daily fluid requirements\n\n\n**B. Carbohydrates**\n\n\n- Carbohydrates should make up 45-60% of the total energy intake\n- Monitoring  carbohydrate  intake,  whether  by  carbohydrate  counting,  exchanges or experienced-based estimation, remains a key strategy in achieving optimum glycaemic control\n- The use of glycaemic index and glycaemic load may provide a modest an additional benefit compared to considering only total carbohydrate content\n- Limit the intake of sugar alcohols (maltitol, mannitol, sorbitol, lactitol, isomalt, xylitol) to &lt; 10 g per day\n- A sucrose intake of up to 10% of total energy intake per day is acceptable\n- Limit the total fructose intake to 60 g per day\n- Increase the intake of soluble and insoluble fibre to 25-50 g per day\n- The use of artificial sweeteners, including acesulfame-K, aspartame, sac -charine and sucralose, are safe when consumed within the daily limits established by the FDA\n\n\n**C. Protein**\n\n\n- Proteins should make up 15-20% of the total energy intake\n- For individuals with type 2 diabetes with normal renal function, there is no evidence to suggest that the usual recommended protein intake should be modified\n- In type 2 diabetes, ingested protein can increase the insulin response without increasing plasma glucose levels; therefore, protein should not be used in the treatment and prevention of Hypoglycemia\n\n\n**D. Fat**\n\n\n- The fat intake should be restricted to &lt; 35% of the total energy intake\n- The saturated fat (solid fats, and animal fats) intake should be restricted to &lt; 7% of the total energy intake\n- Most of the fat intake should be unsaturated fats (vegetable oils)\n- Minimize the intake of trans-fats\n- Two more servings of fish per week will provide the recommended ome -ga-3 polyunsaturated fatty acids\n\n\n**E. Salt**\n\n\n- Limit all kinds of salt intake\n\n\n**F. Vitamins and minerals**\n\n\n- Mineral and vitamin supplementation may be needed in selected groups, such as the elderly, lactating and pregnant women, and vegans\n- Encourage to take a variety of fruits and vegetables, fish and foods rich in vitamin D\n\n\n**G. Alcohol**\n\n\n- Adults who choose to consume alcohol should do so in moderation: one unit per day or less for women, and two units per day or less for men\n- Moderate alcohol consumption, with food, does not cause acute hyperglycaemia or Hypoglycemia.\n- Individuals on insulin or insulin secretagogues should be aware of the risks of delayed Hypoglycemia (for up to 24 hours after consumption); alcohol should be consumed with food to reduce the risk of Hypoglycemia\n\n\n**Tools used in meal planning in in diabetes nutrition therapy**\n\n\nThere are several tools used in meal planning, however, there is no ideal meal plan that works for everyone living with diabetes. Below are some of the tools used in meal planning in diabetes care\n\n\n1. Plate Model\n2. Handy portion guide\n3. Glycemic Index and glycemic load\n4. Food groups and food servings\n5. Carbohydrate counting\n\n\n**Plate Model**\n\n\nThis method helps the patient to easily measure the food portions while keeping simple and practical. It divides the plate, 9 inches in diameter, into portions of vegetables, fruits, starch and proteins as indicated below\n\n\n![Figure 10: Plate Model](images/picture_031_page_52.png)\n\n\n**Figure 10: Plate Model**\n\n\nSource: Adapted from the Harvard T.H Chan school of Public Health, The Nutrition Source (www.hsph.harvard.edu/nutritionsource)\n\n\nHandy portion guide\n\n\nThis method used patients' hands to provide quick tips for estimating portion sizes\n\n\nFigure 11: Handy portion guide\n\n\n![Glycemic Index and glycemic load](images/picture_032_page_53.png)\n\n\n**Glycemic Index and glycemic load**\n\n\nThe glycemic index is a value assigned to foods based on how slowly or how quickly these foods cause increases in blood glucose levels. It ranks the carbohydrates on a scale from 0 to 100 according to the extent to which they raise blood sugar (glucose) levels after eating. Foods low in the glycemic index (GI) scale tend to release glucose slowly and steadily while foods high on the glycemic index release glucose rapidly\n\n\nFigure 12: An illustration of low and high glycemic index food\n\n\n![53 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS](images/picture_033_page_53.png)\n\n\nBelow is a comprehensive list of low and high glycemic foods, people living with diabetes are advised to choose more foods from the low glycemic index\n\n\nTable 17: Examples of low and high glycemic index foods\n\n\n| High glycemic foods                                                                                                                                                                                                                                                                             | Low glycemic foods                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Glucose Baked potatoes French Fries Rice Flour Mashed Potatoes Potato Chips Honey Cooked Carrots Corn Flakes Cooked Broad beans Pumpkin Watermelon Sugar (Sucrose) White bread Refined sweetened cereal Chocolate bars Boiled peeled potatoes Cola soda Cookies Corn White rice Noodles Raisins | Whole wheat or bran bread Brown rice Sweet potatoes Whole wheat pasta Fresh peas Whole wheat sugar free cereal Oatmeal Whole grain pasta Kidney beans Fresh unsweetened fruit juice Raw carrots Dairy products Dried beans Brown or yellow lentils Chick peas Fresh fruit Green vegetables, tomatoes, eggplant, zucchini, garlic, onions etc Green beans Sugar free marmalade Green Lentils Split peas Dark Chocolate (>70% cocoa Fruits (Banana, Grapes, Orange, |\n\n\n**Food groups and food servings**\n\n\nThis method is used as a tool that is used to help the patient figure out how many servings of each food are they required to eat from every group. The key to eating well is to enjoy a variety of nutritious foods from each of the food groups.\n\n\nTable 18: Food groups and recommended servings per each food group\n\n\n| Food group                | Number of servings   | What is a serving?                                                                                                                                        |\n|---------------------------|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Starches and breads       | 6-11                 | 1 Slice bread ½ cup cooked rice, cereal ¼ cup dry cereal, ½ cup pasta 3 biscuits (eat whole-grain, fortified or en - riched starches, bread, and cereals) |\n| Vegetables                | 3-5                  | ½ cup vegetables cooked 1 cup vegetables raw                                                                                                              |\n| Fruits                    | 2-4                  | 1 cup fruit juice (fresh, frozen or canned without sugar) 1 medium piece fresh fruit                                                                      |\n| Milk and milk products    | 2-3                  | 1 cup skim / low fat milk / ¾ cup plain or artificially sweetened yogurt                                                                                  |\n| Meat and meat substitutes | 2-3                  | 57-85 g cooked lean meat fish or poultry 28.5 g meat is equivalent to: - 1 egg 28.5 g cheese ¼ cup fish (Omena, tuna, salmon or cheese                    |\n| Fat                       | Use sparingly        | 1 teaspoon margarine 1 teaspoon salad dressing 1 teaspoon oil or mayonnaise 1 tablespoon peanut-butter                                                    |\n\n\n**Carbohydrate counting**\n\n\nCarbohydrate counting, is a meal planning tool for people living with type 1or type 2 diabetes. It involves keeping track of the amount of carbohydrate in the foods that a person eats each day.\n\n\nCarbohydrates are one of the main nutrients found in food and drinks. They include sugars, starches, and fibre. Carbohydrate counting can help one control their blood glucose levels because carbohydrates affect the blood glucose more than other nutrients.\n\n\nHealthy carbohydrates, such as whole grains, fruits, and vegetables, are an important part of a healthy eating plan because they provide both energy and nutrients, such as vitamins and minerals, and fibre. Fibre helps in preventing constipation, lower cholesterol levels, and control the weight.\n\n\nUnhealthy carbohydrates are often food and drinks with added sugars. Although unhealthy carbohydrates can also provide energy, they have little to no nutrients.\n\n\nThe amount of carbohydrate in foods is measured in grams. To count grams of carbohydrate in foods you eat, a patient will need to;\n\n\n- Know\twhich\tfoods\tcontain\tcarbohydrates\n- Learn\tto\testimate\tthe\tnumber\tof\tgrams\tof\tcarbohydrate\tin\tthe\tfoods\n- Add\tup\tthe\tnumber\tof\tgrams\tof\tcarbohydrate\tfrom\teach\tfood\tto\tget\tyour\ttotal for the day\n\n\n**Foods that contain carbohydrates include**\n\n\n- grains,\tsuch\tas\tbread,\tnoodles,\tpasta,\tcrackers,\tcereals,\tand\trice\n- fruits,\tsuch\tas\tapples,\tbananas,\tberries,\tmangoes,\tmelons,\tand\toranges\n- dairy\tproducts,\tsuch\tas\tmilk\tand\tyogurt\n- legumes,\tincluding\tdried\tbeans,\tlentils,\tand\tpeas\n- snack\tfoods\tand\tsweets,\tsuch\tas\tcakes,\tcookies,\tcandy,\tand\tother\tdesserts\n- juices,\tsoft\tdrinks,\tfruit\tdrinks,\tsports\tdrinks,\tand\tenergy\tdrinks\tthat\tcontain sugars\n- vegetables,\tespecially\t'starchy'\tvegetables\tsuch\tas\tpotatoes,\tcorn,\tand\tpeas\n\n\nFoods that do not contain carbohydrates include meat, fish, and poultry; most types of cheese; nuts; and oils and other fats.\n\n\n**Example of the grams of carbohydrates on needs based on an 1800 kilo calories diet per day**\n\n\nCarbohydrate intake for most people should be between 45 and 65 percent of total calories per day. People on low-calorie diets and people who are physically inactive may want to aim for the lower end of that range.\n\n\nOne gram of carbohydrate provides about 4 calories, thus divide the number of calories per day from carbohydrates by 4 to get the number of grams. For example, if a diet is based on an 1,800 total calories per day and get 45 percent of your calories from\n\n\ncarbohydrates, then the grams from of carbohydrates is about 200 grams of carbohydrate daily. Calculated follows:\n\n\n- 0.45\tx\t1,800\tcalories\t=\t810\tcalories\n- 810\t÷\t4\t=\t202.5\tgrams\tof\tcarbohydrate\n\n\nSpread out the grams of carbohydrate intake throughout the day. There is a need to involve a dietitian or a nutritionist to counsel the patient on what foods to eat, how much to eat, and when to eat based on the weight, activity level, medicines, and blood glucose targets. This method also requires the patient to be motivated, read all the food labels and be willing to calculate the number of grams of carbohydrates intake per day\n\n\n**Physical activity and exercise**\n\n\nPhysical activity or exercise is one of the essentials in the prevention and management of Type 2 diabetes mellitus. Regular physical activity improves metabolic control, increases insulin sensitivity, improves cardiovascular health, and helps weight loss and its maintenance, as well as giving a sense of well-being.\n\n\n**There are two main types of physical activity:**\n\n\n- i. Aerobic or endurance exercise (e.g. walking or running)\n- ii. Anaerobic or resistance exercise (e.g. lifting weights).\n\n\nBoth types of activity may be prescribed to persons with Type 2 diabetes mellitus, but the aerobic form is usually preferred.\n\n\nIn most parts of Kenya, prescribing formal exercise in gyms or requiring special equipment is a recipe for non-adherence. Therefore, patients should be encouraged to integrate increased physical activity into their daily routine. The plan should impose minimum, if any, extra financial outlay in new equipment and materials for physical activity.\n\n\n**General principles and recommendations for physical activity in Type 2 diabetes mellitus**\n\n\n- A\tdetailed\tphysical\tevaluation\tof\tcardiovascular,\trenal,\teye\tand\tfoot\tstatus (including neurological) should be performed before starting an exercise programme.\n- The\tpresence\tof\tchronic\tcomplications\tmay\tpreclude\tcertain\tforms\tof\texercises.\n- Prescribed\tphysical\tactivity\tprogrammes\tshould\tbe\tappropriate\tfor\tthe patient's age, socio-economic status, state of physical fitness, lifestyle, and level of glycaemic control.\n- While\texercise\tgenerally\timproves\tmetabolic\tcontrol,\tit\tcan\talso\tprecipitate acute complications like hypoglycemia and hyperglycaemia.\n- The\tphysical\tactivity\tshould\tbe\tregular\t(3\tdays/week),\tlast\tat\tleast\t20\t-\t30 minutes per session, and be of at least moderate intensity.\n- Activities\tlike\twalking,\tclimbing\tsteps\t(instead\tof\ttaking\tlifts)\tshould\tbe encouraged.\n\n\n- For\tsedentary\tpersons\tliving\twith\tdiabetes,\ta\tgradual\tintroduction\tusing\ta low-intensity activity like walking is mandatory.\n- Avoid\tstrenuous\texercise\tif\tambient\tglycaemia\tis\t&gt;\t250\tmg/dl\t(14\tmmol/L),\tthe patient   has ketonuria or blood glucose is less than 80 mg/dl (4.5 mmol/L).\n- To\tavoid\texercise-induced\thypoglycaemia,\tdosages\tof\tinsulin\tsecretagogues\tor insulin may need to be reduced and/or peri-exercise carbohydrate intake increased.\n- Blood\tglucose\tshould\tbe\tmonitored\t(using\tstrips\tand\tmeters)\tbefore\tand\tafter planned strenuous physical activity as delayed hypoglycemia may occur.\n- Proper\tfootwear\tmust\talways\tbe\tworn.\n\n\nTable 19: Aerobic exercise recommended for individuals with type 2 diabetes\n\n\n| Definition                                                                                                                                  | Intensity   | Frequency                                                    | Examples                                                                                                            |\n|---------------------------------------------------------------------------------------------------------------------------------------------|-------------|--------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|\n| Activities that consist of rhythmic, repetitive and con- tinuous movement of the same large muscle groups for at least 10 minutes at a time | Moderate:   | Minimum 150 minutes per week (30 minutes per day for 5 days) | Cycling, brisk walking, continuous swimming, dancing, water aerobics, raking leaves, shamba work, house hold chores |\n|                                                                                                                                             | Or          | Or                                                           | Or                                                                                                                  |\n|                                                                                                                                             | Vigorous:   | Minimum 75 minutes per week (30 minutes 3 times a week)      | Brisk walking up an incline, jogging, aerobics, hockey, basketball, fast swimming, fast dancing                     |\n|                                                                                                                                             | Or          | Or                                                           | Or                                                                                                                  |\n\n\nTable 20: Resistance exercise recommended for individuals with type 2 diabetes\n\n\n| Definition                                                                                     | Frequency                                                                                                                                                                   | Examples                                                                                             |\n|------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|\n| Activities that require muscular strength to move a weight or work against a resistance load a | Two to three times per week: Start with one set of 10-15 repetitions at moderate weight Progress to two sets of 10-15 repetitions Progress to three sets at heavier weights | Exercise with weight machines, free weight lifting, Resistance band (e.g. Thera-Band ® ) exer- cises |\n\n\n*Resistance exercise should only be attempted if there are no contraindications to this kind of activity\n\n\n**Physical activity recommendations in Children and Adolescents**\n\n\n- Children\tand\tadolescents\twith\tType\t1\tor\tType\t2\tdiabetes\tshould\tengage\tin\t60 minutes per day or more of moderate- or vigorous-intensity aerobic activity, as well as vigorous muscle strengthening and bone strengthening activities at least 3 days per week.\n- Preparations\tare\tneeded\tas\texercise\tmay\tinduce\thypoglycemia.\tWhere possible, patients and families should be given tailored advice about what and how much carbohydrate to take before, during, and after exercise, as well as advice about insulin adjustment.\n- Where\tmonitoring\tis\tavailable,\tblood\tglucose\tneeds\tto\tbe\tmeasured\tbefore, during and after exercise.\n- Approximately\t1.0\t-\t1.5\tg\tcarbohydrate/kg\tbody\tweight/hour\tshould\tbe consumed before and during strenuous exercise if the child is unable to monitor and reduce insulin dosage. E.g. ½ long banana/small apple, small orange.\n\n\n- Hypoglycemia\tis\tmore\tlikely\tto\toccur\twith\tprolonged\tnon-intense\tphysical activity. It often occurs shortly after any type of exercise but is possible up to 24 hours afterwards (increased insulin sensitivity). Risk of post-exercise nocturnal hypoglycemia is high. The evening dose of intermediate- or long-acting insulin often needs to be decreased by 10-20% after exercise in the afternoon or evening, especially if not exercising on a regular basis. Special care\tshould\tbe\ttaken\tthat\tthe\tbedtime\tblood\tglucose\tlevel\tis\t&gt;\t7.0\tmmol/L\t(125 mg/dl).\n- Water\tshould\tbe\tconsumed\tto\tavoid\tdehydration.\n- Where\tunaccustomed\texercise\tis\tbeing\ttaken,\te.g.\tat\ta\tdiabetes\tcamp, reduction in total daily dose of insulin (20- 50%) is advised to avoid hypoglycemia.\n- Insulin\tis\tabsorbed\tquicker\twhen\tit\tis\tinjected\tnear\tto\tmuscles\tthat\tare\tbeing exercised - e.g. legs in soccer. Hypoglycemia is then more likely to occur. Preferred injection site: abdomen\n- If\tblood\tglucose\tlevels\tare\thigh\t(&gt;14\tmmol/l)\twith\tketonuria/ketonaemia, exercise could be dangerous and should be avoided. Give approximately 0.05 U/kg, or 5% of total daily insulin dose as short-acting (soluble) iinsulin and postpone exercise until ketones have cleared. If ketones cannot be measured, a child who is feeling nauseous should not participate in exercise. Children and young people engaged in competitive or more intensive sport will require additional support. This should include detailed discussion about the activity and tailored advice on insulin and food adjustments.\n\n\n### 2.2.2. Pharmacological Management\n\n\nThe goals of caring for patients with diabetes mellitus are to maintain blood glucose under control and prevent or slow down the rate of development of both acute and long-term complications. In initiating treatment for people living with type 2 diabetes the use of HbA1c test is key. The table below provides a guide for initiating therapy using the HbA1c levels.\n\n\nFigure 13: Medical management of Type 2 Diabetes Based on HbA1c levels\n\n\n![61 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS](images/picture_034_page_61.png)\n\n\nSource: Tb/DM Flowchart, MOH\n\n\nPharmacological therapy includes oral glucose lowering agents, insulin and injectable GLP-1 agonists.\n\n\n**i. Oral Glucose Lowering Agents (OGLAs)**\n\n\nThese were previously referred to as oral hypoglycaemic agents\n\n\n**Indications:**\n\n\n- Oral\tpharmacotherapy\tis\tindicated\tfor\tindividual\twith\tType\t2\tdiabetes\n- It\tis\tindicated\twhen\tan\tindividual's\tglycaemic\ttargets\tare\tnot\tmet\tby the combination of dietary modifications and physical activity/exercise.\n- In\tsome\tcases,\toral\tpharmacotherapy\tor\tinsulin\tis\tindicated\tat\tthe\tfirst presentation\tof\tdiabetes,\ti.e.\ta\tfasting\tblood\tglucose\tlevel\t&gt;\t11\tmmol/L or\trandom\tblood\tglucose\tlevel\t&gt;\t15\tmmol/L.\n\n\n**Choice of Oral Glucose Lowering Agents (OGLAs)**\n\n\n- The\tchoice\tof\tOGLAs\tshould\tdepend\ton\tthe\tpatient's\tcharacteristics, lifestyle, degree of glycaemic control, cardiovascular and renal risks, access to drugs, economic status and agreement between the doctor and the person living with diabetes.\n- The\tfirst\tline\toral\tagent\tof\tchoice\tis\tMetformin\tunless\tcontra-indicated.\n- The\tsulphonylureas\tand\tmetformin\tare\tthe\tagents\tmost\twidely available.\n- Use\tof\tthe\tstepped-care\tapproach\tis\trecommended,\tas\tmonotherapy\tis seldom sufficient, because of the progressive nature of the disease (see figure 15).\n- Combination\ttherapy\tshould\tbe\tconsidered\tas\tinitial\tchoice\tif\tHBA1C\tis greater than 8 %.\n- Three-drug\tcombination\ttherapy\tcan\tbe\tused\twhen\ttwo-drug regimens fail to achieve target values. Such patients should be referred to a specialist. Use of combination therapy often results in an increased number of tablets to be taken and creates new adherence problems.\n- Fixed\tcombination\ttherapies\tincrease\tadherence\tbut\tmay\tinhibit flexibility in dosing prescription.\n\n\nTable 21 summarizes the characteristics of the OGLAs which are frequently used in controlling glycaemia in diabetes care. The list is not exhaustive but includes agents that are most commonly used in Kenya.\n\n\nTable 21: Oral glucose lowering agents, dosage, side effects and Contraindications\n\n\n| Table 21: Name of Drug                                                                                                                                                                      | Oral Mini- mum dose                                                                                                                                                                         | glucose Max- imal daily                                                                                                                                                                     | lowering Frequen- cy                                                                                                                                                                        | agents, dosage, side Major Side Effects                                                                                                                                                     | effects and Contraindications Contraindications/use with caution                                                                                                                            |\n|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| dose A. Sulphonylureas Mechanism of action: Stimulate the pancreas to release insulin (regardless of time and glucose levels)                                                               | dose A. Sulphonylureas Mechanism of action: Stimulate the pancreas to release insulin (regardless of time and glucose levels)                                                               | dose A. Sulphonylureas Mechanism of action: Stimulate the pancreas to release insulin (regardless of time and glucose levels)                                                               | dose A. Sulphonylureas Mechanism of action: Stimulate the pancreas to release insulin (regardless of time and glucose levels)                                                               | dose A. Sulphonylureas Mechanism of action: Stimulate the pancreas to release insulin (regardless of time and glucose levels)                                                               | dose A. Sulphonylureas Mechanism of action: Stimulate the pancreas to release insulin (regardless of time and glucose levels)                                                               |\n| Glibenclamide                                                                                                                                                                               | 2.5 mg                                                                                                                                                                                      | 15 mg                                                                                                                                                                                       | OD or BD                                                                                                                                                                                    | Hypoglycemia, weight gain skin rashes                                                                                                                                                       | Caution in liver and renal disease                                                                                                                                                          |\n| GliclazideMR                                                                                                                                                                                | 30 mg                                                                                                                                                                                       | 120 mg                                                                                                                                                                                      | OD                                                                                                                                                                                          | Hypoglycemia, weight gain skin rashes                                                                                                                                                       | Pregnancy, caution in liver disease                                                                                                                                                         |\n| Glimepiride                                                                                                                                                                                 | 1 mg                                                                                                                                                                                        | 4 mg                                                                                                                                                                                        | OD                                                                                                                                                                                          | Hypoglycemia weight gain skin rashes                                                                                                                                                        | Pregnancy, caution in liver and renal disease                                                                                                                                               |\n| Glipizide                                                                                                                                                                                   | 5 mg                                                                                                                                                                                        | 40 mg                                                                                                                                                                                       | OD or BD                                                                                                                                                                                    | Hypoglycemia weight gain skin rashes                                                                                                                                                        | Pregnancy, caution in liver and renal disease                                                                                                                                               |\n| B. Biguanide Mechanism of action: (i)Reduce glucose production in liver (ii) cause (mild) reduction in peripheral insulin resistance                                                        | B. Biguanide Mechanism of action: (i)Reduce glucose production in liver (ii) cause (mild) reduction in peripheral insulin resistance                                                        | B. Biguanide Mechanism of action: (i)Reduce glucose production in liver (ii) cause (mild) reduction in peripheral insulin resistance                                                        | B. Biguanide Mechanism of action: (i)Reduce glucose production in liver (ii) cause (mild) reduction in peripheral insulin resistance                                                        | B. Biguanide Mechanism of action: (i)Reduce glucose production in liver (ii) cause (mild) reduction in peripheral insulin resistance                                                        | B. Biguanide Mechanism of action: (i)Reduce glucose production in liver (ii) cause (mild) reduction in peripheral insulin resistance                                                        |\n| Metformin                                                                                                                                                                                   | 500 mg                                                                                                                                                                                      | 2000 mg                                                                                                                                                                                     | OD or BD                                                                                                                                                                                    | Abdominal pain, nausea, loose bowel motions, lactic aci- dosis Vitamin B12 deficien - cy with prolonged use.                                                                                | Renal failure, GFR<30 ml/min Heart failure stage 3 or 4 and liver failure                                                                                                                   |\n| C. Thiazolidinediones Mechanism of action: (i) Improved insulin sensitivity in muscle, adipose tissue and liver (ii)Reduce glucose output from liver                                        | C. Thiazolidinediones Mechanism of action: (i) Improved insulin sensitivity in muscle, adipose tissue and liver (ii)Reduce glucose output from liver                                        | C. Thiazolidinediones Mechanism of action: (i) Improved insulin sensitivity in muscle, adipose tissue and liver (ii)Reduce glucose output from liver                                        | C. Thiazolidinediones Mechanism of action: (i) Improved insulin sensitivity in muscle, adipose tissue and liver (ii)Reduce glucose output from liver                                        | C. Thiazolidinediones Mechanism of action: (i) Improved insulin sensitivity in muscle, adipose tissue and liver (ii)Reduce glucose output from liver                                        | C. Thiazolidinediones Mechanism of action: (i) Improved insulin sensitivity in muscle, adipose tissue and liver (ii)Reduce glucose output from liver                                        |\n| Pioglitazone                                                                                                                                                                                | 15 mg                                                                                                                                                                                       | 45 mg                                                                                                                                                                                       | OD                                                                                                                                                                                          | Liver impairment, fluid retention weight gain, dilutional anaemia, osteoporosis                                                                                                             | Heart failure and liver failure; pregnancy, Bone fractures                                                                                                                                  |\n| D. Meglitinides Mechanism of action: Stimulate pancreas to release more insulin (possibly related to blood glucose level)                                                                   | D. Meglitinides Mechanism of action: Stimulate pancreas to release more insulin (possibly related to blood glucose level)                                                                   | D. Meglitinides Mechanism of action: Stimulate pancreas to release more insulin (possibly related to blood glucose level)                                                                   | D. Meglitinides Mechanism of action: Stimulate pancreas to release more insulin (possibly related to blood glucose level)                                                                   | D. Meglitinides Mechanism of action: Stimulate pancreas to release more insulin (possibly related to blood glucose level)                                                                   | D. Meglitinides Mechanism of action: Stimulate pancreas to release more insulin (possibly related to blood glucose level)                                                                   |\n| Repaglinide                                                                                                                                                                                 | 1.0 mg                                                                                                                                                                                      | 16 mg                                                                                                                                                                                       | BD, TDS or QID (Before meals)                                                                                                                                                               | Liver impairment, fluid retention weight gain, dilutional anaemia                                                                                                                           |                                                                                                                                                                                             |\n| E. Alpha glucosidase inhibitors Mechanism of action: Slow digestion of complex sugars (sucrose and starch) and therefore delays absorption, leading to slow post-meal rise in blood glucose | E. Alpha glucosidase inhibitors Mechanism of action: Slow digestion of complex sugars (sucrose and starch) and therefore delays absorption, leading to slow post-meal rise in blood glucose | E. Alpha glucosidase inhibitors Mechanism of action: Slow digestion of complex sugars (sucrose and starch) and therefore delays absorption, leading to slow post-meal rise in blood glucose | E. Alpha glucosidase inhibitors Mechanism of action: Slow digestion of complex sugars (sucrose and starch) and therefore delays absorption, leading to slow post-meal rise in blood glucose | E. Alpha glucosidase inhibitors Mechanism of action: Slow digestion of complex sugars (sucrose and starch) and therefore delays absorption, leading to slow post-meal rise in blood glucose | E. Alpha glucosidase inhibitors Mechanism of action: Slow digestion of complex sugars (sucrose and starch) and therefore delays absorption, leading to slow post-meal rise in blood glucose |\n| Acarbose                                                                                                                                                                                    | 25 mg                                                                                                                                                                                       | 300 mg                                                                                                                                                                                      | TID (during meal)                                                                                                                                                                           | Dyspepsia loose bowel motions, flatulence                                                                                                                                                   | None                                                                                                                                                                                        |\n\n\n| F. DPP4 inhibitors (Gliptins) Mechanism of action: Improve pancreatic islet glucose sensing →Increase glucose-medicated insulin secretion and suppresses glucagon secretion             | F. DPP4 inhibitors (Gliptins) Mechanism of action: Improve pancreatic islet glucose sensing →Increase glucose-medicated insulin secretion and suppresses glucagon secretion             | F. DPP4 inhibitors (Gliptins) Mechanism of action: Improve pancreatic islet glucose sensing →Increase glucose-medicated insulin secretion and suppresses glucagon secretion             | F. DPP4 inhibitors (Gliptins) Mechanism of action: Improve pancreatic islet glucose sensing →Increase glucose-medicated insulin secretion and suppresses glucagon secretion             | F. DPP4 inhibitors (Gliptins) Mechanism of action: Improve pancreatic islet glucose sensing →Increase glucose-medicated insulin secretion and suppresses glucagon secretion             | F. DPP4 inhibitors (Gliptins) Mechanism of action: Improve pancreatic islet glucose sensing →Increase glucose-medicated insulin secretion and suppresses glucagon secretion             |\n|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Vildagliptin                                                                                                                                                                            | 50 mg                                                                                                                                                                                   | 100 mg                                                                                                                                                                                  | OD or BD                                                                                                                                                                                | Urticaria, angioedema, and immune mediated dermatologic effects. Acute Pancreatitis, Risk of hypoglycaemia (in combination with sulfonylureas                                           | Sitagliptin 100 mg Saxagliptin 5 mg 10 mg                                                                                                                                               |\n|                                                                                                                                                                                         |                                                                                                                                                                                         |                                                                                                                                                                                         | OD                                                                                                                                                                                      | Urticaria, angioedema, and immune mediated dermatologic effects. Acute Pancreatitis, Risk of hypoglycaemia (in combination with sulfonylureas                                           | Sitagliptin 100 mg Saxagliptin 5 mg 10 mg                                                                                                                                               |\n|                                                                                                                                                                                         |                                                                                                                                                                                         |                                                                                                                                                                                         | OD                                                                                                                                                                                      | Urticaria, angioedema, and immune mediated dermatologic effects. Acute Pancreatitis, Risk of hypoglycaemia (in combination with sulfonylureas                                           | Sitagliptin 100 mg Saxagliptin 5 mg 10 mg                                                                                                                                               |\n| Linagliptin                                                                                                                                                                             | 5 mg                                                                                                                                                                                    | 5 mg                                                                                                                                                                                    | OD                                                                                                                                                                                      | Urticaria, angioedema, and immune mediated dermatologic effects. Acute Pancreatitis, Risk of hypoglycaemia (in combination with sulfonylureas                                           | Sitagliptin 100 mg Saxagliptin 5 mg 10 mg                                                                                                                                               |\n| G. SGLT-2 inhibitors Mechanism of action: Suppress renal glucose reabsorption by blocking the sodium-glucose co-transporter 2 (SGLT-2) resulting in increased urinary glucose excretion | G. SGLT-2 inhibitors Mechanism of action: Suppress renal glucose reabsorption by blocking the sodium-glucose co-transporter 2 (SGLT-2) resulting in increased urinary glucose excretion | G. SGLT-2 inhibitors Mechanism of action: Suppress renal glucose reabsorption by blocking the sodium-glucose co-transporter 2 (SGLT-2) resulting in increased urinary glucose excretion | G. SGLT-2 inhibitors Mechanism of action: Suppress renal glucose reabsorption by blocking the sodium-glucose co-transporter 2 (SGLT-2) resulting in increased urinary glucose excretion | G. SGLT-2 inhibitors Mechanism of action: Suppress renal glucose reabsorption by blocking the sodium-glucose co-transporter 2 (SGLT-2) resulting in increased urinary glucose excretion | G. SGLT-2 inhibitors Mechanism of action: Suppress renal glucose reabsorption by blocking the sodium-glucose co-transporter 2 (SGLT-2) resulting in increased urinary glucose excretion |\n| Canagliflozin                                                                                                                                                                           | 100 mg                                                                                                                                                                                  | 300 mg                                                                                                                                                                                  | OD                                                                                                                                                                                      | Polyurea, UTI, DKA, genital candidiasis, hypotension                                                                                                                                    | Renal failure (action dependent on normal GFR) Or sensitivity to active ingredients or it's excipients                                                                                  |\n| Dapagliflozin                                                                                                                                                                           | 5 mg                                                                                                                                                                                    | 10 mg                                                                                                                                                                                   | OD                                                                                                                                                                                      | Polyurea, UTI, DKA, genital candidiasis, hypotension                                                                                                                                    | Renal failure (action dependent on normal GFR) Or sensitivity to active ingredients or it's excipients                                                                                  |\n| Empagliflozin                                                                                                                                                                           | 10 mg                                                                                                                                                                                   | 25 mg                                                                                                                                                                                   | OD                                                                                                                                                                                      | Polyurea, UTI, DKA, genital candidiasis, hypotension                                                                                                                                    | Renal failure (action dependent on normal GFR) Or sensitivity to active ingredients or it's excipients                                                                                  |\n\n\n|                | Metformin                                                                     | Sulfonylurea                                    | Glinides                 | Pioglitazone Alpha-     | Glucosidase Inhibitors     | DPP-4 Inhibitors                                | GLP-1Agonists SGLT-2Inhibitors   |                                                                                                           |\n|----------------|-------------------------------------------------------------------------------|-------------------------------------------------|--------------------------|-------------------------|----------------------------|-------------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------|\n| Hypo           | Neutral                                                                       | Moderate/SevereModerate                         |                          | Neutral                 | Neutral                    | Neutral                                         | Neutral                          | Neutral                                                                                                   |\n| Weight         | Slight loss                                                                   | Gain                                            | Gain                     | Gain                    | Neutral                    | Neutral                                         | Loss                             | Loss                                                                                                      |\n| 3A,3B          | CKD stages Reduced dose inCaution higher stage 3A Contraindicated in stage 3B | risk hypo                                       | Caution higher risk hypo | r Neutral               | Neutral                    | Neutralbut must reduce dose except linagliptin  | Caution with exenatideER         | Contraindicatedin stage3B                                                                                 |\n| 4,5            | CKD stages Contraindicated                                                    | Contraindicated except glipizide and gliclazide | Contraindicated          |                         | ContraindicatedNeutral but | must reduce dose except linagliptin             |                                  | ContraindicatedContraindicated                                                                            |\n| GISE           | Moderate                                                                      | Neutral                                         | Neutral                  | Neutral                 | Moderate                   | Neutral                                         | Moderate                         | Neutral                                                                                                   |\n| OtherSE        |                                                                               |                                                 |                          | Edema and bone fracture |                            | Pancreatitis Heart failure (not a class effect) |                                  | Fungal genital infections, fractures, amputations (Bone fractures and amputationsmaynot be a class effect |\n| MajorCV events | Benefit                                                                       | Neutral                                         | Neutral                  | Neutral                 | Neutral                    | Neutral                                         | Benefit (2 RCT*)                 | Benefit (2 RCT*)                                                                                          |\n| CHF            | Neutral                                                                       | Neutral                                         | Neutral                  | Increased risk          | Neutral                    | Neutral                                         | Neutral                          | Benefit (2RCT**)                                                                                          |\n\n\nCKD, chronic kidney disease; CH, chronic heart failure; CV, cardiovascular; hypo, hypoglycemia; GI, gastrointestinal; SE, side effects; RCT, randomized controlled trial.\n\n\n* Reduced risk in RCTs designed for non-inferiority with liraglutide, semaglutide, empagliflozin and canagliflozin\n\n\n** Reduced risk in RCT designed for non-inferiority with empagliflozin and canagliflozin\n\n\nFigure 14: Risks and benefits of glucose-lowering agents (excluding insulin)\n\n\n(Source: IDF Clinical Practice Recommendations for managing Type 2 Diabetes in Primary Care - 2017)\n\n\n**ii. Insulin Therapy in type 2 diabetes**\n\n\nDiabetes is a progressive condition, and many patients with type 2 diabetes eventually require and benefit from insulin therapy. Early patient education about expected disease progression, and avoidance of threats of future insulin therapy is important thus easing the transition to insulin therapy.\n\n\nFigure 15: Initiating Insulin Therapy in Type 2 diabetes\n\n\n![Adapted from 'Guidelines for the Management of People with Type 2 Diabetes in Shropshire, 2013'](images/picture_035_page_65.png)\n\n\nAdapted from 'Guidelines for the Management of People with Type 2 Diabetes in Shropshire, 2013'\n\n\n**Additional indications for use of insulin in type 2 diabetes**\n\n\n- Presentation\tin\thyperglycemic\temergency\n- Peri-operative\tperiod\tespecially\tmajor\tor\temergency\tsurgery\n- Other\tmedical\tconditions\trequiring\ttight\tglycaemic\tcontrol\te.\tg\tacute\tMI, stroke, sepsis\n- Organ\tfailure\t(e.g.\trenal,\tliver,\theart)\n\n\nNB: Latent autoimmune diabetes of adults (LADA) is a subset of Type 1 DM presenting in adulthood. All patients diagnosed with LADA should receive insulin as with all type 1 DM patients.\n\n\n**The regimen and dose of insulin therapy varies from patient to patient.**\n\n\nFigure 15: Initiating pharmacotherapy in type 2 diabetes\n\n\n![Source: Adapted from the American Diabetes Association: Diabetes Care Journals http://care.diabetesjournals.org/content/40/Supplement_1/S64)](images/picture_036_page_66.png)\n\n\nSource: Adapted from the American Diabetes Association: Diabetes Care Journals http://care.diabetesjournals.org/content/40/Supplement\\_1/S64)\n\n\nDose titration / adjustment requires gradual, safe and prompt titration of insulin dose according to self-blood glucose monitoring (SMBG), towards an optimal dose to ensure maximum benefit from prescribed treatment. Advancing insulin therapy for patients not achieving HbA1c goals on optimally titrated basal insulin alone often requires premeal insulin dosing.\n\n\nTable 22: Adjusting dose of premixed insulin in adults with type 2\n\n\n| Fasting Glucose before Breakfast (in the absence of nocturnal hypos               | Lunch Pre Meal value                                                     | Evening Pre Meal value                                                            | Before Bed Value                                                                        |\n|-----------------------------------------------------------------------------------|--------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|\n| INSULIN This dose will affect pre- lunch and pre-evening meal glucose levels      |                                                                          | INSULIN This dose will affect bedtime and morning fasting glucose levels          |                                                                                         |\n| Target 4 to 7 mmol/L                                                              | Target 4 to 7 mmol/L                                                     | Target 4 to 7 mmol/L                                                              | Target 6 to 8 mmol/L                                                                    |\n| Blood Glucose Monitoring out of range?                                            | Blood Glucose Monitoring out of range?                                   | Blood Glucose Monitoring out of range?                                            | Blood Glucose Monitoring out of range?                                                  |\n| High = Increase previous evening's insulin by 2 units or 10% whichever is greater | High = Increase breakfast insulin by 2 units or 10% whichever is greater | High = Increase previous evening's insulin by 2 units or 10% whichever is greater | High = Increase evening meal insulin but not if blood tests at breakfast are 4-5 mmol/L |\n| Low = Decrease previous evening's insulin by 2 units or                           | Low = Decrease breakfast insulin by 2                                    | Low = Decrease breakfast insulin by 2                                             | Low = Decrease evening meal insulin                                                     |\n\n\nSource:  Adapted from Guidelines for the Management of People with Type 2 Diabetes in Shropshire, 2013\n\n\nInsulin is the most effective drug available to achieve glycemic targets in patients with T2DM yet there is reluctance among patients and physicians to initiate insulin. There are many barriers to insulin treatment among health care providers and patients.\n\n\nTable 23: Barriers to insulin therapy\n\n\n| PATIENT BARRIERS                                                                                                                                                                                                                                                                                                                                                                                                   | PROVIDER BARRIERS                                                                                                                                                                                                                                                                                                                                       | SYSTEM BARRIERS                                                                                                                                                                                                                                                                                                                                 |\n|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Psychological resistance • Myth-based fear of insulin • Fear of hypoglycaemia • Concern about weight gain • Fear of needles and pain • Self-blame • Loss of control • Social stigma Lifestyle • Time-consuming; inconve- nient • Travel issues Physical/mental • Poor recall/cognitive impair- ment • Visual/hearing/dexterity im- pairment • Learning difficulties; low literacy Financial • Reimbursement issues | Perceived patient resis- tance • Patient's adherence behaviour • Belief that patient's improved status ne- gates need to start insulin therapy • Concerns about ad- verse effects (hypoglycaemia; weight gain) • Provider time con- straints (instruction; titration) • Lack of resources/ or- ganizational structure to facilitate guideline adherence | Health system barriers • Overburdened workload among providers • Access to education • Limited training of provid- ers in injection technique • Underutilization of re - sources (within clinical practices, hospitals, and community) • Reimbursement issues • Poor follow-up system • Suboptimal team collabo- ration; poor chronic care mode |\n\n\nSource: Strategies for Insulin Injection Therapy in Diabetes Self-Management, American Association of Diabetes Educators, 2011\n\n\n**iii. Injectable GLP-1 agonists**\n\n\nGLP-1 receptor agonists bind to GLP-1 receptors on existing tissues (pancreas, hypothalamus and stomach). They act to pharmacologically enhance glucose-dependent insulin release, with additional effects on reducing glucagon release, increasing satiety, and increasing gastric emptying.\n\n\nGLP-1 agonists are currently only available in parenteral (subcutaneous) formulation. Two GLP-1 agonists are currently available: exenatide, which has a half-life of four hours and requires twice-daily injection, and liraglutide, which has a half-life of 11-13 hours and requires once-daily injections.\n\n\n### 2.2.3. Blood Glucose monitoring\n\n\nFigure 17: Self-Monitoring of Blood Glucose as a component of diabetes education\n\n\n![69 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS](images/picture_037_page_69.png)\n\n\nSelf-Monitoring of Blood Glucose (SMBG) is an approach whereby people living with diabetes measure their blood glucose themselves using a glucose meter (glucometer). Based on the reading, they can adjust or check the effect of their treatment (diet, exercise, insulin, OGLAs, stress management etc.). Within the wider context of diabetes self-management, self-monitoring supports the maintenance of blood glucose at levels as close as possible to target values.\n\n\nTo fully benefit from self-monitoring, it is essential that a person living with diabetes be trained by a health care professional on the following components:\n\n\n- The\ttechnical\taspects\tof\tself-monitoring;\n- Blood\tglucose\ttargets;\n- When\tand\thow\toften\tto\tmeasure\tblood\tglucose;\n- What\taction\tto\ttake\tbased\ton\tthe\treadings\tobtained;\n- Re-evaluating\t(every\t3\tto\t6\tmonths)\twhen,\tand\thow\toften,\tto self-monitor, based on your clinical condition and readings.\n\n\nWithout this information, self-monitoring of blood glucose will not fulfill its potential purpose, thus affecting the patient motivation and attainment of the treatment goals.\n\n\n**Type 1 DM**\n\n\nAt least 4\n\n\n2 to 8\n\n\n**Type 2 DM on Insulin or Insulin + OGLAs**\n\n\n**New onset DM/Uncontrolled DM/DM during acute illness**\n\n\n![times/day and should](images/picture_038_page_71.png)\n\n\ntimes/day and should\n\n\ninclude preprandial\n\n\nand bedtime times/day\n\n\n- Paired testing at least 3-4 days a week (1 day/week pre and post breakfast, 1 day per/week pre and post lunch, and 1 day/week pre and post dinner) or as\n\n\nfrequently as possible\n\n\n- At least 4 times/day and should include preprandial and bedtime levels\n- At least 4 times/day\n- At least FBG and one more preprandial\n- At least 4 tests in a week on 4 consecutive days or on alternate days (including 1 FBG and 3 postprandial values)\n\n\n**Type 2 DM on OGLAs**\n\n\n**New onset DM/Uncontrolled DM/DM during acute illness**\n\n\n![value every day](images/picture_039_page_71.png)\n\n\n- At least 4 times/ day and should\n- preprandial and bedtime levels\n\n\nvalue every day\n\n\nAt least 4 tests in a month - at least 1\n\n\n- At least FBG once a week\n- At least FBG on alternate days\n\n\ninclude levels\n\n\ntest/week (including\n\n\n1 FBG and 3\n\n\n- postprandial values\n\n\nin a month)\n\n\n**Diabetes in Pregnancy**\n\n\n![Initially one value/](images/picture_040_page_71.png)\n\n\n![Initially one value/](images/picture_041_page_71.png)\n\n\nInitially one value/\n\n\nday (different values on each\n\n\nPatients with\n\n\n- At least 4 times/day (FBG and 3 postprandial)\n- FBG and 3 postprandial values at least once a week or staggered over a week\n\n\nday)\n\n\n**Diabetes and Hypoglycemia Unawareness Brittle**\n\n\n**Patients on Premix Insulin, Basal Bolus Therapy**\n\n\n![Patients on Basal Insulin](images/picture_042_page_71.png)\n\n\n- 3 preprandial (including FBG) and 3 postprandial tests on alternate days till target HbA1c and blood glucose levels are reached\n\n\n**Patients on Basal Insulin**\n\n\n- After achievement of fasting target, postprandial correction should be done\n- Paired testing every day (pre and st post breakfast on 1  day, pre and nd post lunch on 2 day,  pre and rd post dinner on 3 day, and then to keep repeating the cycle)\n- One FBG and one postprandial value (any meal, preferably after largest meal of the day) every week\n- Less frequent testing can be done after achievement of the target (fasting and one meal-related testing can be done, can be staggered, changing every 2 days)\n- FBG twice a week or once in 3 days\n- After achievement of fasting target, postprandial\n- correction should be done\n\n\n**Figure 19: Guidance on Self-Monitoring of Blood Glucose for people living with diabetes**\n\n\n**(Source: Research Society for the Study of Diabetes in India, RSSDI)**\n\n\n**Methods for Monitoring Glycaemic Control**\n\n\nClinical and laboratory methods are employed to monitor or assess whether the individualized glycaemic targets are being attained.\n\n\n- HbA1c\tis\tthe\tstandard\ttest\tfor\tmonitoring\tglucose\tcontrol.\tThis\tshould\tbe\tdone every 3 months until patient is well controlled and subsequently every 6 months. (refer to table 18 for targets) Changes in therapy ought to be guided by glucose control as depicted by the HbA1c.\n- Self-monitoring\tof\tBlood\tGlucose\t(SMBG)\tshould\tbe\tencouraged.\tIt\tis\tthe\tmain measure used to titrate drug doses on a day to day basis\n- Results\tof\tself-blood\tglucose\ttests\tshould\tbe\trecorded\tin\ta\tlogbook\tor\tdiary indicating the day and time of testing\n- The\tclinic\tprotocol\tshould\tset\tout\tthe\tparameters\tto\tbe\tmonitored\tat\tthe\tinitial visit, regular follow-up visits, and at the annual review (refer to table 14  for assessment and follow-up)\n\n\n**Examples of Self-Monitoring of Blood Glucose (SMBG) testing profiles**\n\n\nIntensive\tor\t'focused'\tSMBG\tprotocols\tuse\t'pattern\tanalysis' ,\ta\tsystematic\tapproach\tto creating glucose profiles that can identify daily glycaemic patterns and then take appropriate action based upon those results. These profiles can be generated by performing 5 to\t7\tmeasurements\tper\tday\tover\t1\tto\t3\tdays,\tor\tthrough\t'staggered'\ttesting,\tin\twhich\tthe individual performs pre- and postprandial testing for alternating meals over the course of a week\n\n\nMeal-based SMBG (before and after selected meals) helps individuals living with diabetes understand the effects of their treatment on blood glucose concentrations and assists clinicians in identifying postprandial hyperglycaemia, guides therapeutic adjustments and provides more timely feedback regarding medication changes. The table below summarizes the SMBG testing profiles\n\n\nTable 24: Examples of Self-Monitoring of Blood Glucose (SMBG) testing profiles\n\n\n|                            | Testing points             | Testing points             | Testing points             | Testing points             | Testing points             | Testing points             | Testing points             |\n|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|\n| Day                        | Pre-Break- fast            | 2 hours Post- Breakfast    | Pre- lunch                 | 2-hours Post- lunch        | Pre-sup- per               | 2-hours post-sup- per      | Bedtime                    |\n| 7-point testing profile    | 7-point testing profile    | 7-point testing profile    | 7-point testing profile    | 7-point testing profile    | 7-point testing profile    | 7-point testing profile    | 7-point testing profile    |\n| Monday                     |                            |                            |                            |                            |                            |                            |                            |\n| Tuesday                    | X                          | X                          | X                          | X                          | X                          | X                          | X                          |\n| Wednesday                  | X                          | X                          | X                          | X                          | X                          | X                          | X                          |\n| Thursday                   | X                          | X                          | X                          | X                          | X                          | X                          | X                          |\n| Friday                     |                            |                            |                            |                            |                            |                            |                            |\n| Saturday                   |                            |                            |                            |                            |                            |                            |                            |\n| Sunday                     |                            |                            |                            |                            |                            |                            |                            |\n| Staggered testing profile  | Staggered testing profile  | Staggered testing profile  | Staggered testing profile  | Staggered testing profile  | Staggered testing profile  | Staggered testing profile  | Staggered testing profile  |\n| Monday                     | X                          | X                          |                            |                            |                            |                            |                            |\n| Tuesday                    |                            |                            | X                          | X                          |                            |                            |                            |\n| Wednesday                  |                            |                            |                            |                            | X                          | X                          |                            |\n| Thursday                   | X                          | X                          |                            |                            |                            |                            |                            |\n| Friday                     |                            |                            | X                          | X                          |                            |                            |                            |\n| Saturday                   |                            |                            |                            |                            | X                          | X                          |                            |\n| Sunday                     | X                          | X                          |                            |                            |                            |                            |                            |\n| Meal-based testing profile | Meal-based testing profile | Meal-based testing profile | Meal-based testing profile | Meal-based testing profile | Meal-based testing profile | Meal-based testing profile | Meal-based testing profile |\n| Monday                     | X                          | X                          |                            |                            |                            |                            |                            |\n| Tuesday                    |                            |                            |                            |                            |                            |                            |                            |\n| Wednesday                  |                            |                            | X                          | X                          |                            |                            |                            |\n| Thursday                   |                            |                            |                            |                            |                            |                            |                            |\n| Friday                     |                            |                            |                            |                            |                            |                            |                            |\n| Saturday                   |                            |                            |                            |                            | X                          | X                          |                            |\n| Sunday                     |                            |                            |                            |                            |                            |                            |                            |\n\n\nSource: IDF Guideline on Self-Monitoring of Blood Glucose in Non-Insulin Treated Type 2 Diabetes\n\n\nTable 25: Targets for HbA1c, fasting plasma glucose and postprandial glucose in different patient types\n\n\n| Patient type                                                                                   | Target HbA1c                  | Target FPG                    | Target PPG                                                         |\n|------------------------------------------------------------------------------------------------|-------------------------------|-------------------------------|--------------------------------------------------------------------|\n| Young Low risk Newly diagnosed                                                                 | < 6.5%                        | 4.0-7.0 mmol/l                | 4.4-7.8 mmol/l                                                     |\n| No cardiovascular disease Majority of patients                                                 | < 7%                          | 4.0-7.0 mmol/l                | 5.0 -10.0 mmol/l                                                   |\n| Elderly High risk (high cardio- vascular risk) Hypoglycaemic unaware Poor short-term prognosis | < 8%                          | 4.0-9.8 mmol/l                | < 11.0 mmol/l                                                      |\n| Targets for other measurement                                                                  | Targets for other measurement | Targets for other measurement | Targets for other measurement                                      |\n| Weight and height                                                                              |                               | BMI of 18.5 - 24.9 kg/m2      | A10% weight loss from the current weight if obese is recommend- ed |\n| Waist circumference                                                                            |                               | Male                          | Female                                                             |\n|                                                                                                |                               | <90 cm                        | <84 cm                                                             |\n| Blood pressure (mmHg)                                                                          |                               | systolic                      | diastolic                                                          |\n|                                                                                                |                               | <140 mmHg                     | < 90 mmHg                                                          |\n| If persistent, microalbuminuria / proteinuria                                                  |                               | <125 mmHg                     | <75 mmHg                                                           |\n| Lipids (fasting)                                                                               |                               | Male                          | Female                                                             |\n| Total cholesterol                                                                              |                               | <4.8 mmol/l                   | <4.8 mmol/l                                                        |\n| LDLcholesterol                                                                                 |                               | <2.6 mmol/l                   | <2.6 mmol/l                                                        |\n| HDLcholesterol                                                                                 |                               | >1.0 mmol/l                   | >1.3 mmol/l                                                        |\n| Triglycerides                                                                                  |                               | <1.7 mmol/l                   | <1.7 mmol/l                                                        |\n\n\nCHAPTER THREE\n\n\n75 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS\n\n\n",
        "startLine": 990,
        "endLine": 2605,
        "introContent": null,
        "sections": [
          {
            "id": "section-2-0",
            "level": "h2",
            "number": "2.0",
            "title": "2.0. Introduction",
            "slug": "20-introduction",
            "url": "/guidelines/chapter-two-management-of-diabetes/20-introduction",
            "parentId": "chapter-2",
            "breadcrumb": [
              "CHAPTER TWO: MANAGEMENT OF DIABETES",
              "2.0. Introduction"
            ],
            "tokenCount": 145,
            "content": "## 2.0. Introduction\n\n\nThe overall goal of diabetes management is to improve the quality of life and productivity of people living with diabetes, control comorbidities, and prevent complications by:\n\n\n- Early\tdiagnosis\n- Treatment\tto\ttarget\n- Regular\tscreening\tfor\tcomplications\tand\tcomorbid\tconditions\n- Education\ton\tdiabetes\tand\tcomplications,\tself-care\tand\tdiet\n- Community\tawareness\ton\tdiabetes\n- Establishing\tdiabetes\tcomprehensive\tcentres\tserved\tby\ta functional referral system\n- Having\ta\tmotivated,\tpassionate\tand\twell-educated\tdiabetes management team\n- Provision\tof\tessential\tcommodities\tand\ttechnologies\n\n\n",
            "startLine": 993,
            "endLine": 1008,
            "introContent": null,
            "keywords": [],
            "subsections": null
          },
          {
            "id": "section-2-1",
            "level": "h2",
            "number": "2.1",
            "title": "2.1. Management of Type 1 Diabetes",
            "slug": "21-management-of-type-1-diabetes",
            "url": "/guidelines/chapter-two-management-of-diabetes/21-management-of-type-1-diabetes",
            "parentId": "chapter-2",
            "breadcrumb": [
              "CHAPTER TWO: MANAGEMENT OF DIABETES",
              "2.1. Management of Type 1 Diabetes"
            ],
            "tokenCount": 7011,
            "content": "## 2.1. Management of Type 1 Diabetes\n\n\nAll children and adolescents with type 1 diabetes require insulin. Poorly controlled type 1 diabetes increases the risk of stunted growth and diabetes complications, including diabetic ketoacidosis.\n\n\nComprehensive Type 1 diabetes management includes:\n\n\n- a) Insulin treatment\n- b) Blood glucose monitoring\n- c) HbA1c monitoring\n- d) Nutritional management and physical activity\n- e) Diabetes education\n6. f ) Rules for sick days\n- g) Psychosocial support\n8. A thorough clinical assessment of a patient with type 1 diabetes is recommended\n\n\nbefore initiating any therapy and during ongoing therapy.\n\n\nTable 7: Patient assessment at initial and follow-up visits\n\n\n|                                                                              | Initial visit   | Three- to six-monthly visits   | Annual visit   |\n|------------------------------------------------------------------------------|-----------------|--------------------------------|----------------|\n| History                                                                      |                 |                                |                |\n| Symptoms of hyperglycaemia, and duration of symptoms*                        | X               | X                              | X              |\n| Hypoglycaemic symptoms**                                                     |                 | X                              | X              |\n| Relevant family history                                                      | X               |                                |                |\n| Other risk factors (e.g. low or high birthweight)                            | X               |                                |                |\n| Relevant medical history                                                     |                 |                                |                |\n| - Co-morbid conditions (autoimmune diseases e.g. Thyroid)                    | X               |                                | X              |\n| - Symptoms of complications: visual, infection, foot, edema and palpitations | X               | X                              | X              |\n| Drugs                                                                        |                 |                                |                |\n| - Current (Side-effects and adherence)                                       | X               | X                              | X              |\n| - Allergies                                                                  | X               |                                | X              |\n| Hypoglycaemic symptoms**                                                     | X               | X                              | X              |\n| Vaccinations                                                                 |                 |                                |                |\n| - KEPI (date)                                                                | X               | X                              | X              |\n| - Influenza (date)                                                           | X               |                                | X              |\n| - Pneumococcal***                                                            | X               |                                |                |\n| Lifestyle                                                                    |                 |                                |                |\n| - Weight /height                                                             | X               |                                | X              |\n| - Physical activity                                                          | X               |                                | X              |\n| - Eating pattern and food availability                                       | X               | X                              | X              |\n| - Teenagers: Alcohol and drug use, tobac- co use                             | X               | X                              | X              |\n| - Sexual activity                                                            | X               | X                              | X              |\n| Psychosocial support                                                         |                 |                                |                |\n| - Family, school and the community support                                   | X               |                                | X              |\n| - Depression, anxiety and other mental disorders                             | X               | X                              | X              |\n| Education                                                                    |                 |                                |                |\n| - Level of education and school perfor- mance                                | X               | X                              | X              |\n| - Absenteeism per term                                                       | X               | X                              | X              |\n| - Family and community support (Parent                                       | X               |                                | X              |\n| Home monitoring of blood glucose (glucometer and strips; chart)              | X               | X                              | X              |\n| Physical examination                                                         |                 |                                |                |\n| Weight                                                                       | X               | X                              | X              |\n\n\n| Height                                                                             | Height                                                                                     | X   | X   | X   |\n|------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|-----|-----|-----|\n| Body mass index (BMI) for age and sex                                              | Body mass index (BMI) for age and sex                                                      | X   | X   | X   |\n| Mid upper arm circumference (MUAC)                                                 | Mid upper arm circumference (MUAC)                                                         | X   | X   | X   |\n| Tanner pubertal staging                                                            | Tanner pubertal staging                                                                    | X   | X   | X   |\n| Blood pressure (mmHg)                                                              | Blood pressure (mmHg)                                                                      | X   | X   | X   |\n| Injection sites assessment                                                         | Injection sites assessment                                                                 | X   | X   | X   |\n| Oral cavity                                                                        | Oral cavity                                                                                |     |     |     |\n| -                                                                                  | Dental caries                                                                              | X   |     | X   |\n| -                                                                                  | Gum disease                                                                                | X   |     | X   |\n| Eyes                                                                               | Eyes                                                                                       |     |     |     |\n| -                                                                                  | Visual acuity                                                                              | X   |     | X   |\n| -                                                                                  | Direct fundoscopy (dilated pupils), indi- rect fundoscopy, or fundus photographs           | X   |     | Xa  |\n| Special investigations                                                             | Special investigations                                                                     |     |     |     |\n| Blood tests                                                                        | Blood tests                                                                                |     |     |     |\n| -                                                                                  | Glucose                                                                                    | X   | X   | X   |\n| -                                                                                  | HbA1c                                                                                      |     |     |     |\n| -                                                                                  | (Six-monthly if at target, otherwise three- monthly. Also, whenever treatment is adjusted) | X   | X   | X   |\n| -                                                                                  | TSH                                                                                        | X   |     | X   |\n| -                                                                                  | Lipids: Total cholesterol, HDLcholester- ol, LDLcholesterol, triglycerides                 |     |     | X   |\n| -                                                                                  | Creatinine, and calculate estimated GFR                                                    |     |     | X   |\n| -                                                                                  | Potassium                                                                                  |     |     | X   |\n| -                                                                                  | HIV                                                                                        | X   |     | X   |\n| Urine                                                                              | Urine                                                                                      |     |     |     |\n| -                                                                                  | Glucose                                                                                    | X   |     | X   |\n| -                                                                                  | Ketones                                                                                    | X   |     | X   |\n| -                                                                                  | Protein (current g/lines albumin/creati- nine ratio)                                       |     |     | X   |\n| Other important tasks                                                              | Other important tasks                                                                      |     |     |     |\n| Education: Self-management and lifestyle ad- justment, including smoking cessation | Education: Self-management and lifestyle ad- justment, including smoking cessation         | X   | X   | X   |\n| Setting goals                                                                      | Setting goals                                                                              | X   | X   | X   |\n| Family planning for teenagers and preconception counselling                        | Family planning for teenagers and preconception counselling                                | X   |     | X   |\n| Medication revision/adjustment                                                     | Medication revision/adjustment                                                             | X   | X   | X   |\n\n\n\n\na Int erval for ret inop at y  sc reening c an b e inc reased t o onc e every 2 y ears if t h e last  2 ex am inat ions w ere norm al; m ore frequent ex am inat ions are required in t h e p resenc e of ab norm alit ies.\n\n\n\n\n* y m om of h y p erg ly aem ia inc lude p oly dip sia,  h eadac es,  b lurred vision,  p oly uria,  fat ig ue/ b ody  m alaise,  w eig t  loss ** S y m om s/ sig ns of H y p og ly em iaS ak iness,  nervousness or anx iet y ,  sw eat ing c ills and c lam y  ex rem it ies,  irrit onfusion,  inc luding delirium t ac y c ardia,  lig eadedness or diz z iness,  h ung er and nausea,  b lurred/ im aired vision,  t ing ling or num ness in t h e lip s or t ong ue,  h eadac es,  w eak ness or fat ig ue,  m ood c ang es,  lac of c oordinat ion,  nig ares or c ry ing out  during sleep ,  seiz ures,  loss of c onsc iousness\n\n\n\n\n6\n\n\n4\n\n\n\n\n*** neum oc oc al vac ine sh ould b e adm inist ered onc e. R evac inat ion is rec om ended for individuals &gt; y r. if vac inat ed &gt; y rs. ag o,  or p at ient s w it renal disease,  asp lenia and im unoc om rom ised st at es\n\n\nab\n\n\n5\n\n\n\n\n,\n\n\n\n\n,\n\n\n\n\nilit y ,\n\n\n### 2.1.1. Insulin treatment\n\n\n**Types of Insulin**\n\n\n**There are two broad categories of insulin: -**\n\n\n**1. Human Insulin- comes in three forms:**\n\n\n- Short-acting\t(regular/soluble)\tinsulin\n- Intermediate-acting\tinsulin-\te.g.\tNeutral\tprotamine\tHagedorn (NPH) insulin, Humulin N, Insulatard,\n- Pre-mix\tshort-acting\t(regular)\tand\tintermediate-acting\t(NPH) insulins - usually in the combination 70/30 (Mixtard, Humulin), Humulin 50/50\n\n\n**2. Analogue insulin**\n\n\n**Examples are:**\n\n\n- Rapid-acting\t-\te.g.\tHumalog,\tNovo\trapid,\tApidra\n- Long-acting\t-\te.g.\tLevemir,\tLantus\n- Pre-mix\t-\te.g.\tHumalog\t75/25,\tNoVo\tmix\t70/30\n\n\n**The two most common regimens used are:**\n\n\n- i.   Basal bolus regimen (the preferred option) - with short or rapid acting insulin given with main meals (usually three times per day) and intermediate-acting or long-acting insulin given once or twice daily (evening, or morning and evening).\n- ii.   Twice-daily insulin using pre-mixed insulin or short acting and NPH\n\n\nTable 8: Types of Insulin, mode of action and administration of Insulin\n\n\n| Insulin type           | Common Brand Names                                                                     | Onset of Action   | Peak of action       | Duration of action   | When to give              |\n|------------------------|----------------------------------------------------------------------------------------|-------------------|----------------------|----------------------|---------------------------|\n| Rapid acting           | Insulin lispro (Humalog), In- sulin glulisine (Apidra) and Insulin aspart (NoVo Rapid) | 15-30 minutes     | 1-2 hours            | 3-5 hours            | immediately prior to meal |\n| Short acting (soluble) | Actrapid, Hu- mulin R                                                                  | 30-60 minutes     | 2-4 hours            | 5-8 hours            | 30 minutes prior to meal  |\n| Intermediate acting    | NPH, Humulin N, Insulatard                                                             | 2-4 hours         | 4-10 hours           | 12-24 hours          | 30 minutes prior to meal  |\n| Long-acting            | Insulin detemir (Levemir)                                                              | 1-2 hours         | 6-12 hours           | 20-24 hours          | once or twice daily       |\n| Long-acting            | Insulin glargine (Lan- tus)                                                            | 2-4 hours         | relatively peak-less | 24 hours or less     | once daily                |\n| Mixed                  | Humulin 70/30 or Mixtard 70/30 Humalog 75/25                                           | 30 minutes        | 4-12 hours           | 8-24 hours           | 30 minutes prior to meal  |\n\n\n**Insulin requirements**\n\n\n- Pre-pubertal\tchildren\t(outside\tthe\tpartial\tremission\tphase)\tusually require 0.5-1.0 IU/kg/day.\n- During\tpuberty,\trequirements\tmay\trise\tsubstantially\tabove\t1\tand even up to 2 U/kg/day.\n- The\t''correct''\tdose\tof\tinsulin\tis\tthat\twhich\tachieves\tthe\tbest\tattainable glycaemic control for an individual child or adolescent, without causing obvious Hypoglycemia, and resulting in normal growth and development.\n\n\n**Initiating therapy in a child who is not in DKA**\n\n\nDuring insulin initiation, calculate a total daily dose of 0.5-0.75 U/kg/day. This can be given using either of the following regimens:\n\n\n- a. Basal bolus regimen\n- b. Twice-daily injections\n- C. Basal Bolus Regimen - also called Multiple Daily Injections (MDI). This is the preferred option.\n\n\n**This regimen can be given using two combinations**\n\n\n- Short-acting\tand\tlong-acting\tinsulin\tanalogues\n- Short-acting\tand\tintermediate-acting\tinsulin\tanalogues\n- i. Short-acting and long-acting insulin analogues If short-acting (soluble)/rapid acting and long-acting analogue insulins are used, give:\n- 60%\tof\tthe\ttotal\tdaily\tdose\tas\tshort-acting\t(soluble)\tinsulin\t(divided\tup between 3-4 pre-meal boluses)\n- 40%\tof\tthe\ttotal\tdaily\tdose\tas\ta\tsingle\tevening\tinjection\tof\tlong-acting analogue insulin. (Sometimes this dose does not last for 24 hours and then can be split into two doses - morning and evening).\n\n\n**Exampl e:**\n\n\nFor a 4 2-kg chil d who is started on 0 .5 U kg / day, the total daily dose is 21 units.\n\n\n/\n\n\nTable 9: Example of administration of short- and long-acting insulin as multiple daily injections\n\n\n|                  | Short-acting   | Long-acting   |\n|------------------|----------------|---------------|\n| Before breakfast | 4 Units        |               |\n| Before lunch     | 4 Units        |               |\n| Before dinner    | 4 Units        | 9 Units       |\n\n\n(rounded off to the nearest whole number).\n\n\nPre-meal doses can be adjusted depending on the size and frequency of the patient meals\n\n\n**ii. Short-acting and intermediate-acting insulin analogues**\n\n\nIf short-acting (soluble) and intermediate-acting insulin is used, give:\n\n\n- 70%\tof\tthe\ttotal\tdaily\tdose\tas\tshort-acting\t(soluble)\tinsulin (divided up between 3-4 pre-meal boluses)\n- 30%\tof\tthe\ttotal\tdaily\tdose\tas\ta\tsingle\tevening\tinjection\tof intermediate-acting insulin\n\n\n**Example:**\n\n\nFor a 42-kg child who is started on 0.5 U/kg/day , the total daily dose is 21 Units.\n\n\nTable 10: Example of administration of Short and Intermediate-acting Insulin as multiple daily injections. as multiple daily injections.\n\n\n|                  | Short-acting (soluble insulin) Intermediate-acting (NPH)   |         |\n|------------------|------------------------------------------------------------|---------|\n| Before breakfast | 5 Units                                                    |         |\n| Before lunch     | 5 Units                                                    |         |\n| Before dinner    | 5 Units                                                    | 6 Units |\n\n\n(rounded off to the nearest whole number)\n\n\nPre-meal doses can be adjusted depending on the size and frequency of the patient meals\n\n\nNB: In circumstances where meals are skipped or food is not available, Give the intermediate- acting insulin and skip the short acting insulin until the food is available. Do NOT completely stop insulin administration. Subsequently, doses can be adjusted daily according to blood glucose levels.\n\n\n**b. Twice daily injections**\n\n\nA starting point is to give two-thirds of the total daily insulin in the morning before breakfast and one-third before the evening meal. This may be given as pre-mixed insulin or short acting and intermediate acting insulin separately.\n\n\n**Example:**\n\n\nFor a 42-kg child who is started on 0.5 U/kg/day, the total daily dose is 21 Units. Two-thirds of this dose (14 units) is given in the morning (before breakfast), and one-third of the dose (7 units) before the evening meal. At each injection, 1/3 is short acting and 2/3 is intermediate-acting.\n\n\nTable 11: Example of administration of Short acting, Intermediate-acting and pre-mixed Insulin\n\n\n| Before breakfast    | Short-acting 5 Units   | Intermediate-acting 9 Units   | Pre-mixed insulin 14 Units   |\n|---------------------|------------------------|-------------------------------|------------------------------|\n| Before evening meal | 2 Units                | 5 Units                       | 7 Units                      |\n\n\n(rounded off to the nearest whole number)\n\n\n**It is important to note that:**\n\n\n- i. Insulin requirements can decrease for a time during the 'honeymoon period'  before rising again.\n- ii. The total daily dose required will generally increase as the child grows, and once puberty ensues a higher dose per kg per day is often needed.\n\n\nDuring  periods  of  regular  change  in  consumption  of  food  (e.g.  Ramadan)  the  total amount of insulin should not be reduced but redistributed according to the amount and timing of carbohydrate intake. However, if the total calorie intake is reduced during Ramadan, the daily amount of bolus insulin for meals usually needs to be reduced, for example to two-thirds or three-quarters of the usual dose.\n\n\n**Insulin injection techniques**\n\n\nProper injection technique is vital to ensure insulin is administered in the subcutaneous tissue. It is important to avoid intramuscular insulin injections.\n\n\nWhen starting the patient on insulin, the healthcare provider needs to ensure that the patient understands each of these essential topics\n\n\n- a. The Injection regimen\n\n\nOnce daily, twice daily or basal bolus\n\n\n**b. Choice of devices used**\n\n\n- o insulin vial and syringes or\n- o pen device\n\n\n**Howtoinject insulinwith a syringe**\n\n\n![Washyourhands.](images/picture_016_page_36.png)\n\n\n![Washyourhands.](images/picture_017_page_36.png)\n\n\nWashyourhands.\n\n\nCheckthe Insulin for lumps,crystals or discoloring.\n\n\nGentlyrollcloudy Insulin betweenyour handsuntil it is unitormly cloudy.\n\n\nNever shake Insulin.\n\n\nWipethetopofthe insulinvialwithaclean cloth/swab\n\n\n![Pull the plungerdown to letunitsof alr into the syringe.](images/picture_018_page_36.png)\n\n\nPull the plungerdown to letunitsof alr into the syringe.\n\n\nThe unitsofalr should equal the units of insulin that you plan to inject.\n\n\n![The unitsofalr should equal the units of insulin that you plan to inject.](images/picture_019_page_36.png)\n\n\n![The unitsofalr should equal the units of insulin that you plan to inject.](images/picture_020_page_36.png)\n\n\n![Figure 22](images/picture_021_page_36.png)\n\n\n![Figure 23](images/picture_022_page_36.png)\n\n\n![Figure 24](images/picture_023_page_36.png)\n\n\n![Push the alrinto the Insulinbottle.](images/picture_024_page_36.png)\n\n\n![Push the alrinto the Insulinbottle.](images/picture_025_page_36.png)\n\n\nPush the alrinto the Insulinbottle.\n\n\nLeave theneedle Inthe bottle.\n\n\nTurn theInsulinbottleand syringeupside down.\n\n\nBesure theneedleIsIn the Insulin,notIn theair space inside thebottle.\n\n\nPull theplungerdown to get\\_units of insulin into the syringe.\n\n\nFigure 5: Injection technique using an insulin syringe (Source: Optimizing Injection Technique in Diabetes Management Recommendations for Best Practice in Injection Technique, FIT guidelines South Africa, 1st edition)\n\n\nLookforairbubblesinthe syringe.lf there are alr bubbles,push the Insulin backIntothebottleand start againfrom step5.\n\n\nWhenyouhavetherlght Insulinunitswithnoalr bubbles,pull the syringe outof thebottle.\n\n\nClean theinjectionsite using a clean swab/cloth andletthesitedrybefore injecting\n\n\nPlnch up the area of skin thatyou wiped\n\n\nHold the syringe like a pencll.Besure the needle does nottouchanything.\n\n\nPush theneedle Into the pinchedskin ata90degree angle.Pushthe plunger to Inject the Insulin.\n\n\nRelease the pinch,thenpull the syringe needleout of your skin.\n\n\nlfyounotice a drop of blood,pressafingeronthe Injectionspot forafew seconds.\n\n\nPlace the used syringe Into a sharps container.\n\n\nDonotreuse the syringe\n\n\n**Partsofaninsulinsyringe**\n\n\n![How to inject](images/picture_026_page_37.png)\n\n\n**How to inject**\n\n\nWipe thetopof theinsulin bottle.Arrange your supplles.Washyour hands. To expose theplunger, twist thewhiteplungercap then pullit off.\n\n\nPull theinsulin syringe plunger down;align the thinblacklineofthe plunger(closest to the needle)withthedesired numberof units on the insulin syringe.You needair in theinsulin syringe equal to theamountof insulinyou willtake.\n\n\nPullthe plunger down slowly. Alignthethinblacklineofthe plunger(closest to the needle)withthedesired number of unitsonthe insulin syringe.\n\n\nHold the insulin syringe like apencil.Pinch upyour skin andpush the needle quickly through the skin at 90'(straight in)to the skin surface.Push the insulin in\n\n\n10\n\n\n8\n\n\n11\n\n\nIfyou aretaking cloudy insulin,rollthebottle betweenyour hands until it isuniformly cloudy.To avoid theformationofairbubbles, donot shake thebottleof insulin.\n\n\nHold theinsulin syringe like apencil.Push the needle straightthrough the center of therubbertopof the insulinbottleandpush the plunger down completely.\n\n\nIf airbubbles appear in theinsulin syringe,inject theinsulin backinto the vial.Thenredrawtheinsulin following steps6and7.\n\n\nDo notrecap used needles. Use the needle once and dispose ofit properly.\n\n\nFigure 6: Injection Technique using the insulin pen (Source: Optimizing Injection Technique in Diabetes Management Recommendations for Best Practice in Injection Technique, FIT guidelines South Africa, 1 st edition)\n\n\n![To expose theneedle,twist theorange needle shield then pull it straightoff. being carefulnotto bend the needleor let the needle touch anything.](images/picture_027_page_37.png)\n\n\nTo expose theneedle,twist theorange needle shield then pull it straightoff. being carefulnotto bend the needleor let the needle touch anything.\n\n\nLeave theneedle inthe insulinbottle.Carefullyturn thebottle and theinsulin syringeupside down sothe bottle is on top.\n\n\nConfirm thedoseiscorrect, and thencleana small area of skin.Letit dry completely before injecting.\n\n\n**Pen device**\n\n\nFigure7:  Structure of an Insulin Pen Device and how to use it.\n\n\n![c. Proper injection techniques](images/picture_028_page_38.png)\n\n\n**c. Proper injection techniques**\n\n\nDemonstrate the injection technique to the patient and the caregiver/family and have the patient repeat back before they leave.\n\n\n- -Injection sites: These are the abdomen, thighs, buttocks and upper arm. Injection sites should be clean disinfection of injection site is usually not required outside the hospital settings. Patients should never inject into sites of lipohypertrophy, inflammation or other lesions. (Refer to figure 14)\n- -Sites rotation is important to avoid lipohypertrophy. Patients should be given an easy to follow rotation scheme from the beginning of therapy which should be reviewed annually.\n- -Injection at a 900 angle unless the patient is very thin\n- -Use of lifted skin folds: A correct skin fold is made by lifting the skin with the thumb and index finger. Refer to figure 6 and 7)\n\n\n**Insulin injection sites for adults**\n\n\nFigure 8: Adult Insulin Injection Sites\n\n\n![39 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS](images/picture_029_page_39.png)\n\n\nFigure9: Recommended sites for injection in children\n\n\n![(Source: Optimizing Injection Technique in Diabetes Management Recommendations for Best Practice in Injection Technique, FIT guidelines South Africa, 1st edition)](images/picture_030_page_40.png)\n\n\n(Source: Optimizing Injection Technique in Diabetes Management Recommendations for Best Practice in Injection Technique, FIT guidelines South Africa, 1st edition)\n\n\n**d. Injection complications and how to avoid them (lipohypertrophy)**\n\n\n- e. Optimal needle length - use of shorter needles which are less traumatic to the patient and help in insulin adherence.\n\n\nShorter needles also reduce the incidence of intramuscular injections which can lead to more rapid insulin absorption and hypoglycemia\n\n\n- -Children: 6 mm for the insulin syringes and 4 - 6 mm in pen device\n- -Adults: 4 mm to 8 mm\n\n\n**f. Safe disposal of used sharps**\n\n\nCorrect disposal procedure of used insulin syringes/needles should be taught to the patient (storing in sealed containers and brought to the hospital for proper disposal). Sharps should NEVER be placed directly in household or public trash.\n\n\n**Insulin storage**\n\n\n- i. Insulin vials should be stored at 4-8 °C in a refrigerator where available or in some other method of cooler. In hot climates where refrigeration is not available, cooling jars, earthenware pot, and charcoal pot will help to preserve insulin activity.\n- ii. If using PEN device, insulin can be kept at room temperature for 28 days iii. Insulin must NEVER be frozen.\n- iv. Direct sunlight or extreme heat (in hot climates or in a vehicle) damages insulin.\n- v. Patients should not use insulins that have changed in appearance (clumping, frosting, precipitation, or discolouration).\n- vi. Once opened, an insulin vial should be discarded after 4 weeks.\n\n\n### 2.1.2. Blood Glucose Monitoring\n\n\nBlood glucose monitoring is essential in the safe management of childhood and adolescent diabetes to help prevent acute and chronic complications, and educate and empower the child and family. Every patient must have a glucometer and blood glucose test strips\n\n\nPatterns of blood glucose levels are generally more useful than single blood glucose readings. In case of scarce blood glucose testing strips, structured(point) testing for 2-3 consecutive day's pre-and post-meal will be better than staggered testing (Table 20).\n\n\nIf strips are readily available, a blood glucose test should regularly be done before each meal and at bedtime, prior to and following exercise.\n\n\nExercise, physical activity or play may result in low BGLs during or immediately after exercise, or a delayed hypoglycaemic effect many hours later (up to 16 hours). All blood glucose reading should be recorded in a diary or book indicating the date and time.\n\n\nTable 12: Recommended Target Blood Glucose Levels and HbA1c\n\n\n| Measurement       | Recommended level   |\n|-------------------|---------------------|\n| Pre-meal glucose  | 4.0 -7.0 mmol/L     |\n| Post-meal glucose | 5.0 -10.0 mmol/L    |\n| Bedtime glucose   | 6.0 - 10.0 mmol/L   |\n| 3 a.m. glucose    | 5.0-8.0 mmol/L      |\n| HbA1c             | <7.5%               |\n\n\nGlycaemic targets can relaxed accordingly to protect against hypoglycaemia if regular SMBG is not available\n\n\nTable 13: Interpretation of Blood Glucose Level (BGL)\n\n\n| Blood Glucose Level (BGL)                                        | Interpretation                                                               |\n|------------------------------------------------------------------|------------------------------------------------------------------------------|\n| Pre-meal BGLis always high                                       | Preceding dose of intermediate or long-act- ing insulin is insufficient      |\n| Pre-meal BGLis always low                                        | Previous dose of intermediate or long-acting insulin is too high             |\n| Pre-meal BGLis some- times very high and at other times very low | Either insulin, food or exercise are not con- sistent and should be reviewed |\n| BGL2 hours after the meal is too high                            | The meal dose of short-acting (regular) insu- lin was too low                |\n| BGL2 hours' post-meal is too low                                 | The previous meal dose of short-acting (reg- ular) insulin was too high      |\n\n\nNOTE: It is important to note that the level of blood glucose can rise in the early morning (dawn phenomenon). Therefore, care should be taken if increasing the evening intermediate/long-acting dose as hypoglycemia can occur in the middle of the night and this can be dangerous.\n\n\n**Correction Factor: How to Lower Pre-Meal Hyperglycemia**\n\n\nA constant correction factor (CF) is used to calculate insulin sensitivity factor (ISF) for everyone depending on the type of insulin used.\n\n\nThe insulin sensitivity factor is a number that gives the level of glucose change expected per unit of insulin increase or decrease.\n\n\n**The CF/TDD=ISF**\n\n\n1 unit of insulin causes a change of glucose level equivalent to the calculated ISF.\n\n\n### 2.1.3. Educating a child living with diabetes and his/her family\n\n\nA child living with diabetes and the family should be educated on the following aspects of diabetes management:\n\n\n- Insulin\tsecretion,\taction,\tand\tphysiology\n- Insulin\tinjections,\ttypes,\tabsorption,\taction\tprofiles,\tvariability\tand adjustments\n- Nutrition\t-\tfood\tplans;\tqualitative\tand\tquantitative\tadvice\ton\tintake\tof carbohydrate, fat, proteins, and fibre; coping with special events and eating out;\tgrowth\tand\tweight\tgain;\t'diabetic\tfoods';\tsweeteners\tand\tdrinks, prevention of disordered eating\n- Monitoring\t(glucose,\tketone),\tincluding\tglycated\themoglobin\tand\tagreed glucose targets\n- Hypoglycemia\tand\tits\tprevention,\trecognition\tand\tmanagement\tincluding use of glucagon\n- Hyperglycemia\tprevention,\trecognition\tand\tmanagement\n- Sick\tday\tmanagement:\tketosis,\tand\tprevention\tof\tketoacidosis\n- Problem-solving\tand\tadjustments\tto\ttreatment\tin\teveryday\tlife,\tmotivation\tand coping with unexpected glucose fluctuations\n- Goal\tsetting\n- Micro-\tand\tmacrovascular\tcomplications\tand\ttheir\tprevention,\tand\tthe\tneed for regular assessment\n- Exercise,\tholiday\tplanning,\tand\ttravel,\tincluding\teducational\tholidays\tand\tcamps\n- Smoking,\talcohol,\tand\tdrugs\n- Diabetes\tin\tschools\n- Sexuality,\tcontraception,\tpregnancy,\tand\tchildbirth\n\n\n### 2.1.4. Nutritional management in Children living with diabetes and his/her family\n\n\n- Children\tliving\twith\tdiabetes\tneed\ta\thealthy\tdiet\twith\tfood\tin\tamounts\tand proportions appropriate to the age and stage of growth (use the healthy plate model)\n- Nutritional\tcounselling\tshould\tbe\tadapted\tto\tcultural,\tethnic\tand\tfamily traditions as well as the cognitive and psychosocial needs of the individual child\n- Match\tthe\tdose,\ttype\tand\tregimen\tof\tinsulin\tto\tthe\tamount\tand\ttiming\tof\tfood\n- Include\ta\thealthy\tsnack\tbetween\tthe\tmain\tmeals,\tbefore,\tduring\tand\tafter exercise\n- Nutritional\tadvice\tshould\taddress\tfood\tavailability/food\tinsecurity,\tdiet,\tfood\tin take and physical activity patterns\n- Excessive\trestriction\tof\tcarbohydrate\tintake\tto\tlower\tblood\tglucose\tlevels should  be avoided\n- Sugary\tsoft\tdrinks\tor\tfoods\twith\thigh\tlevels\tof\tsaturated\tfat\tshould\tbe\tavoided.\n- Prevention\tand\tmanagement\tof\thypoglycemia,\tparticularly\tbefore,\tduring\tand after exercise should be addressed\n- Education\tshould\tinclude\tpreventing\thypoglycemia\n\n\n- Ideally\tthere\tshould\tbe\tan\texperienced\tdietitian\tin\tthe\tdiabetes\tteam\twho ought  to have individualized sessions with the child and the family/ caregiver\n- Unexpected\tweight\tloss\tmay\tbe\ta\tsign\tof\t(1)\tillness\te.g.\tinfections,\tcoeliac disease etc., (2) insulin omission, or (3) an eating disorder\n- Growth\tmonitoring\tshould\tbe\tdone\tuntil\tthe\tage\tof\t18\tyears\n\n\n",
            "startLine": 1009,
            "endLine": 1667,
            "introContent": {
              "content": "All children and adolescents with type 1 diabetes require insulin. Poorly controlled type 1 diabetes increases the risk of stunted growth and diabetes complications, including diabetic ketoacidosis.\n\n\nComprehensive Type 1 diabetes management includes:\n\n\n- a) Insulin treatment\n- b) Blood glucose monitoring\n- c) HbA1c monitoring\n- d) Nutritional management and physical activity\n- e) Diabetes education\n6. f ) Rules for sick days\n- g) Psychosocial support\n8. A thorough clinical assessment of a patient with type 1 diabetes is recommended\n\n\nbefore initiating any therapy and during ongoing therapy.\n\n\nTable 7: Patient assessment at initial and follow-up visits\n\n\n|                                                                              | Initial visit   | Three- to six-monthly visits   | Annual visit   |\n|------------------------------------------------------------------------------|-----------------|--------------------------------|----------------|\n| History                                                                      |                 |                                |                |\n| Symptoms of hyperglycaemia, and duration of symptoms*                        | X               | X                              | X              |\n| Hypoglycaemic symptoms**                                                     |                 | X                              | X              |\n| Relevant family history                                                      | X               |                                |                |\n| Other risk factors (e.g. low or high birthweight)                            | X               |                                |                |\n| Relevant medical history                                                     |                 |                                |                |\n| - Co-morbid conditions (autoimmune diseases e.g. Thyroid)                    | X               |                                | X              |\n| - Symptoms of complications: visual, infection, foot, edema and palpitations | X               | X                              | X              |\n| Drugs                                                                        |                 |                                |                |\n| - Current (Side-effects and adherence)                                       | X               | X                              | X              |\n| - Allergies                                                                  | X               |                                | X              |\n| Hypoglycaemic symptoms**                                                     | X               | X                              | X              |\n| Vaccinations                                                                 |                 |                                |                |\n| - KEPI (date)                                                                | X               | X                              | X              |\n| - Influenza (date)                                                           | X               |                                | X              |\n| - Pneumococcal***                                                            | X               |                                |                |\n| Lifestyle                                                                    |                 |                                |                |\n| - Weight /height                                                             | X               |                                | X              |\n| - Physical activity                                                          | X               |                                | X              |\n| - Eating pattern and food availability                                       | X               | X                              | X              |\n| - Teenagers: Alcohol and drug use, tobac- co use                             | X               | X                              | X              |\n| - Sexual activity                                                            | X               | X                              | X              |\n| Psychosocial support                                                         |                 |                                |                |\n| - Family, school and the community support                                   | X               |                                | X              |\n| - Depression, anxiety and other mental disorders                             | X               | X                              | X              |\n| Education                                                                    |                 |                                |                |\n| - Level of education and school perfor- mance                                | X               | X                              | X              |\n| - Absenteeism per term                                                       | X               | X                              | X              |\n| - Family and community support (Parent                                       | X               |                                | X              |\n| Home monitoring of blood glucose (glucometer and strips; chart)              | X               | X                              | X              |\n| Physical examination                                                         |                 |                                |                |\n| Weight                                                                       | X               | X                              | X              |\n\n\n| Height                                                                             | Height                                                                                     | X   | X   | X   |\n|------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|-----|-----|-----|\n| Body mass index (BMI) for age and sex                                              | Body mass index (BMI) for age and sex                                                      | X   | X   | X   |\n| Mid upper arm circumference (MUAC)                                                 | Mid upper arm circumference (MUAC)                                                         | X   | X   | X   |\n| Tanner pubertal staging                                                            | Tanner pubertal staging                                                                    | X   | X   | X   |\n| Blood pressure (mmHg)                                                              | Blood pressure (mmHg)                                                                      | X   | X   | X   |\n| Injection sites assessment                                                         | Injection sites assessment                                                                 | X   | X   | X   |\n| Oral cavity                                                                        | Oral cavity                                                                                |     |     |     |\n| -                                                                                  | Dental caries                                                                              | X   |     | X   |\n| -                                                                                  | Gum disease                                                                                | X   |     | X   |\n| Eyes                                                                               | Eyes                                                                                       |     |     |     |\n| -                                                                                  | Visual acuity                                                                              | X   |     | X   |\n| -                                                                                  | Direct fundoscopy (dilated pupils), indi- rect fundoscopy, or fundus photographs           | X   |     | Xa  |\n| Special investigations                                                             | Special investigations                                                                     |     |     |     |\n| Blood tests                                                                        | Blood tests                                                                                |     |     |     |\n| -                                                                                  | Glucose                                                                                    | X   | X   | X   |\n| -                                                                                  | HbA1c                                                                                      |     |     |     |\n| -                                                                                  | (Six-monthly if at target, otherwise three- monthly. Also, whenever treatment is adjusted) | X   | X   | X   |\n| -                                                                                  | TSH                                                                                        | X   |     | X   |\n| -                                                                                  | Lipids: Total cholesterol, HDLcholester- ol, LDLcholesterol, triglycerides                 |     |     | X   |\n| -                                                                                  | Creatinine, and calculate estimated GFR                                                    |     |     | X   |\n| -                                                                                  | Potassium                                                                                  |     |     | X   |\n| -                                                                                  | HIV                                                                                        | X   |     | X   |\n| Urine                                                                              | Urine                                                                                      |     |     |     |\n| -                                                                                  | Glucose                                                                                    | X   |     | X   |\n| -                                                                                  | Ketones                                                                                    | X   |     | X   |\n| -                                                                                  | Protein (current g/lines albumin/creati- nine ratio)                                       |     |     | X   |\n| Other important tasks                                                              | Other important tasks                                                                      |     |     |     |\n| Education: Self-management and lifestyle ad- justment, including smoking cessation | Education: Self-management and lifestyle ad- justment, including smoking cessation         | X   | X   | X   |\n| Setting goals                                                                      | Setting goals                                                                              | X   | X   | X   |\n| Family planning for teenagers and preconception counselling                        | Family planning for teenagers and preconception counselling                                | X   |     | X   |\n| Medication revision/adjustment                                                     | Medication revision/adjustment                                                             | X   | X   | X   |\n\n\n\n\na Int erval for ret inop at y  sc reening c an b e inc reased t o onc e every 2 y ears if t h e last  2 ex am inat ions w ere norm al; m ore frequent ex am inat ions are required in t h e p resenc e of ab norm alit ies.\n\n\n\n\n* y m om of h y p erg ly aem ia inc lude p oly dip sia,  h eadac es,  b lurred vision,  p oly uria,  fat ig ue/ b ody  m alaise,  w eig t  loss ** S y m om s/ sig ns of H y p og ly em iaS ak iness,  nervousness or anx iet y ,  sw eat ing c ills and c lam y  ex rem it ies,  irrit onfusion,  inc luding delirium t ac y c ardia,  lig eadedness or diz z iness,  h ung er and nausea,  b lurred/ im aired vision,  t ing ling or num ness in t h e lip s or t ong ue,  h eadac es,  w eak ness or fat ig ue,  m ood c ang es,  lac of c oordinat ion,  nig ares or c ry ing out  during sleep ,  seiz ures,  loss of c onsc iousness\n\n\n\n\n6\n\n\n4\n\n\n\n\n*** neum oc oc al vac ine sh ould b e adm inist ered onc e. R evac inat ion is rec om ended for individuals &gt; y r. if vac inat ed &gt; y rs. ag o,  or p at ient s w it renal disease,  asp lenia and im unoc om rom ised st at es\n\n\nab\n\n\n5\n\n\n\n\n,\n\n\n\n\n,\n\n\n\n\nilit y ,",
              "tokenCount": 1826,
              "startLine": 1010,
              "endLine": 1147
            },
            "keywords": [],
            "subsections": [
              {
                "id": "subsection-2-1-1",
                "level": "h3",
                "number": "2.1.1",
                "title": "2.1.1. Insulin treatment",
                "slug": "211-insulin-treatment",
                "url": "/guidelines/21-management-of-type-1-diabetes/211-insulin-treatment",
                "parentId": "section-2-1",
                "breadcrumb": [
                  "CHAPTER TWO: MANAGEMENT OF DIABETES",
                  "2.1. Management of Type 1 Diabetes",
                  "2.1.1. Insulin treatment"
                ],
                "tokenCount": 3766,
                "content": "### 2.1.1. Insulin treatment\n\n\n**Types of Insulin**\n\n\n**There are two broad categories of insulin: -**\n\n\n**1. Human Insulin- comes in three forms:**\n\n\n- Short-acting\t(regular/soluble)\tinsulin\n- Intermediate-acting\tinsulin-\te.g.\tNeutral\tprotamine\tHagedorn (NPH) insulin, Humulin N, Insulatard,\n- Pre-mix\tshort-acting\t(regular)\tand\tintermediate-acting\t(NPH) insulins - usually in the combination 70/30 (Mixtard, Humulin), Humulin 50/50\n\n\n**2. Analogue insulin**\n\n\n**Examples are:**\n\n\n- Rapid-acting\t-\te.g.\tHumalog,\tNovo\trapid,\tApidra\n- Long-acting\t-\te.g.\tLevemir,\tLantus\n- Pre-mix\t-\te.g.\tHumalog\t75/25,\tNoVo\tmix\t70/30\n\n\n**The two most common regimens used are:**\n\n\n- i.   Basal bolus regimen (the preferred option) - with short or rapid acting insulin given with main meals (usually three times per day) and intermediate-acting or long-acting insulin given once or twice daily (evening, or morning and evening).\n- ii.   Twice-daily insulin using pre-mixed insulin or short acting and NPH\n\n\nTable 8: Types of Insulin, mode of action and administration of Insulin\n\n\n| Insulin type           | Common Brand Names                                                                     | Onset of Action   | Peak of action       | Duration of action   | When to give              |\n|------------------------|----------------------------------------------------------------------------------------|-------------------|----------------------|----------------------|---------------------------|\n| Rapid acting           | Insulin lispro (Humalog), In- sulin glulisine (Apidra) and Insulin aspart (NoVo Rapid) | 15-30 minutes     | 1-2 hours            | 3-5 hours            | immediately prior to meal |\n| Short acting (soluble) | Actrapid, Hu- mulin R                                                                  | 30-60 minutes     | 2-4 hours            | 5-8 hours            | 30 minutes prior to meal  |\n| Intermediate acting    | NPH, Humulin N, Insulatard                                                             | 2-4 hours         | 4-10 hours           | 12-24 hours          | 30 minutes prior to meal  |\n| Long-acting            | Insulin detemir (Levemir)                                                              | 1-2 hours         | 6-12 hours           | 20-24 hours          | once or twice daily       |\n| Long-acting            | Insulin glargine (Lan- tus)                                                            | 2-4 hours         | relatively peak-less | 24 hours or less     | once daily                |\n| Mixed                  | Humulin 70/30 or Mixtard 70/30 Humalog 75/25                                           | 30 minutes        | 4-12 hours           | 8-24 hours           | 30 minutes prior to meal  |\n\n\n**Insulin requirements**\n\n\n- Pre-pubertal\tchildren\t(outside\tthe\tpartial\tremission\tphase)\tusually require 0.5-1.0 IU/kg/day.\n- During\tpuberty,\trequirements\tmay\trise\tsubstantially\tabove\t1\tand even up to 2 U/kg/day.\n- The\t''correct''\tdose\tof\tinsulin\tis\tthat\twhich\tachieves\tthe\tbest\tattainable glycaemic control for an individual child or adolescent, without causing obvious Hypoglycemia, and resulting in normal growth and development.\n\n\n**Initiating therapy in a child who is not in DKA**\n\n\nDuring insulin initiation, calculate a total daily dose of 0.5-0.75 U/kg/day. This can be given using either of the following regimens:\n\n\n- a. Basal bolus regimen\n- b. Twice-daily injections\n- C. Basal Bolus Regimen - also called Multiple Daily Injections (MDI). This is the preferred option.\n\n\n**This regimen can be given using two combinations**\n\n\n- Short-acting\tand\tlong-acting\tinsulin\tanalogues\n- Short-acting\tand\tintermediate-acting\tinsulin\tanalogues\n- i. Short-acting and long-acting insulin analogues If short-acting (soluble)/rapid acting and long-acting analogue insulins are used, give:\n- 60%\tof\tthe\ttotal\tdaily\tdose\tas\tshort-acting\t(soluble)\tinsulin\t(divided\tup between 3-4 pre-meal boluses)\n- 40%\tof\tthe\ttotal\tdaily\tdose\tas\ta\tsingle\tevening\tinjection\tof\tlong-acting analogue insulin. (Sometimes this dose does not last for 24 hours and then can be split into two doses - morning and evening).\n\n\n**Exampl e:**\n\n\nFor a 4 2-kg chil d who is started on 0 .5 U kg / day, the total daily dose is 21 units.\n\n\n/\n\n\nTable 9: Example of administration of short- and long-acting insulin as multiple daily injections\n\n\n|                  | Short-acting   | Long-acting   |\n|------------------|----------------|---------------|\n| Before breakfast | 4 Units        |               |\n| Before lunch     | 4 Units        |               |\n| Before dinner    | 4 Units        | 9 Units       |\n\n\n(rounded off to the nearest whole number).\n\n\nPre-meal doses can be adjusted depending on the size and frequency of the patient meals\n\n\n**ii. Short-acting and intermediate-acting insulin analogues**\n\n\nIf short-acting (soluble) and intermediate-acting insulin is used, give:\n\n\n- 70%\tof\tthe\ttotal\tdaily\tdose\tas\tshort-acting\t(soluble)\tinsulin (divided up between 3-4 pre-meal boluses)\n- 30%\tof\tthe\ttotal\tdaily\tdose\tas\ta\tsingle\tevening\tinjection\tof intermediate-acting insulin\n\n\n**Example:**\n\n\nFor a 42-kg child who is started on 0.5 U/kg/day , the total daily dose is 21 Units.\n\n\nTable 10: Example of administration of Short and Intermediate-acting Insulin as multiple daily injections. as multiple daily injections.\n\n\n|                  | Short-acting (soluble insulin) Intermediate-acting (NPH)   |         |\n|------------------|------------------------------------------------------------|---------|\n| Before breakfast | 5 Units                                                    |         |\n| Before lunch     | 5 Units                                                    |         |\n| Before dinner    | 5 Units                                                    | 6 Units |\n\n\n(rounded off to the nearest whole number)\n\n\nPre-meal doses can be adjusted depending on the size and frequency of the patient meals\n\n\nNB: In circumstances where meals are skipped or food is not available, Give the intermediate- acting insulin and skip the short acting insulin until the food is available. Do NOT completely stop insulin administration. Subsequently, doses can be adjusted daily according to blood glucose levels.\n\n\n**b. Twice daily injections**\n\n\nA starting point is to give two-thirds of the total daily insulin in the morning before breakfast and one-third before the evening meal. This may be given as pre-mixed insulin or short acting and intermediate acting insulin separately.\n\n\n**Example:**\n\n\nFor a 42-kg child who is started on 0.5 U/kg/day, the total daily dose is 21 Units. Two-thirds of this dose (14 units) is given in the morning (before breakfast), and one-third of the dose (7 units) before the evening meal. At each injection, 1/3 is short acting and 2/3 is intermediate-acting.\n\n\nTable 11: Example of administration of Short acting, Intermediate-acting and pre-mixed Insulin\n\n\n| Before breakfast    | Short-acting 5 Units   | Intermediate-acting 9 Units   | Pre-mixed insulin 14 Units   |\n|---------------------|------------------------|-------------------------------|------------------------------|\n| Before evening meal | 2 Units                | 5 Units                       | 7 Units                      |\n\n\n(rounded off to the nearest whole number)\n\n\n**It is important to note that:**\n\n\n- i. Insulin requirements can decrease for a time during the 'honeymoon period'  before rising again.\n- ii. The total daily dose required will generally increase as the child grows, and once puberty ensues a higher dose per kg per day is often needed.\n\n\nDuring  periods  of  regular  change  in  consumption  of  food  (e.g.  Ramadan)  the  total amount of insulin should not be reduced but redistributed according to the amount and timing of carbohydrate intake. However, if the total calorie intake is reduced during Ramadan, the daily amount of bolus insulin for meals usually needs to be reduced, for example to two-thirds or three-quarters of the usual dose.\n\n\n**Insulin injection techniques**\n\n\nProper injection technique is vital to ensure insulin is administered in the subcutaneous tissue. It is important to avoid intramuscular insulin injections.\n\n\nWhen starting the patient on insulin, the healthcare provider needs to ensure that the patient understands each of these essential topics\n\n\n- a. The Injection regimen\n\n\nOnce daily, twice daily or basal bolus\n\n\n**b. Choice of devices used**\n\n\n- o insulin vial and syringes or\n- o pen device\n\n\n**Howtoinject insulinwith a syringe**\n\n\n![Washyourhands.](images/picture_016_page_36.png)\n\n\n![Washyourhands.](images/picture_017_page_36.png)\n\n\nWashyourhands.\n\n\nCheckthe Insulin for lumps,crystals or discoloring.\n\n\nGentlyrollcloudy Insulin betweenyour handsuntil it is unitormly cloudy.\n\n\nNever shake Insulin.\n\n\nWipethetopofthe insulinvialwithaclean cloth/swab\n\n\n![Pull the plungerdown to letunitsof alr into the syringe.](images/picture_018_page_36.png)\n\n\nPull the plungerdown to letunitsof alr into the syringe.\n\n\nThe unitsofalr should equal the units of insulin that you plan to inject.\n\n\n![The unitsofalr should equal the units of insulin that you plan to inject.](images/picture_019_page_36.png)\n\n\n![The unitsofalr should equal the units of insulin that you plan to inject.](images/picture_020_page_36.png)\n\n\n![Figure 22](images/picture_021_page_36.png)\n\n\n![Figure 23](images/picture_022_page_36.png)\n\n\n![Figure 24](images/picture_023_page_36.png)\n\n\n![Push the alrinto the Insulinbottle.](images/picture_024_page_36.png)\n\n\n![Push the alrinto the Insulinbottle.](images/picture_025_page_36.png)\n\n\nPush the alrinto the Insulinbottle.\n\n\nLeave theneedle Inthe bottle.\n\n\nTurn theInsulinbottleand syringeupside down.\n\n\nBesure theneedleIsIn the Insulin,notIn theair space inside thebottle.\n\n\nPull theplungerdown to get\\_units of insulin into the syringe.\n\n\nFigure 5: Injection technique using an insulin syringe (Source: Optimizing Injection Technique in Diabetes Management Recommendations for Best Practice in Injection Technique, FIT guidelines South Africa, 1st edition)\n\n\nLookforairbubblesinthe syringe.lf there are alr bubbles,push the Insulin backIntothebottleand start againfrom step5.\n\n\nWhenyouhavetherlght Insulinunitswithnoalr bubbles,pull the syringe outof thebottle.\n\n\nClean theinjectionsite using a clean swab/cloth andletthesitedrybefore injecting\n\n\nPlnch up the area of skin thatyou wiped\n\n\nHold the syringe like a pencll.Besure the needle does nottouchanything.\n\n\nPush theneedle Into the pinchedskin ata90degree angle.Pushthe plunger to Inject the Insulin.\n\n\nRelease the pinch,thenpull the syringe needleout of your skin.\n\n\nlfyounotice a drop of blood,pressafingeronthe Injectionspot forafew seconds.\n\n\nPlace the used syringe Into a sharps container.\n\n\nDonotreuse the syringe\n\n\n**Partsofaninsulinsyringe**\n\n\n![How to inject](images/picture_026_page_37.png)\n\n\n**How to inject**\n\n\nWipe thetopof theinsulin bottle.Arrange your supplles.Washyour hands. To expose theplunger, twist thewhiteplungercap then pullit off.\n\n\nPull theinsulin syringe plunger down;align the thinblacklineofthe plunger(closest to the needle)withthedesired numberof units on the insulin syringe.You needair in theinsulin syringe equal to theamountof insulinyou willtake.\n\n\nPullthe plunger down slowly. Alignthethinblacklineofthe plunger(closest to the needle)withthedesired number of unitsonthe insulin syringe.\n\n\nHold the insulin syringe like apencil.Pinch upyour skin andpush the needle quickly through the skin at 90'(straight in)to the skin surface.Push the insulin in\n\n\n10\n\n\n8\n\n\n11\n\n\nIfyou aretaking cloudy insulin,rollthebottle betweenyour hands until it isuniformly cloudy.To avoid theformationofairbubbles, donot shake thebottleof insulin.\n\n\nHold theinsulin syringe like apencil.Push the needle straightthrough the center of therubbertopof the insulinbottleandpush the plunger down completely.\n\n\nIf airbubbles appear in theinsulin syringe,inject theinsulin backinto the vial.Thenredrawtheinsulin following steps6and7.\n\n\nDo notrecap used needles. Use the needle once and dispose ofit properly.\n\n\nFigure 6: Injection Technique using the insulin pen (Source: Optimizing Injection Technique in Diabetes Management Recommendations for Best Practice in Injection Technique, FIT guidelines South Africa, 1 st edition)\n\n\n![To expose theneedle,twist theorange needle shield then pull it straightoff. being carefulnotto bend the needleor let the needle touch anything.](images/picture_027_page_37.png)\n\n\nTo expose theneedle,twist theorange needle shield then pull it straightoff. being carefulnotto bend the needleor let the needle touch anything.\n\n\nLeave theneedle inthe insulinbottle.Carefullyturn thebottle and theinsulin syringeupside down sothe bottle is on top.\n\n\nConfirm thedoseiscorrect, and thencleana small area of skin.Letit dry completely before injecting.\n\n\n**Pen device**\n\n\nFigure7:  Structure of an Insulin Pen Device and how to use it.\n\n\n![c. Proper injection techniques](images/picture_028_page_38.png)\n\n\n**c. Proper injection techniques**\n\n\nDemonstrate the injection technique to the patient and the caregiver/family and have the patient repeat back before they leave.\n\n\n- -Injection sites: These are the abdomen, thighs, buttocks and upper arm. Injection sites should be clean disinfection of injection site is usually not required outside the hospital settings. Patients should never inject into sites of lipohypertrophy, inflammation or other lesions. (Refer to figure 14)\n- -Sites rotation is important to avoid lipohypertrophy. Patients should be given an easy to follow rotation scheme from the beginning of therapy which should be reviewed annually.\n- -Injection at a 900 angle unless the patient is very thin\n- -Use of lifted skin folds: A correct skin fold is made by lifting the skin with the thumb and index finger. Refer to figure 6 and 7)\n\n\n**Insulin injection sites for adults**\n\n\nFigure 8: Adult Insulin Injection Sites\n\n\n![39 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS](images/picture_029_page_39.png)\n\n\nFigure9: Recommended sites for injection in children\n\n\n![(Source: Optimizing Injection Technique in Diabetes Management Recommendations for Best Practice in Injection Technique, FIT guidelines South Africa, 1st edition)](images/picture_030_page_40.png)\n\n\n(Source: Optimizing Injection Technique in Diabetes Management Recommendations for Best Practice in Injection Technique, FIT guidelines South Africa, 1st edition)\n\n\n**d. Injection complications and how to avoid them (lipohypertrophy)**\n\n\n- e. Optimal needle length - use of shorter needles which are less traumatic to the patient and help in insulin adherence.\n\n\nShorter needles also reduce the incidence of intramuscular injections which can lead to more rapid insulin absorption and hypoglycemia\n\n\n- -Children: 6 mm for the insulin syringes and 4 - 6 mm in pen device\n- -Adults: 4 mm to 8 mm\n\n\n**f. Safe disposal of used sharps**\n\n\nCorrect disposal procedure of used insulin syringes/needles should be taught to the patient (storing in sealed containers and brought to the hospital for proper disposal). Sharps should NEVER be placed directly in household or public trash.\n\n\n**Insulin storage**\n\n\n- i. Insulin vials should be stored at 4-8 °C in a refrigerator where available or in some other method of cooler. In hot climates where refrigeration is not available, cooling jars, earthenware pot, and charcoal pot will help to preserve insulin activity.\n- ii. If using PEN device, insulin can be kept at room temperature for 28 days iii. Insulin must NEVER be frozen.\n- iv. Direct sunlight or extreme heat (in hot climates or in a vehicle) damages insulin.\n- v. Patients should not use insulins that have changed in appearance (clumping, frosting, precipitation, or discolouration).\n- vi. Once opened, an insulin vial should be discarded after 4 weeks.\n\n\n",
                "startLine": 1148,
                "endLine": 1566,
                "introContent": null,
                "keywords": [],
                "subsections": null
              },
              {
                "id": "subsection-2-1-2",
                "level": "h3",
                "number": "2.1.2",
                "title": "2.1.2. Blood Glucose Monitoring",
                "slug": "212-blood-glucose-monitoring",
                "url": "/guidelines/21-management-of-type-1-diabetes/212-blood-glucose-monitoring",
                "parentId": "section-2-1",
                "breadcrumb": [
                  "CHAPTER TWO: MANAGEMENT OF DIABETES",
                  "2.1. Management of Type 1 Diabetes",
                  "2.1.2. Blood Glucose Monitoring"
                ],
                "tokenCount": 695,
                "content": "### 2.1.2. Blood Glucose Monitoring\n\n\nBlood glucose monitoring is essential in the safe management of childhood and adolescent diabetes to help prevent acute and chronic complications, and educate and empower the child and family. Every patient must have a glucometer and blood glucose test strips\n\n\nPatterns of blood glucose levels are generally more useful than single blood glucose readings. In case of scarce blood glucose testing strips, structured(point) testing for 2-3 consecutive day's pre-and post-meal will be better than staggered testing (Table 20).\n\n\nIf strips are readily available, a blood glucose test should regularly be done before each meal and at bedtime, prior to and following exercise.\n\n\nExercise, physical activity or play may result in low BGLs during or immediately after exercise, or a delayed hypoglycaemic effect many hours later (up to 16 hours). All blood glucose reading should be recorded in a diary or book indicating the date and time.\n\n\nTable 12: Recommended Target Blood Glucose Levels and HbA1c\n\n\n| Measurement       | Recommended level   |\n|-------------------|---------------------|\n| Pre-meal glucose  | 4.0 -7.0 mmol/L     |\n| Post-meal glucose | 5.0 -10.0 mmol/L    |\n| Bedtime glucose   | 6.0 - 10.0 mmol/L   |\n| 3 a.m. glucose    | 5.0-8.0 mmol/L      |\n| HbA1c             | <7.5%               |\n\n\nGlycaemic targets can relaxed accordingly to protect against hypoglycaemia if regular SMBG is not available\n\n\nTable 13: Interpretation of Blood Glucose Level (BGL)\n\n\n| Blood Glucose Level (BGL)                                        | Interpretation                                                               |\n|------------------------------------------------------------------|------------------------------------------------------------------------------|\n| Pre-meal BGLis always high                                       | Preceding dose of intermediate or long-act- ing insulin is insufficient      |\n| Pre-meal BGLis always low                                        | Previous dose of intermediate or long-acting insulin is too high             |\n| Pre-meal BGLis some- times very high and at other times very low | Either insulin, food or exercise are not con- sistent and should be reviewed |\n| BGL2 hours after the meal is too high                            | The meal dose of short-acting (regular) insu- lin was too low                |\n| BGL2 hours' post-meal is too low                                 | The previous meal dose of short-acting (reg- ular) insulin was too high      |\n\n\nNOTE: It is important to note that the level of blood glucose can rise in the early morning (dawn phenomenon). Therefore, care should be taken if increasing the evening intermediate/long-acting dose as hypoglycemia can occur in the middle of the night and this can be dangerous.\n\n\n**Correction Factor: How to Lower Pre-Meal Hyperglycemia**\n\n\nA constant correction factor (CF) is used to calculate insulin sensitivity factor (ISF) for everyone depending on the type of insulin used.\n\n\nThe insulin sensitivity factor is a number that gives the level of glucose change expected per unit of insulin increase or decrease.\n\n\n**The CF/TDD=ISF**\n\n\n1 unit of insulin causes a change of glucose level equivalent to the calculated ISF.\n\n\n",
                "startLine": 1567,
                "endLine": 1626,
                "introContent": null,
                "keywords": [],
                "subsections": null
              },
              {
                "id": "subsection-2-1-3",
                "level": "h3",
                "number": "2.1.3",
                "title": "2.1.3. Educating a child living with diabetes and his/her family",
                "slug": "213-educating-a-child-living-with-diabetes-and-hisher-family",
                "url": "/guidelines/21-management-of-type-1-diabetes/213-educating-a-child-living-with-diabetes-and-hisher-family",
                "parentId": "section-2-1",
                "breadcrumb": [
                  "CHAPTER TWO: MANAGEMENT OF DIABETES",
                  "2.1. Management of Type 1 Diabetes",
                  "2.1.3. Educating a child living with diabetes and his/her family"
                ],
                "tokenCount": 339,
                "content": "### 2.1.3. Educating a child living with diabetes and his/her family\n\n\nA child living with diabetes and the family should be educated on the following aspects of diabetes management:\n\n\n- Insulin\tsecretion,\taction,\tand\tphysiology\n- Insulin\tinjections,\ttypes,\tabsorption,\taction\tprofiles,\tvariability\tand adjustments\n- Nutrition\t-\tfood\tplans;\tqualitative\tand\tquantitative\tadvice\ton\tintake\tof carbohydrate, fat, proteins, and fibre; coping with special events and eating out;\tgrowth\tand\tweight\tgain;\t'diabetic\tfoods';\tsweeteners\tand\tdrinks, prevention of disordered eating\n- Monitoring\t(glucose,\tketone),\tincluding\tglycated\themoglobin\tand\tagreed glucose targets\n- Hypoglycemia\tand\tits\tprevention,\trecognition\tand\tmanagement\tincluding use of glucagon\n- Hyperglycemia\tprevention,\trecognition\tand\tmanagement\n- Sick\tday\tmanagement:\tketosis,\tand\tprevention\tof\tketoacidosis\n- Problem-solving\tand\tadjustments\tto\ttreatment\tin\teveryday\tlife,\tmotivation\tand coping with unexpected glucose fluctuations\n- Goal\tsetting\n- Micro-\tand\tmacrovascular\tcomplications\tand\ttheir\tprevention,\tand\tthe\tneed for regular assessment\n- Exercise,\tholiday\tplanning,\tand\ttravel,\tincluding\teducational\tholidays\tand\tcamps\n- Smoking,\talcohol,\tand\tdrugs\n- Diabetes\tin\tschools\n- Sexuality,\tcontraception,\tpregnancy,\tand\tchildbirth\n\n\n",
                "startLine": 1627,
                "endLine": 1648,
                "introContent": null,
                "keywords": [],
                "subsections": null
              },
              {
                "id": "subsection-2-1-4",
                "level": "h3",
                "number": "2.1.4",
                "title": "2.1.4. Nutritional management in Children living with diabetes and his/her family",
                "slug": "214-nutritional-management-in-children-living-with-diabetes-and-hisher-family",
                "url": "/guidelines/21-management-of-type-1-diabetes/214-nutritional-management-in-children-living-with-diabetes-and-hisher-family",
                "parentId": "section-2-1",
                "breadcrumb": [
                  "CHAPTER TWO: MANAGEMENT OF DIABETES",
                  "2.1. Management of Type 1 Diabetes",
                  "2.1.4. Nutritional management in Children living with diabetes and his/her family"
                ],
                "tokenCount": 371,
                "content": "### 2.1.4. Nutritional management in Children living with diabetes and his/her family\n\n\n- Children\tliving\twith\tdiabetes\tneed\ta\thealthy\tdiet\twith\tfood\tin\tamounts\tand proportions appropriate to the age and stage of growth (use the healthy plate model)\n- Nutritional\tcounselling\tshould\tbe\tadapted\tto\tcultural,\tethnic\tand\tfamily traditions as well as the cognitive and psychosocial needs of the individual child\n- Match\tthe\tdose,\ttype\tand\tregimen\tof\tinsulin\tto\tthe\tamount\tand\ttiming\tof\tfood\n- Include\ta\thealthy\tsnack\tbetween\tthe\tmain\tmeals,\tbefore,\tduring\tand\tafter exercise\n- Nutritional\tadvice\tshould\taddress\tfood\tavailability/food\tinsecurity,\tdiet,\tfood\tin take and physical activity patterns\n- Excessive\trestriction\tof\tcarbohydrate\tintake\tto\tlower\tblood\tglucose\tlevels should  be avoided\n- Sugary\tsoft\tdrinks\tor\tfoods\twith\thigh\tlevels\tof\tsaturated\tfat\tshould\tbe\tavoided.\n- Prevention\tand\tmanagement\tof\thypoglycemia,\tparticularly\tbefore,\tduring\tand after exercise should be addressed\n- Education\tshould\tinclude\tpreventing\thypoglycemia\n\n\n- Ideally\tthere\tshould\tbe\tan\texperienced\tdietitian\tin\tthe\tdiabetes\tteam\twho ought  to have individualized sessions with the child and the family/ caregiver\n- Unexpected\tweight\tloss\tmay\tbe\ta\tsign\tof\t(1)\tillness\te.g.\tinfections,\tcoeliac disease etc., (2) insulin omission, or (3) an eating disorder\n- Growth\tmonitoring\tshould\tbe\tdone\tuntil\tthe\tage\tof\t18\tyears\n\n\n",
                "startLine": 1649,
                "endLine": 1667,
                "introContent": null,
                "keywords": [],
                "subsections": null
              }
            ]
          },
          {
            "id": "section-2-2",
            "level": "h2",
            "number": "2.2",
            "title": "2.2. Management of Type 2 Diabetes",
            "slug": "22-management-of-type-2-diabetes",
            "url": "/guidelines/chapter-two-management-of-diabetes/22-management-of-type-2-diabetes",
            "parentId": "chapter-2",
            "breadcrumb": [
              "CHAPTER TWO: MANAGEMENT OF DIABETES",
              "2.2. Management of Type 2 Diabetes"
            ],
            "tokenCount": 15202,
            "content": "## 2.2. Management of Type 2 Diabetes\n\n\nThe successful establishment of the diabetes health-care team and its supportive infrastructure is critical for the achievement of management goals. This includes provision of education for health-care professionals and for people living with diabetes.\n\n\nA thorough clinical assessment of a patient with type 2 diabetes is recommended before initiating any therapy and during ongoing therapy.\n\n\nTable 14: Clinical Assessment for initial and follow-up visits for Type 2 Diabetes\n\n\n|                                                                                                                                                                   | Initial visit                                                 | Three- to six-monthly visits                                  | Annual visit                                                  |\n|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|\n| History                                                                                                                                                           |                                                               |                                                               |                                                               |\n| Symptoms of hyperglycaemia* and duration of symptoms                                                                                                              | X                                                             | X                                                             | X                                                             |\n| Hypoglycaemic** symptoms                                                                                                                                          | X                                                             | X                                                             | X                                                             |\n| Relevant family history                                                                                                                                           | X                                                             |                                                               |                                                               |\n| Other risk factors (e.g. gestational diabetes, PCOS, hypertension)                                                                                                | X                                                             | X                                                             | X                                                             |\n| Relevant medical history (includingTB infection and exposure)                                                                                                     | Relevant medical history (includingTB infection and exposure) | Relevant medical history (includingTB infection and exposure) | Relevant medical history (includingTB infection and exposure) |\n| - Co-morbid conditions                                                                                                                                            | X                                                             |                                                               | X                                                             |\n| - Symptoms of complications: Cardiovas- cular, neurological, bladder function, sexual function (i.e. erectile dysfunction or low libido), feet, visual, infection | X                                                             | X                                                             | X                                                             |\n| Drugs                                                                                                                                                             |                                                               |                                                               |                                                               |\n| - Side effects                                                                                                                                                    |                                                               | X                                                             | X                                                             |\n| - Adherence                                                                                                                                                       |                                                               | X                                                             | X                                                             |\n| - Allergies                                                                                                                                                       | X                                                             | X                                                             | X                                                             |\n| Vaccinations                                                                                                                                                      |                                                               |                                                               |                                                               |\n| - Pneumococcal (date)                                                                                                                                             | X                                                             |                                                               | X                                                             |\n| - Influenza (date)                                                                                                                                                | X                                                             |                                                               | X                                                             |\n| Lifestyle                                                                                                                                                         |                                                               |                                                               |                                                               |\n| - Weight                                                                                                                                                          | X                                                             | X                                                             | X                                                             |\n| - Physical activity/sedentary lifestyle                                                                                                                           | X                                                             | X                                                             | X                                                             |\n\n\n| -                                                      | Eating pattern                                                                                     | X   | X   | X   |\n|--------------------------------------------------------|----------------------------------------------------------------------------------------------------|-----|-----|-----|\n| -                                                      | Smoking                                                                                            | X   | X   | X   |\n| -                                                      | Drug abuse                                                                                         | X   | X   | X   |\n| -                                                      | Alcohol                                                                                            | X   | X   | X   |\n| Psychosocial support                                   | Psychosocial support                                                                               |     |     |     |\n| -                                                      | Occupation                                                                                         | X   |     | X   |\n| -                                                      | Family and community support (sup- port groups)                                                    | X   |     | X   |\n| -                                                      | Depression, anxiety and other mental disorders                                                     | X   | X   | X   |\n| Home monitoring of blood glucose (glucom-              | Home monitoring of blood glucose (glucom-                                                          | X   | X   | X   |\n| Physical examination                                   | Physical examination                                                                               |     |     |     |\n| Weight                                                 | Weight                                                                                             | X   | X   | X   |\n| Height                                                 | Height                                                                                             | X   | X   | X   |\n| Body mass index (BMI) (kg/m 2 )                        | Body mass index (BMI) (kg/m 2 )                                                                    | X   | X   | X   |\n| Waist circumference (cm)                               | Waist circumference (cm)                                                                           | X   | X   | X   |\n| Heart rate and rhythm                                  | Heart rate and rhythm                                                                              | X   | X   | X   |\n| Blood pressure in mmHg(both systolic and diastolic BP) | Blood pressure in mmHg(both systolic and diastolic BP)                                             | X   | X   | X   |\n| Injection sites, if appropriate                        | Injection sites, if appropriate                                                                    | X   | X   | X   |\n| Feet                                                   | Feet                                                                                               |     |     |     |\n| -                                                      | Inspection: Ulcers, soft tissue, deformi- ties, Footwear                                           | X   | X   | X   |\n| -                                                      | Monofilament assessment                                                                            | X   |     | X   |\n| -                                                      | Vibration sense using tuning fork, or pinprick sensation                                           | X   |     | X   |\n| -                                                      | Ankle jerk                                                                                         | X   |     | X   |\n| -                                                      | Foot pulses                                                                                        | X   |     | X   |\n| Oral cavity                                            | Oral cavity                                                                                        |     |     |     |\n| -                                                      | Dental caries                                                                                      | X   |     | X   |\n| -                                                      | Gumdisease                                                                                         | X   |     | X   |\n| Eyes                                                   | Eyes                                                                                               |     |     |     |\n| -                                                      | Visual acuity                                                                                      | X   |     | X   |\n| -                                                      | Direct fundoscopy (dilated pupils), indirect fundoscopy, or fundus photo- graphs                   | X   |     | X a |\n| Systemic examination                                   | Systemic examination                                                                               |     |     |     |\n| Cardiovascular system examination                      | Cardiovascular system examination                                                                  | X   |     | X   |\n| Special investigations                                 | Special investigations                                                                             |     |     |     |\n| Blood tests                                            | Blood tests                                                                                        |     |     |     |\n| -                                                      | Glucose                                                                                            | X   | X   | X   |\n| -                                                      | HbA1c (Six-monthly if at target, otherwise three- monthly. Also, whenever treat- ment is adjusted) | X   | X   | X   |\n\n\n| - Lipids: Total cholesterol, HDL cholester-                                                                                                                                | X   |    | X   |\n|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----|-----|\n| - Creatinine, and calculate estimated GFR                                                                                                                                  | X   |    | X   |\n| - Potassium                                                                                                                                                                | X   |    | X   |\n| - TSH                                                                                                                                                                      | X   |    | X   |\n| - HIV                                                                                                                                                                      | X   |    | X   |\n| Urine                                                                                                                                                                      |     |    |     |\n| - Glucose                                                                                                                                                                  | X   |    | X   |\n| - Protein                                                                                                                                                                  |     |    |     |\n| - Ketones                                                                                                                                                                  | X   |    | X   |\n| - Leucocytes                                                                                                                                                               | X   |    | X   |\n| Urine microalbuminuria                                                                                                                                                     | X   |    | X   |\n| Uric acid                                                                                                                                                                  | X   |    | X   |\n| Full Hemogram                                                                                                                                                              | X   |    | X   |\n| Liver Function Tests (ALT, AST, ALP)                                                                                                                                       | X   |    | X   |\n| Urine microalbuminuria                                                                                                                                                     | X   |    | X   |\n| Uric acid                                                                                                                                                                  | X   |    | X   |\n| Full Hemogram                                                                                                                                                              | X   |    | X   |\n| Liver Function Tests (ALT, AST, ALP)                                                                                                                                       | X   |    | X   |\n| ECG                                                                                                                                                                        | X   |    | X   |\n| Cancer screening (Pap smear, breast, PSA)                                                                                                                                  | X   |    | X   |\n| Cancer screening (Pap smear, breast, PSA)                                                                                                                                  | X   |    | X   |\n| Other important tasks                                                                                                                                                      |     |    |     |\n| Education: Self-management and lifestyle adjustment, including tobacco cessation, alcohol cessation, Hypoglycemia avoidance and treatment, nutrition and physical activity | X   | X  | X   |\n| Setting goals                                                                                                                                                              | X   | X  | X   |\n| Preconception counselling and family planning                                                                                                                              |     | X  | X   |\n| Medication revision/adjustment                                                                                                                                             | X   | X  | X   |\n| Immunizations                                                                                                                                                              | X   |    | X   |\n\n\n\n\na Int erval for ret inop at y  sc reening c an b e inc reased t o onc e every 2 y ears if t h e last  2 ex am inat ions w ere norm al; m ore frequent  ex am inat ions are required in t h e p resenc e of ab norm alit ies.\n\n\n* y m om of h y p erg ly aem ia inc lude p oly dip sia,  h eadac es,  b lurred vision,  p oly uria,  fat ig ue/ b ody  m alaise,  w eig\n\n\n\n\n,\n\n\n\n\nt  loss\n\n\n** S y m om s/ sig ns of H y p og ly em iaN ervousness or anx iet y ,  sw eat ing c ills and c lam y  ex rem it ies,  irrit ab ilit y ,  c onfusion,  inc luding delirium ac y c ardia,  lig eadedness or diz z iness,  h ung er and nausea,  b lurred/ im aired vision,  t ing ling or num ness in t h e lip s or t ong ue,  h eadac es,  w eak ness or fat ig ue,  m ood c ang es,  lac of c oordinat ion,  nig ares or c ry ing out  during sleep ,  seiz ures,  loss of c onsc iousness. -p oly y st ic ovarian sy ndrom e\n\n\n\n\n-\n\n\n,\n\n\n**Management of Type 2 diabetes entails the following components:**\n\n\n- i. Treatment of hyperglycemia\n- ii. Treatment of hypertension and dyslipidemia\n- iii. Prevention and treatment of micro-vascular complications\n- iv. Prevention and treatment of macro-vascular complications\n- v. Prevention and treatment of non-vascular complications\n\n\n**Treatment of hyperglycemia**\n\n\nTreatment of hyperglycaemia in type 2 diabetes consist of the following;\n\n\n**a. Non -pharmacological**\n\n\n- i. Education\n- ii. Diet\n- iii. Physical activity\n- iv. Blood glucose monitoring\n\n\n**b. Pharmacological**\n\n\n- i. Oral glucose lowering agents (oral hypoglycaemic agents)\n- ii. Insulin\n- iii. Combination Therapies - e.g. Oral glucose lowering agents and insulin\n- iv. Non-insulin injectable glucose lowering agents (GLP-1 agonists)\n\n\n### 2.2.1. Non-pharmacological management\n\n\nThis is the cornerstone in achieving diabetes control. It includes diabetes education, medical nutrition therapy, physical activity and self-monitoring of blood glucose.\n\n\n**Diabetes Education**\n\n\nDiabetes education to the diabetic patient and the family is important in ensuring good glycemic control and prevention of diabetic complications. The diabetes education is a continuous process in the patients' follow up\n\n\n**Principles of diabetes education**\n\n\n- An\tevidence-based,\tstructured\teducation\tprogramme\tshould\tbe\toffered\tto\tall patients at the time of diagnosis, and consolidated at regular intervals thereafter. The aim is to promote patient self-management\n- Diabetes\teducation\tis\ta\tcontinuous\tprocess\tand\tdifferent\ttopics\tshould\tbe covered at separate sessions to ensure a proper understanding of the issues\n- The\tprogramme\tshould\tbe\tpresented\tby\teducators\twho\thave\tbeen appropriately trained\n- Diabetes\tself-management\teducation\t(DSME)\tshould\tbe\tindividualized. Small-group education is the most cost-effective option but individual education sessions should also be utilized where necessary\n- Educators\tshould\tensure\tthat\tactive\tlearning\tis\ttaking\tplace\n- Psychological\tand\temotional\tassessment\tis\tneeded\tat\tregular\tintervals\n- A\tregular\taudit\tof\tthe\tprogramme\tand\tits\teffect\ton\toutcomes\tis\tadvised\n\n\nTable 15:  Structured diabetes education outline\n\n\n| Visits                          | Education to be conducted during the diabetes clinic visit                                                                                                                                                                                                                                                                  |\n|---------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Visit 1                         | • Support system • Overview of Diabetes • Blood glucose monitoring • Nutrition • Physical Activity • Self-Glucose Monitoring                                                                                                                                                                                                |\n| Visit 2                         | • Hypoglycaemia • Hyperglycaemia • Sick Days • Mindful eating • Dining Out • Physical Activity                                                                                                                                                                                                                              |\n| Visit 3                         | • Stress and diabetes • Natural changes of diabetes • Blood pressure control • Heart health • Tobacco use • Eating for better health • Physical Activity                                                                                                                                                                    |\n| Visit 4                         | • Diabetes and alcohol • Diabetes changes over time • Problem-solving: glucose results • Complications: preventing and delaying • Foot care • Sleep habits                                                                                                                                                                  |\n| Visit 5                         | • Pregnancy: preparing, managing diabetes during pregnancy and appropriate postnatal care • Psychosocial issues, stress management and coping skills • What is the role of alternative medicine: How to make informed choices about their use of traditional and alternative medicine, potential harm and drug interactions |\n| Educating the elderly patients: | • Assess knowledge and understanding of diabetes • Evaluate ability to learn and apply new self-care skills • Asses nutrition and physical activity • Address poly-pharmacy and co-morbidities • Assess for cognitive dysfunction, depression and physical disability                                                       |\n\n\n**Dietary Management of Type 2 Diabetes Mellitus**\n\n\nDietary modification is one of the cornerstones of diabetes management. It is based on the principle of healthy eating in the context of socio-economic, cultural and psychological influences of food choices.\n\n\n**Principles of dietary management of Type 2 diabetes mellitus**\n\n\nAll members of the diabetes-care team must have knowledge about nutrition to be able to educate people living with diabetes with the support of a nutritionist. Dietary counseling is best given by a dietitian or nutritionist.\n\n\n**The following are principles of dietary management:**\n\n\n- To\tachieve\tideal/desired\tweight,\tan\tappropriate\tdiet\tand\texercise\tregimen should be agreed upon between the nutritionist and the patient/care giver\n- Three\tmain\tmeals\tshould\tbe\teaten\tin\ta\tday,\tand\tbinge\teating\tshould\tbe\tavoided\n- The\tdiet\tshould\tbe\tindividualized,\tbased\ton\ttraditional\teating\tpatterns,\tBMI, comorbid conditions; and should be palatable and affordable\n- Animal\tfat,\tsalt,\tdiet\tdrinks,\tsweeteners\tand\tfoods\tmarketed\tas\t'diabetic\tfoods' should be avoided\n- Tailoring\tthe\tnutritional\tintervention,\tso\tthat\tthere\tis\ta\tcareful\tmatch\tof\tboth\ta meal-planning approach and educational materials with the patient needs, and so that there is still some allowance for flexibility\n- Foods\tand\tdrinks\trich\tin\trefined\tsugars\t(simple\tsugars)\tshould\tbe\tavoided\n- Eating\tplans\tshould\tbe\thigher\tin\tcomplex\tcarbohydrates\t(starches)\tand\tfibre content\n- Vegetables\tand\tlimited\tnumbers\tof\tfruits\tshould\tbe\tencouraged\n- Food\tquantities\tshould\tbe\tmeasured\tin\tvolumes\tusing\tavailable\thousehold items, such as cups, or be countable, such as number of fruits or slices of yam or bread\n- Alcohol\tshould\tbe\tavoided\n- Sweeteners\tare\tnot\tessential\tand\tshould\tbe\tavoided\tas\tmuch\tas\tpossible\n- Drinking\tof\twater\tthroughout\tthe\tday\tshould\tbe\tencouraged\t(average\t8 glasses  of 250 mls each)\n\n\n**Table 16: Dietary Recommendations in Management of Type 2 Diabetes**\n\n\n**A. Follow a healthy, balanced eating plan**\n\n\n- Eat a variety of fresh fruit and vegetables every day, but avoid fruit juices\n- At least half of the grain intake must be from whole grain products\n- Use a variety of meat alternatives, including pulses, beans and other legumes\n- Consume white meat at least twice per week\n- Limit the intake of processed and fast foods\n- Increase the intake of water to meet daily fluid requirements\n\n\n**B. Carbohydrates**\n\n\n- Carbohydrates should make up 45-60% of the total energy intake\n- Monitoring  carbohydrate  intake,  whether  by  carbohydrate  counting,  exchanges or experienced-based estimation, remains a key strategy in achieving optimum glycaemic control\n- The use of glycaemic index and glycaemic load may provide a modest an additional benefit compared to considering only total carbohydrate content\n- Limit the intake of sugar alcohols (maltitol, mannitol, sorbitol, lactitol, isomalt, xylitol) to &lt; 10 g per day\n- A sucrose intake of up to 10% of total energy intake per day is acceptable\n- Limit the total fructose intake to 60 g per day\n- Increase the intake of soluble and insoluble fibre to 25-50 g per day\n- The use of artificial sweeteners, including acesulfame-K, aspartame, sac -charine and sucralose, are safe when consumed within the daily limits established by the FDA\n\n\n**C. Protein**\n\n\n- Proteins should make up 15-20% of the total energy intake\n- For individuals with type 2 diabetes with normal renal function, there is no evidence to suggest that the usual recommended protein intake should be modified\n- In type 2 diabetes, ingested protein can increase the insulin response without increasing plasma glucose levels; therefore, protein should not be used in the treatment and prevention of Hypoglycemia\n\n\n**D. Fat**\n\n\n- The fat intake should be restricted to &lt; 35% of the total energy intake\n- The saturated fat (solid fats, and animal fats) intake should be restricted to &lt; 7% of the total energy intake\n- Most of the fat intake should be unsaturated fats (vegetable oils)\n- Minimize the intake of trans-fats\n- Two more servings of fish per week will provide the recommended ome -ga-3 polyunsaturated fatty acids\n\n\n**E. Salt**\n\n\n- Limit all kinds of salt intake\n\n\n**F. Vitamins and minerals**\n\n\n- Mineral and vitamin supplementation may be needed in selected groups, such as the elderly, lactating and pregnant women, and vegans\n- Encourage to take a variety of fruits and vegetables, fish and foods rich in vitamin D\n\n\n**G. Alcohol**\n\n\n- Adults who choose to consume alcohol should do so in moderation: one unit per day or less for women, and two units per day or less for men\n- Moderate alcohol consumption, with food, does not cause acute hyperglycaemia or Hypoglycemia.\n- Individuals on insulin or insulin secretagogues should be aware of the risks of delayed Hypoglycemia (for up to 24 hours after consumption); alcohol should be consumed with food to reduce the risk of Hypoglycemia\n\n\n**Tools used in meal planning in in diabetes nutrition therapy**\n\n\nThere are several tools used in meal planning, however, there is no ideal meal plan that works for everyone living with diabetes. Below are some of the tools used in meal planning in diabetes care\n\n\n1. Plate Model\n2. Handy portion guide\n3. Glycemic Index and glycemic load\n4. Food groups and food servings\n5. Carbohydrate counting\n\n\n**Plate Model**\n\n\nThis method helps the patient to easily measure the food portions while keeping simple and practical. It divides the plate, 9 inches in diameter, into portions of vegetables, fruits, starch and proteins as indicated below\n\n\n![Figure 10: Plate Model](images/picture_031_page_52.png)\n\n\n**Figure 10: Plate Model**\n\n\nSource: Adapted from the Harvard T.H Chan school of Public Health, The Nutrition Source (www.hsph.harvard.edu/nutritionsource)\n\n\nHandy portion guide\n\n\nThis method used patients' hands to provide quick tips for estimating portion sizes\n\n\nFigure 11: Handy portion guide\n\n\n![Glycemic Index and glycemic load](images/picture_032_page_53.png)\n\n\n**Glycemic Index and glycemic load**\n\n\nThe glycemic index is a value assigned to foods based on how slowly or how quickly these foods cause increases in blood glucose levels. It ranks the carbohydrates on a scale from 0 to 100 according to the extent to which they raise blood sugar (glucose) levels after eating. Foods low in the glycemic index (GI) scale tend to release glucose slowly and steadily while foods high on the glycemic index release glucose rapidly\n\n\nFigure 12: An illustration of low and high glycemic index food\n\n\n![53 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS](images/picture_033_page_53.png)\n\n\nBelow is a comprehensive list of low and high glycemic foods, people living with diabetes are advised to choose more foods from the low glycemic index\n\n\nTable 17: Examples of low and high glycemic index foods\n\n\n| High glycemic foods                                                                                                                                                                                                                                                                             | Low glycemic foods                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Glucose Baked potatoes French Fries Rice Flour Mashed Potatoes Potato Chips Honey Cooked Carrots Corn Flakes Cooked Broad beans Pumpkin Watermelon Sugar (Sucrose) White bread Refined sweetened cereal Chocolate bars Boiled peeled potatoes Cola soda Cookies Corn White rice Noodles Raisins | Whole wheat or bran bread Brown rice Sweet potatoes Whole wheat pasta Fresh peas Whole wheat sugar free cereal Oatmeal Whole grain pasta Kidney beans Fresh unsweetened fruit juice Raw carrots Dairy products Dried beans Brown or yellow lentils Chick peas Fresh fruit Green vegetables, tomatoes, eggplant, zucchini, garlic, onions etc Green beans Sugar free marmalade Green Lentils Split peas Dark Chocolate (>70% cocoa Fruits (Banana, Grapes, Orange, |\n\n\n**Food groups and food servings**\n\n\nThis method is used as a tool that is used to help the patient figure out how many servings of each food are they required to eat from every group. The key to eating well is to enjoy a variety of nutritious foods from each of the food groups.\n\n\nTable 18: Food groups and recommended servings per each food group\n\n\n| Food group                | Number of servings   | What is a serving?                                                                                                                                        |\n|---------------------------|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Starches and breads       | 6-11                 | 1 Slice bread ½ cup cooked rice, cereal ¼ cup dry cereal, ½ cup pasta 3 biscuits (eat whole-grain, fortified or en - riched starches, bread, and cereals) |\n| Vegetables                | 3-5                  | ½ cup vegetables cooked 1 cup vegetables raw                                                                                                              |\n| Fruits                    | 2-4                  | 1 cup fruit juice (fresh, frozen or canned without sugar) 1 medium piece fresh fruit                                                                      |\n| Milk and milk products    | 2-3                  | 1 cup skim / low fat milk / ¾ cup plain or artificially sweetened yogurt                                                                                  |\n| Meat and meat substitutes | 2-3                  | 57-85 g cooked lean meat fish or poultry 28.5 g meat is equivalent to: - 1 egg 28.5 g cheese ¼ cup fish (Omena, tuna, salmon or cheese                    |\n| Fat                       | Use sparingly        | 1 teaspoon margarine 1 teaspoon salad dressing 1 teaspoon oil or mayonnaise 1 tablespoon peanut-butter                                                    |\n\n\n**Carbohydrate counting**\n\n\nCarbohydrate counting, is a meal planning tool for people living with type 1or type 2 diabetes. It involves keeping track of the amount of carbohydrate in the foods that a person eats each day.\n\n\nCarbohydrates are one of the main nutrients found in food and drinks. They include sugars, starches, and fibre. Carbohydrate counting can help one control their blood glucose levels because carbohydrates affect the blood glucose more than other nutrients.\n\n\nHealthy carbohydrates, such as whole grains, fruits, and vegetables, are an important part of a healthy eating plan because they provide both energy and nutrients, such as vitamins and minerals, and fibre. Fibre helps in preventing constipation, lower cholesterol levels, and control the weight.\n\n\nUnhealthy carbohydrates are often food and drinks with added sugars. Although unhealthy carbohydrates can also provide energy, they have little to no nutrients.\n\n\nThe amount of carbohydrate in foods is measured in grams. To count grams of carbohydrate in foods you eat, a patient will need to;\n\n\n- Know\twhich\tfoods\tcontain\tcarbohydrates\n- Learn\tto\testimate\tthe\tnumber\tof\tgrams\tof\tcarbohydrate\tin\tthe\tfoods\n- Add\tup\tthe\tnumber\tof\tgrams\tof\tcarbohydrate\tfrom\teach\tfood\tto\tget\tyour\ttotal for the day\n\n\n**Foods that contain carbohydrates include**\n\n\n- grains,\tsuch\tas\tbread,\tnoodles,\tpasta,\tcrackers,\tcereals,\tand\trice\n- fruits,\tsuch\tas\tapples,\tbananas,\tberries,\tmangoes,\tmelons,\tand\toranges\n- dairy\tproducts,\tsuch\tas\tmilk\tand\tyogurt\n- legumes,\tincluding\tdried\tbeans,\tlentils,\tand\tpeas\n- snack\tfoods\tand\tsweets,\tsuch\tas\tcakes,\tcookies,\tcandy,\tand\tother\tdesserts\n- juices,\tsoft\tdrinks,\tfruit\tdrinks,\tsports\tdrinks,\tand\tenergy\tdrinks\tthat\tcontain sugars\n- vegetables,\tespecially\t'starchy'\tvegetables\tsuch\tas\tpotatoes,\tcorn,\tand\tpeas\n\n\nFoods that do not contain carbohydrates include meat, fish, and poultry; most types of cheese; nuts; and oils and other fats.\n\n\n**Example of the grams of carbohydrates on needs based on an 1800 kilo calories diet per day**\n\n\nCarbohydrate intake for most people should be between 45 and 65 percent of total calories per day. People on low-calorie diets and people who are physically inactive may want to aim for the lower end of that range.\n\n\nOne gram of carbohydrate provides about 4 calories, thus divide the number of calories per day from carbohydrates by 4 to get the number of grams. For example, if a diet is based on an 1,800 total calories per day and get 45 percent of your calories from\n\n\ncarbohydrates, then the grams from of carbohydrates is about 200 grams of carbohydrate daily. Calculated follows:\n\n\n- 0.45\tx\t1,800\tcalories\t=\t810\tcalories\n- 810\t÷\t4\t=\t202.5\tgrams\tof\tcarbohydrate\n\n\nSpread out the grams of carbohydrate intake throughout the day. There is a need to involve a dietitian or a nutritionist to counsel the patient on what foods to eat, how much to eat, and when to eat based on the weight, activity level, medicines, and blood glucose targets. This method also requires the patient to be motivated, read all the food labels and be willing to calculate the number of grams of carbohydrates intake per day\n\n\n**Physical activity and exercise**\n\n\nPhysical activity or exercise is one of the essentials in the prevention and management of Type 2 diabetes mellitus. Regular physical activity improves metabolic control, increases insulin sensitivity, improves cardiovascular health, and helps weight loss and its maintenance, as well as giving a sense of well-being.\n\n\n**There are two main types of physical activity:**\n\n\n- i. Aerobic or endurance exercise (e.g. walking or running)\n- ii. Anaerobic or resistance exercise (e.g. lifting weights).\n\n\nBoth types of activity may be prescribed to persons with Type 2 diabetes mellitus, but the aerobic form is usually preferred.\n\n\nIn most parts of Kenya, prescribing formal exercise in gyms or requiring special equipment is a recipe for non-adherence. Therefore, patients should be encouraged to integrate increased physical activity into their daily routine. The plan should impose minimum, if any, extra financial outlay in new equipment and materials for physical activity.\n\n\n**General principles and recommendations for physical activity in Type 2 diabetes mellitus**\n\n\n- A\tdetailed\tphysical\tevaluation\tof\tcardiovascular,\trenal,\teye\tand\tfoot\tstatus (including neurological) should be performed before starting an exercise programme.\n- The\tpresence\tof\tchronic\tcomplications\tmay\tpreclude\tcertain\tforms\tof\texercises.\n- Prescribed\tphysical\tactivity\tprogrammes\tshould\tbe\tappropriate\tfor\tthe patient's age, socio-economic status, state of physical fitness, lifestyle, and level of glycaemic control.\n- While\texercise\tgenerally\timproves\tmetabolic\tcontrol,\tit\tcan\talso\tprecipitate acute complications like hypoglycemia and hyperglycaemia.\n- The\tphysical\tactivity\tshould\tbe\tregular\t(3\tdays/week),\tlast\tat\tleast\t20\t-\t30 minutes per session, and be of at least moderate intensity.\n- Activities\tlike\twalking,\tclimbing\tsteps\t(instead\tof\ttaking\tlifts)\tshould\tbe encouraged.\n\n\n- For\tsedentary\tpersons\tliving\twith\tdiabetes,\ta\tgradual\tintroduction\tusing\ta low-intensity activity like walking is mandatory.\n- Avoid\tstrenuous\texercise\tif\tambient\tglycaemia\tis\t&gt;\t250\tmg/dl\t(14\tmmol/L),\tthe patient   has ketonuria or blood glucose is less than 80 mg/dl (4.5 mmol/L).\n- To\tavoid\texercise-induced\thypoglycaemia,\tdosages\tof\tinsulin\tsecretagogues\tor insulin may need to be reduced and/or peri-exercise carbohydrate intake increased.\n- Blood\tglucose\tshould\tbe\tmonitored\t(using\tstrips\tand\tmeters)\tbefore\tand\tafter planned strenuous physical activity as delayed hypoglycemia may occur.\n- Proper\tfootwear\tmust\talways\tbe\tworn.\n\n\nTable 19: Aerobic exercise recommended for individuals with type 2 diabetes\n\n\n| Definition                                                                                                                                  | Intensity   | Frequency                                                    | Examples                                                                                                            |\n|---------------------------------------------------------------------------------------------------------------------------------------------|-------------|--------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|\n| Activities that consist of rhythmic, repetitive and con- tinuous movement of the same large muscle groups for at least 10 minutes at a time | Moderate:   | Minimum 150 minutes per week (30 minutes per day for 5 days) | Cycling, brisk walking, continuous swimming, dancing, water aerobics, raking leaves, shamba work, house hold chores |\n|                                                                                                                                             | Or          | Or                                                           | Or                                                                                                                  |\n|                                                                                                                                             | Vigorous:   | Minimum 75 minutes per week (30 minutes 3 times a week)      | Brisk walking up an incline, jogging, aerobics, hockey, basketball, fast swimming, fast dancing                     |\n|                                                                                                                                             | Or          | Or                                                           | Or                                                                                                                  |\n\n\nTable 20: Resistance exercise recommended for individuals with type 2 diabetes\n\n\n| Definition                                                                                     | Frequency                                                                                                                                                                   | Examples                                                                                             |\n|------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|\n| Activities that require muscular strength to move a weight or work against a resistance load a | Two to three times per week: Start with one set of 10-15 repetitions at moderate weight Progress to two sets of 10-15 repetitions Progress to three sets at heavier weights | Exercise with weight machines, free weight lifting, Resistance band (e.g. Thera-Band ® ) exer- cises |\n\n\n*Resistance exercise should only be attempted if there are no contraindications to this kind of activity\n\n\n**Physical activity recommendations in Children and Adolescents**\n\n\n- Children\tand\tadolescents\twith\tType\t1\tor\tType\t2\tdiabetes\tshould\tengage\tin\t60 minutes per day or more of moderate- or vigorous-intensity aerobic activity, as well as vigorous muscle strengthening and bone strengthening activities at least 3 days per week.\n- Preparations\tare\tneeded\tas\texercise\tmay\tinduce\thypoglycemia.\tWhere possible, patients and families should be given tailored advice about what and how much carbohydrate to take before, during, and after exercise, as well as advice about insulin adjustment.\n- Where\tmonitoring\tis\tavailable,\tblood\tglucose\tneeds\tto\tbe\tmeasured\tbefore, during and after exercise.\n- Approximately\t1.0\t-\t1.5\tg\tcarbohydrate/kg\tbody\tweight/hour\tshould\tbe consumed before and during strenuous exercise if the child is unable to monitor and reduce insulin dosage. E.g. ½ long banana/small apple, small orange.\n\n\n- Hypoglycemia\tis\tmore\tlikely\tto\toccur\twith\tprolonged\tnon-intense\tphysical activity. It often occurs shortly after any type of exercise but is possible up to 24 hours afterwards (increased insulin sensitivity). Risk of post-exercise nocturnal hypoglycemia is high. The evening dose of intermediate- or long-acting insulin often needs to be decreased by 10-20% after exercise in the afternoon or evening, especially if not exercising on a regular basis. Special care\tshould\tbe\ttaken\tthat\tthe\tbedtime\tblood\tglucose\tlevel\tis\t&gt;\t7.0\tmmol/L\t(125 mg/dl).\n- Water\tshould\tbe\tconsumed\tto\tavoid\tdehydration.\n- Where\tunaccustomed\texercise\tis\tbeing\ttaken,\te.g.\tat\ta\tdiabetes\tcamp, reduction in total daily dose of insulin (20- 50%) is advised to avoid hypoglycemia.\n- Insulin\tis\tabsorbed\tquicker\twhen\tit\tis\tinjected\tnear\tto\tmuscles\tthat\tare\tbeing exercised - e.g. legs in soccer. Hypoglycemia is then more likely to occur. Preferred injection site: abdomen\n- If\tblood\tglucose\tlevels\tare\thigh\t(&gt;14\tmmol/l)\twith\tketonuria/ketonaemia, exercise could be dangerous and should be avoided. Give approximately 0.05 U/kg, or 5% of total daily insulin dose as short-acting (soluble) iinsulin and postpone exercise until ketones have cleared. If ketones cannot be measured, a child who is feeling nauseous should not participate in exercise. Children and young people engaged in competitive or more intensive sport will require additional support. This should include detailed discussion about the activity and tailored advice on insulin and food adjustments.\n\n\n### 2.2.2. Pharmacological Management\n\n\nThe goals of caring for patients with diabetes mellitus are to maintain blood glucose under control and prevent or slow down the rate of development of both acute and long-term complications. In initiating treatment for people living with type 2 diabetes the use of HbA1c test is key. The table below provides a guide for initiating therapy using the HbA1c levels.\n\n\nFigure 13: Medical management of Type 2 Diabetes Based on HbA1c levels\n\n\n![61 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS](images/picture_034_page_61.png)\n\n\nSource: Tb/DM Flowchart, MOH\n\n\nPharmacological therapy includes oral glucose lowering agents, insulin and injectable GLP-1 agonists.\n\n\n**i. Oral Glucose Lowering Agents (OGLAs)**\n\n\nThese were previously referred to as oral hypoglycaemic agents\n\n\n**Indications:**\n\n\n- Oral\tpharmacotherapy\tis\tindicated\tfor\tindividual\twith\tType\t2\tdiabetes\n- It\tis\tindicated\twhen\tan\tindividual's\tglycaemic\ttargets\tare\tnot\tmet\tby the combination of dietary modifications and physical activity/exercise.\n- In\tsome\tcases,\toral\tpharmacotherapy\tor\tinsulin\tis\tindicated\tat\tthe\tfirst presentation\tof\tdiabetes,\ti.e.\ta\tfasting\tblood\tglucose\tlevel\t&gt;\t11\tmmol/L or\trandom\tblood\tglucose\tlevel\t&gt;\t15\tmmol/L.\n\n\n**Choice of Oral Glucose Lowering Agents (OGLAs)**\n\n\n- The\tchoice\tof\tOGLAs\tshould\tdepend\ton\tthe\tpatient's\tcharacteristics, lifestyle, degree of glycaemic control, cardiovascular and renal risks, access to drugs, economic status and agreement between the doctor and the person living with diabetes.\n- The\tfirst\tline\toral\tagent\tof\tchoice\tis\tMetformin\tunless\tcontra-indicated.\n- The\tsulphonylureas\tand\tmetformin\tare\tthe\tagents\tmost\twidely available.\n- Use\tof\tthe\tstepped-care\tapproach\tis\trecommended,\tas\tmonotherapy\tis seldom sufficient, because of the progressive nature of the disease (see figure 15).\n- Combination\ttherapy\tshould\tbe\tconsidered\tas\tinitial\tchoice\tif\tHBA1C\tis greater than 8 %.\n- Three-drug\tcombination\ttherapy\tcan\tbe\tused\twhen\ttwo-drug regimens fail to achieve target values. Such patients should be referred to a specialist. Use of combination therapy often results in an increased number of tablets to be taken and creates new adherence problems.\n- Fixed\tcombination\ttherapies\tincrease\tadherence\tbut\tmay\tinhibit flexibility in dosing prescription.\n\n\nTable 21 summarizes the characteristics of the OGLAs which are frequently used in controlling glycaemia in diabetes care. The list is not exhaustive but includes agents that are most commonly used in Kenya.\n\n\nTable 21: Oral glucose lowering agents, dosage, side effects and Contraindications\n\n\n| Table 21: Name of Drug                                                                                                                                                                      | Oral Mini- mum dose                                                                                                                                                                         | glucose Max- imal daily                                                                                                                                                                     | lowering Frequen- cy                                                                                                                                                                        | agents, dosage, side Major Side Effects                                                                                                                                                     | effects and Contraindications Contraindications/use with caution                                                                                                                            |\n|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| dose A. Sulphonylureas Mechanism of action: Stimulate the pancreas to release insulin (regardless of time and glucose levels)                                                               | dose A. Sulphonylureas Mechanism of action: Stimulate the pancreas to release insulin (regardless of time and glucose levels)                                                               | dose A. Sulphonylureas Mechanism of action: Stimulate the pancreas to release insulin (regardless of time and glucose levels)                                                               | dose A. Sulphonylureas Mechanism of action: Stimulate the pancreas to release insulin (regardless of time and glucose levels)                                                               | dose A. Sulphonylureas Mechanism of action: Stimulate the pancreas to release insulin (regardless of time and glucose levels)                                                               | dose A. Sulphonylureas Mechanism of action: Stimulate the pancreas to release insulin (regardless of time and glucose levels)                                                               |\n| Glibenclamide                                                                                                                                                                               | 2.5 mg                                                                                                                                                                                      | 15 mg                                                                                                                                                                                       | OD or BD                                                                                                                                                                                    | Hypoglycemia, weight gain skin rashes                                                                                                                                                       | Caution in liver and renal disease                                                                                                                                                          |\n| GliclazideMR                                                                                                                                                                                | 30 mg                                                                                                                                                                                       | 120 mg                                                                                                                                                                                      | OD                                                                                                                                                                                          | Hypoglycemia, weight gain skin rashes                                                                                                                                                       | Pregnancy, caution in liver disease                                                                                                                                                         |\n| Glimepiride                                                                                                                                                                                 | 1 mg                                                                                                                                                                                        | 4 mg                                                                                                                                                                                        | OD                                                                                                                                                                                          | Hypoglycemia weight gain skin rashes                                                                                                                                                        | Pregnancy, caution in liver and renal disease                                                                                                                                               |\n| Glipizide                                                                                                                                                                                   | 5 mg                                                                                                                                                                                        | 40 mg                                                                                                                                                                                       | OD or BD                                                                                                                                                                                    | Hypoglycemia weight gain skin rashes                                                                                                                                                        | Pregnancy, caution in liver and renal disease                                                                                                                                               |\n| B. Biguanide Mechanism of action: (i)Reduce glucose production in liver (ii) cause (mild) reduction in peripheral insulin resistance                                                        | B. Biguanide Mechanism of action: (i)Reduce glucose production in liver (ii) cause (mild) reduction in peripheral insulin resistance                                                        | B. Biguanide Mechanism of action: (i)Reduce glucose production in liver (ii) cause (mild) reduction in peripheral insulin resistance                                                        | B. Biguanide Mechanism of action: (i)Reduce glucose production in liver (ii) cause (mild) reduction in peripheral insulin resistance                                                        | B. Biguanide Mechanism of action: (i)Reduce glucose production in liver (ii) cause (mild) reduction in peripheral insulin resistance                                                        | B. Biguanide Mechanism of action: (i)Reduce glucose production in liver (ii) cause (mild) reduction in peripheral insulin resistance                                                        |\n| Metformin                                                                                                                                                                                   | 500 mg                                                                                                                                                                                      | 2000 mg                                                                                                                                                                                     | OD or BD                                                                                                                                                                                    | Abdominal pain, nausea, loose bowel motions, lactic aci- dosis Vitamin B12 deficien - cy with prolonged use.                                                                                | Renal failure, GFR<30 ml/min Heart failure stage 3 or 4 and liver failure                                                                                                                   |\n| C. Thiazolidinediones Mechanism of action: (i) Improved insulin sensitivity in muscle, adipose tissue and liver (ii)Reduce glucose output from liver                                        | C. Thiazolidinediones Mechanism of action: (i) Improved insulin sensitivity in muscle, adipose tissue and liver (ii)Reduce glucose output from liver                                        | C. Thiazolidinediones Mechanism of action: (i) Improved insulin sensitivity in muscle, adipose tissue and liver (ii)Reduce glucose output from liver                                        | C. Thiazolidinediones Mechanism of action: (i) Improved insulin sensitivity in muscle, adipose tissue and liver (ii)Reduce glucose output from liver                                        | C. Thiazolidinediones Mechanism of action: (i) Improved insulin sensitivity in muscle, adipose tissue and liver (ii)Reduce glucose output from liver                                        | C. Thiazolidinediones Mechanism of action: (i) Improved insulin sensitivity in muscle, adipose tissue and liver (ii)Reduce glucose output from liver                                        |\n| Pioglitazone                                                                                                                                                                                | 15 mg                                                                                                                                                                                       | 45 mg                                                                                                                                                                                       | OD                                                                                                                                                                                          | Liver impairment, fluid retention weight gain, dilutional anaemia, osteoporosis                                                                                                             | Heart failure and liver failure; pregnancy, Bone fractures                                                                                                                                  |\n| D. Meglitinides Mechanism of action: Stimulate pancreas to release more insulin (possibly related to blood glucose level)                                                                   | D. Meglitinides Mechanism of action: Stimulate pancreas to release more insulin (possibly related to blood glucose level)                                                                   | D. Meglitinides Mechanism of action: Stimulate pancreas to release more insulin (possibly related to blood glucose level)                                                                   | D. Meglitinides Mechanism of action: Stimulate pancreas to release more insulin (possibly related to blood glucose level)                                                                   | D. Meglitinides Mechanism of action: Stimulate pancreas to release more insulin (possibly related to blood glucose level)                                                                   | D. Meglitinides Mechanism of action: Stimulate pancreas to release more insulin (possibly related to blood glucose level)                                                                   |\n| Repaglinide                                                                                                                                                                                 | 1.0 mg                                                                                                                                                                                      | 16 mg                                                                                                                                                                                       | BD, TDS or QID (Before meals)                                                                                                                                                               | Liver impairment, fluid retention weight gain, dilutional anaemia                                                                                                                           |                                                                                                                                                                                             |\n| E. Alpha glucosidase inhibitors Mechanism of action: Slow digestion of complex sugars (sucrose and starch) and therefore delays absorption, leading to slow post-meal rise in blood glucose | E. Alpha glucosidase inhibitors Mechanism of action: Slow digestion of complex sugars (sucrose and starch) and therefore delays absorption, leading to slow post-meal rise in blood glucose | E. Alpha glucosidase inhibitors Mechanism of action: Slow digestion of complex sugars (sucrose and starch) and therefore delays absorption, leading to slow post-meal rise in blood glucose | E. Alpha glucosidase inhibitors Mechanism of action: Slow digestion of complex sugars (sucrose and starch) and therefore delays absorption, leading to slow post-meal rise in blood glucose | E. Alpha glucosidase inhibitors Mechanism of action: Slow digestion of complex sugars (sucrose and starch) and therefore delays absorption, leading to slow post-meal rise in blood glucose | E. Alpha glucosidase inhibitors Mechanism of action: Slow digestion of complex sugars (sucrose and starch) and therefore delays absorption, leading to slow post-meal rise in blood glucose |\n| Acarbose                                                                                                                                                                                    | 25 mg                                                                                                                                                                                       | 300 mg                                                                                                                                                                                      | TID (during meal)                                                                                                                                                                           | Dyspepsia loose bowel motions, flatulence                                                                                                                                                   | None                                                                                                                                                                                        |\n\n\n| F. DPP4 inhibitors (Gliptins) Mechanism of action: Improve pancreatic islet glucose sensing →Increase glucose-medicated insulin secretion and suppresses glucagon secretion             | F. DPP4 inhibitors (Gliptins) Mechanism of action: Improve pancreatic islet glucose sensing →Increase glucose-medicated insulin secretion and suppresses glucagon secretion             | F. DPP4 inhibitors (Gliptins) Mechanism of action: Improve pancreatic islet glucose sensing →Increase glucose-medicated insulin secretion and suppresses glucagon secretion             | F. DPP4 inhibitors (Gliptins) Mechanism of action: Improve pancreatic islet glucose sensing →Increase glucose-medicated insulin secretion and suppresses glucagon secretion             | F. DPP4 inhibitors (Gliptins) Mechanism of action: Improve pancreatic islet glucose sensing →Increase glucose-medicated insulin secretion and suppresses glucagon secretion             | F. DPP4 inhibitors (Gliptins) Mechanism of action: Improve pancreatic islet glucose sensing →Increase glucose-medicated insulin secretion and suppresses glucagon secretion             |\n|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Vildagliptin                                                                                                                                                                            | 50 mg                                                                                                                                                                                   | 100 mg                                                                                                                                                                                  | OD or BD                                                                                                                                                                                | Urticaria, angioedema, and immune mediated dermatologic effects. Acute Pancreatitis, Risk of hypoglycaemia (in combination with sulfonylureas                                           | Sitagliptin 100 mg Saxagliptin 5 mg 10 mg                                                                                                                                               |\n|                                                                                                                                                                                         |                                                                                                                                                                                         |                                                                                                                                                                                         | OD                                                                                                                                                                                      | Urticaria, angioedema, and immune mediated dermatologic effects. Acute Pancreatitis, Risk of hypoglycaemia (in combination with sulfonylureas                                           | Sitagliptin 100 mg Saxagliptin 5 mg 10 mg                                                                                                                                               |\n|                                                                                                                                                                                         |                                                                                                                                                                                         |                                                                                                                                                                                         | OD                                                                                                                                                                                      | Urticaria, angioedema, and immune mediated dermatologic effects. Acute Pancreatitis, Risk of hypoglycaemia (in combination with sulfonylureas                                           | Sitagliptin 100 mg Saxagliptin 5 mg 10 mg                                                                                                                                               |\n| Linagliptin                                                                                                                                                                             | 5 mg                                                                                                                                                                                    | 5 mg                                                                                                                                                                                    | OD                                                                                                                                                                                      | Urticaria, angioedema, and immune mediated dermatologic effects. Acute Pancreatitis, Risk of hypoglycaemia (in combination with sulfonylureas                                           | Sitagliptin 100 mg Saxagliptin 5 mg 10 mg                                                                                                                                               |\n| G. SGLT-2 inhibitors Mechanism of action: Suppress renal glucose reabsorption by blocking the sodium-glucose co-transporter 2 (SGLT-2) resulting in increased urinary glucose excretion | G. SGLT-2 inhibitors Mechanism of action: Suppress renal glucose reabsorption by blocking the sodium-glucose co-transporter 2 (SGLT-2) resulting in increased urinary glucose excretion | G. SGLT-2 inhibitors Mechanism of action: Suppress renal glucose reabsorption by blocking the sodium-glucose co-transporter 2 (SGLT-2) resulting in increased urinary glucose excretion | G. SGLT-2 inhibitors Mechanism of action: Suppress renal glucose reabsorption by blocking the sodium-glucose co-transporter 2 (SGLT-2) resulting in increased urinary glucose excretion | G. SGLT-2 inhibitors Mechanism of action: Suppress renal glucose reabsorption by blocking the sodium-glucose co-transporter 2 (SGLT-2) resulting in increased urinary glucose excretion | G. SGLT-2 inhibitors Mechanism of action: Suppress renal glucose reabsorption by blocking the sodium-glucose co-transporter 2 (SGLT-2) resulting in increased urinary glucose excretion |\n| Canagliflozin                                                                                                                                                                           | 100 mg                                                                                                                                                                                  | 300 mg                                                                                                                                                                                  | OD                                                                                                                                                                                      | Polyurea, UTI, DKA, genital candidiasis, hypotension                                                                                                                                    | Renal failure (action dependent on normal GFR) Or sensitivity to active ingredients or it's excipients                                                                                  |\n| Dapagliflozin                                                                                                                                                                           | 5 mg                                                                                                                                                                                    | 10 mg                                                                                                                                                                                   | OD                                                                                                                                                                                      | Polyurea, UTI, DKA, genital candidiasis, hypotension                                                                                                                                    | Renal failure (action dependent on normal GFR) Or sensitivity to active ingredients or it's excipients                                                                                  |\n| Empagliflozin                                                                                                                                                                           | 10 mg                                                                                                                                                                                   | 25 mg                                                                                                                                                                                   | OD                                                                                                                                                                                      | Polyurea, UTI, DKA, genital candidiasis, hypotension                                                                                                                                    | Renal failure (action dependent on normal GFR) Or sensitivity to active ingredients or it's excipients                                                                                  |\n\n\n|                | Metformin                                                                     | Sulfonylurea                                    | Glinides                 | Pioglitazone Alpha-     | Glucosidase Inhibitors     | DPP-4 Inhibitors                                | GLP-1Agonists SGLT-2Inhibitors   |                                                                                                           |\n|----------------|-------------------------------------------------------------------------------|-------------------------------------------------|--------------------------|-------------------------|----------------------------|-------------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------|\n| Hypo           | Neutral                                                                       | Moderate/SevereModerate                         |                          | Neutral                 | Neutral                    | Neutral                                         | Neutral                          | Neutral                                                                                                   |\n| Weight         | Slight loss                                                                   | Gain                                            | Gain                     | Gain                    | Neutral                    | Neutral                                         | Loss                             | Loss                                                                                                      |\n| 3A,3B          | CKD stages Reduced dose inCaution higher stage 3A Contraindicated in stage 3B | risk hypo                                       | Caution higher risk hypo | r Neutral               | Neutral                    | Neutralbut must reduce dose except linagliptin  | Caution with exenatideER         | Contraindicatedin stage3B                                                                                 |\n| 4,5            | CKD stages Contraindicated                                                    | Contraindicated except glipizide and gliclazide | Contraindicated          |                         | ContraindicatedNeutral but | must reduce dose except linagliptin             |                                  | ContraindicatedContraindicated                                                                            |\n| GISE           | Moderate                                                                      | Neutral                                         | Neutral                  | Neutral                 | Moderate                   | Neutral                                         | Moderate                         | Neutral                                                                                                   |\n| OtherSE        |                                                                               |                                                 |                          | Edema and bone fracture |                            | Pancreatitis Heart failure (not a class effect) |                                  | Fungal genital infections, fractures, amputations (Bone fractures and amputationsmaynot be a class effect |\n| MajorCV events | Benefit                                                                       | Neutral                                         | Neutral                  | Neutral                 | Neutral                    | Neutral                                         | Benefit (2 RCT*)                 | Benefit (2 RCT*)                                                                                          |\n| CHF            | Neutral                                                                       | Neutral                                         | Neutral                  | Increased risk          | Neutral                    | Neutral                                         | Neutral                          | Benefit (2RCT**)                                                                                          |\n\n\nCKD, chronic kidney disease; CH, chronic heart failure; CV, cardiovascular; hypo, hypoglycemia; GI, gastrointestinal; SE, side effects; RCT, randomized controlled trial.\n\n\n* Reduced risk in RCTs designed for non-inferiority with liraglutide, semaglutide, empagliflozin and canagliflozin\n\n\n** Reduced risk in RCT designed for non-inferiority with empagliflozin and canagliflozin\n\n\nFigure 14: Risks and benefits of glucose-lowering agents (excluding insulin)\n\n\n(Source: IDF Clinical Practice Recommendations for managing Type 2 Diabetes in Primary Care - 2017)\n\n\n**ii. Insulin Therapy in type 2 diabetes**\n\n\nDiabetes is a progressive condition, and many patients with type 2 diabetes eventually require and benefit from insulin therapy. Early patient education about expected disease progression, and avoidance of threats of future insulin therapy is important thus easing the transition to insulin therapy.\n\n\nFigure 15: Initiating Insulin Therapy in Type 2 diabetes\n\n\n![Adapted from 'Guidelines for the Management of People with Type 2 Diabetes in Shropshire, 2013'](images/picture_035_page_65.png)\n\n\nAdapted from 'Guidelines for the Management of People with Type 2 Diabetes in Shropshire, 2013'\n\n\n**Additional indications for use of insulin in type 2 diabetes**\n\n\n- Presentation\tin\thyperglycemic\temergency\n- Peri-operative\tperiod\tespecially\tmajor\tor\temergency\tsurgery\n- Other\tmedical\tconditions\trequiring\ttight\tglycaemic\tcontrol\te.\tg\tacute\tMI, stroke, sepsis\n- Organ\tfailure\t(e.g.\trenal,\tliver,\theart)\n\n\nNB: Latent autoimmune diabetes of adults (LADA) is a subset of Type 1 DM presenting in adulthood. All patients diagnosed with LADA should receive insulin as with all type 1 DM patients.\n\n\n**The regimen and dose of insulin therapy varies from patient to patient.**\n\n\nFigure 15: Initiating pharmacotherapy in type 2 diabetes\n\n\n![Source: Adapted from the American Diabetes Association: Diabetes Care Journals http://care.diabetesjournals.org/content/40/Supplement_1/S64)](images/picture_036_page_66.png)\n\n\nSource: Adapted from the American Diabetes Association: Diabetes Care Journals http://care.diabetesjournals.org/content/40/Supplement\\_1/S64)\n\n\nDose titration / adjustment requires gradual, safe and prompt titration of insulin dose according to self-blood glucose monitoring (SMBG), towards an optimal dose to ensure maximum benefit from prescribed treatment. Advancing insulin therapy for patients not achieving HbA1c goals on optimally titrated basal insulin alone often requires premeal insulin dosing.\n\n\nTable 22: Adjusting dose of premixed insulin in adults with type 2\n\n\n| Fasting Glucose before Breakfast (in the absence of nocturnal hypos               | Lunch Pre Meal value                                                     | Evening Pre Meal value                                                            | Before Bed Value                                                                        |\n|-----------------------------------------------------------------------------------|--------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|\n| INSULIN This dose will affect pre- lunch and pre-evening meal glucose levels      |                                                                          | INSULIN This dose will affect bedtime and morning fasting glucose levels          |                                                                                         |\n| Target 4 to 7 mmol/L                                                              | Target 4 to 7 mmol/L                                                     | Target 4 to 7 mmol/L                                                              | Target 6 to 8 mmol/L                                                                    |\n| Blood Glucose Monitoring out of range?                                            | Blood Glucose Monitoring out of range?                                   | Blood Glucose Monitoring out of range?                                            | Blood Glucose Monitoring out of range?                                                  |\n| High = Increase previous evening's insulin by 2 units or 10% whichever is greater | High = Increase breakfast insulin by 2 units or 10% whichever is greater | High = Increase previous evening's insulin by 2 units or 10% whichever is greater | High = Increase evening meal insulin but not if blood tests at breakfast are 4-5 mmol/L |\n| Low = Decrease previous evening's insulin by 2 units or                           | Low = Decrease breakfast insulin by 2                                    | Low = Decrease breakfast insulin by 2                                             | Low = Decrease evening meal insulin                                                     |\n\n\nSource:  Adapted from Guidelines for the Management of People with Type 2 Diabetes in Shropshire, 2013\n\n\nInsulin is the most effective drug available to achieve glycemic targets in patients with T2DM yet there is reluctance among patients and physicians to initiate insulin. There are many barriers to insulin treatment among health care providers and patients.\n\n\nTable 23: Barriers to insulin therapy\n\n\n| PATIENT BARRIERS                                                                                                                                                                                                                                                                                                                                                                                                   | PROVIDER BARRIERS                                                                                                                                                                                                                                                                                                                                       | SYSTEM BARRIERS                                                                                                                                                                                                                                                                                                                                 |\n|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Psychological resistance • Myth-based fear of insulin • Fear of hypoglycaemia • Concern about weight gain • Fear of needles and pain • Self-blame • Loss of control • Social stigma Lifestyle • Time-consuming; inconve- nient • Travel issues Physical/mental • Poor recall/cognitive impair- ment • Visual/hearing/dexterity im- pairment • Learning difficulties; low literacy Financial • Reimbursement issues | Perceived patient resis- tance • Patient's adherence behaviour • Belief that patient's improved status ne- gates need to start insulin therapy • Concerns about ad- verse effects (hypoglycaemia; weight gain) • Provider time con- straints (instruction; titration) • Lack of resources/ or- ganizational structure to facilitate guideline adherence | Health system barriers • Overburdened workload among providers • Access to education • Limited training of provid- ers in injection technique • Underutilization of re - sources (within clinical practices, hospitals, and community) • Reimbursement issues • Poor follow-up system • Suboptimal team collabo- ration; poor chronic care mode |\n\n\nSource: Strategies for Insulin Injection Therapy in Diabetes Self-Management, American Association of Diabetes Educators, 2011\n\n\n**iii. Injectable GLP-1 agonists**\n\n\nGLP-1 receptor agonists bind to GLP-1 receptors on existing tissues (pancreas, hypothalamus and stomach). They act to pharmacologically enhance glucose-dependent insulin release, with additional effects on reducing glucagon release, increasing satiety, and increasing gastric emptying.\n\n\nGLP-1 agonists are currently only available in parenteral (subcutaneous) formulation. Two GLP-1 agonists are currently available: exenatide, which has a half-life of four hours and requires twice-daily injection, and liraglutide, which has a half-life of 11-13 hours and requires once-daily injections.\n\n\n### 2.2.3. Blood Glucose monitoring\n\n\nFigure 17: Self-Monitoring of Blood Glucose as a component of diabetes education\n\n\n![69 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS](images/picture_037_page_69.png)\n\n\nSelf-Monitoring of Blood Glucose (SMBG) is an approach whereby people living with diabetes measure their blood glucose themselves using a glucose meter (glucometer). Based on the reading, they can adjust or check the effect of their treatment (diet, exercise, insulin, OGLAs, stress management etc.). Within the wider context of diabetes self-management, self-monitoring supports the maintenance of blood glucose at levels as close as possible to target values.\n\n\nTo fully benefit from self-monitoring, it is essential that a person living with diabetes be trained by a health care professional on the following components:\n\n\n- The\ttechnical\taspects\tof\tself-monitoring;\n- Blood\tglucose\ttargets;\n- When\tand\thow\toften\tto\tmeasure\tblood\tglucose;\n- What\taction\tto\ttake\tbased\ton\tthe\treadings\tobtained;\n- Re-evaluating\t(every\t3\tto\t6\tmonths)\twhen,\tand\thow\toften,\tto self-monitor, based on your clinical condition and readings.\n\n\nWithout this information, self-monitoring of blood glucose will not fulfill its potential purpose, thus affecting the patient motivation and attainment of the treatment goals.\n\n\n**Type 1 DM**\n\n\nAt least 4\n\n\n2 to 8\n\n\n**Type 2 DM on Insulin or Insulin + OGLAs**\n\n\n**New onset DM/Uncontrolled DM/DM during acute illness**\n\n\n![times/day and should](images/picture_038_page_71.png)\n\n\ntimes/day and should\n\n\ninclude preprandial\n\n\nand bedtime times/day\n\n\n- Paired testing at least 3-4 days a week (1 day/week pre and post breakfast, 1 day per/week pre and post lunch, and 1 day/week pre and post dinner) or as\n\n\nfrequently as possible\n\n\n- At least 4 times/day and should include preprandial and bedtime levels\n- At least 4 times/day\n- At least FBG and one more preprandial\n- At least 4 tests in a week on 4 consecutive days or on alternate days (including 1 FBG and 3 postprandial values)\n\n\n**Type 2 DM on OGLAs**\n\n\n**New onset DM/Uncontrolled DM/DM during acute illness**\n\n\n![value every day](images/picture_039_page_71.png)\n\n\n- At least 4 times/ day and should\n- preprandial and bedtime levels\n\n\nvalue every day\n\n\nAt least 4 tests in a month - at least 1\n\n\n- At least FBG once a week\n- At least FBG on alternate days\n\n\ninclude levels\n\n\ntest/week (including\n\n\n1 FBG and 3\n\n\n- postprandial values\n\n\nin a month)\n\n\n**Diabetes in Pregnancy**\n\n\n![Initially one value/](images/picture_040_page_71.png)\n\n\n![Initially one value/](images/picture_041_page_71.png)\n\n\nInitially one value/\n\n\nday (different values on each\n\n\nPatients with\n\n\n- At least 4 times/day (FBG and 3 postprandial)\n- FBG and 3 postprandial values at least once a week or staggered over a week\n\n\nday)\n\n\n**Diabetes and Hypoglycemia Unawareness Brittle**\n\n\n**Patients on Premix Insulin, Basal Bolus Therapy**\n\n\n![Patients on Basal Insulin](images/picture_042_page_71.png)\n\n\n- 3 preprandial (including FBG) and 3 postprandial tests on alternate days till target HbA1c and blood glucose levels are reached\n\n\n**Patients on Basal Insulin**\n\n\n- After achievement of fasting target, postprandial correction should be done\n- Paired testing every day (pre and st post breakfast on 1  day, pre and nd post lunch on 2 day,  pre and rd post dinner on 3 day, and then to keep repeating the cycle)\n- One FBG and one postprandial value (any meal, preferably after largest meal of the day) every week\n- Less frequent testing can be done after achievement of the target (fasting and one meal-related testing can be done, can be staggered, changing every 2 days)\n- FBG twice a week or once in 3 days\n- After achievement of fasting target, postprandial\n- correction should be done\n\n\n**Figure 19: Guidance on Self-Monitoring of Blood Glucose for people living with diabetes**\n\n\n**(Source: Research Society for the Study of Diabetes in India, RSSDI)**\n\n\n**Methods for Monitoring Glycaemic Control**\n\n\nClinical and laboratory methods are employed to monitor or assess whether the individualized glycaemic targets are being attained.\n\n\n- HbA1c\tis\tthe\tstandard\ttest\tfor\tmonitoring\tglucose\tcontrol.\tThis\tshould\tbe\tdone every 3 months until patient is well controlled and subsequently every 6 months. (refer to table 18 for targets) Changes in therapy ought to be guided by glucose control as depicted by the HbA1c.\n- Self-monitoring\tof\tBlood\tGlucose\t(SMBG)\tshould\tbe\tencouraged.\tIt\tis\tthe\tmain measure used to titrate drug doses on a day to day basis\n- Results\tof\tself-blood\tglucose\ttests\tshould\tbe\trecorded\tin\ta\tlogbook\tor\tdiary indicating the day and time of testing\n- The\tclinic\tprotocol\tshould\tset\tout\tthe\tparameters\tto\tbe\tmonitored\tat\tthe\tinitial visit, regular follow-up visits, and at the annual review (refer to table 14  for assessment and follow-up)\n\n\n**Examples of Self-Monitoring of Blood Glucose (SMBG) testing profiles**\n\n\nIntensive\tor\t'focused'\tSMBG\tprotocols\tuse\t'pattern\tanalysis' ,\ta\tsystematic\tapproach\tto creating glucose profiles that can identify daily glycaemic patterns and then take appropriate action based upon those results. These profiles can be generated by performing 5 to\t7\tmeasurements\tper\tday\tover\t1\tto\t3\tdays,\tor\tthrough\t'staggered'\ttesting,\tin\twhich\tthe individual performs pre- and postprandial testing for alternating meals over the course of a week\n\n\nMeal-based SMBG (before and after selected meals) helps individuals living with diabetes understand the effects of their treatment on blood glucose concentrations and assists clinicians in identifying postprandial hyperglycaemia, guides therapeutic adjustments and provides more timely feedback regarding medication changes. The table below summarizes the SMBG testing profiles\n\n\nTable 24: Examples of Self-Monitoring of Blood Glucose (SMBG) testing profiles\n\n\n|                            | Testing points             | Testing points             | Testing points             | Testing points             | Testing points             | Testing points             | Testing points             |\n|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|\n| Day                        | Pre-Break- fast            | 2 hours Post- Breakfast    | Pre- lunch                 | 2-hours Post- lunch        | Pre-sup- per               | 2-hours post-sup- per      | Bedtime                    |\n| 7-point testing profile    | 7-point testing profile    | 7-point testing profile    | 7-point testing profile    | 7-point testing profile    | 7-point testing profile    | 7-point testing profile    | 7-point testing profile    |\n| Monday                     |                            |                            |                            |                            |                            |                            |                            |\n| Tuesday                    | X                          | X                          | X                          | X                          | X                          | X                          | X                          |\n| Wednesday                  | X                          | X                          | X                          | X                          | X                          | X                          | X                          |\n| Thursday                   | X                          | X                          | X                          | X                          | X                          | X                          | X                          |\n| Friday                     |                            |                            |                            |                            |                            |                            |                            |\n| Saturday                   |                            |                            |                            |                            |                            |                            |                            |\n| Sunday                     |                            |                            |                            |                            |                            |                            |                            |\n| Staggered testing profile  | Staggered testing profile  | Staggered testing profile  | Staggered testing profile  | Staggered testing profile  | Staggered testing profile  | Staggered testing profile  | Staggered testing profile  |\n| Monday                     | X                          | X                          |                            |                            |                            |                            |                            |\n| Tuesday                    |                            |                            | X                          | X                          |                            |                            |                            |\n| Wednesday                  |                            |                            |                            |                            | X                          | X                          |                            |\n| Thursday                   | X                          | X                          |                            |                            |                            |                            |                            |\n| Friday                     |                            |                            | X                          | X                          |                            |                            |                            |\n| Saturday                   |                            |                            |                            |                            | X                          | X                          |                            |\n| Sunday                     | X                          | X                          |                            |                            |                            |                            |                            |\n| Meal-based testing profile | Meal-based testing profile | Meal-based testing profile | Meal-based testing profile | Meal-based testing profile | Meal-based testing profile | Meal-based testing profile | Meal-based testing profile |\n| Monday                     | X                          | X                          |                            |                            |                            |                            |                            |\n| Tuesday                    |                            |                            |                            |                            |                            |                            |                            |\n| Wednesday                  |                            |                            | X                          | X                          |                            |                            |                            |\n| Thursday                   |                            |                            |                            |                            |                            |                            |                            |\n| Friday                     |                            |                            |                            |                            |                            |                            |                            |\n| Saturday                   |                            |                            |                            |                            | X                          | X                          |                            |\n| Sunday                     |                            |                            |                            |                            |                            |                            |                            |\n\n\nSource: IDF Guideline on Self-Monitoring of Blood Glucose in Non-Insulin Treated Type 2 Diabetes\n\n\nTable 25: Targets for HbA1c, fasting plasma glucose and postprandial glucose in different patient types\n\n\n| Patient type                                                                                   | Target HbA1c                  | Target FPG                    | Target PPG                                                         |\n|------------------------------------------------------------------------------------------------|-------------------------------|-------------------------------|--------------------------------------------------------------------|\n| Young Low risk Newly diagnosed                                                                 | < 6.5%                        | 4.0-7.0 mmol/l                | 4.4-7.8 mmol/l                                                     |\n| No cardiovascular disease Majority of patients                                                 | < 7%                          | 4.0-7.0 mmol/l                | 5.0 -10.0 mmol/l                                                   |\n| Elderly High risk (high cardio- vascular risk) Hypoglycaemic unaware Poor short-term prognosis | < 8%                          | 4.0-9.8 mmol/l                | < 11.0 mmol/l                                                      |\n| Targets for other measurement                                                                  | Targets for other measurement | Targets for other measurement | Targets for other measurement                                      |\n| Weight and height                                                                              |                               | BMI of 18.5 - 24.9 kg/m2      | A10% weight loss from the current weight if obese is recommend- ed |\n| Waist circumference                                                                            |                               | Male                          | Female                                                             |\n|                                                                                                |                               | <90 cm                        | <84 cm                                                             |\n| Blood pressure (mmHg)                                                                          |                               | systolic                      | diastolic                                                          |\n|                                                                                                |                               | <140 mmHg                     | < 90 mmHg                                                          |\n| If persistent, microalbuminuria / proteinuria                                                  |                               | <125 mmHg                     | <75 mmHg                                                           |\n| Lipids (fasting)                                                                               |                               | Male                          | Female                                                             |\n| Total cholesterol                                                                              |                               | <4.8 mmol/l                   | <4.8 mmol/l                                                        |\n| LDLcholesterol                                                                                 |                               | <2.6 mmol/l                   | <2.6 mmol/l                                                        |\n| HDLcholesterol                                                                                 |                               | >1.0 mmol/l                   | >1.3 mmol/l                                                        |\n| Triglycerides                                                                                  |                               | <1.7 mmol/l                   | <1.7 mmol/l                                                        |\n\n\nCHAPTER THREE\n\n\n75 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS\n\n\n",
            "startLine": 1668,
            "endLine": 2605,
            "introContent": {
              "content": "The successful establishment of the diabetes health-care team and its supportive infrastructure is critical for the achievement of management goals. This includes provision of education for health-care professionals and for people living with diabetes.\n\n\nA thorough clinical assessment of a patient with type 2 diabetes is recommended before initiating any therapy and during ongoing therapy.\n\n\nTable 14: Clinical Assessment for initial and follow-up visits for Type 2 Diabetes\n\n\n|                                                                                                                                                                   | Initial visit                                                 | Three- to six-monthly visits                                  | Annual visit                                                  |\n|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|\n| History                                                                                                                                                           |                                                               |                                                               |                                                               |\n| Symptoms of hyperglycaemia* and duration of symptoms                                                                                                              | X                                                             | X                                                             | X                                                             |\n| Hypoglycaemic** symptoms                                                                                                                                          | X                                                             | X                                                             | X                                                             |\n| Relevant family history                                                                                                                                           | X                                                             |                                                               |                                                               |\n| Other risk factors (e.g. gestational diabetes, PCOS, hypertension)                                                                                                | X                                                             | X                                                             | X                                                             |\n| Relevant medical history (includingTB infection and exposure)                                                                                                     | Relevant medical history (includingTB infection and exposure) | Relevant medical history (includingTB infection and exposure) | Relevant medical history (includingTB infection and exposure) |\n| - Co-morbid conditions                                                                                                                                            | X                                                             |                                                               | X                                                             |\n| - Symptoms of complications: Cardiovas- cular, neurological, bladder function, sexual function (i.e. erectile dysfunction or low libido), feet, visual, infection | X                                                             | X                                                             | X                                                             |\n| Drugs                                                                                                                                                             |                                                               |                                                               |                                                               |\n| - Side effects                                                                                                                                                    |                                                               | X                                                             | X                                                             |\n| - Adherence                                                                                                                                                       |                                                               | X                                                             | X                                                             |\n| - Allergies                                                                                                                                                       | X                                                             | X                                                             | X                                                             |\n| Vaccinations                                                                                                                                                      |                                                               |                                                               |                                                               |\n| - Pneumococcal (date)                                                                                                                                             | X                                                             |                                                               | X                                                             |\n| - Influenza (date)                                                                                                                                                | X                                                             |                                                               | X                                                             |\n| Lifestyle                                                                                                                                                         |                                                               |                                                               |                                                               |\n| - Weight                                                                                                                                                          | X                                                             | X                                                             | X                                                             |\n| - Physical activity/sedentary lifestyle                                                                                                                           | X                                                             | X                                                             | X                                                             |\n\n\n| -                                                      | Eating pattern                                                                                     | X   | X   | X   |\n|--------------------------------------------------------|----------------------------------------------------------------------------------------------------|-----|-----|-----|\n| -                                                      | Smoking                                                                                            | X   | X   | X   |\n| -                                                      | Drug abuse                                                                                         | X   | X   | X   |\n| -                                                      | Alcohol                                                                                            | X   | X   | X   |\n| Psychosocial support                                   | Psychosocial support                                                                               |     |     |     |\n| -                                                      | Occupation                                                                                         | X   |     | X   |\n| -                                                      | Family and community support (sup- port groups)                                                    | X   |     | X   |\n| -                                                      | Depression, anxiety and other mental disorders                                                     | X   | X   | X   |\n| Home monitoring of blood glucose (glucom-              | Home monitoring of blood glucose (glucom-                                                          | X   | X   | X   |\n| Physical examination                                   | Physical examination                                                                               |     |     |     |\n| Weight                                                 | Weight                                                                                             | X   | X   | X   |\n| Height                                                 | Height                                                                                             | X   | X   | X   |\n| Body mass index (BMI) (kg/m 2 )                        | Body mass index (BMI) (kg/m 2 )                                                                    | X   | X   | X   |\n| Waist circumference (cm)                               | Waist circumference (cm)                                                                           | X   | X   | X   |\n| Heart rate and rhythm                                  | Heart rate and rhythm                                                                              | X   | X   | X   |\n| Blood pressure in mmHg(both systolic and diastolic BP) | Blood pressure in mmHg(both systolic and diastolic BP)                                             | X   | X   | X   |\n| Injection sites, if appropriate                        | Injection sites, if appropriate                                                                    | X   | X   | X   |\n| Feet                                                   | Feet                                                                                               |     |     |     |\n| -                                                      | Inspection: Ulcers, soft tissue, deformi- ties, Footwear                                           | X   | X   | X   |\n| -                                                      | Monofilament assessment                                                                            | X   |     | X   |\n| -                                                      | Vibration sense using tuning fork, or pinprick sensation                                           | X   |     | X   |\n| -                                                      | Ankle jerk                                                                                         | X   |     | X   |\n| -                                                      | Foot pulses                                                                                        | X   |     | X   |\n| Oral cavity                                            | Oral cavity                                                                                        |     |     |     |\n| -                                                      | Dental caries                                                                                      | X   |     | X   |\n| -                                                      | Gumdisease                                                                                         | X   |     | X   |\n| Eyes                                                   | Eyes                                                                                               |     |     |     |\n| -                                                      | Visual acuity                                                                                      | X   |     | X   |\n| -                                                      | Direct fundoscopy (dilated pupils), indirect fundoscopy, or fundus photo- graphs                   | X   |     | X a |\n| Systemic examination                                   | Systemic examination                                                                               |     |     |     |\n| Cardiovascular system examination                      | Cardiovascular system examination                                                                  | X   |     | X   |\n| Special investigations                                 | Special investigations                                                                             |     |     |     |\n| Blood tests                                            | Blood tests                                                                                        |     |     |     |\n| -                                                      | Glucose                                                                                            | X   | X   | X   |\n| -                                                      | HbA1c (Six-monthly if at target, otherwise three- monthly. Also, whenever treat- ment is adjusted) | X   | X   | X   |\n\n\n| - Lipids: Total cholesterol, HDL cholester-                                                                                                                                | X   |    | X   |\n|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----|-----|\n| - Creatinine, and calculate estimated GFR                                                                                                                                  | X   |    | X   |\n| - Potassium                                                                                                                                                                | X   |    | X   |\n| - TSH                                                                                                                                                                      | X   |    | X   |\n| - HIV                                                                                                                                                                      | X   |    | X   |\n| Urine                                                                                                                                                                      |     |    |     |\n| - Glucose                                                                                                                                                                  | X   |    | X   |\n| - Protein                                                                                                                                                                  |     |    |     |\n| - Ketones                                                                                                                                                                  | X   |    | X   |\n| - Leucocytes                                                                                                                                                               | X   |    | X   |\n| Urine microalbuminuria                                                                                                                                                     | X   |    | X   |\n| Uric acid                                                                                                                                                                  | X   |    | X   |\n| Full Hemogram                                                                                                                                                              | X   |    | X   |\n| Liver Function Tests (ALT, AST, ALP)                                                                                                                                       | X   |    | X   |\n| Urine microalbuminuria                                                                                                                                                     | X   |    | X   |\n| Uric acid                                                                                                                                                                  | X   |    | X   |\n| Full Hemogram                                                                                                                                                              | X   |    | X   |\n| Liver Function Tests (ALT, AST, ALP)                                                                                                                                       | X   |    | X   |\n| ECG                                                                                                                                                                        | X   |    | X   |\n| Cancer screening (Pap smear, breast, PSA)                                                                                                                                  | X   |    | X   |\n| Cancer screening (Pap smear, breast, PSA)                                                                                                                                  | X   |    | X   |\n| Other important tasks                                                                                                                                                      |     |    |     |\n| Education: Self-management and lifestyle adjustment, including tobacco cessation, alcohol cessation, Hypoglycemia avoidance and treatment, nutrition and physical activity | X   | X  | X   |\n| Setting goals                                                                                                                                                              | X   | X  | X   |\n| Preconception counselling and family planning                                                                                                                              |     | X  | X   |\n| Medication revision/adjustment                                                                                                                                             | X   | X  | X   |\n| Immunizations                                                                                                                                                              | X   |    | X   |\n\n\n\n\na Int erval for ret inop at y  sc reening c an b e inc reased t o onc e every 2 y ears if t h e last  2 ex am inat ions w ere norm al; m ore frequent  ex am inat ions are required in t h e p resenc e of ab norm alit ies.\n\n\n* y m om of h y p erg ly aem ia inc lude p oly dip sia,  h eadac es,  b lurred vision,  p oly uria,  fat ig ue/ b ody  m alaise,  w eig\n\n\n\n\n,\n\n\n\n\nt  loss\n\n\n** S y m om s/ sig ns of H y p og ly em iaN ervousness or anx iet y ,  sw eat ing c ills and c lam y  ex rem it ies,  irrit ab ilit y ,  c onfusion,  inc luding delirium ac y c ardia,  lig eadedness or diz z iness,  h ung er and nausea,  b lurred/ im aired vision,  t ing ling or num ness in t h e lip s or t ong ue,  h eadac es,  w eak ness or fat ig ue,  m ood c ang es,  lac of c oordinat ion,  nig ares or c ry ing out  during sleep ,  seiz ures,  loss of c onsc iousness. -p oly y st ic ovarian sy ndrom e\n\n\n\n\n-\n\n\n,\n\n\n**Management of Type 2 diabetes entails the following components:**\n\n\n- i. Treatment of hyperglycemia\n- ii. Treatment of hypertension and dyslipidemia\n- iii. Prevention and treatment of micro-vascular complications\n- iv. Prevention and treatment of macro-vascular complications\n- v. Prevention and treatment of non-vascular complications\n\n\n**Treatment of hyperglycemia**\n\n\nTreatment of hyperglycaemia in type 2 diabetes consist of the following;\n\n\n**a. Non -pharmacological**\n\n\n- i. Education\n- ii. Diet\n- iii. Physical activity\n- iv. Blood glucose monitoring\n\n\n**b. Pharmacological**\n\n\n- i. Oral glucose lowering agents (oral hypoglycaemic agents)\n- ii. Insulin\n- iii. Combination Therapies - e.g. Oral glucose lowering agents and insulin\n- iv. Non-insulin injectable glucose lowering agents (GLP-1 agonists)",
              "tokenCount": 2266,
              "startLine": 1669,
              "endLine": 1832
            },
            "keywords": [],
            "subsections": [
              {
                "id": "subsection-2-2-1",
                "level": "h3",
                "number": "2.2.1",
                "title": "2.2.1. Non-pharmacological management",
                "slug": "221-non-pharmacological-management",
                "url": "/guidelines/22-management-of-type-2-diabetes/221-non-pharmacological-management",
                "parentId": "section-2-2",
                "breadcrumb": [
                  "CHAPTER TWO: MANAGEMENT OF DIABETES",
                  "2.2. Management of Type 2 Diabetes",
                  "2.2.1. Non-pharmacological management"
                ],
                "tokenCount": 5055,
                "content": "### 2.2.1. Non-pharmacological management\n\n\nThis is the cornerstone in achieving diabetes control. It includes diabetes education, medical nutrition therapy, physical activity and self-monitoring of blood glucose.\n\n\n**Diabetes Education**\n\n\nDiabetes education to the diabetic patient and the family is important in ensuring good glycemic control and prevention of diabetic complications. The diabetes education is a continuous process in the patients' follow up\n\n\n**Principles of diabetes education**\n\n\n- An\tevidence-based,\tstructured\teducation\tprogramme\tshould\tbe\toffered\tto\tall patients at the time of diagnosis, and consolidated at regular intervals thereafter. The aim is to promote patient self-management\n- Diabetes\teducation\tis\ta\tcontinuous\tprocess\tand\tdifferent\ttopics\tshould\tbe covered at separate sessions to ensure a proper understanding of the issues\n- The\tprogramme\tshould\tbe\tpresented\tby\teducators\twho\thave\tbeen appropriately trained\n- Diabetes\tself-management\teducation\t(DSME)\tshould\tbe\tindividualized. Small-group education is the most cost-effective option but individual education sessions should also be utilized where necessary\n- Educators\tshould\tensure\tthat\tactive\tlearning\tis\ttaking\tplace\n- Psychological\tand\temotional\tassessment\tis\tneeded\tat\tregular\tintervals\n- A\tregular\taudit\tof\tthe\tprogramme\tand\tits\teffect\ton\toutcomes\tis\tadvised\n\n\nTable 15:  Structured diabetes education outline\n\n\n| Visits                          | Education to be conducted during the diabetes clinic visit                                                                                                                                                                                                                                                                  |\n|---------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Visit 1                         | • Support system • Overview of Diabetes • Blood glucose monitoring • Nutrition • Physical Activity • Self-Glucose Monitoring                                                                                                                                                                                                |\n| Visit 2                         | • Hypoglycaemia • Hyperglycaemia • Sick Days • Mindful eating • Dining Out • Physical Activity                                                                                                                                                                                                                              |\n| Visit 3                         | • Stress and diabetes • Natural changes of diabetes • Blood pressure control • Heart health • Tobacco use • Eating for better health • Physical Activity                                                                                                                                                                    |\n| Visit 4                         | • Diabetes and alcohol • Diabetes changes over time • Problem-solving: glucose results • Complications: preventing and delaying • Foot care • Sleep habits                                                                                                                                                                  |\n| Visit 5                         | • Pregnancy: preparing, managing diabetes during pregnancy and appropriate postnatal care • Psychosocial issues, stress management and coping skills • What is the role of alternative medicine: How to make informed choices about their use of traditional and alternative medicine, potential harm and drug interactions |\n| Educating the elderly patients: | • Assess knowledge and understanding of diabetes • Evaluate ability to learn and apply new self-care skills • Asses nutrition and physical activity • Address poly-pharmacy and co-morbidities • Assess for cognitive dysfunction, depression and physical disability                                                       |\n\n\n**Dietary Management of Type 2 Diabetes Mellitus**\n\n\nDietary modification is one of the cornerstones of diabetes management. It is based on the principle of healthy eating in the context of socio-economic, cultural and psychological influences of food choices.\n\n\n**Principles of dietary management of Type 2 diabetes mellitus**\n\n\nAll members of the diabetes-care team must have knowledge about nutrition to be able to educate people living with diabetes with the support of a nutritionist. Dietary counseling is best given by a dietitian or nutritionist.\n\n\n**The following are principles of dietary management:**\n\n\n- To\tachieve\tideal/desired\tweight,\tan\tappropriate\tdiet\tand\texercise\tregimen should be agreed upon between the nutritionist and the patient/care giver\n- Three\tmain\tmeals\tshould\tbe\teaten\tin\ta\tday,\tand\tbinge\teating\tshould\tbe\tavoided\n- The\tdiet\tshould\tbe\tindividualized,\tbased\ton\ttraditional\teating\tpatterns,\tBMI, comorbid conditions; and should be palatable and affordable\n- Animal\tfat,\tsalt,\tdiet\tdrinks,\tsweeteners\tand\tfoods\tmarketed\tas\t'diabetic\tfoods' should be avoided\n- Tailoring\tthe\tnutritional\tintervention,\tso\tthat\tthere\tis\ta\tcareful\tmatch\tof\tboth\ta meal-planning approach and educational materials with the patient needs, and so that there is still some allowance for flexibility\n- Foods\tand\tdrinks\trich\tin\trefined\tsugars\t(simple\tsugars)\tshould\tbe\tavoided\n- Eating\tplans\tshould\tbe\thigher\tin\tcomplex\tcarbohydrates\t(starches)\tand\tfibre content\n- Vegetables\tand\tlimited\tnumbers\tof\tfruits\tshould\tbe\tencouraged\n- Food\tquantities\tshould\tbe\tmeasured\tin\tvolumes\tusing\tavailable\thousehold items, such as cups, or be countable, such as number of fruits or slices of yam or bread\n- Alcohol\tshould\tbe\tavoided\n- Sweeteners\tare\tnot\tessential\tand\tshould\tbe\tavoided\tas\tmuch\tas\tpossible\n- Drinking\tof\twater\tthroughout\tthe\tday\tshould\tbe\tencouraged\t(average\t8 glasses  of 250 mls each)\n\n\n**Table 16: Dietary Recommendations in Management of Type 2 Diabetes**\n\n\n**A. Follow a healthy, balanced eating plan**\n\n\n- Eat a variety of fresh fruit and vegetables every day, but avoid fruit juices\n- At least half of the grain intake must be from whole grain products\n- Use a variety of meat alternatives, including pulses, beans and other legumes\n- Consume white meat at least twice per week\n- Limit the intake of processed and fast foods\n- Increase the intake of water to meet daily fluid requirements\n\n\n**B. Carbohydrates**\n\n\n- Carbohydrates should make up 45-60% of the total energy intake\n- Monitoring  carbohydrate  intake,  whether  by  carbohydrate  counting,  exchanges or experienced-based estimation, remains a key strategy in achieving optimum glycaemic control\n- The use of glycaemic index and glycaemic load may provide a modest an additional benefit compared to considering only total carbohydrate content\n- Limit the intake of sugar alcohols (maltitol, mannitol, sorbitol, lactitol, isomalt, xylitol) to &lt; 10 g per day\n- A sucrose intake of up to 10% of total energy intake per day is acceptable\n- Limit the total fructose intake to 60 g per day\n- Increase the intake of soluble and insoluble fibre to 25-50 g per day\n- The use of artificial sweeteners, including acesulfame-K, aspartame, sac -charine and sucralose, are safe when consumed within the daily limits established by the FDA\n\n\n**C. Protein**\n\n\n- Proteins should make up 15-20% of the total energy intake\n- For individuals with type 2 diabetes with normal renal function, there is no evidence to suggest that the usual recommended protein intake should be modified\n- In type 2 diabetes, ingested protein can increase the insulin response without increasing plasma glucose levels; therefore, protein should not be used in the treatment and prevention of Hypoglycemia\n\n\n**D. Fat**\n\n\n- The fat intake should be restricted to &lt; 35% of the total energy intake\n- The saturated fat (solid fats, and animal fats) intake should be restricted to &lt; 7% of the total energy intake\n- Most of the fat intake should be unsaturated fats (vegetable oils)\n- Minimize the intake of trans-fats\n- Two more servings of fish per week will provide the recommended ome -ga-3 polyunsaturated fatty acids\n\n\n**E. Salt**\n\n\n- Limit all kinds of salt intake\n\n\n**F. Vitamins and minerals**\n\n\n- Mineral and vitamin supplementation may be needed in selected groups, such as the elderly, lactating and pregnant women, and vegans\n- Encourage to take a variety of fruits and vegetables, fish and foods rich in vitamin D\n\n\n**G. Alcohol**\n\n\n- Adults who choose to consume alcohol should do so in moderation: one unit per day or less for women, and two units per day or less for men\n- Moderate alcohol consumption, with food, does not cause acute hyperglycaemia or Hypoglycemia.\n- Individuals on insulin or insulin secretagogues should be aware of the risks of delayed Hypoglycemia (for up to 24 hours after consumption); alcohol should be consumed with food to reduce the risk of Hypoglycemia\n\n\n**Tools used in meal planning in in diabetes nutrition therapy**\n\n\nThere are several tools used in meal planning, however, there is no ideal meal plan that works for everyone living with diabetes. Below are some of the tools used in meal planning in diabetes care\n\n\n1. Plate Model\n2. Handy portion guide\n3. Glycemic Index and glycemic load\n4. Food groups and food servings\n5. Carbohydrate counting\n\n\n**Plate Model**\n\n\nThis method helps the patient to easily measure the food portions while keeping simple and practical. It divides the plate, 9 inches in diameter, into portions of vegetables, fruits, starch and proteins as indicated below\n\n\n![Figure 10: Plate Model](images/picture_031_page_52.png)\n\n\n**Figure 10: Plate Model**\n\n\nSource: Adapted from the Harvard T.H Chan school of Public Health, The Nutrition Source (www.hsph.harvard.edu/nutritionsource)\n\n\nHandy portion guide\n\n\nThis method used patients' hands to provide quick tips for estimating portion sizes\n\n\nFigure 11: Handy portion guide\n\n\n![Glycemic Index and glycemic load](images/picture_032_page_53.png)\n\n\n**Glycemic Index and glycemic load**\n\n\nThe glycemic index is a value assigned to foods based on how slowly or how quickly these foods cause increases in blood glucose levels. It ranks the carbohydrates on a scale from 0 to 100 according to the extent to which they raise blood sugar (glucose) levels after eating. Foods low in the glycemic index (GI) scale tend to release glucose slowly and steadily while foods high on the glycemic index release glucose rapidly\n\n\nFigure 12: An illustration of low and high glycemic index food\n\n\n![53 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS](images/picture_033_page_53.png)\n\n\nBelow is a comprehensive list of low and high glycemic foods, people living with diabetes are advised to choose more foods from the low glycemic index\n\n\nTable 17: Examples of low and high glycemic index foods\n\n\n| High glycemic foods                                                                                                                                                                                                                                                                             | Low glycemic foods                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Glucose Baked potatoes French Fries Rice Flour Mashed Potatoes Potato Chips Honey Cooked Carrots Corn Flakes Cooked Broad beans Pumpkin Watermelon Sugar (Sucrose) White bread Refined sweetened cereal Chocolate bars Boiled peeled potatoes Cola soda Cookies Corn White rice Noodles Raisins | Whole wheat or bran bread Brown rice Sweet potatoes Whole wheat pasta Fresh peas Whole wheat sugar free cereal Oatmeal Whole grain pasta Kidney beans Fresh unsweetened fruit juice Raw carrots Dairy products Dried beans Brown or yellow lentils Chick peas Fresh fruit Green vegetables, tomatoes, eggplant, zucchini, garlic, onions etc Green beans Sugar free marmalade Green Lentils Split peas Dark Chocolate (>70% cocoa Fruits (Banana, Grapes, Orange, |\n\n\n**Food groups and food servings**\n\n\nThis method is used as a tool that is used to help the patient figure out how many servings of each food are they required to eat from every group. The key to eating well is to enjoy a variety of nutritious foods from each of the food groups.\n\n\nTable 18: Food groups and recommended servings per each food group\n\n\n| Food group                | Number of servings   | What is a serving?                                                                                                                                        |\n|---------------------------|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Starches and breads       | 6-11                 | 1 Slice bread ½ cup cooked rice, cereal ¼ cup dry cereal, ½ cup pasta 3 biscuits (eat whole-grain, fortified or en - riched starches, bread, and cereals) |\n| Vegetables                | 3-5                  | ½ cup vegetables cooked 1 cup vegetables raw                                                                                                              |\n| Fruits                    | 2-4                  | 1 cup fruit juice (fresh, frozen or canned without sugar) 1 medium piece fresh fruit                                                                      |\n| Milk and milk products    | 2-3                  | 1 cup skim / low fat milk / ¾ cup plain or artificially sweetened yogurt                                                                                  |\n| Meat and meat substitutes | 2-3                  | 57-85 g cooked lean meat fish or poultry 28.5 g meat is equivalent to: - 1 egg 28.5 g cheese ¼ cup fish (Omena, tuna, salmon or cheese                    |\n| Fat                       | Use sparingly        | 1 teaspoon margarine 1 teaspoon salad dressing 1 teaspoon oil or mayonnaise 1 tablespoon peanut-butter                                                    |\n\n\n**Carbohydrate counting**\n\n\nCarbohydrate counting, is a meal planning tool for people living with type 1or type 2 diabetes. It involves keeping track of the amount of carbohydrate in the foods that a person eats each day.\n\n\nCarbohydrates are one of the main nutrients found in food and drinks. They include sugars, starches, and fibre. Carbohydrate counting can help one control their blood glucose levels because carbohydrates affect the blood glucose more than other nutrients.\n\n\nHealthy carbohydrates, such as whole grains, fruits, and vegetables, are an important part of a healthy eating plan because they provide both energy and nutrients, such as vitamins and minerals, and fibre. Fibre helps in preventing constipation, lower cholesterol levels, and control the weight.\n\n\nUnhealthy carbohydrates are often food and drinks with added sugars. Although unhealthy carbohydrates can also provide energy, they have little to no nutrients.\n\n\nThe amount of carbohydrate in foods is measured in grams. To count grams of carbohydrate in foods you eat, a patient will need to;\n\n\n- Know\twhich\tfoods\tcontain\tcarbohydrates\n- Learn\tto\testimate\tthe\tnumber\tof\tgrams\tof\tcarbohydrate\tin\tthe\tfoods\n- Add\tup\tthe\tnumber\tof\tgrams\tof\tcarbohydrate\tfrom\teach\tfood\tto\tget\tyour\ttotal for the day\n\n\n**Foods that contain carbohydrates include**\n\n\n- grains,\tsuch\tas\tbread,\tnoodles,\tpasta,\tcrackers,\tcereals,\tand\trice\n- fruits,\tsuch\tas\tapples,\tbananas,\tberries,\tmangoes,\tmelons,\tand\toranges\n- dairy\tproducts,\tsuch\tas\tmilk\tand\tyogurt\n- legumes,\tincluding\tdried\tbeans,\tlentils,\tand\tpeas\n- snack\tfoods\tand\tsweets,\tsuch\tas\tcakes,\tcookies,\tcandy,\tand\tother\tdesserts\n- juices,\tsoft\tdrinks,\tfruit\tdrinks,\tsports\tdrinks,\tand\tenergy\tdrinks\tthat\tcontain sugars\n- vegetables,\tespecially\t'starchy'\tvegetables\tsuch\tas\tpotatoes,\tcorn,\tand\tpeas\n\n\nFoods that do not contain carbohydrates include meat, fish, and poultry; most types of cheese; nuts; and oils and other fats.\n\n\n**Example of the grams of carbohydrates on needs based on an 1800 kilo calories diet per day**\n\n\nCarbohydrate intake for most people should be between 45 and 65 percent of total calories per day. People on low-calorie diets and people who are physically inactive may want to aim for the lower end of that range.\n\n\nOne gram of carbohydrate provides about 4 calories, thus divide the number of calories per day from carbohydrates by 4 to get the number of grams. For example, if a diet is based on an 1,800 total calories per day and get 45 percent of your calories from\n\n\ncarbohydrates, then the grams from of carbohydrates is about 200 grams of carbohydrate daily. Calculated follows:\n\n\n- 0.45\tx\t1,800\tcalories\t=\t810\tcalories\n- 810\t÷\t4\t=\t202.5\tgrams\tof\tcarbohydrate\n\n\nSpread out the grams of carbohydrate intake throughout the day. There is a need to involve a dietitian or a nutritionist to counsel the patient on what foods to eat, how much to eat, and when to eat based on the weight, activity level, medicines, and blood glucose targets. This method also requires the patient to be motivated, read all the food labels and be willing to calculate the number of grams of carbohydrates intake per day\n\n\n**Physical activity and exercise**\n\n\nPhysical activity or exercise is one of the essentials in the prevention and management of Type 2 diabetes mellitus. Regular physical activity improves metabolic control, increases insulin sensitivity, improves cardiovascular health, and helps weight loss and its maintenance, as well as giving a sense of well-being.\n\n\n**There are two main types of physical activity:**\n\n\n- i. Aerobic or endurance exercise (e.g. walking or running)\n- ii. Anaerobic or resistance exercise (e.g. lifting weights).\n\n\nBoth types of activity may be prescribed to persons with Type 2 diabetes mellitus, but the aerobic form is usually preferred.\n\n\nIn most parts of Kenya, prescribing formal exercise in gyms or requiring special equipment is a recipe for non-adherence. Therefore, patients should be encouraged to integrate increased physical activity into their daily routine. The plan should impose minimum, if any, extra financial outlay in new equipment and materials for physical activity.\n\n\n**General principles and recommendations for physical activity in Type 2 diabetes mellitus**\n\n\n- A\tdetailed\tphysical\tevaluation\tof\tcardiovascular,\trenal,\teye\tand\tfoot\tstatus (including neurological) should be performed before starting an exercise programme.\n- The\tpresence\tof\tchronic\tcomplications\tmay\tpreclude\tcertain\tforms\tof\texercises.\n- Prescribed\tphysical\tactivity\tprogrammes\tshould\tbe\tappropriate\tfor\tthe patient's age, socio-economic status, state of physical fitness, lifestyle, and level of glycaemic control.\n- While\texercise\tgenerally\timproves\tmetabolic\tcontrol,\tit\tcan\talso\tprecipitate acute complications like hypoglycemia and hyperglycaemia.\n- The\tphysical\tactivity\tshould\tbe\tregular\t(3\tdays/week),\tlast\tat\tleast\t20\t-\t30 minutes per session, and be of at least moderate intensity.\n- Activities\tlike\twalking,\tclimbing\tsteps\t(instead\tof\ttaking\tlifts)\tshould\tbe encouraged.\n\n\n- For\tsedentary\tpersons\tliving\twith\tdiabetes,\ta\tgradual\tintroduction\tusing\ta low-intensity activity like walking is mandatory.\n- Avoid\tstrenuous\texercise\tif\tambient\tglycaemia\tis\t&gt;\t250\tmg/dl\t(14\tmmol/L),\tthe patient   has ketonuria or blood glucose is less than 80 mg/dl (4.5 mmol/L).\n- To\tavoid\texercise-induced\thypoglycaemia,\tdosages\tof\tinsulin\tsecretagogues\tor insulin may need to be reduced and/or peri-exercise carbohydrate intake increased.\n- Blood\tglucose\tshould\tbe\tmonitored\t(using\tstrips\tand\tmeters)\tbefore\tand\tafter planned strenuous physical activity as delayed hypoglycemia may occur.\n- Proper\tfootwear\tmust\talways\tbe\tworn.\n\n\nTable 19: Aerobic exercise recommended for individuals with type 2 diabetes\n\n\n| Definition                                                                                                                                  | Intensity   | Frequency                                                    | Examples                                                                                                            |\n|---------------------------------------------------------------------------------------------------------------------------------------------|-------------|--------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|\n| Activities that consist of rhythmic, repetitive and con- tinuous movement of the same large muscle groups for at least 10 minutes at a time | Moderate:   | Minimum 150 minutes per week (30 minutes per day for 5 days) | Cycling, brisk walking, continuous swimming, dancing, water aerobics, raking leaves, shamba work, house hold chores |\n|                                                                                                                                             | Or          | Or                                                           | Or                                                                                                                  |\n|                                                                                                                                             | Vigorous:   | Minimum 75 minutes per week (30 minutes 3 times a week)      | Brisk walking up an incline, jogging, aerobics, hockey, basketball, fast swimming, fast dancing                     |\n|                                                                                                                                             | Or          | Or                                                           | Or                                                                                                                  |\n\n\nTable 20: Resistance exercise recommended for individuals with type 2 diabetes\n\n\n| Definition                                                                                     | Frequency                                                                                                                                                                   | Examples                                                                                             |\n|------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|\n| Activities that require muscular strength to move a weight or work against a resistance load a | Two to three times per week: Start with one set of 10-15 repetitions at moderate weight Progress to two sets of 10-15 repetitions Progress to three sets at heavier weights | Exercise with weight machines, free weight lifting, Resistance band (e.g. Thera-Band ® ) exer- cises |\n\n\n*Resistance exercise should only be attempted if there are no contraindications to this kind of activity\n\n\n**Physical activity recommendations in Children and Adolescents**\n\n\n- Children\tand\tadolescents\twith\tType\t1\tor\tType\t2\tdiabetes\tshould\tengage\tin\t60 minutes per day or more of moderate- or vigorous-intensity aerobic activity, as well as vigorous muscle strengthening and bone strengthening activities at least 3 days per week.\n- Preparations\tare\tneeded\tas\texercise\tmay\tinduce\thypoglycemia.\tWhere possible, patients and families should be given tailored advice about what and how much carbohydrate to take before, during, and after exercise, as well as advice about insulin adjustment.\n- Where\tmonitoring\tis\tavailable,\tblood\tglucose\tneeds\tto\tbe\tmeasured\tbefore, during and after exercise.\n- Approximately\t1.0\t-\t1.5\tg\tcarbohydrate/kg\tbody\tweight/hour\tshould\tbe consumed before and during strenuous exercise if the child is unable to monitor and reduce insulin dosage. E.g. ½ long banana/small apple, small orange.\n\n\n- Hypoglycemia\tis\tmore\tlikely\tto\toccur\twith\tprolonged\tnon-intense\tphysical activity. It often occurs shortly after any type of exercise but is possible up to 24 hours afterwards (increased insulin sensitivity). Risk of post-exercise nocturnal hypoglycemia is high. The evening dose of intermediate- or long-acting insulin often needs to be decreased by 10-20% after exercise in the afternoon or evening, especially if not exercising on a regular basis. Special care\tshould\tbe\ttaken\tthat\tthe\tbedtime\tblood\tglucose\tlevel\tis\t&gt;\t7.0\tmmol/L\t(125 mg/dl).\n- Water\tshould\tbe\tconsumed\tto\tavoid\tdehydration.\n- Where\tunaccustomed\texercise\tis\tbeing\ttaken,\te.g.\tat\ta\tdiabetes\tcamp, reduction in total daily dose of insulin (20- 50%) is advised to avoid hypoglycemia.\n- Insulin\tis\tabsorbed\tquicker\twhen\tit\tis\tinjected\tnear\tto\tmuscles\tthat\tare\tbeing exercised - e.g. legs in soccer. Hypoglycemia is then more likely to occur. Preferred injection site: abdomen\n- If\tblood\tglucose\tlevels\tare\thigh\t(&gt;14\tmmol/l)\twith\tketonuria/ketonaemia, exercise could be dangerous and should be avoided. Give approximately 0.05 U/kg, or 5% of total daily insulin dose as short-acting (soluble) iinsulin and postpone exercise until ketones have cleared. If ketones cannot be measured, a child who is feeling nauseous should not participate in exercise. Children and young people engaged in competitive or more intensive sport will require additional support. This should include detailed discussion about the activity and tailored advice on insulin and food adjustments.\n\n\n",
                "startLine": 1833,
                "endLine": 2178,
                "introContent": null,
                "keywords": [],
                "subsections": null
              },
              {
                "id": "subsection-2-2-2",
                "level": "h3",
                "number": "2.2.2",
                "title": "2.2.2. Pharmacological Management",
                "slug": "222-pharmacological-management",
                "url": "/guidelines/22-management-of-type-2-diabetes/222-pharmacological-management",
                "parentId": "section-2-2",
                "breadcrumb": [
                  "CHAPTER TWO: MANAGEMENT OF DIABETES",
                  "2.2. Management of Type 2 Diabetes",
                  "2.2.2. Pharmacological Management"
                ],
                "tokenCount": 5207,
                "content": "### 2.2.2. Pharmacological Management\n\n\nThe goals of caring for patients with diabetes mellitus are to maintain blood glucose under control and prevent or slow down the rate of development of both acute and long-term complications. In initiating treatment for people living with type 2 diabetes the use of HbA1c test is key. The table below provides a guide for initiating therapy using the HbA1c levels.\n\n\nFigure 13: Medical management of Type 2 Diabetes Based on HbA1c levels\n\n\n![61 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS](images/picture_034_page_61.png)\n\n\nSource: Tb/DM Flowchart, MOH\n\n\nPharmacological therapy includes oral glucose lowering agents, insulin and injectable GLP-1 agonists.\n\n\n**i. Oral Glucose Lowering Agents (OGLAs)**\n\n\nThese were previously referred to as oral hypoglycaemic agents\n\n\n**Indications:**\n\n\n- Oral\tpharmacotherapy\tis\tindicated\tfor\tindividual\twith\tType\t2\tdiabetes\n- It\tis\tindicated\twhen\tan\tindividual's\tglycaemic\ttargets\tare\tnot\tmet\tby the combination of dietary modifications and physical activity/exercise.\n- In\tsome\tcases,\toral\tpharmacotherapy\tor\tinsulin\tis\tindicated\tat\tthe\tfirst presentation\tof\tdiabetes,\ti.e.\ta\tfasting\tblood\tglucose\tlevel\t&gt;\t11\tmmol/L or\trandom\tblood\tglucose\tlevel\t&gt;\t15\tmmol/L.\n\n\n**Choice of Oral Glucose Lowering Agents (OGLAs)**\n\n\n- The\tchoice\tof\tOGLAs\tshould\tdepend\ton\tthe\tpatient's\tcharacteristics, lifestyle, degree of glycaemic control, cardiovascular and renal risks, access to drugs, economic status and agreement between the doctor and the person living with diabetes.\n- The\tfirst\tline\toral\tagent\tof\tchoice\tis\tMetformin\tunless\tcontra-indicated.\n- The\tsulphonylureas\tand\tmetformin\tare\tthe\tagents\tmost\twidely available.\n- Use\tof\tthe\tstepped-care\tapproach\tis\trecommended,\tas\tmonotherapy\tis seldom sufficient, because of the progressive nature of the disease (see figure 15).\n- Combination\ttherapy\tshould\tbe\tconsidered\tas\tinitial\tchoice\tif\tHBA1C\tis greater than 8 %.\n- Three-drug\tcombination\ttherapy\tcan\tbe\tused\twhen\ttwo-drug regimens fail to achieve target values. Such patients should be referred to a specialist. Use of combination therapy often results in an increased number of tablets to be taken and creates new adherence problems.\n- Fixed\tcombination\ttherapies\tincrease\tadherence\tbut\tmay\tinhibit flexibility in dosing prescription.\n\n\nTable 21 summarizes the characteristics of the OGLAs which are frequently used in controlling glycaemia in diabetes care. The list is not exhaustive but includes agents that are most commonly used in Kenya.\n\n\nTable 21: Oral glucose lowering agents, dosage, side effects and Contraindications\n\n\n| Table 21: Name of Drug                                                                                                                                                                      | Oral Mini- mum dose                                                                                                                                                                         | glucose Max- imal daily                                                                                                                                                                     | lowering Frequen- cy                                                                                                                                                                        | agents, dosage, side Major Side Effects                                                                                                                                                     | effects and Contraindications Contraindications/use with caution                                                                                                                            |\n|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| dose A. Sulphonylureas Mechanism of action: Stimulate the pancreas to release insulin (regardless of time and glucose levels)                                                               | dose A. Sulphonylureas Mechanism of action: Stimulate the pancreas to release insulin (regardless of time and glucose levels)                                                               | dose A. Sulphonylureas Mechanism of action: Stimulate the pancreas to release insulin (regardless of time and glucose levels)                                                               | dose A. Sulphonylureas Mechanism of action: Stimulate the pancreas to release insulin (regardless of time and glucose levels)                                                               | dose A. Sulphonylureas Mechanism of action: Stimulate the pancreas to release insulin (regardless of time and glucose levels)                                                               | dose A. Sulphonylureas Mechanism of action: Stimulate the pancreas to release insulin (regardless of time and glucose levels)                                                               |\n| Glibenclamide                                                                                                                                                                               | 2.5 mg                                                                                                                                                                                      | 15 mg                                                                                                                                                                                       | OD or BD                                                                                                                                                                                    | Hypoglycemia, weight gain skin rashes                                                                                                                                                       | Caution in liver and renal disease                                                                                                                                                          |\n| GliclazideMR                                                                                                                                                                                | 30 mg                                                                                                                                                                                       | 120 mg                                                                                                                                                                                      | OD                                                                                                                                                                                          | Hypoglycemia, weight gain skin rashes                                                                                                                                                       | Pregnancy, caution in liver disease                                                                                                                                                         |\n| Glimepiride                                                                                                                                                                                 | 1 mg                                                                                                                                                                                        | 4 mg                                                                                                                                                                                        | OD                                                                                                                                                                                          | Hypoglycemia weight gain skin rashes                                                                                                                                                        | Pregnancy, caution in liver and renal disease                                                                                                                                               |\n| Glipizide                                                                                                                                                                                   | 5 mg                                                                                                                                                                                        | 40 mg                                                                                                                                                                                       | OD or BD                                                                                                                                                                                    | Hypoglycemia weight gain skin rashes                                                                                                                                                        | Pregnancy, caution in liver and renal disease                                                                                                                                               |\n| B. Biguanide Mechanism of action: (i)Reduce glucose production in liver (ii) cause (mild) reduction in peripheral insulin resistance                                                        | B. Biguanide Mechanism of action: (i)Reduce glucose production in liver (ii) cause (mild) reduction in peripheral insulin resistance                                                        | B. Biguanide Mechanism of action: (i)Reduce glucose production in liver (ii) cause (mild) reduction in peripheral insulin resistance                                                        | B. Biguanide Mechanism of action: (i)Reduce glucose production in liver (ii) cause (mild) reduction in peripheral insulin resistance                                                        | B. Biguanide Mechanism of action: (i)Reduce glucose production in liver (ii) cause (mild) reduction in peripheral insulin resistance                                                        | B. Biguanide Mechanism of action: (i)Reduce glucose production in liver (ii) cause (mild) reduction in peripheral insulin resistance                                                        |\n| Metformin                                                                                                                                                                                   | 500 mg                                                                                                                                                                                      | 2000 mg                                                                                                                                                                                     | OD or BD                                                                                                                                                                                    | Abdominal pain, nausea, loose bowel motions, lactic aci- dosis Vitamin B12 deficien - cy with prolonged use.                                                                                | Renal failure, GFR<30 ml/min Heart failure stage 3 or 4 and liver failure                                                                                                                   |\n| C. Thiazolidinediones Mechanism of action: (i) Improved insulin sensitivity in muscle, adipose tissue and liver (ii)Reduce glucose output from liver                                        | C. Thiazolidinediones Mechanism of action: (i) Improved insulin sensitivity in muscle, adipose tissue and liver (ii)Reduce glucose output from liver                                        | C. Thiazolidinediones Mechanism of action: (i) Improved insulin sensitivity in muscle, adipose tissue and liver (ii)Reduce glucose output from liver                                        | C. Thiazolidinediones Mechanism of action: (i) Improved insulin sensitivity in muscle, adipose tissue and liver (ii)Reduce glucose output from liver                                        | C. Thiazolidinediones Mechanism of action: (i) Improved insulin sensitivity in muscle, adipose tissue and liver (ii)Reduce glucose output from liver                                        | C. Thiazolidinediones Mechanism of action: (i) Improved insulin sensitivity in muscle, adipose tissue and liver (ii)Reduce glucose output from liver                                        |\n| Pioglitazone                                                                                                                                                                                | 15 mg                                                                                                                                                                                       | 45 mg                                                                                                                                                                                       | OD                                                                                                                                                                                          | Liver impairment, fluid retention weight gain, dilutional anaemia, osteoporosis                                                                                                             | Heart failure and liver failure; pregnancy, Bone fractures                                                                                                                                  |\n| D. Meglitinides Mechanism of action: Stimulate pancreas to release more insulin (possibly related to blood glucose level)                                                                   | D. Meglitinides Mechanism of action: Stimulate pancreas to release more insulin (possibly related to blood glucose level)                                                                   | D. Meglitinides Mechanism of action: Stimulate pancreas to release more insulin (possibly related to blood glucose level)                                                                   | D. Meglitinides Mechanism of action: Stimulate pancreas to release more insulin (possibly related to blood glucose level)                                                                   | D. Meglitinides Mechanism of action: Stimulate pancreas to release more insulin (possibly related to blood glucose level)                                                                   | D. Meglitinides Mechanism of action: Stimulate pancreas to release more insulin (possibly related to blood glucose level)                                                                   |\n| Repaglinide                                                                                                                                                                                 | 1.0 mg                                                                                                                                                                                      | 16 mg                                                                                                                                                                                       | BD, TDS or QID (Before meals)                                                                                                                                                               | Liver impairment, fluid retention weight gain, dilutional anaemia                                                                                                                           |                                                                                                                                                                                             |\n| E. Alpha glucosidase inhibitors Mechanism of action: Slow digestion of complex sugars (sucrose and starch) and therefore delays absorption, leading to slow post-meal rise in blood glucose | E. Alpha glucosidase inhibitors Mechanism of action: Slow digestion of complex sugars (sucrose and starch) and therefore delays absorption, leading to slow post-meal rise in blood glucose | E. Alpha glucosidase inhibitors Mechanism of action: Slow digestion of complex sugars (sucrose and starch) and therefore delays absorption, leading to slow post-meal rise in blood glucose | E. Alpha glucosidase inhibitors Mechanism of action: Slow digestion of complex sugars (sucrose and starch) and therefore delays absorption, leading to slow post-meal rise in blood glucose | E. Alpha glucosidase inhibitors Mechanism of action: Slow digestion of complex sugars (sucrose and starch) and therefore delays absorption, leading to slow post-meal rise in blood glucose | E. Alpha glucosidase inhibitors Mechanism of action: Slow digestion of complex sugars (sucrose and starch) and therefore delays absorption, leading to slow post-meal rise in blood glucose |\n| Acarbose                                                                                                                                                                                    | 25 mg                                                                                                                                                                                       | 300 mg                                                                                                                                                                                      | TID (during meal)                                                                                                                                                                           | Dyspepsia loose bowel motions, flatulence                                                                                                                                                   | None                                                                                                                                                                                        |\n\n\n| F. DPP4 inhibitors (Gliptins) Mechanism of action: Improve pancreatic islet glucose sensing →Increase glucose-medicated insulin secretion and suppresses glucagon secretion             | F. DPP4 inhibitors (Gliptins) Mechanism of action: Improve pancreatic islet glucose sensing →Increase glucose-medicated insulin secretion and suppresses glucagon secretion             | F. DPP4 inhibitors (Gliptins) Mechanism of action: Improve pancreatic islet glucose sensing →Increase glucose-medicated insulin secretion and suppresses glucagon secretion             | F. DPP4 inhibitors (Gliptins) Mechanism of action: Improve pancreatic islet glucose sensing →Increase glucose-medicated insulin secretion and suppresses glucagon secretion             | F. DPP4 inhibitors (Gliptins) Mechanism of action: Improve pancreatic islet glucose sensing →Increase glucose-medicated insulin secretion and suppresses glucagon secretion             | F. DPP4 inhibitors (Gliptins) Mechanism of action: Improve pancreatic islet glucose sensing →Increase glucose-medicated insulin secretion and suppresses glucagon secretion             |\n|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Vildagliptin                                                                                                                                                                            | 50 mg                                                                                                                                                                                   | 100 mg                                                                                                                                                                                  | OD or BD                                                                                                                                                                                | Urticaria, angioedema, and immune mediated dermatologic effects. Acute Pancreatitis, Risk of hypoglycaemia (in combination with sulfonylureas                                           | Sitagliptin 100 mg Saxagliptin 5 mg 10 mg                                                                                                                                               |\n|                                                                                                                                                                                         |                                                                                                                                                                                         |                                                                                                                                                                                         | OD                                                                                                                                                                                      | Urticaria, angioedema, and immune mediated dermatologic effects. Acute Pancreatitis, Risk of hypoglycaemia (in combination with sulfonylureas                                           | Sitagliptin 100 mg Saxagliptin 5 mg 10 mg                                                                                                                                               |\n|                                                                                                                                                                                         |                                                                                                                                                                                         |                                                                                                                                                                                         | OD                                                                                                                                                                                      | Urticaria, angioedema, and immune mediated dermatologic effects. Acute Pancreatitis, Risk of hypoglycaemia (in combination with sulfonylureas                                           | Sitagliptin 100 mg Saxagliptin 5 mg 10 mg                                                                                                                                               |\n| Linagliptin                                                                                                                                                                             | 5 mg                                                                                                                                                                                    | 5 mg                                                                                                                                                                                    | OD                                                                                                                                                                                      | Urticaria, angioedema, and immune mediated dermatologic effects. Acute Pancreatitis, Risk of hypoglycaemia (in combination with sulfonylureas                                           | Sitagliptin 100 mg Saxagliptin 5 mg 10 mg                                                                                                                                               |\n| G. SGLT-2 inhibitors Mechanism of action: Suppress renal glucose reabsorption by blocking the sodium-glucose co-transporter 2 (SGLT-2) resulting in increased urinary glucose excretion | G. SGLT-2 inhibitors Mechanism of action: Suppress renal glucose reabsorption by blocking the sodium-glucose co-transporter 2 (SGLT-2) resulting in increased urinary glucose excretion | G. SGLT-2 inhibitors Mechanism of action: Suppress renal glucose reabsorption by blocking the sodium-glucose co-transporter 2 (SGLT-2) resulting in increased urinary glucose excretion | G. SGLT-2 inhibitors Mechanism of action: Suppress renal glucose reabsorption by blocking the sodium-glucose co-transporter 2 (SGLT-2) resulting in increased urinary glucose excretion | G. SGLT-2 inhibitors Mechanism of action: Suppress renal glucose reabsorption by blocking the sodium-glucose co-transporter 2 (SGLT-2) resulting in increased urinary glucose excretion | G. SGLT-2 inhibitors Mechanism of action: Suppress renal glucose reabsorption by blocking the sodium-glucose co-transporter 2 (SGLT-2) resulting in increased urinary glucose excretion |\n| Canagliflozin                                                                                                                                                                           | 100 mg                                                                                                                                                                                  | 300 mg                                                                                                                                                                                  | OD                                                                                                                                                                                      | Polyurea, UTI, DKA, genital candidiasis, hypotension                                                                                                                                    | Renal failure (action dependent on normal GFR) Or sensitivity to active ingredients or it's excipients                                                                                  |\n| Dapagliflozin                                                                                                                                                                           | 5 mg                                                                                                                                                                                    | 10 mg                                                                                                                                                                                   | OD                                                                                                                                                                                      | Polyurea, UTI, DKA, genital candidiasis, hypotension                                                                                                                                    | Renal failure (action dependent on normal GFR) Or sensitivity to active ingredients or it's excipients                                                                                  |\n| Empagliflozin                                                                                                                                                                           | 10 mg                                                                                                                                                                                   | 25 mg                                                                                                                                                                                   | OD                                                                                                                                                                                      | Polyurea, UTI, DKA, genital candidiasis, hypotension                                                                                                                                    | Renal failure (action dependent on normal GFR) Or sensitivity to active ingredients or it's excipients                                                                                  |\n\n\n|                | Metformin                                                                     | Sulfonylurea                                    | Glinides                 | Pioglitazone Alpha-     | Glucosidase Inhibitors     | DPP-4 Inhibitors                                | GLP-1Agonists SGLT-2Inhibitors   |                                                                                                           |\n|----------------|-------------------------------------------------------------------------------|-------------------------------------------------|--------------------------|-------------------------|----------------------------|-------------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------|\n| Hypo           | Neutral                                                                       | Moderate/SevereModerate                         |                          | Neutral                 | Neutral                    | Neutral                                         | Neutral                          | Neutral                                                                                                   |\n| Weight         | Slight loss                                                                   | Gain                                            | Gain                     | Gain                    | Neutral                    | Neutral                                         | Loss                             | Loss                                                                                                      |\n| 3A,3B          | CKD stages Reduced dose inCaution higher stage 3A Contraindicated in stage 3B | risk hypo                                       | Caution higher risk hypo | r Neutral               | Neutral                    | Neutralbut must reduce dose except linagliptin  | Caution with exenatideER         | Contraindicatedin stage3B                                                                                 |\n| 4,5            | CKD stages Contraindicated                                                    | Contraindicated except glipizide and gliclazide | Contraindicated          |                         | ContraindicatedNeutral but | must reduce dose except linagliptin             |                                  | ContraindicatedContraindicated                                                                            |\n| GISE           | Moderate                                                                      | Neutral                                         | Neutral                  | Neutral                 | Moderate                   | Neutral                                         | Moderate                         | Neutral                                                                                                   |\n| OtherSE        |                                                                               |                                                 |                          | Edema and bone fracture |                            | Pancreatitis Heart failure (not a class effect) |                                  | Fungal genital infections, fractures, amputations (Bone fractures and amputationsmaynot be a class effect |\n| MajorCV events | Benefit                                                                       | Neutral                                         | Neutral                  | Neutral                 | Neutral                    | Neutral                                         | Benefit (2 RCT*)                 | Benefit (2 RCT*)                                                                                          |\n| CHF            | Neutral                                                                       | Neutral                                         | Neutral                  | Increased risk          | Neutral                    | Neutral                                         | Neutral                          | Benefit (2RCT**)                                                                                          |\n\n\nCKD, chronic kidney disease; CH, chronic heart failure; CV, cardiovascular; hypo, hypoglycemia; GI, gastrointestinal; SE, side effects; RCT, randomized controlled trial.\n\n\n* Reduced risk in RCTs designed for non-inferiority with liraglutide, semaglutide, empagliflozin and canagliflozin\n\n\n** Reduced risk in RCT designed for non-inferiority with empagliflozin and canagliflozin\n\n\nFigure 14: Risks and benefits of glucose-lowering agents (excluding insulin)\n\n\n(Source: IDF Clinical Practice Recommendations for managing Type 2 Diabetes in Primary Care - 2017)\n\n\n**ii. Insulin Therapy in type 2 diabetes**\n\n\nDiabetes is a progressive condition, and many patients with type 2 diabetes eventually require and benefit from insulin therapy. Early patient education about expected disease progression, and avoidance of threats of future insulin therapy is important thus easing the transition to insulin therapy.\n\n\nFigure 15: Initiating Insulin Therapy in Type 2 diabetes\n\n\n![Adapted from 'Guidelines for the Management of People with Type 2 Diabetes in Shropshire, 2013'](images/picture_035_page_65.png)\n\n\nAdapted from 'Guidelines for the Management of People with Type 2 Diabetes in Shropshire, 2013'\n\n\n**Additional indications for use of insulin in type 2 diabetes**\n\n\n- Presentation\tin\thyperglycemic\temergency\n- Peri-operative\tperiod\tespecially\tmajor\tor\temergency\tsurgery\n- Other\tmedical\tconditions\trequiring\ttight\tglycaemic\tcontrol\te.\tg\tacute\tMI, stroke, sepsis\n- Organ\tfailure\t(e.g.\trenal,\tliver,\theart)\n\n\nNB: Latent autoimmune diabetes of adults (LADA) is a subset of Type 1 DM presenting in adulthood. All patients diagnosed with LADA should receive insulin as with all type 1 DM patients.\n\n\n**The regimen and dose of insulin therapy varies from patient to patient.**\n\n\nFigure 15: Initiating pharmacotherapy in type 2 diabetes\n\n\n![Source: Adapted from the American Diabetes Association: Diabetes Care Journals http://care.diabetesjournals.org/content/40/Supplement_1/S64)](images/picture_036_page_66.png)\n\n\nSource: Adapted from the American Diabetes Association: Diabetes Care Journals http://care.diabetesjournals.org/content/40/Supplement\\_1/S64)\n\n\nDose titration / adjustment requires gradual, safe and prompt titration of insulin dose according to self-blood glucose monitoring (SMBG), towards an optimal dose to ensure maximum benefit from prescribed treatment. Advancing insulin therapy for patients not achieving HbA1c goals on optimally titrated basal insulin alone often requires premeal insulin dosing.\n\n\nTable 22: Adjusting dose of premixed insulin in adults with type 2\n\n\n| Fasting Glucose before Breakfast (in the absence of nocturnal hypos               | Lunch Pre Meal value                                                     | Evening Pre Meal value                                                            | Before Bed Value                                                                        |\n|-----------------------------------------------------------------------------------|--------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|\n| INSULIN This dose will affect pre- lunch and pre-evening meal glucose levels      |                                                                          | INSULIN This dose will affect bedtime and morning fasting glucose levels          |                                                                                         |\n| Target 4 to 7 mmol/L                                                              | Target 4 to 7 mmol/L                                                     | Target 4 to 7 mmol/L                                                              | Target 6 to 8 mmol/L                                                                    |\n| Blood Glucose Monitoring out of range?                                            | Blood Glucose Monitoring out of range?                                   | Blood Glucose Monitoring out of range?                                            | Blood Glucose Monitoring out of range?                                                  |\n| High = Increase previous evening's insulin by 2 units or 10% whichever is greater | High = Increase breakfast insulin by 2 units or 10% whichever is greater | High = Increase previous evening's insulin by 2 units or 10% whichever is greater | High = Increase evening meal insulin but not if blood tests at breakfast are 4-5 mmol/L |\n| Low = Decrease previous evening's insulin by 2 units or                           | Low = Decrease breakfast insulin by 2                                    | Low = Decrease breakfast insulin by 2                                             | Low = Decrease evening meal insulin                                                     |\n\n\nSource:  Adapted from Guidelines for the Management of People with Type 2 Diabetes in Shropshire, 2013\n\n\nInsulin is the most effective drug available to achieve glycemic targets in patients with T2DM yet there is reluctance among patients and physicians to initiate insulin. There are many barriers to insulin treatment among health care providers and patients.\n\n\nTable 23: Barriers to insulin therapy\n\n\n| PATIENT BARRIERS                                                                                                                                                                                                                                                                                                                                                                                                   | PROVIDER BARRIERS                                                                                                                                                                                                                                                                                                                                       | SYSTEM BARRIERS                                                                                                                                                                                                                                                                                                                                 |\n|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Psychological resistance • Myth-based fear of insulin • Fear of hypoglycaemia • Concern about weight gain • Fear of needles and pain • Self-blame • Loss of control • Social stigma Lifestyle • Time-consuming; inconve- nient • Travel issues Physical/mental • Poor recall/cognitive impair- ment • Visual/hearing/dexterity im- pairment • Learning difficulties; low literacy Financial • Reimbursement issues | Perceived patient resis- tance • Patient's adherence behaviour • Belief that patient's improved status ne- gates need to start insulin therapy • Concerns about ad- verse effects (hypoglycaemia; weight gain) • Provider time con- straints (instruction; titration) • Lack of resources/ or- ganizational structure to facilitate guideline adherence | Health system barriers • Overburdened workload among providers • Access to education • Limited training of provid- ers in injection technique • Underutilization of re - sources (within clinical practices, hospitals, and community) • Reimbursement issues • Poor follow-up system • Suboptimal team collabo- ration; poor chronic care mode |\n\n\nSource: Strategies for Insulin Injection Therapy in Diabetes Self-Management, American Association of Diabetes Educators, 2011\n\n\n**iii. Injectable GLP-1 agonists**\n\n\nGLP-1 receptor agonists bind to GLP-1 receptors on existing tissues (pancreas, hypothalamus and stomach). They act to pharmacologically enhance glucose-dependent insulin release, with additional effects on reducing glucagon release, increasing satiety, and increasing gastric emptying.\n\n\nGLP-1 agonists are currently only available in parenteral (subcutaneous) formulation. Two GLP-1 agonists are currently available: exenatide, which has a half-life of four hours and requires twice-daily injection, and liraglutide, which has a half-life of 11-13 hours and requires once-daily injections.\n\n\n",
                "startLine": 2179,
                "endLine": 2364,
                "introContent": null,
                "keywords": [],
                "subsections": null
              },
              {
                "id": "subsection-2-2-3",
                "level": "h3",
                "number": "2.2.3",
                "title": "2.2.3. Blood Glucose monitoring",
                "slug": "223-blood-glucose-monitoring",
                "url": "/guidelines/22-management-of-type-2-diabetes/223-blood-glucose-monitoring",
                "parentId": "section-2-2",
                "breadcrumb": [
                  "CHAPTER TWO: MANAGEMENT OF DIABETES",
                  "2.2. Management of Type 2 Diabetes",
                  "2.2.3. Blood Glucose monitoring"
                ],
                "tokenCount": 2661,
                "content": "### 2.2.3. Blood Glucose monitoring\n\n\nFigure 17: Self-Monitoring of Blood Glucose as a component of diabetes education\n\n\n![69 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS](images/picture_037_page_69.png)\n\n\nSelf-Monitoring of Blood Glucose (SMBG) is an approach whereby people living with diabetes measure their blood glucose themselves using a glucose meter (glucometer). Based on the reading, they can adjust or check the effect of their treatment (diet, exercise, insulin, OGLAs, stress management etc.). Within the wider context of diabetes self-management, self-monitoring supports the maintenance of blood glucose at levels as close as possible to target values.\n\n\nTo fully benefit from self-monitoring, it is essential that a person living with diabetes be trained by a health care professional on the following components:\n\n\n- The\ttechnical\taspects\tof\tself-monitoring;\n- Blood\tglucose\ttargets;\n- When\tand\thow\toften\tto\tmeasure\tblood\tglucose;\n- What\taction\tto\ttake\tbased\ton\tthe\treadings\tobtained;\n- Re-evaluating\t(every\t3\tto\t6\tmonths)\twhen,\tand\thow\toften,\tto self-monitor, based on your clinical condition and readings.\n\n\nWithout this information, self-monitoring of blood glucose will not fulfill its potential purpose, thus affecting the patient motivation and attainment of the treatment goals.\n\n\n**Type 1 DM**\n\n\nAt least 4\n\n\n2 to 8\n\n\n**Type 2 DM on Insulin or Insulin + OGLAs**\n\n\n**New onset DM/Uncontrolled DM/DM during acute illness**\n\n\n![times/day and should](images/picture_038_page_71.png)\n\n\ntimes/day and should\n\n\ninclude preprandial\n\n\nand bedtime times/day\n\n\n- Paired testing at least 3-4 days a week (1 day/week pre and post breakfast, 1 day per/week pre and post lunch, and 1 day/week pre and post dinner) or as\n\n\nfrequently as possible\n\n\n- At least 4 times/day and should include preprandial and bedtime levels\n- At least 4 times/day\n- At least FBG and one more preprandial\n- At least 4 tests in a week on 4 consecutive days or on alternate days (including 1 FBG and 3 postprandial values)\n\n\n**Type 2 DM on OGLAs**\n\n\n**New onset DM/Uncontrolled DM/DM during acute illness**\n\n\n![value every day](images/picture_039_page_71.png)\n\n\n- At least 4 times/ day and should\n- preprandial and bedtime levels\n\n\nvalue every day\n\n\nAt least 4 tests in a month - at least 1\n\n\n- At least FBG once a week\n- At least FBG on alternate days\n\n\ninclude levels\n\n\ntest/week (including\n\n\n1 FBG and 3\n\n\n- postprandial values\n\n\nin a month)\n\n\n**Diabetes in Pregnancy**\n\n\n![Initially one value/](images/picture_040_page_71.png)\n\n\n![Initially one value/](images/picture_041_page_71.png)\n\n\nInitially one value/\n\n\nday (different values on each\n\n\nPatients with\n\n\n- At least 4 times/day (FBG and 3 postprandial)\n- FBG and 3 postprandial values at least once a week or staggered over a week\n\n\nday)\n\n\n**Diabetes and Hypoglycemia Unawareness Brittle**\n\n\n**Patients on Premix Insulin, Basal Bolus Therapy**\n\n\n![Patients on Basal Insulin](images/picture_042_page_71.png)\n\n\n- 3 preprandial (including FBG) and 3 postprandial tests on alternate days till target HbA1c and blood glucose levels are reached\n\n\n**Patients on Basal Insulin**\n\n\n- After achievement of fasting target, postprandial correction should be done\n- Paired testing every day (pre and st post breakfast on 1  day, pre and nd post lunch on 2 day,  pre and rd post dinner on 3 day, and then to keep repeating the cycle)\n- One FBG and one postprandial value (any meal, preferably after largest meal of the day) every week\n- Less frequent testing can be done after achievement of the target (fasting and one meal-related testing can be done, can be staggered, changing every 2 days)\n- FBG twice a week or once in 3 days\n- After achievement of fasting target, postprandial\n- correction should be done\n\n\n**Figure 19: Guidance on Self-Monitoring of Blood Glucose for people living with diabetes**\n\n\n**(Source: Research Society for the Study of Diabetes in India, RSSDI)**\n\n\n**Methods for Monitoring Glycaemic Control**\n\n\nClinical and laboratory methods are employed to monitor or assess whether the individualized glycaemic targets are being attained.\n\n\n- HbA1c\tis\tthe\tstandard\ttest\tfor\tmonitoring\tglucose\tcontrol.\tThis\tshould\tbe\tdone every 3 months until patient is well controlled and subsequently every 6 months. (refer to table 18 for targets) Changes in therapy ought to be guided by glucose control as depicted by the HbA1c.\n- Self-monitoring\tof\tBlood\tGlucose\t(SMBG)\tshould\tbe\tencouraged.\tIt\tis\tthe\tmain measure used to titrate drug doses on a day to day basis\n- Results\tof\tself-blood\tglucose\ttests\tshould\tbe\trecorded\tin\ta\tlogbook\tor\tdiary indicating the day and time of testing\n- The\tclinic\tprotocol\tshould\tset\tout\tthe\tparameters\tto\tbe\tmonitored\tat\tthe\tinitial visit, regular follow-up visits, and at the annual review (refer to table 14  for assessment and follow-up)\n\n\n**Examples of Self-Monitoring of Blood Glucose (SMBG) testing profiles**\n\n\nIntensive\tor\t'focused'\tSMBG\tprotocols\tuse\t'pattern\tanalysis' ,\ta\tsystematic\tapproach\tto creating glucose profiles that can identify daily glycaemic patterns and then take appropriate action based upon those results. These profiles can be generated by performing 5 to\t7\tmeasurements\tper\tday\tover\t1\tto\t3\tdays,\tor\tthrough\t'staggered'\ttesting,\tin\twhich\tthe individual performs pre- and postprandial testing for alternating meals over the course of a week\n\n\nMeal-based SMBG (before and after selected meals) helps individuals living with diabetes understand the effects of their treatment on blood glucose concentrations and assists clinicians in identifying postprandial hyperglycaemia, guides therapeutic adjustments and provides more timely feedback regarding medication changes. The table below summarizes the SMBG testing profiles\n\n\nTable 24: Examples of Self-Monitoring of Blood Glucose (SMBG) testing profiles\n\n\n|                            | Testing points             | Testing points             | Testing points             | Testing points             | Testing points             | Testing points             | Testing points             |\n|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|\n| Day                        | Pre-Break- fast            | 2 hours Post- Breakfast    | Pre- lunch                 | 2-hours Post- lunch        | Pre-sup- per               | 2-hours post-sup- per      | Bedtime                    |\n| 7-point testing profile    | 7-point testing profile    | 7-point testing profile    | 7-point testing profile    | 7-point testing profile    | 7-point testing profile    | 7-point testing profile    | 7-point testing profile    |\n| Monday                     |                            |                            |                            |                            |                            |                            |                            |\n| Tuesday                    | X                          | X                          | X                          | X                          | X                          | X                          | X                          |\n| Wednesday                  | X                          | X                          | X                          | X                          | X                          | X                          | X                          |\n| Thursday                   | X                          | X                          | X                          | X                          | X                          | X                          | X                          |\n| Friday                     |                            |                            |                            |                            |                            |                            |                            |\n| Saturday                   |                            |                            |                            |                            |                            |                            |                            |\n| Sunday                     |                            |                            |                            |                            |                            |                            |                            |\n| Staggered testing profile  | Staggered testing profile  | Staggered testing profile  | Staggered testing profile  | Staggered testing profile  | Staggered testing profile  | Staggered testing profile  | Staggered testing profile  |\n| Monday                     | X                          | X                          |                            |                            |                            |                            |                            |\n| Tuesday                    |                            |                            | X                          | X                          |                            |                            |                            |\n| Wednesday                  |                            |                            |                            |                            | X                          | X                          |                            |\n| Thursday                   | X                          | X                          |                            |                            |                            |                            |                            |\n| Friday                     |                            |                            | X                          | X                          |                            |                            |                            |\n| Saturday                   |                            |                            |                            |                            | X                          | X                          |                            |\n| Sunday                     | X                          | X                          |                            |                            |                            |                            |                            |\n| Meal-based testing profile | Meal-based testing profile | Meal-based testing profile | Meal-based testing profile | Meal-based testing profile | Meal-based testing profile | Meal-based testing profile | Meal-based testing profile |\n| Monday                     | X                          | X                          |                            |                            |                            |                            |                            |\n| Tuesday                    |                            |                            |                            |                            |                            |                            |                            |\n| Wednesday                  |                            |                            | X                          | X                          |                            |                            |                            |\n| Thursday                   |                            |                            |                            |                            |                            |                            |                            |\n| Friday                     |                            |                            |                            |                            |                            |                            |                            |\n| Saturday                   |                            |                            |                            |                            | X                          | X                          |                            |\n| Sunday                     |                            |                            |                            |                            |                            |                            |                            |\n\n\nSource: IDF Guideline on Self-Monitoring of Blood Glucose in Non-Insulin Treated Type 2 Diabetes\n\n\nTable 25: Targets for HbA1c, fasting plasma glucose and postprandial glucose in different patient types\n\n\n| Patient type                                                                                   | Target HbA1c                  | Target FPG                    | Target PPG                                                         |\n|------------------------------------------------------------------------------------------------|-------------------------------|-------------------------------|--------------------------------------------------------------------|\n| Young Low risk Newly diagnosed                                                                 | < 6.5%                        | 4.0-7.0 mmol/l                | 4.4-7.8 mmol/l                                                     |\n| No cardiovascular disease Majority of patients                                                 | < 7%                          | 4.0-7.0 mmol/l                | 5.0 -10.0 mmol/l                                                   |\n| Elderly High risk (high cardio- vascular risk) Hypoglycaemic unaware Poor short-term prognosis | < 8%                          | 4.0-9.8 mmol/l                | < 11.0 mmol/l                                                      |\n| Targets for other measurement                                                                  | Targets for other measurement | Targets for other measurement | Targets for other measurement                                      |\n| Weight and height                                                                              |                               | BMI of 18.5 - 24.9 kg/m2      | A10% weight loss from the current weight if obese is recommend- ed |\n| Waist circumference                                                                            |                               | Male                          | Female                                                             |\n|                                                                                                |                               | <90 cm                        | <84 cm                                                             |\n| Blood pressure (mmHg)                                                                          |                               | systolic                      | diastolic                                                          |\n|                                                                                                |                               | <140 mmHg                     | < 90 mmHg                                                          |\n| If persistent, microalbuminuria / proteinuria                                                  |                               | <125 mmHg                     | <75 mmHg                                                           |\n| Lipids (fasting)                                                                               |                               | Male                          | Female                                                             |\n| Total cholesterol                                                                              |                               | <4.8 mmol/l                   | <4.8 mmol/l                                                        |\n| LDLcholesterol                                                                                 |                               | <2.6 mmol/l                   | <2.6 mmol/l                                                        |\n| HDLcholesterol                                                                                 |                               | >1.0 mmol/l                   | >1.3 mmol/l                                                        |\n| Triglycerides                                                                                  |                               | <1.7 mmol/l                   | <1.7 mmol/l                                                        |\n\n\nCHAPTER THREE\n\n\n75 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS\n\n\n",
                "startLine": 2365,
                "endLine": 2605,
                "introContent": null,
                "keywords": [],
                "subsections": null
              }
            ]
          }
        ]
      },
      {
        "id": "chapter-3",
        "level": "h1",
        "number": "3",
        "title": "CHAPTER THREE: MANAGEMENT OF COMPLICATIONS AND COMORBIDITIES IN DIABETES MELLITUS",
        "slug": "chapter-three-management-of-complications-and-comorbidities-in-diabetes-mellitus",
        "url": "/guidelines/chapter-three-management-of-complications-and-comorbidities-in-diabetes-mellitus",
        "tokenCount": 14191,
        "summary": null,
        "content": "# CHAPTER THREE: MANAGEMENT OF COMPLICATIONS AND COMORBIDITIES IN DIABETES MELLITUS\n\n\n## 3.1. Introduction\n\n\nDiabetes may present with both acute and chronic complications, and various comorbidities.\n\n\n- a. Acute complications include Diabetes Ketoacidosis, Hyperosmolar Hyper glycemic State, Hypoglycemia\n- b. Chronic complications may be categorized as micro and macrovascular\n- Microvascular\tinclude\tretinopathy,\tneuropathy, nephropathy, sexual dysfunction and diabetic foot\n- Macrovascular\tinclude\tcoronary\tartery\tdisease,\tstroke, peripheral  vascular disease and diabetic foot\n- Dental\tdisorders\n- c. Common comorbidities include hypertension, mental disorders and lipid disorders.\n\n\nThe above complications and comorbidities contribute to the high morbidity and mortality from diabetes mellitus. Most deaths resulting from diabetes are attributable to cardiovascular disease.\n\n\n## 3.2. Acute Complications\n\n\n### 3.2.1. Introduction\n\n\nThe acute metabolic emergencies of diabetes ketoacidosis, hyperosmolar hyperglycaemic state, hypoglycemia and lactic acidosis may present with coma or altered levels of consciousness in people living with diabetes. Other considerations include stroke, seizures, trauma, drug overdose, infection, and ethanol intoxication.\n\n\n### 3.2.2. Diabetic Ketoacidosis (DKA)\n\n\nDKA is one of the most serious metabolic emergencies in diabetes mellitus. It is more common in Type 1 diabetes, but may occur in patients with Type 2 diabetes (ketosis-prone type 2 diabetes).\n\n\nDefinition: Diabetic ketoacidosis (DKA) is an acute, major, life-threatening complication of diabetes characterized by hyperglycemia, ketoacidosis, and ketonuria. Diabetic Ketoacidosis is characterized by:\n\n\n- History\tof\tpolyuria,\tpolydipsia,\tabdominal\tpain,\tnausea,\tvomiting,\tmissed medication, failed insulin pump for those who use it, and intercurrent illness.\n- Clinical\tsigns:\tdehydration,\tlethargy,\ttachypnea,\tdeep\tbreathing (Kussmaul breathing), acetone breath.\n- Biochemical\tparameters:\n- a. Hyperglycemia\tof\t≥11.1\tmmol/L\t(May\trarely\tpresent\twith normal blood glucose)\n- b. Metabolic acidosis (PH&lt;7.3 and bicarbonate&lt; 15 mmol/L)\n- c. Ketonuria or presence of blood ketones.\n\n\n**Management of DKA**\n\n\nThe main stay of management of DKA is judicious use of insulin and rehydration for both Type 1 and 2 diabetes mellitus.\n\n\n**Management of DKA in Type 1 Diabetes**\n\n\nManaging Diabetic Ketoacidosis in Type 1 Diabetes includes the following components:\n\n\n1. Confirm the diagnosis\n\n\n| •                                     | Capillary blood glucose test > 11 mmol/L D   |\n|---------------------------------------|----------------------------------------------|\n| • Urinary or plasma ketones           | K                                            |\n| • pH < 7.3 or bicarbonate < 15 mmol/L | A                                            |\n\n\n**2. History and Examination**\n\n\n- Obtain\tas\tmuch\tinformation\tabout\tthe\tpatient's\tdiabetes\t(date\tof\tdiagnosis, medication, known complications etc.)\n- Identify\tany\tprecipitating\tcauses\t(change\tin\tinsulin,\tintercurrent\tinfection, myocardial infarction)\n- Assess\tthe\tdegree\tof\tdehydration\t(BP,\tcapillary\trefill\ttime,\ttissue\tturgor, temperature of extremities)\n- Assess\tlevel\tof\tconsciousness\tusing\tGlasgow\tComa\tScale\t(GCS)\n\n\n**3. Investigations**\n\n\n- •\n\n\n**Blood**\n\n\n- -Urea/electrolytes\n- -Glucose\n- -Bicarbonate\n- -Liver function tests\n- -Full blood count\n- -Arterial/ venous blood gases\n- -Cardiac enzymes\n- -Blood cultures\n- D\n\n\n- Chest\tradiograph\t(CXR)-\tpreferably\tportable\n- Electrocardiogram\t(ECG)\n- Cultures:\tMid-stream\turine\t(MSU)\tand\tother\tappropriate\tcultures e.g. cerebrospinal fluid (CSF) if meningitis suspected\n\n\n**4. Management (see flow chart)**\n\n\n- Fluids\tare\ta\tcritical\tpart\tof\ttreating\tDKA.\tAdults\twith\tDKA\tgenerally need an average of 6 Litres for adequate rehydration. Keep a fluid balance chart ± a urinary catheter if urine output is poor. Consider central venous pressure (CVP) monitoring if fluid status is difficult to assess clinically or likely to need intensive care unit (ICU) support\n- Insulin\tis\tneeded\tto\thelp\tswitch\tfrom\ta\tcatabolic\tto\tan\tanabolic\tstate which will result in uptake of glucose into tissues and the reduction of gluconeogenesis. The end-result is to switch off the production of free fatty acids and ketones.\n- Potassium\treplacement:\tHypokalemia\tand\thyperkalemia\tare\tpotentially life-threatening conditions that can occur during the treatment of DKA. Check potassium (K+) levels after 2 hours and at 4, 8,12,16 and 24 hours or until transfer to subcutaneous insulin. Check magnesium levels at 12-24 hours.\n- Oxygen:\tshould\tbe\tgiven\tand\toxygen\tsaturations\tmonitored.\tAim\tfor oxygen\tsaturations\t(SPO2)\t&gt;\t96%.\n- Nasogastric\ttube:\tshould\tbe\tinserted\tas\tgastric\tdilation\tis\tcommon with potential risk of aspiration\n- Conscious\tlevel:\tIf\tGCS\tis\treduced,\tposition\tthe\tpatient\tin\trecovery position and consider intubation for airway protection (intubate if the patient has GCS of less than 8)\n- Antibiotics\tif\tinfection\tsuspected\t(see\tantibiotic\tprotocol)\n- Heparin\tprophylaxis\n\n\nRemember to reassess the patient frequently during the first few hours (clinical status, volume status, hourly glucose tests, potassium and sodium, blood gases) and adjust management according to any clinical changes.\n\n\n**5. Cerebral oedema**\n\n\nCerebral oedema is a rare but often fatal complication of DKA.\n\n\nIt can be idiosyncratic, but its occurrence may be related to various factors including the degree of hyperglycaemia, acidosis, dehydration and electrolyte disturbance at presentation, as well as over-rapid correction of acidosis, dehydration or hyperglycaemia.\n\n\nThe rapidly rising intracranial pressure may present as change in neurological status (restlessness,  irritability,  increased  drowsiness,  incontinence,  seizures,  coma),  specific neurological signs (e.g. unreactive pupils, cranial nerve palsies) or abnormal respiratory pattern, decorticate posture). The Cushing's triad (bradycardia, hypertension and wide pulse pressure) is a late presentation.\n\n\n**If cerebral oedema is suspected TREAT URGENTLY:**\n\n\n- Hypoglycemia\tas\ta\tcause\tof\tthe\tchange\tin\tneurological\tstate.\n- Reduce\tthe\trate\tof\tfluid\tadministration\tby\tone-third\n- Give\tmannitol\t0.5-1\tg/kg\tIV\tover\t10-15\tminutes,\tand\trepeat\tif\tthere\tis\tno\tinitial response in 30 minutes to 2 hours.\n- Hypertonic\tsaline\t(3%)\t2.5-5\tml/kg\tover\t10-15\tminutes\tmay\tbe\tan\talternative\tto mannitol, especially if there is no initial response to mannitol.\n- Elevate\tthe\thead\tof\tthe\tbed.\n- Intubation\tmay\tbe\tnecessary\tfor\ta\tpatient\twith\timpending\trespiratory\tfailure.\n- After\ttreatment\thas\tbeen\tstarted,\tif\tavailable,\ta\tcranial\tCT\tscan\tshould\tbe\tdone to rule out other possible intracerebral causes of neurological deterioration, especially thrombosis or haemorrhage which may benefit from specific therapy.\n\n\nCerebral oedema is an unpredictable complication of DKA, often occurring when the general condition of the child has improved and monitoring is less strict. Survivors are often left with significant neurological deficits. Meticulous management of the DKA can decrease the risk of developing cerebral oedema. DKA should therefore be managed at the best available facility.\n\n\n**6. Monitoring**\n\n\nIf  biochemical parameters of DKA (pH, anion gap, urine ketones) do not improve, reassess patient, review insulin therapy, and consider other possible causes of impaired response to insulin, e.g. infection or errors in insulin preparation. Also consider that the primary illness may be a serious infection (such as malaria) with stress hyperglycaemia rather than diabetes\n\n\n- Mannitol\tor\thypertonic\tsaline\tshould\tbe\tavailable\tat\tthe\tbedside\tfor rapid treatment in case of cerebral oedema.\n- When\tthe\tchild\tstarts\ttaking\toral\tfluids,\tmake\tsure\tthe\tIV\trate\tof\tfluids\tis decreased accordingly, not to exceed the total hourly fluid input requirements.\n- This\tfluid\trestriction\tshould\tbe\tapplied\tfor\t48\thrs\tfrom\tadmission (72 hrs if  there is severe hyperglycaemia at onset of treatment).\n- If\treplacing\tfluid\torally,\tensure\tthat\tthe\tchild\thas\tORS\tor\tfruit\tjuice\tonce the glucose is below 15 mmol/l (270 mg/dl).\n\n\nOnce the urine ketones are absent, consider making the transition to subcutaneous (SC) insulin\n\n\n**7. Transitioning to subcutaneous insulin**\n\n\nOnce the DKA has been adequately treated (hydration corrected, glucose controlled, ketones cleared) the patient can be transitioned to subcutaneous insulin.\n\n\nThe first SC dose of short-acting insulin should be given 1-2 hours before stopping the insulin infusion.\n\n\nImportant: It is often easier to transition to subcutaneous insulin at the next mealtime.\n\n\nIf the child is newly diagnosed:\n\n\n- Pre-pubertal:\t0.5-0.75\tU/Kg/day\n- Pubertal:\t0.75-0.1\tU/Kg/day\n\n\nOtherwise determine insulin dose from consideration of the dose before admission.\n\n\n**Algorithim for the management of diabetic Ketoacidosis**\n\n\n![HGT-hourly glucose test, KCL-potassium chloride, S/C-subcutaneous](images/picture_043_page_80.png)\n\n\nHGT-hourly glucose test, KCL-potassium chloride, S/C-subcutaneous\n\n\nTable 26:  Fluid maintenance and replacement volumes based on body weight and assumption of 10% dehydration in DKA\n\n\n| Body weight kg   | Maintenance   | DKA: Give maintenance + 5% of body weight/24-hr   | DKA: Give maintenance + 5% of body weight/24-hr   |\n|------------------|---------------|---------------------------------------------------|---------------------------------------------------|\n| Body weight kg   | mL/24 hr      | mL/24hr                                           | mL/hr                                             |\n| 4                | 325           | 530                                               | 22                                                |\n| 5                | 405           | 650                                               | 27                                                |\n| 6                | 485           | 790                                               | 33                                                |\n| 7                | 570           | 920                                               | 38                                                |\n| 8                | 640           | 1040                                              | 43                                                |\n| 9                | 710           | 1160                                              | 48                                                |\n| 10               | 780           | 1280                                              | 53                                                |\n| 11               | 840           | 1390                                              | 58                                                |\n| 12               | 890           | 1490                                              | 62                                                |\n| 13               | 940           | 1590                                              | 66                                                |\n| 14               | 990           | 1690                                              | 70                                                |\n| 15               | 1030          | 1780                                              | 74                                                |\n| 16               | 1070          | 1870                                              | 78                                                |\n| 17               | 1120          | 1970                                              | 82                                                |\n| 18               | 1150          | 2050                                              | 85                                                |\n| 19               | 1190          | 2140                                              | 89                                                |\n| 20               | 1230          | 2230                                              | 93                                                |\n| 22               | 1300          | 2400                                              | 100                                               |\n| 24               | 1360          | 2560                                              | 107                                               |\n| 26               | 1430          | 2730                                              | 114                                               |\n| 28               | 1490          | 2890                                              | 120                                               |\n| 30               | 1560          | 3060                                              | 128                                               |\n| 32               | 1620          | 3220                                              | 134                                               |\n| 34               | 1680          | 3360                                              | 140                                               |\n| 36               | 1730          | 3460                                              | 144                                               |\n| 38               | 1790          | 3580                                              | 149                                               |\n| 40               | 1850          | 3700                                              | 154                                               |\n| 45               | 1980          | 3960                                              | 165                                               |\n| 50               | 2100          | 4200                                              | 175                                               |\n| 55               | 2210          | 4420                                              | 184                                               |\n| 60               | 2320          | 4640                                              | 193                                               |\n| 65               | 2410          | 4820                                              | 201                                               |\n| 70               | 2500          | 5000                                              | 208                                               |\n| 75               | 2590          | 5180                                              | 216                                               |\n| 80               | 2690          | 5380                                              | 224                                               |\n\n\n### 3.2.3. Diabetic Hyperosmolar Hyperglycaemic State\n\n\nHyperosmolar Hyperglycaemic State (HHS) is characterized by the slow development of marked\thyperglycaemia\t(usually\t&gt;\t30\tmmol/L\tor\t540\tmg/dl\tand\tusually\treading\t'unre -cordable' on the glucometer), dehydration and pre-renal azotemia (elevated blood urea and creatinine). Ketonuria may be slight or absent. Two-thirds of cases are in previously undiagnosed cases of diabetes.\n\n\nInfections, diuretic treatment, and drinking glucose-rich beverages, myocardial or cerebral ischemia may all be precipitating factors.\n\n\nThe condition usually affects middle- aged or elderly patients and carries a high mortality.\n\n\n**Treatment**\n\n\nInitial  treatment is the same as for Diabetic Ketoacidosis; but usually insulin requirements are lower than in DKA and individuals respond well to rehydration. Owing to its high mortality, immediate referral for relevant specialist care is recommended.\n\n\nECG should be done and Heparin/anti-thrombotic agents should be given in the absence of contraindications.\n\n\n### 3.2.4. Hypoglycemia\n\n\nHypoglycemia is a medical emergency and should be treated promptly if serious complications are to be avoided.\n\n\nIt is characterized by blood glucose levels &lt; 4 mmol/L. Some patients might experience hypoglycaemic symptoms at higher blood glucose levels and clinicians should individualize care.\n\n\n**The commonest causes of hypoglycemia are:**\n\n\n- Engaging\tin\tmore\texercise\tthan\tusual\n- Delay\tor\tomission\tof\ta\tsnack\tor\tmain\tmeal\n- Poor\tinjection\ttechnique\n- Insulin\toverdose\n- Eating\tinsufficient\tcarbohydrate\n- Excessive\tuse\tof\talcohol\n- Sulphonylureas\toverdose\n- Use\tof\tlong-acting\toral\tglucose-lowering\tagents\n- Herbal\tmedication\tcausing\tliver\tfailure\tin\tcombination\twith\tdiabetes medications\n\n\n**Presentation**\n\n\n- Severe\thunger\n- Sudden\tweakness\n- Cold\tclammy\tskin\n- Profuse\tsweating\n- Headache\n- Palpitations\n- Sudden\tcollapse-\tmore\tfrequent\tin\tType\t1\tDM\tor\twhere\tthere\tis\thypoglycaemic unawareness\n- Cerebral\tsigns/\tsymptoms-\tirritability,\tconfusion,\tdisorientation,\tcoma\n\n\n**Management**\n\n\n- Oral\tglucose\t/sweetened\tdrink-\twithout\tmilk\t(Not\tdiet\tdrink)\tif\tpatient\tis conscious.\n- If\tpatient\tis\tunconscious,\tIV\t50%\tglucose\tbolus\t(40\t-\t50\tml\tdiluted\twith\tequal volume normal saline) and followed by 10% glucose infusion if necessary. In children use 10% dextrose 2-5 ml/Kg.\n- Injectable\tglucagon\t1\tmg\tIM\tif\tavailable\tcan\talso\tbe\tadministered\tin unconscious patients.\n- On\trecovery,\tgive\ta\tlong-acting\tcarbohydrate\tsnack.\n- Prolonged\tIV\tdextrose\tinfusion\t(10%\tfor\t12\t-\t24\th.)\tmay\tbe\tnecessary\tif hypoglycemia is a result of long-acting sulphonylureas/ long and intermediate-acting insulin or alcohol.\n- If\tIV\taccess\tis\timpossible,\tconsider\tnasogastric\tglucose\n- On\trecovery,\tattempt\tto\tidentify\tthe\tcause\tof\thypoglycemia\tand\taddress\tit\n- Assess\tthe\ttype\tof\tinsulin\tused,\tinjection\tsites\t(since\tlipohypertrophy\tcan\talter the rate of absorption) and injection techniques.\n- Enquire\tinto\tand\taddress\tinappropriate\thabits\tof\teating,\texercise\tand\talcohol consumption.\n- Review\tof\tother\tdrug\ttherapy\tand\trenal\tfunction,\n- Adjustment\tof\tthe\tdosage\tof\tinsulin\tor\toral\tglucose-lowering\tagents\tif appropriate\n\n\nTable 27: Management of hypoglycaemia\n\n\n|                                                   | Blood glucose                 | Description                                                                                                          | Action                                                                                                                                                                                                                                                                                                                                                                                               |\n|---------------------------------------------------|-------------------------------|----------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Level 1 Hypoglycaemia alert                       | ≤ 3.9 mmol/L but ≥ 3.0 mmol/L | Requires treatment with fast-acting carbohydrate Patient alert and able to eat                                       | • Treat with oral glucose • Give a sugary snack and recheck blood glucose in 15 min • If blood glucose remains ≤ 3.9 mmol/L, repeat the previous step • Give a carbohydrate meal when blood glucose is ≥ 5.0 mmol/L                                                                                                                                                                                  |\n| Level 2 Clinically sig- nificant hypo - glycaemia | < 3.0 mmol/L                  | Indicates serious, clinically significant hypoglycaemia Patient may be alert or may have reduced conscious- ness     | • Treat with iv glucose • Give 10 ml 50% glucose iv and recheck blood glucose in 2 min • If blood glucose remains < 5mmol/L, repeat the previous step • Give an infusion of 10% glucose iv if more than 2 doses of iv glucose required • Give a carbohydrate meal when blood glucose is ≥ 5.0 mmol/L and the patient is alert and able to eat • Observe for 4 hrs, checking blood glucose every 1 hr |\n| Level 3 Severe hypogly- caemia                    | No specific value             | Associated with severe cognitive impairment requir- ing external help for recovery Patient has reduced consciousness | • Treat as for Level 2 hypoglycae - mia • Likely to need hospital admission                                                                                                                                                                                                                                                                                                                          |\n\n\nSource: Adapted from ADA Guidelines, 2018\n\n\n### 3.2.5. Sick Day Management\n\n\n**Introduction**\n\n\nAn inter-current illness can destabilize the metabolic state of a child or adult living with diabetes (especially type 1), leading to a hyperglycemic crisis, e.g. Diabetic ketoacidosis. Ailments that reduce intake significantly may also predispose to hypoglycemia. These can be prevented by certain simple steps highlighted as 'Sick Day Management' . The aim of the sick day management is prevention of diabetic ketoacidosis and hypoglycemia.\n\n\n**Metabolic Disturbance as a Result of Inter-Current Illness**\n\n\nThe stress factors, e.g. infection, inflammatory disease, injury, surgery, and severe emotional disturbances, result in the secretion of stress or counter-regulatory hormones: glucagon, growth hormone, epinephrine, and cortisol. Acting in synergy, these hormones create a state of insulin resistance, causing increased hepatic glucose production and reduced peripheral glucose utilization. Though calorie intake is low in illness, blood glucose levels increase and ketonaemia and ketonuria may occur.\n\n\nUnchecked, these metabolic disturbances may progress to full-blown diabetic ketoacidosis.\n\n\nSick day management thus serves to prevent ketoacidosis.\n\n\n**Principles of treatment**\n\n\n- Do\tnot\tstop\tInsulin\tbut\tadjust\taccording\tto\tindividualized\tneeds.\n- If\tsupplemental\tinsulin\tis\trequired,\tan\tadditional\t10%\t-\t20%\tof\tusual\tdaily\tdose may be safely given with monitoring (see table 23)\n- Treat\tunderlying\tillness.\n- Prevent\tdehydration.\n- Monitor\tblood\tglucose\tand\turine\tketones\tevery\t4\thours.\n- Watch\tout\tfor\tsymptoms\tthat\trequire\thospital\tcare\t(admission).\n- If\tblood\tglucose\tis\tlow,\tthe\tdose\tof\tinsulin\tshould\tbe\treduced.\n- Treat\tunderlying\tdisease:\tSeek\tmedical\tattention\tsooner\trather\tthan\tlater\n- Any\tunderlying\tillness\tshould\tbe\ttreated\ton\tits\tmerit\te.g.\tfor\tan\tinfection\tgive antibiotics.\n- One\tshould\tbe\tadvised\tto\trest\tand\tavoid\tstrenuous\texercise/activity.\n- Prevent\tdehydration.\tHigh\tfluid\tintake\tis\timportant\tto\tprevent\tdehydration. Fluids chosen should contain sodium and potassium to replace loss of these electrolytes as occurs in uncontrolled Diabetes: if one is not able to follow meal plan, use fluids with sugar to provide carbohydrate. Fluids can be oral rehydration salts, broth, (meat soup), fruit juice, regular soda.\n\n\nTable 28: Minimum amounts of fluid for oral rehydration\n\n\n| Volume per hour   | Volume per hour   | Volume per hour   | Volume per hour   |\n|-------------------|-------------------|-------------------|-------------------|\n| Age in years      | Weight in kg      | ml                | oz.               |\n| 5                 | 20                | 45 -90            | 1.5 - 3           |\n| 10                | 30                | 75 - 120          | 2.5 - 4           |\n| 15                | 55                | 120 - 240         | 4 - 8             |\n| 16+               | 56 +              | 240 - 300         | 8 - 10            |\n\n\nSource: Adapted from Challenges in diabetes management, Lifescan 1998.\n\n\n**Guidelines for regular insulin during sick days**\n\n\n**NB: Start with the usual dose**\n\n\n- Two-dose\ttreatment\t(NPH\t+\trapid-acting\tor\tshort-acting\tinsulin)\n- May\tchange\tit\tto\ta\t4-5-dose\tregimen,\textras\tbeing\tthe\trapid/\tshort\tacting insulin at 20 - 25% TDI\n- Or\tfollow\tthe\ttable\t(Table\t23)\n\n\nTable 29: Guidelines for supplemental regular insulin\n\n\n| BGin mmol/L   | 15-17   | 17-20   | >20     |\n|---------------|---------|---------|---------|\n| Age in years  |         |         |         |\n| 0 - 6         | 0.5-1U  | 1-2U    | 2-3U    |\n| 7 - 11        | 1-2U    | 2-3U    | 3-5U    |\n| 12 - 15       | 2-3U    | 3-4U    | 4-8U    |\n| > 16          | 3-4U    | 4-6U    | 6 - 12U |\n\n\nAdapted from IDF, 2014\n\n\n**Signs and symptoms that necessitate hospital care/admission**\n\n\n- If\tthe\tunderlying\tcondition\tis\tunclear,\tfever\tpersists,\tor\tfamily\tmembers\tare\tun comfortable providing home care for any reason\n- Weight\tloss\tcontinues\tsuggesting\tworsening\tdehydration\tand\tpotential circulatory compromise\n- Vomiting\tpersists\tbeyond\t2\thrs\t(particularly\tin\tyoung\tchildren)\n- Caregivers/patients\tare\tunable\tto\tkeep\tblood\tglucose\tabove\t3.5\tmmol/L\t(60 mg/dL)\n- Blood\tGlucose\tcontinues\tto\trise\tdespite\tsupplemental\tinsulin\n- Fruity\tbreath\todor\t(acetone)\tpersists\tor\tworsens\n- Ketonuria\tis\theavy\tand\tincreasing/persistent\tor\tblood\tketones\tare\t&gt;1.0-1.5 mmol/L\n- The\tpatient\tis\tbecoming\texhausted,\tconfused,\thyperventilating\t(Kussmaul breathing) or has severe abdominal pain\n- Change\tin\tneurologic\tstatus,\tmental\tconfusion,\tloss\tof\tconsciousness, seizures, progression of confusion may indicate impending or present cerebral edema; and treatment of cerebral edema is a medical emergency requiring immediate assistance with advanced medical facilities to prevent morbidity and mortality\n- The\tchild\tis\tvery\tyoung\t(less\tthan\t2-5\tyears)\n- Other\tco-morbidities\te.g.,\tepilepsy,\tmalaria\tor\tother\tinfections,\tor\tother diabetes related complications.\n- Patients/relatives\tare\texhausted,\tare\tnot\table\tto\tcommunicate\tdue\tto\tlanguage barrier or request emergency support.\n\n\nSick day management is vital in minimizing the impact of intercurrent illness. In many cases this prevents hospital admission and the accompanying costs, reducing not only the economic burden of diabetes; but also reducing the days lost because of illness. However, this is limited to those who can afford blood glucose machines and urine test strips, as well as to those patients who are highly motivated. With good education and motivation, most sick day episodes can thus be successfully managed at home or in a primary care setting.\n\n\n## 3.3. Chronic Complications of Diabetes\n\n\n### 3.3.1. Macrovascular Complications\n\n\nThe risk of CVD for people with type 2 diabetes is increased by two to three times for men and three to five times for women compared with people without diabetes. Outcomes following myocardial infarction, stroke or revascularization are also worse in people living with diabetes compared to individuals without diabetes. Atherosclerosis is often accelerated, severe and diffuse in diabetes. Chronic hyperglycaemia is an additional risk factor for atherosclerosis in patients with diabetes and adds to the well-known standard risk factor burden of race, gender, hypertension, dyslipidaemia, smoking, social deprivation and obesity. Table 24 summarizes the traditional modifiable risk factors for CVD and the recommended target values in diabetes.\n\n\nTable 30: CVD risk factors and targets for type 2 diabetes\n\n\n| Traditional CVD risk factors   | Targets                                                          |\n|--------------------------------|------------------------------------------------------------------|\n| Cigarette smoking              | Cessation                                                        |\n| Dyslipidaemia                  |                                                                  |\n| - Total cholesterol            | <4.5 mmol/L                                                      |\n| - LDLcholesterol               | <1.8 mmol/L                                                      |\n| - HDLcholesterol               | > 1.0 mmol/L (men) >1.2 mmol/L (women)                           |\n| - Triglycerides                | <1.7 mmol/L                                                      |\n| Obesity                        |                                                                  |\n| - Waist circumference          | <94 cm (men); <90 cm (men of South Asian descent) <80 cm (women) |\n| - Body mass index              | <25 kg/m2                                                        |\n| Hypertension                   |                                                                  |\n| - Systolic blood pressure      | <140 mmHg                                                        |\n| - Diastolic blood pressure     | <80 mmHg                                                         |\n\n\n**Two major processes lead to cardiovascular disease:**\n\n\n- Atherosclerosis,\tand\n- Hypertension\n\n\n**The clinical spectrum of cardiovascular disease is:**\n\n\n- a. Coronary artery disease\n- b. Cerebrovascular disease\n- c. Peripheral vascular disease\n\n\n**Coronary artery disease**\n\n\nCoronary artery disease (CAD) is the cause of death in more than half of all diabetic patients. Patients with diabetes but without other conventional risk factors for atherosclerosis have a risk of death from CAD 2- 4 times that of age-matched controls. Those with type 2 diabetes commonly have other associated risk factors, such as hypertension or hyperlipidemia, thus further increasing their cardiovascular risk. Women living with diabetes are at increased risk, with a risk of cardiovascular death up to 7.5 times that of women without diabetes. Individuals with diabetes and CAD fare worse than do other patients with CAD. These patients present with:\n\n\n- Chest\tpain\t(angina):\t-this\tcan\tbe\ta\tmild,\tuncomfortable\tfeeling,\tsimilar\tto\tin -digestion. However, a severe angina attack can cause a painful feeling of heaviness or tightness, usually in the centre of the chest, which may spread to the arms, neck, jaw, back or stomach. Angina is often triggered by physical activity or stressful situations.\n- Lightheadedness\n- Sweating\n- Nausea\n- Breathlessness\n\n\nThose who present with a myocardial infarction (MI) are at increased risk of dying from their event or of developing heart failure. They benefit less from therapies such as thrombolysis in the setting of an acute MI. Therefore, early detection of CAD is important to ensure that medical interventions to improve outcome are instituted.\n\n\n**The spectrum of coronary artery disease includes: -**\n\n\n- Angina\t(which\tmay\tbe\tsilent).\n- Acute\tcoronary\tsyndrome.\n- Congestive\tcardiac\tfailure.\n- Sudden\tdeath.\n\n\n**Silent ischemia**\n\n\nSilent ischemia is a particular concern in diabetic patients. Clinically, patients with diabetes are more likely to be without chest pain in the setting of unstable angina or MI, and thus late presentation contributes to a higher mortality in these patients. People with diabetes may also be less likely to experience exertional angina or chest pain with exercise testing, thus potentially increasing the difficulty of diagnosing significant CAD. This may further increase diabetic patients' risk in terms of late diagnosis and presentation.\n\n\n**Cerebrovascular disease**\n\n\nCerebrovascular complications make diabetic patients 2-6 times more susceptible to a stroke event. The risk is further increased in the DM patients who also have hyperlipidemia or hypertension. The cerebrovascular risk increases by 2-3-fold in type 2 DM patients with elevated systolic blood pressure. In addition, when patients with diabetes\n\n\nand hyperglycemia experience an acute ischemic stroke they are more likely to die or be severely disabled and less likely to benefit from the thrombolytic therapy.\n\n\n**Cerebrovascular diseases in diabetes can present either as:**\n\n\n- i. Stroke\n- ii. Transient ischaemic attack\n- iii. Cognitive impairment/dementia\n\n\n**Stroke**\n\n\nStroke refers to the partial or complete interruption of blood supply to the brain resulting in brain ischemia. The manifestations of stroke typically last longer than 24 hours. There are two main forms of stroke: -\n\n\n- a. Ischemic stroke: Occurs when there is occlusion (blockage) to the blood vessels supplying the brain by a thrombus or embolus. It is the more common form of stroke in diabetics.\n- b. hemorrhagic stroke: Occurs when a weakened blood vessel bursts or ruptures leading to an intracranial bleed. Common in individuals with uncontrolled hypertension.\n\n\n**Symptoms of stroke include:**\n\n\n- Sudden\tnumbness\tor\tweakness\tin\tthe\tface,\tarm,\tor\tleg,\tespecially\ton one side of the body\n- Sudden\tconfusion,\ttrouble\tspeaking,\tor\tdifficulty\tunderstanding\tspeech\n- Sudden\ttrouble\tseeing\tin\tone\tor\tboth\teyes\n- Sudden\ttrouble\twalking,\tdizziness,\tloss\tof\tbalance,\tor\tlack\tof coordination\n- Sudden\tsevere\theadache\twith\tno\tknown\tcause\n- c. Transient Ischaemic Attack (TIA): Transient ischaemic attack refers to temporary obstruction of blood supply to the brain. Symptoms mimic those of stroke, but typically last less than 24 hours.\n- d. Cognitive impairment: Diabetes increases the risk of developing cognitive decline and dementia, including vascular dementia and Alzheimer's disease (AD) especially in the elderly\n\n\n**Evaluation for Cerebrovascular disease will include: -**\n\n\n- Carotid\tDoppler\n- MRI\tand\n- MRI\tangiography\twhere\tindicated.\n\n\n**Treatment**\n\n\nThe treatment of the cerebrovascular disease in DM patients is divided into three levels:\n\n\n- i. First level: to prevent the brain vessels complications by adequately controlling the blood glucose when the patients are at the stage of insulin resistance or at the early stage of diabetes; to reduce the risk factors caused by the hyperglycemia\n\n\n- a. Lifestyle modification-smoking cessation, diet and physical activity\n- b. Glycemic control: OGLAs/insulin therapy\n- c. Anti-platelet therapy\n- d. Blood pressure control\n- e. Treatment of dyslipidemia: statins\n- ii. Second level: to control glucose intensively after the cerebrovascular diseases occur in DM patients. The blood pressure should be reduced to the normal range to avoid the vasculopathy-induced stroke.\n- iii. Tertiary prevention: to improve the cerebral circulation after the stroke in DM patients. The patients with ischemic stroke should be treated by thrombolytic therapy in the early phase of hyper-acute cerebral infarction\n\n\n**Peripheral vascular disease (PVD)**\n\n\nPVD is a common cardiovascular complication in persons living with diabetes. In contrast to PVD in non-diabetic individuals, it is more prevalent and, because of the involvement of the distal territory of vessels and its association with peripheral neuropathy, it is more commonly asymptomatic.\n\n\nPatients with PVD and diabetes thus may present later with more severe disease and have a greater risk of amputation. Moreover, the presence of PVD is a marker of excess cardiovascular risk.\n\n\nIt is important to diagnose PVD in patients with diabetes to elicit symptoms, prevent disability and limb loss, and identify a patient at high risk of MI, stroke, and death.\n\n\n**The clinical spectrum of PVD include: -**\n\n\n- i. Intermittent claudication-defined as pain, cramping, or aching in the calves, thighs, or buttocks that appears reproducibly with walking exercise and is relieved by rest.\n- ii. Critical Limb Ischemia-this is a triad characterized by: -\n- Rest\tpain\n- Foot\tulcers:\tthese\tischemic\tulcers\ttypically\tpresent\ton\tthe\tlateral surface of the ankle or the distal digits\n- Gangrene\n\n\n**Peripheral signs of peripheral vascular disease are the classic 'five P's,':**\n\n\n- Pulselessness\n- Paralysis\n- Paresthesia\n- Pain\n- Pallor\n\n\nThe assessment of PVD in patients with diabetes should include a thorough medical history and physical examination to identify those patients with risk factors, symptoms and signs of PVD.\n\n\n- Walking\thistory\tto\telicit\tclaudication\tsymptoms\n- Foot\tinspection-\tabsence\tof\thair\tgrowth,\tpallor\ton\televation,\tcool\tand dry\n\n\nfissured skin, fissures and ulcerations in the interdigital spaces\n\n\n- Palpation\tof\tperipheral\tpulses\t(femoral,\tpopliteal\tand\tdorsalis\tpedis pulses)\n\n\nThe diagnosis is made with a determination of the ABI. It is recommended that patients with\tdiabetes\twho\tare\t&gt;\t50\tyears\tof\tage\thave\tan\tABI\tperformed.\tAn\tABI\tis\talso\tuseful\tin patients with other PVD risk factors and in those with symptoms.\n\n\nFigure 22: How to perform an ankle-branchial index Source: National Heart Lung and Blood Institute (NIH) - National Heart Lung and Blood Institute (NIH)\n\n\n![KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS| 92](images/picture_044_page_92.png)\n\n\n**The diagnostic criteria for PVD based on the ABI are interpreted as follows:**\n\n\nTable 31: Interpretation of ankle-brachial index (ABI) values\n\n\n| ABI reading   | Interpretation       |\n|---------------|----------------------|\n| 0.91-1.30     | Normal               |\n| 0.70-0.90     | Mild obstruction     |\n| 0.40-0.69     | Moderate obstruction |\n| < 0.40        | Severe obstruction   |\n| > 1.30        | Poorly compressible  |\n\n\nAn\tABI\tvalue\t&gt;\t1.3\tsuggests\tpoorly\tcompressible\tarteries\tat\tthe\tankle\tlevel\tdue\tto\tthe presence of medial arterial calcification. This renders the diagnosis of PVD by ABI alone less reliable.\n\n\nIn addition to ABI, evaluation for peripheral vascular disease should also include Doppler and angiography of the lower limbs.\n\n\n**Treatment of the patient with diabetes and PVD should be two-fold:**\n\n\n- i. Primary and secondary risk modification\n2. -Cigarette smoking cessation,\n3. -Glycemic control\n4. -Treatment of hypertension\n5. -Treatment of dyslipidemia\n6. -Anti-platelet therapy (aspirin, clopidogrel)\n- ii. Treatment of PVD symptoms (claudication and critical limb ischemia) and limiting progression of disease\n8. -Exercise rehabilitation\n9. -Pharmacologic therapy (e.g. Pentoxifylline, cilostazol)\n10. -Wound care (debridement, offloading the ulcers, appropriate dressings, treatment of infections)\n11. -Revascularization (for patients with debilitating claudication or CLI)\n\n\n**Follow-up considerations: Cardiovascular complications in DM patients**\n\n\n- Initial\tassessment\tfor\tcardiovascular\trisk\tshould\tbe\tdone\tin\tall\tdiabetic\tpatients, and annually thereafter.\n- The\tassessment\tshould\tbe\tmore\tfrequent\tif\tthe\tpatient\thas\thad\ta cardiovascular   event (Refer to ESH/ESC CVD risk stratification tool in ANNEX I).\n- Referral\tfor\tspecialist\tcare\tis\trequired\tin\tpeople\tpresenting\twith\ttypical\tand atypical symptoms of angina, features of congestive cardiac failure, unexplained breathlessness, cardiomegaly, arrhythmias, transient ischaemic attacks or intermittent claudication of the legs.\n\n\n### 3.3.2. Chronic Microvascular Complications\n\n\nMicrovascular complications involve the kidney, eyes, lower extremities. They may be present at the time of diagnosis of diabetes as the detection of the disease is frequently delayed. Most of these complications can be prevented or their progression delayed by optimal treatment of hyperglycaemia and hypertension.\n\n\nScreening for the complications and prompt interventions reduce the risk of major outcomes such as blindness, nephropathy, and leg amputations.\n\n\n**Diabetes Nephropathy**\n\n\nDiabetes is one of the most common causes of chronic kidney disease. In Africa, there is a high morbidity and economic burden in patients with end-stage renal disease due to late presentation, delayed diagnosis and limited access to renal replacement therapy.\n\n\nDiabetes nephropathy progresses from subclinical disease to microalbuminuria. Persistent microalbuminuria is a marker for the development of overt nephropathy in diabetes as well as being a well-established marker of increased cardiovascular risk. Patients with microalbuminuria\twho\tprogress\tto\tmacro-albuminuria\t(&gt;\t300\tmg/24\th.)\tare\tlikely\tto\tprogress to end-stage renal disease. Intervention at the stage of microalbuminuria can retard the progression to end-stage renal disease.\n\n\n**Who should be screened?**\n\n\n- Patients\twith\tType\t1\tdiabetes\tfor\ta\tduration\tof\t&gt;5\tyears\n- Patients\twith\tType\t2\tdiabetes\tat\tdiagnosis\n\n\n**Detection and surveillance**\n\n\n- Check\tfor\tproteinuria\tyearly\tusing\treagent\tstrips.\n- For\tpatients\twho\ttest\tpositive,\texclude\turinary\ttract\tinfections\tby using urine strips to check for nitrites and leucocytes or urine microscopy and culture and treat infection if present.\n- During\tthe\tnext\tvisit,\tcheck\tfor\tpresence\tof\tinfection,\tif\tnone\ttest\tfor proteinuria. If proteinuria (trace or greater) is present and there is no infection, refer for renal evaluation.\n- For\tpatients\twho\ttest\tnegative\tfor\tproteinuria\tcheck\tfor\tmicroalbuminuria annually using reagent strips or the albumin-creatinine ratio.\n- If\tnegative,\trepeat\ttest\tannually.\tIf\tpositive,\ttest\tsample\tat\tleast\tone\tto\ttwo times within 3 to 6 months to confirm microalbuminuria. If confirmed, start ACEI or ARB treatment and optimize blood pressure control to less than 125/75 mmHg.\n- Measure\tserum\tcreatinine\tbi-annually,\tand\tif\traised\tor\trising,\trefer\tfor\trenal evaluation.\n\n\n**Frequency of screening**\n\n\nTable 32: Frequency of screening for diabetic nephropathy based on status of kidney\n\n\n| Status of Kidney function                                                                                 | Screening Frequency                                                                                                                       |\n|-----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|\n| Albumin-Creatinine Ratio (ACR) - normal range and the eGFR > 60 ml/minute:                                | Annually                                                                                                                                  |\n| Albumin-Creatinine Ratio (ACR) - abnormal range and the eGFR < 60 ml/minute:                              | Serum creatinine must be repeated once three months ACR must be repeated twice within the same three months:                              |\n| ACR is abnormal in two out of three tests if the eGFR < 60 ml/minute, the presence of CKD is con- firmed. | The patient must be referred for further work- up to exclude non-diabetic renal disease or to confirm Chronic Kidney Disease in diabetes. |\n\n\n**General recommendations**\n\n\n- Intensify\tmanagement\tof\tmodifiable\trisk\tfactors\n- Tobacco\tuse\tin\tany\tform\tshould\tbe\tstopped\n- Metformin\tshould\tnot\tbe\tused\tonce\teGFR\t&lt;30\tml/min/1.73\tm2\n- Between\teGFR\tof\tbetween\t30-45\tml/min/1.73\tm2\tconsider\tthe\trisks\tand benefits of metformin.\n- Treat\turinary\tinfections\taggressively.\n- Avoid\tdrugs\ttoxic\tto\tthe\tkidney\te.g.\tNon-steroidal\tanti-inflammatory\tagents (e.g. Diclofenac), Aminoglycosides (e.g. Gentamicin)\n\n\n**Principles of Treatment of Nephropathy and Chronic Kidney Disease**\n\n\n- i. Optimize glycemic control with caution in those with advanced kidney disease and those on renal replacement therapy.\n- ii. Treat blood pressure aggressively with a target of 125/75 mmHg.\n- a. Use ACE inhibitors or ARBs as first-line drug therapy unless contraindicated. These drugs should NOT be used in pregnancy.\n- iii. Diet therapy and counselling\n- iv. Psychosocial counselling\n- v. Criteria for Renal Specialist referral\n- a. Persistent micro-albuminuria\n- b. Inability to optimize blood pressure\n- c. Patients\tintolerant\tof\tACE-Inhibitors/ARBs\tor\t&gt;30%\tincrease\tin creatinine levels within 3 months of initiation of these drugs\n\n\n**When to consider other causes of CKD in Diabetes**\n\n\n- Extreme\tproteinuria\t&gt;6\tg/day\n- Persistent\thematuria\n- Rapidly\tfalling\teGFR\n- Low\tEGFR\twith\tlow\tor\tno\tproteinuria\n- Diabetes\t&lt;5\tyears\n- Family\thistory\tof\tnon-diabetic\trenal\tdisease\te.g.\tpolycystic\tkidney disease\n\n\n**Diabetes Eye Disease**\n\n\nDiabetes eye disease comprises both retinopathy and cataracts.\n\n\n**Retinopathy**\n\n\nRetinopathy is one of the major causes of blindness.\n\n\nRisk factors for retinopathy include poor glycemic control, hypertension and pregnancy, as well as a long duration of diabetes. Diabetic retinopathy is preventable, and its progression is retarded by improved blood pressure and glycemic control. Screening for retinopathy and laser therapy can prevent blindness.\n\n\n**Recommendations**\n\n\n- a. A full eye examination including visual acuity and fundoscopy (preferably after the dilatation of the pupils) should be performed at the initial contact. If no capacity for ophthalmology examination, refer as part of the initial assessment.\n- b. Examinations should be repeated annually or more frequently if retinopathy is progressing.\n- c. A comprehensive eye examination is required in women planning pregnancy, and during the first trimester. An individualized follow-up is required during pregnancy and for one year thereafter. (This does not apply to women with GDM). In women with pre-existing type 1 diabetes, fundoscopy should be performed every trimester.\n- d. If retinopathy is present, intensify the management of blood pressure, glycaemia, lipids and stop smoking.\n- e. Patients with proliferative diabetic retinopathy require guided exercises and should avoid weight-bearing exercises.\n\n\n**Who should be screened?**\n\n\n- All\tpatients\twith\tType\t2\tDiabetes\tMellitus\tat\tpresentation\n- Patients\twith\tType\t1\tDiabetes\tMellitus\tof\t&gt;\t5\tyears\tduration\tsince\tdiagnosis\t(or at presentation if uncontrolled).\n\n\n**Urgent Referral to Ophthalmologist**\n\n\n- Sudden\tdeterioration\tof\tvision\n- 'Floater'\tsensation\tin\tthe\teye\treported\tby\tpatient\n- Fundoscopy\tfindings\tof\tdot\tor\tblot\themorrhages-\t1\tdisc-width\taway\tfrom\tthe macula.\n- Cataract\tpresent,\n- Proliferative\tor\texudative\tretinopathy.\n\n\n**Diabetes Neuropathy**\n\n\nNeuropathies are common complications of diabetes. They significantly increase the risk of ulceration, infection and amputation, and other diabetes-related morbidities like postural hypotension, gastropathies and erectile dysfunction. Once present, it is difficult to reverse, but good glycemic control can reduce symptoms and slow progression.\n\n\n**There are three major categories:**\n\n\n- Motor\tneuropathy\n- Sensory\tneuropathy\n- Autonomic\tneuropathy\n\n\n**Clinical Assessment:**\n\n\n- Detailed\thistory:\tnumbness,\ttingling,\tburning\tsensation\tpain,\thistory\tof\ttrauma\n- Examination\tof\tthe\tfeet:\ttest\tfor\tsensation\tusing\t10\tg\tmonofilament, 128 Hz tuning fork or cotton wool.\n- Lying-and-standing\tblood\tpressure\tand\tpulse\trate\n- Postural/orthostatic\thypotension=Drop\tin\tsystolic\tBP\t&gt;\t20\tmmHg\tor\tdiastolic &gt;10\tmmHg\twith\tchange\tto\tstanding\tposition\n\n\n**General measures:**\n\n\n- Improve\tglycemic\tcontrol.\n- Exclude\tor\ttreat\tother\tcontributory\tfactors:\n- Excess\talcohol\tconsumption\n- Vitamin\tB12\tdeficiency\n- Chronic\trenal\tfailure\n- Poor\tnutrition\n- Smoking\n- HIV\tinfection\n\n\n**Treatment**\n\n\nTreatment of symptomatic peripheral neuropathy is extremely difficult, once diagnosed refer to secondary and/or tertiary center.\n\n\nTreatment options for neuropathy include:\n\n\n**First Line:**\n\n\n- Tricyclic\tAntidepressants\n- Pregabalin\n- Carbamazepine\n- Duloxetine\n- Tapentadol\n\n\n**Others:**\n\n\n- Tramadol\n\n\n- Topical\tcapsaicin\n\n\n**Gastroparesis**\n\n\nIt  is  a  common, but often undiagnosed complication of diabetes. Treatment includes dietary  modification  (small  frequent  meals,  reduce  dietary  fat),  withdrawal/adjusting medications that may affect motility e.g. opioids and prokinetics. Treatment is challenging. Metoclopramide may be used in severe cases judiciously due to side effects.\n\n\n**Diabetic Foot Complications**\n\n\nDiabetic foot complications comprise of peripheral neuropathy (sensory neuropathy, motor and autonomic neuropathy), ischemic and structural deformities. Neuropathy contributes to 90% of the pathophysiology of diabetic foot while ischemia contributes to 10%.\n\n\nApproximately 80% of amputations attributable to diabetes are potentially preventable through early detection, examination and simple interventions.\n\n\n**Most common predisposing factors for ulcers and amputations are:**\n\n\n- Peripheral\tneuropathy\twith\tloss\tof\tsensation\n- Peripheral\tvascular\tdisease\n- Deformities\tand\tabnormal\tbiomechanics\n- Poor\tfoot\thygiene\n- Unsuitable\tor\tno\tfootwear\n- Trauma:\tPerceived\tor\tnon-perceived\n\n\n**Cornerstone of Management of Foot Problems**\n\n\n- Identification\tof\tthe\tfoot\t'at\trisk'\n- Regular\tinspection\tand\texamination\tof\tthe\tfoot\tat\trisk\n- Education\tof\thealth\tworkers,\tpeople\tliving\twith\tdiabetes\tand\ttheir\tfamilies\n- Appropriate\tfootwear:\tThe\tshoes\tand\tsocks\tshould\talso\tbe\tinspected.\n- Early\ttreatment\tof\tnon-ulcerative\tand\tulcerative\tproblems\n\n\n**How to reduce foot ulceration and amputations**\n\n\n- Optimize\tblood\tglucose,\tblood\tpressure\tand\tlipid\tcontrol.\n- Ensure\tgood\tnutrition\tstatus\tto\tpromote\thealing\n- Encourage\tpatient\tto\tstop\ttobacco\tsmoking/use.\n- Perform\ta\tdetailed\tfoot\tevaluation\tat\tpresentation\tand\tannually.\n\n\nPeople with demonstrated risk factors should be examined more frequently. The absence of symptoms does not mean that the feet are healthy, since the patient can have neuropathy, peripheral vascular disease or even an ulcer without any complaints.\n\n\n**Full examination at presentation and annually**\n\n\n- ASK\tFOR:\tSymptoms\tof\tneuropathy\t(numbness,\ttingling\tor\tpain)\tperipheral vascular disease (pain in calves on exercise and at rest)\n- EXAMINE\tSKIN:\tInspect\tfor\tulcers,\tcallus,\tcracking,\tfragility,\tdryness,\tinter\tdigital maceration (break down of the skin between the toes) and nail pathology\n- VASCULAR:\tSkin\tcolor,\tfoot\tand\tankle\tpulses.\n- NEUROPATHY:\tcheck\tprotective\tsensation\tusing\t10\tg\tmonofilament (see figure 25)\n- BONES/JOINTS:\tdeformities,\te.g.\tclaw\ttoes\tand\thammer\ttoes.\n- FOOTWEAR:\tcheck\tfor\tappropriate\tfootwear\tand\tsocks\tboth\tinside\tand outside-ANNEX 3\n\n\nAt the examination, each person's feet must be categorized into: LOW RISK, MEDIUM RISK or HIGH RISK.\n\n\nAn example of an easy-to-use foot-screening assessment sheet for clinical examination is provided in ANNEX 2. It can be attached to the person's records.\n\n\n**FOOT CARE SCREENING FLOW CHART**\n\n\nFigure 23: Diabetic Foot Screening\n\n\n![Source: Adapted from Guidelines for the Management of People with Type 2 Diabetes in Shropshire, 2013)](images/picture_045_page_100.png)\n\n\nSource: Adapted from Guidelines for the Management of People with Type 2 Diabetes in Shropshire, 2013)\n\n\nFigure 24: Performing a monofilament test for foot sensation in diabetes\n\n\n![KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS| 100](images/picture_046_page_100.png)\n\n\n**FOOT ULCER MANAGEMENT FLOW CHART**\n\n\nFigure 25: Performing a monofilament test for foot sensation in diabetes Source: Adapted from Mahesh DM, Paul T, Thomas N. Peripheral neuropathy. A Practical Guide to Diabetes Mellitus. 7th ed. Jaypee; New Delhi. 2016. p. 171-189\n\n\n![Principle of Treatment of Diabetic Foot](images/picture_047_page_101.png)\n\n\n**Principle of Treatment of Diabetic Foot**\n\n\nThis requires interdisciplinary team approach involving:\n\n\n- Education\n- Metabolic\tcontrol\n- Microbiological\tcontrol\n- Biomechanical\tcontrol\t(footwear)\n- Vascular\tstrategies\n- Wound\tcare\n\n\n**Sexual dysfunction**\n\n\nSexual dysfunction is common in diabetes in both men and women and presents with a wide spectrum of symptoms varying from problems with libido to function and has major psychosocial impact on the individual. However, data is limited on the prevalence of  sexual  dysfunction  in  women.  In  men,  the  most  common  presentation  is  erectile dysfunction which increases in prevalence with increasing age. The common causes of erectile dysfunction are psychogenic factors, medications, glycemic control, neurological and vascular dysfunction.\n\n\n**Assessment**\n\n\n- Obtain\ta\tdetailed\tsexual\thistory\tat\tinitial\tassessment\tand\tduring\tfollow\tup.\n- Refer\tappropriately\tbased\ton\thistory\tand\tphysical\texamination.\n\n\n**Therapy**\n\n\n- Counsel\tthe\tpatient\tand\tpartner\n- Review\tmedications\tand\toptimize\ttherapy\tappropriately.\n- Phosphodiesterase-inhibitors\te.g.\tsildenafil\tand\ttadalafil\tcan\tbe\tused\twith caution in some patients with Erectile Dysfunction after cardiovascular assessment and safety is confirmed. Avoid in patients with heart failure and HIV patients on protease inhibitors.\n- Urology\treview\tmay\tbe\trequired\tif\tpoor\tresponse\tto\tpharmacologic\ttherapy.\n- Assistive\tdevices\tand\tmost\tinterventions\tdo\tnot\tchange\tthe\tnatural\thistory\tof the disease but improve the patient's quality of life.\n\n\n**TREATING ERECTILE DYSFUNCTION IN MEN WITH DIABETES**\n\n\n![Figure 25: Management of erectile dysfunction in men living with diabetes Source: Adapted from Guidelines for the Management of People with Type 2 Diabetes in Shropshire, 2013](images/picture_048_page_102.png)\n\n\nFigure 25: Management of erectile dysfunction in men living with diabetes Source: Adapted from Guidelines for the Management of People with Type 2 Diabetes in Shropshire, 2013\n\n\n**Dental Disorders in Diabetes**\n\n\nDental disorders are common in Diabetes. There is a high risk of plaque buildup leading to gingivitis and periodontitis. There is also a higher risk of infection following minor surgeries e.g. extraction\n\n\n**Recommendations**\n\n\n- Observe\tgood\toral\thygiene\tpractices\te.g.\tbrushing\tof\tthe\tteeth\tat\tleast\ttwice daily and flossing.\n- Biannual\t(6-monthly)\tdental\treviews\n\n\n## 3.4. Co-Morbidities in Diabetes Mellitus\n\n\nComorbidities are diseases or medical conditions that co-exist with the primary disease. There are various forms of co-morbidities that contribute to the morbidity and mortality associated with diabetes. They include hypertension, mental health, dyslipidemia among others.\n\n\n### 3.4.1. Hypertension\n\n\n**Principles of management of hypertension in diabetes mellitus**\n\n\n- Determine\tblood\tpressure\tin\tpeople\twith\tType\t2\tdiabetes\tat\tevery\tvisit,\tusing standard techniques (measure with a mercury sphygmomanometer and the right-sized cuff with the patient seated after 5 minutes).\n- Classify\tblood\tpressure\tstatus\tusing\ta\tBP\tof\t≥140/90\tmmHg\tas\thypertensive.\n- Most\tpatients\twith\tdiabetes\tand\thypertension\tshould\tbe\ttreated\tto\ta\tsystolic blood pressure goal of 140 mmHg and a diastolic blood pressure goal of 90 mmHg.\n- Lower\tsystolic\tand\tdiastolic\tblood\tpressure\ttargets,\tsuch\tas\t130/80\tmmHg, may be appropriate for individuals at high risk of cardiovascular disease, if they can be achieved without undue treatment burden.\n- In\tpregnant\tpatients\twith\tdiabetes\tand\tchronic\thypertension,\tblood\tpressure targets of SBP 130-150 and/or DBP 80-105 mmHg are suggested in the interest of optimizing long-term maternal health and minimizing impaired fetal growth.\n- If\thypertensive,\tassessment\tshould\tinclude\ta\tthorough\thistory,\tphysical examination, staging and cardiovascular risk stratification (refer to the risk stratification tool in Annex 1). Look for other components of metabolic syndrome and complications of both diabetes and hypertension.\n\n\n**Non-Pharmacologic Management**\n\n\nIntegrate management of hypertension and that of diabetes, starting with:\n\n\n- Diabetes\tEducation\n- Lifestyle\tmodifications\t(physical\texercise,\tdiet\tand\tweight\tloss)\tand\tsetting\tgoals\n\n\n- Diet\tshould\tbe\tlow\tin\tsodium,\trich\tin\tvegetables\tand\tfruits,\tand\tuse\tof\tlow-fat dairy products\n- Reduce\talcohol\tconsumption\tand\ttobacco\tcessation\n\n\n**Pharmacologic Management**\n\n\n- Pharmacologic\tmanagement\tshould\tbe\tconsidered\tin\tall\tpatients\twith diabetes and a documented sustained blood Pressure of above 140/90 mmHg despite lifestyle modification\n- Individualize\thypertensive\ttherapy\tto\tachieve\tgood\tcontrol.\n- Multiple\tagents\tare\tfrequently\trequired.\tFixed\tdose\tcombinations\tshould\tbe used when Blood pressures are stable and response to individual agents is known.\n- Monitor\tserum\tcreatinine\tand\tpotassium\tonce\ta\tyear\tand\tmore\tfrequently\tif there is evidence of renal impairment.\n- Note\tthe\tpotential\tproblems\twith\tcertain\tanti-hypertensives:\n- -Diuretics in large doses inhibit insulin release\n- -Beta blockers may blunt or mask symptoms of Hypoglycemia and exacerbate peripheral vascular disease\n- -Dyslipidaemia may be worsened by beta blockers and diuretics,\n- -Impotence and postural hypotension may be precipitated or aggravated by alpha blockers and centrally acting agents (e.g. methyldopa).\n- -Angiotensin converting enzyme (ACE) inhibitors may induce hyperkalaemia, renal failure, a persistent cough.\n\n\nTable 33: Principles of management of hypertension by level of severity\n\n\n\n\n| evel of severity                | Management                                                                                                             |\n|---------------------------------|------------------------------------------------------------------------------------------------------------------------|\n| 140/90                          | Repeat Blood pressure on different occasion and initiate lifestyle modification and pharmacologic therapy              |\n| 160/100 mmHg                    | Treat with two classes of oral Anti-Hypertensive drugs                                                                 |\n| 180/120 mmHg                    | Bring BP down to near normal below 160/100 mmHg within 48 hrs.                                                         |\n| If patient has end organ damage | Reduce blood pressure by not more than 25% in the first 1-2 hours with an agent determined by the physician/specialist |\n\n\nNOTE: Avoid sublingual antihypertensive agents that have the potential to dramatically and catastrophically reduce blood pressure.\n\n\n**Management of Hypertension**\n\n\nFigure 26: Algorithm for the management of hypertension in patients with diabetes mellitus\n\n\n![105 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS](images/picture_049_page_105.png)\n\n\n**Algorithm:  Management  of  hypertension  in  diabetes  in Primary Care**\n\n\nFigure 28: Management of hypertension in patients with diabetes in the Primary Care setting\n\n\n![Source: AMPATH](images/picture_050_page_106.png)\n\n\nSource: AMPATH\n\n\n### 3.4.2. Mental Disorders in Diabetes\n\n\nMental health is an important aspect of Diabetes management. Adolescents living with Diabetes are a particularly vulnerable population that requires psychosocial support as an integral part of their management.\n\n\nA wide spectrum of psychosocial and emotional challenges exists in people living with\n\n\n**Diabetes that include:**\n\n\n- Depressive\tdisorders\n- Disordered\teating\tbehavior\n- Anxiety\tdisorders\n\n\nHealthcare providers should be aware that psychotropic agents are known to increase the incidence of diabetes and may affect glycemic control.\n\n\n**Management**\n\n\n- All\tindividuals\tshould\tbe\tscreened\tat\tdiagnosis\tand\tduring\tfollow\tup for any mental health issues and referred appropriately for psychotherapy.\n- Counselling\tat\tdiagnosis\tis\tkey\tto\tacceptance,\tmedication\tcompliance and mitigation of mental disorders\n- Consider\tthe\teffects\ton\tglycemic\tcontrol\twhen\tpatients\tare\ton psychotropics.\n- Encourage\tpeer\tand\tsupport\tgroup\tinvolvement\tas\tpart\tof\troutine\tcare.\n\n\n### 3.4.3. Lipids disorders in Diabetes\n\n\nThe risk of coronary artery disease and other macrovascular disorders is 2 - 4 times higher in people living with diabetes than in non-diabetic subjects and increases in parallel with the degree of dyslipidaemia.\n\n\nTable 34: Desired level of lipids in patients with diabetes (LDL targets in the absence of CKD and CVD, DM in patients &lt; 40 years, duration of &lt;10 years)\n\n\n| Lipids            | Target(mmol/L)   | Target (Mg/dl   |\n|-------------------|------------------|-----------------|\n| Total cholesterol | <4.8             | <93.6           |\n| LDLcholesterol    | <2.6             | <-46.8          |\n| HDLcholesterol    | >1.2 (Female)    | >19.8           |\n| Triglycerides     | <1.7             | <30.6           |\n\n\nCKD-Chronic kidney disease, CVD- Cardiovascular disease\n\n\nTable 35: Lipid Targets for secondary prevention (people with history of cardiovascular event)\n\n\n| Lipids            | Target (mmol/L)   | Target (Mg/dL)   |\n|-------------------|-------------------|------------------|\n| Total cholesterol | <4.8              | <93.6            |\n| LDLcholesterol    | <1.8              | <32.4            |\n| HDLcholesterol    | >1.2              | >19.8            |\n| Triglycerides     | <1.7              | <30.6            |\n\n\n**Assessment**\n\n\nMeasure fasting lipids including total cholesterol, triglycerides and HDL and LDL cholesterol at initial contact.\n\n\n**How often:**\n\n\n- If\tnormal,\tdo\ta\trisk-stratification\tand\tdetermine\tappropriate\ttreatment.\n- If\tabnormal\tor\ton\ttreatment\t(but\tnot\ton\ttarget),\trepeat\tevery\t3-6\tmonths\n\n\n**What to do if results are abnormal:**\n\n\n- Use\tnon-pharmacological\tinterventions\tconcurrently\twith\tstatins\n- Improve\tblood\tglucose\tcontrol\n- Reduce\tsaturated\tfat\tintake\n- Ensure\tregular\tindividualized\texercise\n- Reduce\tweight\tif\tindicated\n- Avoid\talcohol\tintake\tif\ttriglycerides\televated\n- Referral\tto\tdietitian\n- Discourage\tsmoking\n\n\n**Pharmacologic Therapy**\n\n\n- Statin\ttherapy\tis\tthe\tmainstay\tof\tPharmacologic\ttherapy\tfor\tany\tperson\twith type\t2\tdiabetes\t&gt;40\tyears\tregardless\tof\tlipid\tlevel.\tFor\tpatients\twith type 1 diabetes, statin therapy should be started in individuals not responding to lifestyle modification.\n- Fibrates\tmay\tbe\tused\tin\taddition\tfor\tpersistent\thypertriglyceridemia.\n- Nicotinic\tacid\tmay\tbe\tconsidered\tas\tan\talternative\ttherapy\n\n\n**Management**\n\n\n- Manage\tunderlying\tassociated\tcardiovascular\trisk\tfactors.\n- Life-style\tmodification\n- Initiate\taspirin\ttherapy\tif\tindicated\n- Consider\tthe\tuse\tof\tbeta-blockers,\tAngiotensin\tConverting\tEnzyme\t(ACE) inhibitors, Angiotensin Receptor Blockers (ARBs) and good glycaemic control post myocardial infarction.\n\n\n**Recommendation for use of Aspirin**\n\n\nThe use of low dose aspirin (75 mg or 81 mg) in people with Type 2 diabetes reduces cardiovascular events, and is indicated in the following:\n\n\n- Secondary\tprevention\tfor\tcoronary\tand\tcerebrovascular\tdiseases\n- Primary\tprevention\tfor\tpeople\twith\tType\t2\tdiabetes\tover\tthe\tage\tof\t40\tyears, having:\n- Family\thistory\tof\tischaemic\theart\tdisease\t(IHD)\n- Cigarette\tsmoking\n- Hypertension\n- Obesity\n- Proteinuria\n- Dyslipidaemia\n\n\nHowever, contraindications may prevent its use, especially the presence or history of peptic ulcers, dyspepsia, heartburn or bleeding and asthma.\n\n\nAspirin should not be used in uncontrolled and malignant hypertension of more than 160/100 mmHg.\n\n\nHemorrhagic stroke must be ruled out before initiating aspirin therapy in patients with acute cerebrovascular accident. The recommended daily dose is 75 -162 mg of aspirin per day.\n\n\nCHAPTER FOUR\n\n\nKENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS| 110\n\n\n",
        "startLine": 2606,
        "endLine": 3822,
        "introContent": null,
        "sections": [
          {
            "id": "section-3-1",
            "level": "h2",
            "number": "3.1",
            "title": "3.1. Introduction",
            "slug": "31-introduction",
            "url": "/guidelines/chapter-three-management-of-complications-and-comorbidities-in-diabetes-mellitus/31-introduction",
            "parentId": "chapter-3",
            "breadcrumb": [
              "CHAPTER THREE: MANAGEMENT OF COMPLICATIONS AND COMORBIDITIES IN DIABETES MELLITUS",
              "3.1. Introduction"
            ],
            "tokenCount": 169,
            "content": "## 3.1. Introduction\n\n\nDiabetes may present with both acute and chronic complications, and various comorbidities.\n\n\n- a. Acute complications include Diabetes Ketoacidosis, Hyperosmolar Hyper glycemic State, Hypoglycemia\n- b. Chronic complications may be categorized as micro and macrovascular\n- Microvascular\tinclude\tretinopathy,\tneuropathy, nephropathy, sexual dysfunction and diabetic foot\n- Macrovascular\tinclude\tcoronary\tartery\tdisease,\tstroke, peripheral  vascular disease and diabetic foot\n- Dental\tdisorders\n- c. Common comorbidities include hypertension, mental disorders and lipid disorders.\n\n\nThe above complications and comorbidities contribute to the high morbidity and mortality from diabetes mellitus. Most deaths resulting from diabetes are attributable to cardiovascular disease.\n\n\n",
            "startLine": 2609,
            "endLine": 2625,
            "introContent": null,
            "keywords": [],
            "subsections": null
          },
          {
            "id": "section-3-2",
            "level": "h2",
            "number": "3.2",
            "title": "3.2. Acute Complications",
            "slug": "32-acute-complications",
            "url": "/guidelines/chapter-three-management-of-complications-and-comorbidities-in-diabetes-mellitus/32-acute-complications",
            "parentId": "chapter-3",
            "breadcrumb": [
              "CHAPTER THREE: MANAGEMENT OF COMPLICATIONS AND COMORBIDITIES IN DIABETES MELLITUS",
              "3.2. Acute Complications"
            ],
            "tokenCount": 5576,
            "content": "## 3.2. Acute Complications\n\n\n### 3.2.1. Introduction\n\n\nThe acute metabolic emergencies of diabetes ketoacidosis, hyperosmolar hyperglycaemic state, hypoglycemia and lactic acidosis may present with coma or altered levels of consciousness in people living with diabetes. Other considerations include stroke, seizures, trauma, drug overdose, infection, and ethanol intoxication.\n\n\n### 3.2.2. Diabetic Ketoacidosis (DKA)\n\n\nDKA is one of the most serious metabolic emergencies in diabetes mellitus. It is more common in Type 1 diabetes, but may occur in patients with Type 2 diabetes (ketosis-prone type 2 diabetes).\n\n\nDefinition: Diabetic ketoacidosis (DKA) is an acute, major, life-threatening complication of diabetes characterized by hyperglycemia, ketoacidosis, and ketonuria. Diabetic Ketoacidosis is characterized by:\n\n\n- History\tof\tpolyuria,\tpolydipsia,\tabdominal\tpain,\tnausea,\tvomiting,\tmissed medication, failed insulin pump for those who use it, and intercurrent illness.\n- Clinical\tsigns:\tdehydration,\tlethargy,\ttachypnea,\tdeep\tbreathing (Kussmaul breathing), acetone breath.\n- Biochemical\tparameters:\n- a. Hyperglycemia\tof\t≥11.1\tmmol/L\t(May\trarely\tpresent\twith normal blood glucose)\n- b. Metabolic acidosis (PH&lt;7.3 and bicarbonate&lt; 15 mmol/L)\n- c. Ketonuria or presence of blood ketones.\n\n\n**Management of DKA**\n\n\nThe main stay of management of DKA is judicious use of insulin and rehydration for both Type 1 and 2 diabetes mellitus.\n\n\n**Management of DKA in Type 1 Diabetes**\n\n\nManaging Diabetic Ketoacidosis in Type 1 Diabetes includes the following components:\n\n\n1. Confirm the diagnosis\n\n\n| •                                     | Capillary blood glucose test > 11 mmol/L D   |\n|---------------------------------------|----------------------------------------------|\n| • Urinary or plasma ketones           | K                                            |\n| • pH < 7.3 or bicarbonate < 15 mmol/L | A                                            |\n\n\n**2. History and Examination**\n\n\n- Obtain\tas\tmuch\tinformation\tabout\tthe\tpatient's\tdiabetes\t(date\tof\tdiagnosis, medication, known complications etc.)\n- Identify\tany\tprecipitating\tcauses\t(change\tin\tinsulin,\tintercurrent\tinfection, myocardial infarction)\n- Assess\tthe\tdegree\tof\tdehydration\t(BP,\tcapillary\trefill\ttime,\ttissue\tturgor, temperature of extremities)\n- Assess\tlevel\tof\tconsciousness\tusing\tGlasgow\tComa\tScale\t(GCS)\n\n\n**3. Investigations**\n\n\n- •\n\n\n**Blood**\n\n\n- -Urea/electrolytes\n- -Glucose\n- -Bicarbonate\n- -Liver function tests\n- -Full blood count\n- -Arterial/ venous blood gases\n- -Cardiac enzymes\n- -Blood cultures\n- D\n\n\n- Chest\tradiograph\t(CXR)-\tpreferably\tportable\n- Electrocardiogram\t(ECG)\n- Cultures:\tMid-stream\turine\t(MSU)\tand\tother\tappropriate\tcultures e.g. cerebrospinal fluid (CSF) if meningitis suspected\n\n\n**4. Management (see flow chart)**\n\n\n- Fluids\tare\ta\tcritical\tpart\tof\ttreating\tDKA.\tAdults\twith\tDKA\tgenerally need an average of 6 Litres for adequate rehydration. Keep a fluid balance chart ± a urinary catheter if urine output is poor. Consider central venous pressure (CVP) monitoring if fluid status is difficult to assess clinically or likely to need intensive care unit (ICU) support\n- Insulin\tis\tneeded\tto\thelp\tswitch\tfrom\ta\tcatabolic\tto\tan\tanabolic\tstate which will result in uptake of glucose into tissues and the reduction of gluconeogenesis. The end-result is to switch off the production of free fatty acids and ketones.\n- Potassium\treplacement:\tHypokalemia\tand\thyperkalemia\tare\tpotentially life-threatening conditions that can occur during the treatment of DKA. Check potassium (K+) levels after 2 hours and at 4, 8,12,16 and 24 hours or until transfer to subcutaneous insulin. Check magnesium levels at 12-24 hours.\n- Oxygen:\tshould\tbe\tgiven\tand\toxygen\tsaturations\tmonitored.\tAim\tfor oxygen\tsaturations\t(SPO2)\t&gt;\t96%.\n- Nasogastric\ttube:\tshould\tbe\tinserted\tas\tgastric\tdilation\tis\tcommon with potential risk of aspiration\n- Conscious\tlevel:\tIf\tGCS\tis\treduced,\tposition\tthe\tpatient\tin\trecovery position and consider intubation for airway protection (intubate if the patient has GCS of less than 8)\n- Antibiotics\tif\tinfection\tsuspected\t(see\tantibiotic\tprotocol)\n- Heparin\tprophylaxis\n\n\nRemember to reassess the patient frequently during the first few hours (clinical status, volume status, hourly glucose tests, potassium and sodium, blood gases) and adjust management according to any clinical changes.\n\n\n**5. Cerebral oedema**\n\n\nCerebral oedema is a rare but often fatal complication of DKA.\n\n\nIt can be idiosyncratic, but its occurrence may be related to various factors including the degree of hyperglycaemia, acidosis, dehydration and electrolyte disturbance at presentation, as well as over-rapid correction of acidosis, dehydration or hyperglycaemia.\n\n\nThe rapidly rising intracranial pressure may present as change in neurological status (restlessness,  irritability,  increased  drowsiness,  incontinence,  seizures,  coma),  specific neurological signs (e.g. unreactive pupils, cranial nerve palsies) or abnormal respiratory pattern, decorticate posture). The Cushing's triad (bradycardia, hypertension and wide pulse pressure) is a late presentation.\n\n\n**If cerebral oedema is suspected TREAT URGENTLY:**\n\n\n- Hypoglycemia\tas\ta\tcause\tof\tthe\tchange\tin\tneurological\tstate.\n- Reduce\tthe\trate\tof\tfluid\tadministration\tby\tone-third\n- Give\tmannitol\t0.5-1\tg/kg\tIV\tover\t10-15\tminutes,\tand\trepeat\tif\tthere\tis\tno\tinitial response in 30 minutes to 2 hours.\n- Hypertonic\tsaline\t(3%)\t2.5-5\tml/kg\tover\t10-15\tminutes\tmay\tbe\tan\talternative\tto mannitol, especially if there is no initial response to mannitol.\n- Elevate\tthe\thead\tof\tthe\tbed.\n- Intubation\tmay\tbe\tnecessary\tfor\ta\tpatient\twith\timpending\trespiratory\tfailure.\n- After\ttreatment\thas\tbeen\tstarted,\tif\tavailable,\ta\tcranial\tCT\tscan\tshould\tbe\tdone to rule out other possible intracerebral causes of neurological deterioration, especially thrombosis or haemorrhage which may benefit from specific therapy.\n\n\nCerebral oedema is an unpredictable complication of DKA, often occurring when the general condition of the child has improved and monitoring is less strict. Survivors are often left with significant neurological deficits. Meticulous management of the DKA can decrease the risk of developing cerebral oedema. DKA should therefore be managed at the best available facility.\n\n\n**6. Monitoring**\n\n\nIf  biochemical parameters of DKA (pH, anion gap, urine ketones) do not improve, reassess patient, review insulin therapy, and consider other possible causes of impaired response to insulin, e.g. infection or errors in insulin preparation. Also consider that the primary illness may be a serious infection (such as malaria) with stress hyperglycaemia rather than diabetes\n\n\n- Mannitol\tor\thypertonic\tsaline\tshould\tbe\tavailable\tat\tthe\tbedside\tfor rapid treatment in case of cerebral oedema.\n- When\tthe\tchild\tstarts\ttaking\toral\tfluids,\tmake\tsure\tthe\tIV\trate\tof\tfluids\tis decreased accordingly, not to exceed the total hourly fluid input requirements.\n- This\tfluid\trestriction\tshould\tbe\tapplied\tfor\t48\thrs\tfrom\tadmission (72 hrs if  there is severe hyperglycaemia at onset of treatment).\n- If\treplacing\tfluid\torally,\tensure\tthat\tthe\tchild\thas\tORS\tor\tfruit\tjuice\tonce the glucose is below 15 mmol/l (270 mg/dl).\n\n\nOnce the urine ketones are absent, consider making the transition to subcutaneous (SC) insulin\n\n\n**7. Transitioning to subcutaneous insulin**\n\n\nOnce the DKA has been adequately treated (hydration corrected, glucose controlled, ketones cleared) the patient can be transitioned to subcutaneous insulin.\n\n\nThe first SC dose of short-acting insulin should be given 1-2 hours before stopping the insulin infusion.\n\n\nImportant: It is often easier to transition to subcutaneous insulin at the next mealtime.\n\n\nIf the child is newly diagnosed:\n\n\n- Pre-pubertal:\t0.5-0.75\tU/Kg/day\n- Pubertal:\t0.75-0.1\tU/Kg/day\n\n\nOtherwise determine insulin dose from consideration of the dose before admission.\n\n\n**Algorithim for the management of diabetic Ketoacidosis**\n\n\n![HGT-hourly glucose test, KCL-potassium chloride, S/C-subcutaneous](images/picture_043_page_80.png)\n\n\nHGT-hourly glucose test, KCL-potassium chloride, S/C-subcutaneous\n\n\nTable 26:  Fluid maintenance and replacement volumes based on body weight and assumption of 10% dehydration in DKA\n\n\n| Body weight kg   | Maintenance   | DKA: Give maintenance + 5% of body weight/24-hr   | DKA: Give maintenance + 5% of body weight/24-hr   |\n|------------------|---------------|---------------------------------------------------|---------------------------------------------------|\n| Body weight kg   | mL/24 hr      | mL/24hr                                           | mL/hr                                             |\n| 4                | 325           | 530                                               | 22                                                |\n| 5                | 405           | 650                                               | 27                                                |\n| 6                | 485           | 790                                               | 33                                                |\n| 7                | 570           | 920                                               | 38                                                |\n| 8                | 640           | 1040                                              | 43                                                |\n| 9                | 710           | 1160                                              | 48                                                |\n| 10               | 780           | 1280                                              | 53                                                |\n| 11               | 840           | 1390                                              | 58                                                |\n| 12               | 890           | 1490                                              | 62                                                |\n| 13               | 940           | 1590                                              | 66                                                |\n| 14               | 990           | 1690                                              | 70                                                |\n| 15               | 1030          | 1780                                              | 74                                                |\n| 16               | 1070          | 1870                                              | 78                                                |\n| 17               | 1120          | 1970                                              | 82                                                |\n| 18               | 1150          | 2050                                              | 85                                                |\n| 19               | 1190          | 2140                                              | 89                                                |\n| 20               | 1230          | 2230                                              | 93                                                |\n| 22               | 1300          | 2400                                              | 100                                               |\n| 24               | 1360          | 2560                                              | 107                                               |\n| 26               | 1430          | 2730                                              | 114                                               |\n| 28               | 1490          | 2890                                              | 120                                               |\n| 30               | 1560          | 3060                                              | 128                                               |\n| 32               | 1620          | 3220                                              | 134                                               |\n| 34               | 1680          | 3360                                              | 140                                               |\n| 36               | 1730          | 3460                                              | 144                                               |\n| 38               | 1790          | 3580                                              | 149                                               |\n| 40               | 1850          | 3700                                              | 154                                               |\n| 45               | 1980          | 3960                                              | 165                                               |\n| 50               | 2100          | 4200                                              | 175                                               |\n| 55               | 2210          | 4420                                              | 184                                               |\n| 60               | 2320          | 4640                                              | 193                                               |\n| 65               | 2410          | 4820                                              | 201                                               |\n| 70               | 2500          | 5000                                              | 208                                               |\n| 75               | 2590          | 5180                                              | 216                                               |\n| 80               | 2690          | 5380                                              | 224                                               |\n\n\n### 3.2.3. Diabetic Hyperosmolar Hyperglycaemic State\n\n\nHyperosmolar Hyperglycaemic State (HHS) is characterized by the slow development of marked\thyperglycaemia\t(usually\t&gt;\t30\tmmol/L\tor\t540\tmg/dl\tand\tusually\treading\t'unre -cordable' on the glucometer), dehydration and pre-renal azotemia (elevated blood urea and creatinine). Ketonuria may be slight or absent. Two-thirds of cases are in previously undiagnosed cases of diabetes.\n\n\nInfections, diuretic treatment, and drinking glucose-rich beverages, myocardial or cerebral ischemia may all be precipitating factors.\n\n\nThe condition usually affects middle- aged or elderly patients and carries a high mortality.\n\n\n**Treatment**\n\n\nInitial  treatment is the same as for Diabetic Ketoacidosis; but usually insulin requirements are lower than in DKA and individuals respond well to rehydration. Owing to its high mortality, immediate referral for relevant specialist care is recommended.\n\n\nECG should be done and Heparin/anti-thrombotic agents should be given in the absence of contraindications.\n\n\n### 3.2.4. Hypoglycemia\n\n\nHypoglycemia is a medical emergency and should be treated promptly if serious complications are to be avoided.\n\n\nIt is characterized by blood glucose levels &lt; 4 mmol/L. Some patients might experience hypoglycaemic symptoms at higher blood glucose levels and clinicians should individualize care.\n\n\n**The commonest causes of hypoglycemia are:**\n\n\n- Engaging\tin\tmore\texercise\tthan\tusual\n- Delay\tor\tomission\tof\ta\tsnack\tor\tmain\tmeal\n- Poor\tinjection\ttechnique\n- Insulin\toverdose\n- Eating\tinsufficient\tcarbohydrate\n- Excessive\tuse\tof\talcohol\n- Sulphonylureas\toverdose\n- Use\tof\tlong-acting\toral\tglucose-lowering\tagents\n- Herbal\tmedication\tcausing\tliver\tfailure\tin\tcombination\twith\tdiabetes medications\n\n\n**Presentation**\n\n\n- Severe\thunger\n- Sudden\tweakness\n- Cold\tclammy\tskin\n- Profuse\tsweating\n- Headache\n- Palpitations\n- Sudden\tcollapse-\tmore\tfrequent\tin\tType\t1\tDM\tor\twhere\tthere\tis\thypoglycaemic unawareness\n- Cerebral\tsigns/\tsymptoms-\tirritability,\tconfusion,\tdisorientation,\tcoma\n\n\n**Management**\n\n\n- Oral\tglucose\t/sweetened\tdrink-\twithout\tmilk\t(Not\tdiet\tdrink)\tif\tpatient\tis conscious.\n- If\tpatient\tis\tunconscious,\tIV\t50%\tglucose\tbolus\t(40\t-\t50\tml\tdiluted\twith\tequal volume normal saline) and followed by 10% glucose infusion if necessary. In children use 10% dextrose 2-5 ml/Kg.\n- Injectable\tglucagon\t1\tmg\tIM\tif\tavailable\tcan\talso\tbe\tadministered\tin unconscious patients.\n- On\trecovery,\tgive\ta\tlong-acting\tcarbohydrate\tsnack.\n- Prolonged\tIV\tdextrose\tinfusion\t(10%\tfor\t12\t-\t24\th.)\tmay\tbe\tnecessary\tif hypoglycemia is a result of long-acting sulphonylureas/ long and intermediate-acting insulin or alcohol.\n- If\tIV\taccess\tis\timpossible,\tconsider\tnasogastric\tglucose\n- On\trecovery,\tattempt\tto\tidentify\tthe\tcause\tof\thypoglycemia\tand\taddress\tit\n- Assess\tthe\ttype\tof\tinsulin\tused,\tinjection\tsites\t(since\tlipohypertrophy\tcan\talter the rate of absorption) and injection techniques.\n- Enquire\tinto\tand\taddress\tinappropriate\thabits\tof\teating,\texercise\tand\talcohol consumption.\n- Review\tof\tother\tdrug\ttherapy\tand\trenal\tfunction,\n- Adjustment\tof\tthe\tdosage\tof\tinsulin\tor\toral\tglucose-lowering\tagents\tif appropriate\n\n\nTable 27: Management of hypoglycaemia\n\n\n|                                                   | Blood glucose                 | Description                                                                                                          | Action                                                                                                                                                                                                                                                                                                                                                                                               |\n|---------------------------------------------------|-------------------------------|----------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Level 1 Hypoglycaemia alert                       | ≤ 3.9 mmol/L but ≥ 3.0 mmol/L | Requires treatment with fast-acting carbohydrate Patient alert and able to eat                                       | • Treat with oral glucose • Give a sugary snack and recheck blood glucose in 15 min • If blood glucose remains ≤ 3.9 mmol/L, repeat the previous step • Give a carbohydrate meal when blood glucose is ≥ 5.0 mmol/L                                                                                                                                                                                  |\n| Level 2 Clinically sig- nificant hypo - glycaemia | < 3.0 mmol/L                  | Indicates serious, clinically significant hypoglycaemia Patient may be alert or may have reduced conscious- ness     | • Treat with iv glucose • Give 10 ml 50% glucose iv and recheck blood glucose in 2 min • If blood glucose remains < 5mmol/L, repeat the previous step • Give an infusion of 10% glucose iv if more than 2 doses of iv glucose required • Give a carbohydrate meal when blood glucose is ≥ 5.0 mmol/L and the patient is alert and able to eat • Observe for 4 hrs, checking blood glucose every 1 hr |\n| Level 3 Severe hypogly- caemia                    | No specific value             | Associated with severe cognitive impairment requir- ing external help for recovery Patient has reduced consciousness | • Treat as for Level 2 hypoglycae - mia • Likely to need hospital admission                                                                                                                                                                                                                                                                                                                          |\n\n\nSource: Adapted from ADA Guidelines, 2018\n\n\n### 3.2.5. Sick Day Management\n\n\n**Introduction**\n\n\nAn inter-current illness can destabilize the metabolic state of a child or adult living with diabetes (especially type 1), leading to a hyperglycemic crisis, e.g. Diabetic ketoacidosis. Ailments that reduce intake significantly may also predispose to hypoglycemia. These can be prevented by certain simple steps highlighted as 'Sick Day Management' . The aim of the sick day management is prevention of diabetic ketoacidosis and hypoglycemia.\n\n\n**Metabolic Disturbance as a Result of Inter-Current Illness**\n\n\nThe stress factors, e.g. infection, inflammatory disease, injury, surgery, and severe emotional disturbances, result in the secretion of stress or counter-regulatory hormones: glucagon, growth hormone, epinephrine, and cortisol. Acting in synergy, these hormones create a state of insulin resistance, causing increased hepatic glucose production and reduced peripheral glucose utilization. Though calorie intake is low in illness, blood glucose levels increase and ketonaemia and ketonuria may occur.\n\n\nUnchecked, these metabolic disturbances may progress to full-blown diabetic ketoacidosis.\n\n\nSick day management thus serves to prevent ketoacidosis.\n\n\n**Principles of treatment**\n\n\n- Do\tnot\tstop\tInsulin\tbut\tadjust\taccording\tto\tindividualized\tneeds.\n- If\tsupplemental\tinsulin\tis\trequired,\tan\tadditional\t10%\t-\t20%\tof\tusual\tdaily\tdose may be safely given with monitoring (see table 23)\n- Treat\tunderlying\tillness.\n- Prevent\tdehydration.\n- Monitor\tblood\tglucose\tand\turine\tketones\tevery\t4\thours.\n- Watch\tout\tfor\tsymptoms\tthat\trequire\thospital\tcare\t(admission).\n- If\tblood\tglucose\tis\tlow,\tthe\tdose\tof\tinsulin\tshould\tbe\treduced.\n- Treat\tunderlying\tdisease:\tSeek\tmedical\tattention\tsooner\trather\tthan\tlater\n- Any\tunderlying\tillness\tshould\tbe\ttreated\ton\tits\tmerit\te.g.\tfor\tan\tinfection\tgive antibiotics.\n- One\tshould\tbe\tadvised\tto\trest\tand\tavoid\tstrenuous\texercise/activity.\n- Prevent\tdehydration.\tHigh\tfluid\tintake\tis\timportant\tto\tprevent\tdehydration. Fluids chosen should contain sodium and potassium to replace loss of these electrolytes as occurs in uncontrolled Diabetes: if one is not able to follow meal plan, use fluids with sugar to provide carbohydrate. Fluids can be oral rehydration salts, broth, (meat soup), fruit juice, regular soda.\n\n\nTable 28: Minimum amounts of fluid for oral rehydration\n\n\n| Volume per hour   | Volume per hour   | Volume per hour   | Volume per hour   |\n|-------------------|-------------------|-------------------|-------------------|\n| Age in years      | Weight in kg      | ml                | oz.               |\n| 5                 | 20                | 45 -90            | 1.5 - 3           |\n| 10                | 30                | 75 - 120          | 2.5 - 4           |\n| 15                | 55                | 120 - 240         | 4 - 8             |\n| 16+               | 56 +              | 240 - 300         | 8 - 10            |\n\n\nSource: Adapted from Challenges in diabetes management, Lifescan 1998.\n\n\n**Guidelines for regular insulin during sick days**\n\n\n**NB: Start with the usual dose**\n\n\n- Two-dose\ttreatment\t(NPH\t+\trapid-acting\tor\tshort-acting\tinsulin)\n- May\tchange\tit\tto\ta\t4-5-dose\tregimen,\textras\tbeing\tthe\trapid/\tshort\tacting insulin at 20 - 25% TDI\n- Or\tfollow\tthe\ttable\t(Table\t23)\n\n\nTable 29: Guidelines for supplemental regular insulin\n\n\n| BGin mmol/L   | 15-17   | 17-20   | >20     |\n|---------------|---------|---------|---------|\n| Age in years  |         |         |         |\n| 0 - 6         | 0.5-1U  | 1-2U    | 2-3U    |\n| 7 - 11        | 1-2U    | 2-3U    | 3-5U    |\n| 12 - 15       | 2-3U    | 3-4U    | 4-8U    |\n| > 16          | 3-4U    | 4-6U    | 6 - 12U |\n\n\nAdapted from IDF, 2014\n\n\n**Signs and symptoms that necessitate hospital care/admission**\n\n\n- If\tthe\tunderlying\tcondition\tis\tunclear,\tfever\tpersists,\tor\tfamily\tmembers\tare\tun comfortable providing home care for any reason\n- Weight\tloss\tcontinues\tsuggesting\tworsening\tdehydration\tand\tpotential circulatory compromise\n- Vomiting\tpersists\tbeyond\t2\thrs\t(particularly\tin\tyoung\tchildren)\n- Caregivers/patients\tare\tunable\tto\tkeep\tblood\tglucose\tabove\t3.5\tmmol/L\t(60 mg/dL)\n- Blood\tGlucose\tcontinues\tto\trise\tdespite\tsupplemental\tinsulin\n- Fruity\tbreath\todor\t(acetone)\tpersists\tor\tworsens\n- Ketonuria\tis\theavy\tand\tincreasing/persistent\tor\tblood\tketones\tare\t&gt;1.0-1.5 mmol/L\n- The\tpatient\tis\tbecoming\texhausted,\tconfused,\thyperventilating\t(Kussmaul breathing) or has severe abdominal pain\n- Change\tin\tneurologic\tstatus,\tmental\tconfusion,\tloss\tof\tconsciousness, seizures, progression of confusion may indicate impending or present cerebral edema; and treatment of cerebral edema is a medical emergency requiring immediate assistance with advanced medical facilities to prevent morbidity and mortality\n- The\tchild\tis\tvery\tyoung\t(less\tthan\t2-5\tyears)\n- Other\tco-morbidities\te.g.,\tepilepsy,\tmalaria\tor\tother\tinfections,\tor\tother diabetes related complications.\n- Patients/relatives\tare\texhausted,\tare\tnot\table\tto\tcommunicate\tdue\tto\tlanguage barrier or request emergency support.\n\n\nSick day management is vital in minimizing the impact of intercurrent illness. In many cases this prevents hospital admission and the accompanying costs, reducing not only the economic burden of diabetes; but also reducing the days lost because of illness. However, this is limited to those who can afford blood glucose machines and urine test strips, as well as to those patients who are highly motivated. With good education and motivation, most sick day episodes can thus be successfully managed at home or in a primary care setting.\n\n\n",
            "startLine": 2626,
            "endLine": 3022,
            "introContent": null,
            "keywords": [],
            "subsections": [
              {
                "id": "subsection-3-2-1",
                "level": "h3",
                "number": "3.2.1",
                "title": "3.2.1. Introduction",
                "slug": "321-introduction",
                "url": "/guidelines/32-acute-complications/321-introduction",
                "parentId": "section-3-2",
                "breadcrumb": [
                  "CHAPTER THREE: MANAGEMENT OF COMPLICATIONS AND COMORBIDITIES IN DIABETES MELLITUS",
                  "3.2. Acute Complications",
                  "3.2.1. Introduction"
                ],
                "tokenCount": 74,
                "content": "### 3.2.1. Introduction\n\n\nThe acute metabolic emergencies of diabetes ketoacidosis, hyperosmolar hyperglycaemic state, hypoglycemia and lactic acidosis may present with coma or altered levels of consciousness in people living with diabetes. Other considerations include stroke, seizures, trauma, drug overdose, infection, and ethanol intoxication.\n\n\n",
                "startLine": 2629,
                "endLine": 2634,
                "introContent": null,
                "keywords": [],
                "subsections": null
              },
              {
                "id": "subsection-3-2-2",
                "level": "h3",
                "number": "3.2.2",
                "title": "3.2.2. Diabetic Ketoacidosis (DKA)",
                "slug": "322-diabetic-ketoacidosis-dka",
                "url": "/guidelines/32-acute-complications/322-diabetic-ketoacidosis-dka",
                "parentId": "section-3-2",
                "breadcrumb": [
                  "CHAPTER THREE: MANAGEMENT OF COMPLICATIONS AND COMORBIDITIES IN DIABETES MELLITUS",
                  "3.2. Acute Complications",
                  "3.2.2. Diabetic Ketoacidosis (DKA)"
                ],
                "tokenCount": 2749,
                "content": "### 3.2.2. Diabetic Ketoacidosis (DKA)\n\n\nDKA is one of the most serious metabolic emergencies in diabetes mellitus. It is more common in Type 1 diabetes, but may occur in patients with Type 2 diabetes (ketosis-prone type 2 diabetes).\n\n\nDefinition: Diabetic ketoacidosis (DKA) is an acute, major, life-threatening complication of diabetes characterized by hyperglycemia, ketoacidosis, and ketonuria. Diabetic Ketoacidosis is characterized by:\n\n\n- History\tof\tpolyuria,\tpolydipsia,\tabdominal\tpain,\tnausea,\tvomiting,\tmissed medication, failed insulin pump for those who use it, and intercurrent illness.\n- Clinical\tsigns:\tdehydration,\tlethargy,\ttachypnea,\tdeep\tbreathing (Kussmaul breathing), acetone breath.\n- Biochemical\tparameters:\n- a. Hyperglycemia\tof\t≥11.1\tmmol/L\t(May\trarely\tpresent\twith normal blood glucose)\n- b. Metabolic acidosis (PH&lt;7.3 and bicarbonate&lt; 15 mmol/L)\n- c. Ketonuria or presence of blood ketones.\n\n\n**Management of DKA**\n\n\nThe main stay of management of DKA is judicious use of insulin and rehydration for both Type 1 and 2 diabetes mellitus.\n\n\n**Management of DKA in Type 1 Diabetes**\n\n\nManaging Diabetic Ketoacidosis in Type 1 Diabetes includes the following components:\n\n\n1. Confirm the diagnosis\n\n\n| •                                     | Capillary blood glucose test > 11 mmol/L D   |\n|---------------------------------------|----------------------------------------------|\n| • Urinary or plasma ketones           | K                                            |\n| • pH < 7.3 or bicarbonate < 15 mmol/L | A                                            |\n\n\n**2. History and Examination**\n\n\n- Obtain\tas\tmuch\tinformation\tabout\tthe\tpatient's\tdiabetes\t(date\tof\tdiagnosis, medication, known complications etc.)\n- Identify\tany\tprecipitating\tcauses\t(change\tin\tinsulin,\tintercurrent\tinfection, myocardial infarction)\n- Assess\tthe\tdegree\tof\tdehydration\t(BP,\tcapillary\trefill\ttime,\ttissue\tturgor, temperature of extremities)\n- Assess\tlevel\tof\tconsciousness\tusing\tGlasgow\tComa\tScale\t(GCS)\n\n\n**3. Investigations**\n\n\n- •\n\n\n**Blood**\n\n\n- -Urea/electrolytes\n- -Glucose\n- -Bicarbonate\n- -Liver function tests\n- -Full blood count\n- -Arterial/ venous blood gases\n- -Cardiac enzymes\n- -Blood cultures\n- D\n\n\n- Chest\tradiograph\t(CXR)-\tpreferably\tportable\n- Electrocardiogram\t(ECG)\n- Cultures:\tMid-stream\turine\t(MSU)\tand\tother\tappropriate\tcultures e.g. cerebrospinal fluid (CSF) if meningitis suspected\n\n\n**4. Management (see flow chart)**\n\n\n- Fluids\tare\ta\tcritical\tpart\tof\ttreating\tDKA.\tAdults\twith\tDKA\tgenerally need an average of 6 Litres for adequate rehydration. Keep a fluid balance chart ± a urinary catheter if urine output is poor. Consider central venous pressure (CVP) monitoring if fluid status is difficult to assess clinically or likely to need intensive care unit (ICU) support\n- Insulin\tis\tneeded\tto\thelp\tswitch\tfrom\ta\tcatabolic\tto\tan\tanabolic\tstate which will result in uptake of glucose into tissues and the reduction of gluconeogenesis. The end-result is to switch off the production of free fatty acids and ketones.\n- Potassium\treplacement:\tHypokalemia\tand\thyperkalemia\tare\tpotentially life-threatening conditions that can occur during the treatment of DKA. Check potassium (K+) levels after 2 hours and at 4, 8,12,16 and 24 hours or until transfer to subcutaneous insulin. Check magnesium levels at 12-24 hours.\n- Oxygen:\tshould\tbe\tgiven\tand\toxygen\tsaturations\tmonitored.\tAim\tfor oxygen\tsaturations\t(SPO2)\t&gt;\t96%.\n- Nasogastric\ttube:\tshould\tbe\tinserted\tas\tgastric\tdilation\tis\tcommon with potential risk of aspiration\n- Conscious\tlevel:\tIf\tGCS\tis\treduced,\tposition\tthe\tpatient\tin\trecovery position and consider intubation for airway protection (intubate if the patient has GCS of less than 8)\n- Antibiotics\tif\tinfection\tsuspected\t(see\tantibiotic\tprotocol)\n- Heparin\tprophylaxis\n\n\nRemember to reassess the patient frequently during the first few hours (clinical status, volume status, hourly glucose tests, potassium and sodium, blood gases) and adjust management according to any clinical changes.\n\n\n**5. Cerebral oedema**\n\n\nCerebral oedema is a rare but often fatal complication of DKA.\n\n\nIt can be idiosyncratic, but its occurrence may be related to various factors including the degree of hyperglycaemia, acidosis, dehydration and electrolyte disturbance at presentation, as well as over-rapid correction of acidosis, dehydration or hyperglycaemia.\n\n\nThe rapidly rising intracranial pressure may present as change in neurological status (restlessness,  irritability,  increased  drowsiness,  incontinence,  seizures,  coma),  specific neurological signs (e.g. unreactive pupils, cranial nerve palsies) or abnormal respiratory pattern, decorticate posture). The Cushing's triad (bradycardia, hypertension and wide pulse pressure) is a late presentation.\n\n\n**If cerebral oedema is suspected TREAT URGENTLY:**\n\n\n- Hypoglycemia\tas\ta\tcause\tof\tthe\tchange\tin\tneurological\tstate.\n- Reduce\tthe\trate\tof\tfluid\tadministration\tby\tone-third\n- Give\tmannitol\t0.5-1\tg/kg\tIV\tover\t10-15\tminutes,\tand\trepeat\tif\tthere\tis\tno\tinitial response in 30 minutes to 2 hours.\n- Hypertonic\tsaline\t(3%)\t2.5-5\tml/kg\tover\t10-15\tminutes\tmay\tbe\tan\talternative\tto mannitol, especially if there is no initial response to mannitol.\n- Elevate\tthe\thead\tof\tthe\tbed.\n- Intubation\tmay\tbe\tnecessary\tfor\ta\tpatient\twith\timpending\trespiratory\tfailure.\n- After\ttreatment\thas\tbeen\tstarted,\tif\tavailable,\ta\tcranial\tCT\tscan\tshould\tbe\tdone to rule out other possible intracerebral causes of neurological deterioration, especially thrombosis or haemorrhage which may benefit from specific therapy.\n\n\nCerebral oedema is an unpredictable complication of DKA, often occurring when the general condition of the child has improved and monitoring is less strict. Survivors are often left with significant neurological deficits. Meticulous management of the DKA can decrease the risk of developing cerebral oedema. DKA should therefore be managed at the best available facility.\n\n\n**6. Monitoring**\n\n\nIf  biochemical parameters of DKA (pH, anion gap, urine ketones) do not improve, reassess patient, review insulin therapy, and consider other possible causes of impaired response to insulin, e.g. infection or errors in insulin preparation. Also consider that the primary illness may be a serious infection (such as malaria) with stress hyperglycaemia rather than diabetes\n\n\n- Mannitol\tor\thypertonic\tsaline\tshould\tbe\tavailable\tat\tthe\tbedside\tfor rapid treatment in case of cerebral oedema.\n- When\tthe\tchild\tstarts\ttaking\toral\tfluids,\tmake\tsure\tthe\tIV\trate\tof\tfluids\tis decreased accordingly, not to exceed the total hourly fluid input requirements.\n- This\tfluid\trestriction\tshould\tbe\tapplied\tfor\t48\thrs\tfrom\tadmission (72 hrs if  there is severe hyperglycaemia at onset of treatment).\n- If\treplacing\tfluid\torally,\tensure\tthat\tthe\tchild\thas\tORS\tor\tfruit\tjuice\tonce the glucose is below 15 mmol/l (270 mg/dl).\n\n\nOnce the urine ketones are absent, consider making the transition to subcutaneous (SC) insulin\n\n\n**7. Transitioning to subcutaneous insulin**\n\n\nOnce the DKA has been adequately treated (hydration corrected, glucose controlled, ketones cleared) the patient can be transitioned to subcutaneous insulin.\n\n\nThe first SC dose of short-acting insulin should be given 1-2 hours before stopping the insulin infusion.\n\n\nImportant: It is often easier to transition to subcutaneous insulin at the next mealtime.\n\n\nIf the child is newly diagnosed:\n\n\n- Pre-pubertal:\t0.5-0.75\tU/Kg/day\n- Pubertal:\t0.75-0.1\tU/Kg/day\n\n\nOtherwise determine insulin dose from consideration of the dose before admission.\n\n\n**Algorithim for the management of diabetic Ketoacidosis**\n\n\n![HGT-hourly glucose test, KCL-potassium chloride, S/C-subcutaneous](images/picture_043_page_80.png)\n\n\nHGT-hourly glucose test, KCL-potassium chloride, S/C-subcutaneous\n\n\nTable 26:  Fluid maintenance and replacement volumes based on body weight and assumption of 10% dehydration in DKA\n\n\n| Body weight kg   | Maintenance   | DKA: Give maintenance + 5% of body weight/24-hr   | DKA: Give maintenance + 5% of body weight/24-hr   |\n|------------------|---------------|---------------------------------------------------|---------------------------------------------------|\n| Body weight kg   | mL/24 hr      | mL/24hr                                           | mL/hr                                             |\n| 4                | 325           | 530                                               | 22                                                |\n| 5                | 405           | 650                                               | 27                                                |\n| 6                | 485           | 790                                               | 33                                                |\n| 7                | 570           | 920                                               | 38                                                |\n| 8                | 640           | 1040                                              | 43                                                |\n| 9                | 710           | 1160                                              | 48                                                |\n| 10               | 780           | 1280                                              | 53                                                |\n| 11               | 840           | 1390                                              | 58                                                |\n| 12               | 890           | 1490                                              | 62                                                |\n| 13               | 940           | 1590                                              | 66                                                |\n| 14               | 990           | 1690                                              | 70                                                |\n| 15               | 1030          | 1780                                              | 74                                                |\n| 16               | 1070          | 1870                                              | 78                                                |\n| 17               | 1120          | 1970                                              | 82                                                |\n| 18               | 1150          | 2050                                              | 85                                                |\n| 19               | 1190          | 2140                                              | 89                                                |\n| 20               | 1230          | 2230                                              | 93                                                |\n| 22               | 1300          | 2400                                              | 100                                               |\n| 24               | 1360          | 2560                                              | 107                                               |\n| 26               | 1430          | 2730                                              | 114                                               |\n| 28               | 1490          | 2890                                              | 120                                               |\n| 30               | 1560          | 3060                                              | 128                                               |\n| 32               | 1620          | 3220                                              | 134                                               |\n| 34               | 1680          | 3360                                              | 140                                               |\n| 36               | 1730          | 3460                                              | 144                                               |\n| 38               | 1790          | 3580                                              | 149                                               |\n| 40               | 1850          | 3700                                              | 154                                               |\n| 45               | 1980          | 3960                                              | 165                                               |\n| 50               | 2100          | 4200                                              | 175                                               |\n| 55               | 2210          | 4420                                              | 184                                               |\n| 60               | 2320          | 4640                                              | 193                                               |\n| 65               | 2410          | 4820                                              | 201                                               |\n| 70               | 2500          | 5000                                              | 208                                               |\n| 75               | 2590          | 5180                                              | 216                                               |\n| 80               | 2690          | 5380                                              | 224                                               |\n\n\n",
                "startLine": 2635,
                "endLine": 2838,
                "introContent": null,
                "keywords": [],
                "subsections": null
              },
              {
                "id": "subsection-3-2-3",
                "level": "h3",
                "number": "3.2.3",
                "title": "3.2.3. Diabetic Hyperosmolar Hyperglycaemic State",
                "slug": "323-diabetic-hyperosmolar-hyperglycaemic-state",
                "url": "/guidelines/32-acute-complications/323-diabetic-hyperosmolar-hyperglycaemic-state",
                "parentId": "section-3-2",
                "breadcrumb": [
                  "CHAPTER THREE: MANAGEMENT OF COMPLICATIONS AND COMORBIDITIES IN DIABETES MELLITUS",
                  "3.2. Acute Complications",
                  "3.2.3. Diabetic Hyperosmolar Hyperglycaemic State"
                ],
                "tokenCount": 248,
                "content": "### 3.2.3. Diabetic Hyperosmolar Hyperglycaemic State\n\n\nHyperosmolar Hyperglycaemic State (HHS) is characterized by the slow development of marked\thyperglycaemia\t(usually\t&gt;\t30\tmmol/L\tor\t540\tmg/dl\tand\tusually\treading\t'unre -cordable' on the glucometer), dehydration and pre-renal azotemia (elevated blood urea and creatinine). Ketonuria may be slight or absent. Two-thirds of cases are in previously undiagnosed cases of diabetes.\n\n\nInfections, diuretic treatment, and drinking glucose-rich beverages, myocardial or cerebral ischemia may all be precipitating factors.\n\n\nThe condition usually affects middle- aged or elderly patients and carries a high mortality.\n\n\n**Treatment**\n\n\nInitial  treatment is the same as for Diabetic Ketoacidosis; but usually insulin requirements are lower than in DKA and individuals respond well to rehydration. Owing to its high mortality, immediate referral for relevant specialist care is recommended.\n\n\nECG should be done and Heparin/anti-thrombotic agents should be given in the absence of contraindications.\n\n\n",
                "startLine": 2839,
                "endLine": 2859,
                "introContent": null,
                "keywords": [],
                "subsections": null
              },
              {
                "id": "subsection-3-2-4",
                "level": "h3",
                "number": "3.2.4",
                "title": "3.2.4. Hypoglycemia",
                "slug": "324-hypoglycemia",
                "url": "/guidelines/32-acute-complications/324-hypoglycemia",
                "parentId": "section-3-2",
                "breadcrumb": [
                  "CHAPTER THREE: MANAGEMENT OF COMPLICATIONS AND COMORBIDITIES IN DIABETES MELLITUS",
                  "3.2. Acute Complications",
                  "3.2.4. Hypoglycemia"
                ],
                "tokenCount": 1008,
                "content": "### 3.2.4. Hypoglycemia\n\n\nHypoglycemia is a medical emergency and should be treated promptly if serious complications are to be avoided.\n\n\nIt is characterized by blood glucose levels &lt; 4 mmol/L. Some patients might experience hypoglycaemic symptoms at higher blood glucose levels and clinicians should individualize care.\n\n\n**The commonest causes of hypoglycemia are:**\n\n\n- Engaging\tin\tmore\texercise\tthan\tusual\n- Delay\tor\tomission\tof\ta\tsnack\tor\tmain\tmeal\n- Poor\tinjection\ttechnique\n- Insulin\toverdose\n- Eating\tinsufficient\tcarbohydrate\n- Excessive\tuse\tof\talcohol\n- Sulphonylureas\toverdose\n- Use\tof\tlong-acting\toral\tglucose-lowering\tagents\n- Herbal\tmedication\tcausing\tliver\tfailure\tin\tcombination\twith\tdiabetes medications\n\n\n**Presentation**\n\n\n- Severe\thunger\n- Sudden\tweakness\n- Cold\tclammy\tskin\n- Profuse\tsweating\n- Headache\n- Palpitations\n- Sudden\tcollapse-\tmore\tfrequent\tin\tType\t1\tDM\tor\twhere\tthere\tis\thypoglycaemic unawareness\n- Cerebral\tsigns/\tsymptoms-\tirritability,\tconfusion,\tdisorientation,\tcoma\n\n\n**Management**\n\n\n- Oral\tglucose\t/sweetened\tdrink-\twithout\tmilk\t(Not\tdiet\tdrink)\tif\tpatient\tis conscious.\n- If\tpatient\tis\tunconscious,\tIV\t50%\tglucose\tbolus\t(40\t-\t50\tml\tdiluted\twith\tequal volume normal saline) and followed by 10% glucose infusion if necessary. In children use 10% dextrose 2-5 ml/Kg.\n- Injectable\tglucagon\t1\tmg\tIM\tif\tavailable\tcan\talso\tbe\tadministered\tin unconscious patients.\n- On\trecovery,\tgive\ta\tlong-acting\tcarbohydrate\tsnack.\n- Prolonged\tIV\tdextrose\tinfusion\t(10%\tfor\t12\t-\t24\th.)\tmay\tbe\tnecessary\tif hypoglycemia is a result of long-acting sulphonylureas/ long and intermediate-acting insulin or alcohol.\n- If\tIV\taccess\tis\timpossible,\tconsider\tnasogastric\tglucose\n- On\trecovery,\tattempt\tto\tidentify\tthe\tcause\tof\thypoglycemia\tand\taddress\tit\n- Assess\tthe\ttype\tof\tinsulin\tused,\tinjection\tsites\t(since\tlipohypertrophy\tcan\talter the rate of absorption) and injection techniques.\n- Enquire\tinto\tand\taddress\tinappropriate\thabits\tof\teating,\texercise\tand\talcohol consumption.\n- Review\tof\tother\tdrug\ttherapy\tand\trenal\tfunction,\n- Adjustment\tof\tthe\tdosage\tof\tinsulin\tor\toral\tglucose-lowering\tagents\tif appropriate\n\n\nTable 27: Management of hypoglycaemia\n\n\n|                                                   | Blood glucose                 | Description                                                                                                          | Action                                                                                                                                                                                                                                                                                                                                                                                               |\n|---------------------------------------------------|-------------------------------|----------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Level 1 Hypoglycaemia alert                       | ≤ 3.9 mmol/L but ≥ 3.0 mmol/L | Requires treatment with fast-acting carbohydrate Patient alert and able to eat                                       | • Treat with oral glucose • Give a sugary snack and recheck blood glucose in 15 min • If blood glucose remains ≤ 3.9 mmol/L, repeat the previous step • Give a carbohydrate meal when blood glucose is ≥ 5.0 mmol/L                                                                                                                                                                                  |\n| Level 2 Clinically sig- nificant hypo - glycaemia | < 3.0 mmol/L                  | Indicates serious, clinically significant hypoglycaemia Patient may be alert or may have reduced conscious- ness     | • Treat with iv glucose • Give 10 ml 50% glucose iv and recheck blood glucose in 2 min • If blood glucose remains < 5mmol/L, repeat the previous step • Give an infusion of 10% glucose iv if more than 2 doses of iv glucose required • Give a carbohydrate meal when blood glucose is ≥ 5.0 mmol/L and the patient is alert and able to eat • Observe for 4 hrs, checking blood glucose every 1 hr |\n| Level 3 Severe hypogly- caemia                    | No specific value             | Associated with severe cognitive impairment requir- ing external help for recovery Patient has reduced consciousness | • Treat as for Level 2 hypoglycae - mia • Likely to need hospital admission                                                                                                                                                                                                                                                                                                                          |\n\n\nSource: Adapted from ADA Guidelines, 2018\n\n\n",
                "startLine": 2860,
                "endLine": 2924,
                "introContent": null,
                "keywords": [],
                "subsections": null
              },
              {
                "id": "subsection-3-2-5",
                "level": "h3",
                "number": "3.2.5",
                "title": "3.2.5. Sick Day Management",
                "slug": "325-sick-day-management",
                "url": "/guidelines/32-acute-complications/325-sick-day-management",
                "parentId": "section-3-2",
                "breadcrumb": [
                  "CHAPTER THREE: MANAGEMENT OF COMPLICATIONS AND COMORBIDITIES IN DIABETES MELLITUS",
                  "3.2. Acute Complications",
                  "3.2.5. Sick Day Management"
                ],
                "tokenCount": 1486,
                "content": "### 3.2.5. Sick Day Management\n\n\n**Introduction**\n\n\nAn inter-current illness can destabilize the metabolic state of a child or adult living with diabetes (especially type 1), leading to a hyperglycemic crisis, e.g. Diabetic ketoacidosis. Ailments that reduce intake significantly may also predispose to hypoglycemia. These can be prevented by certain simple steps highlighted as 'Sick Day Management' . The aim of the sick day management is prevention of diabetic ketoacidosis and hypoglycemia.\n\n\n**Metabolic Disturbance as a Result of Inter-Current Illness**\n\n\nThe stress factors, e.g. infection, inflammatory disease, injury, surgery, and severe emotional disturbances, result in the secretion of stress or counter-regulatory hormones: glucagon, growth hormone, epinephrine, and cortisol. Acting in synergy, these hormones create a state of insulin resistance, causing increased hepatic glucose production and reduced peripheral glucose utilization. Though calorie intake is low in illness, blood glucose levels increase and ketonaemia and ketonuria may occur.\n\n\nUnchecked, these metabolic disturbances may progress to full-blown diabetic ketoacidosis.\n\n\nSick day management thus serves to prevent ketoacidosis.\n\n\n**Principles of treatment**\n\n\n- Do\tnot\tstop\tInsulin\tbut\tadjust\taccording\tto\tindividualized\tneeds.\n- If\tsupplemental\tinsulin\tis\trequired,\tan\tadditional\t10%\t-\t20%\tof\tusual\tdaily\tdose may be safely given with monitoring (see table 23)\n- Treat\tunderlying\tillness.\n- Prevent\tdehydration.\n- Monitor\tblood\tglucose\tand\turine\tketones\tevery\t4\thours.\n- Watch\tout\tfor\tsymptoms\tthat\trequire\thospital\tcare\t(admission).\n- If\tblood\tglucose\tis\tlow,\tthe\tdose\tof\tinsulin\tshould\tbe\treduced.\n- Treat\tunderlying\tdisease:\tSeek\tmedical\tattention\tsooner\trather\tthan\tlater\n- Any\tunderlying\tillness\tshould\tbe\ttreated\ton\tits\tmerit\te.g.\tfor\tan\tinfection\tgive antibiotics.\n- One\tshould\tbe\tadvised\tto\trest\tand\tavoid\tstrenuous\texercise/activity.\n- Prevent\tdehydration.\tHigh\tfluid\tintake\tis\timportant\tto\tprevent\tdehydration. Fluids chosen should contain sodium and potassium to replace loss of these electrolytes as occurs in uncontrolled Diabetes: if one is not able to follow meal plan, use fluids with sugar to provide carbohydrate. Fluids can be oral rehydration salts, broth, (meat soup), fruit juice, regular soda.\n\n\nTable 28: Minimum amounts of fluid for oral rehydration\n\n\n| Volume per hour   | Volume per hour   | Volume per hour   | Volume per hour   |\n|-------------------|-------------------|-------------------|-------------------|\n| Age in years      | Weight in kg      | ml                | oz.               |\n| 5                 | 20                | 45 -90            | 1.5 - 3           |\n| 10                | 30                | 75 - 120          | 2.5 - 4           |\n| 15                | 55                | 120 - 240         | 4 - 8             |\n| 16+               | 56 +              | 240 - 300         | 8 - 10            |\n\n\nSource: Adapted from Challenges in diabetes management, Lifescan 1998.\n\n\n**Guidelines for regular insulin during sick days**\n\n\n**NB: Start with the usual dose**\n\n\n- Two-dose\ttreatment\t(NPH\t+\trapid-acting\tor\tshort-acting\tinsulin)\n- May\tchange\tit\tto\ta\t4-5-dose\tregimen,\textras\tbeing\tthe\trapid/\tshort\tacting insulin at 20 - 25% TDI\n- Or\tfollow\tthe\ttable\t(Table\t23)\n\n\nTable 29: Guidelines for supplemental regular insulin\n\n\n| BGin mmol/L   | 15-17   | 17-20   | >20     |\n|---------------|---------|---------|---------|\n| Age in years  |         |         |         |\n| 0 - 6         | 0.5-1U  | 1-2U    | 2-3U    |\n| 7 - 11        | 1-2U    | 2-3U    | 3-5U    |\n| 12 - 15       | 2-3U    | 3-4U    | 4-8U    |\n| > 16          | 3-4U    | 4-6U    | 6 - 12U |\n\n\nAdapted from IDF, 2014\n\n\n**Signs and symptoms that necessitate hospital care/admission**\n\n\n- If\tthe\tunderlying\tcondition\tis\tunclear,\tfever\tpersists,\tor\tfamily\tmembers\tare\tun comfortable providing home care for any reason\n- Weight\tloss\tcontinues\tsuggesting\tworsening\tdehydration\tand\tpotential circulatory compromise\n- Vomiting\tpersists\tbeyond\t2\thrs\t(particularly\tin\tyoung\tchildren)\n- Caregivers/patients\tare\tunable\tto\tkeep\tblood\tglucose\tabove\t3.5\tmmol/L\t(60 mg/dL)\n- Blood\tGlucose\tcontinues\tto\trise\tdespite\tsupplemental\tinsulin\n- Fruity\tbreath\todor\t(acetone)\tpersists\tor\tworsens\n- Ketonuria\tis\theavy\tand\tincreasing/persistent\tor\tblood\tketones\tare\t&gt;1.0-1.5 mmol/L\n- The\tpatient\tis\tbecoming\texhausted,\tconfused,\thyperventilating\t(Kussmaul breathing) or has severe abdominal pain\n- Change\tin\tneurologic\tstatus,\tmental\tconfusion,\tloss\tof\tconsciousness, seizures, progression of confusion may indicate impending or present cerebral edema; and treatment of cerebral edema is a medical emergency requiring immediate assistance with advanced medical facilities to prevent morbidity and mortality\n- The\tchild\tis\tvery\tyoung\t(less\tthan\t2-5\tyears)\n- Other\tco-morbidities\te.g.,\tepilepsy,\tmalaria\tor\tother\tinfections,\tor\tother diabetes related complications.\n- Patients/relatives\tare\texhausted,\tare\tnot\table\tto\tcommunicate\tdue\tto\tlanguage barrier or request emergency support.\n\n\nSick day management is vital in minimizing the impact of intercurrent illness. In many cases this prevents hospital admission and the accompanying costs, reducing not only the economic burden of diabetes; but also reducing the days lost because of illness. However, this is limited to those who can afford blood glucose machines and urine test strips, as well as to those patients who are highly motivated. With good education and motivation, most sick day episodes can thus be successfully managed at home or in a primary care setting.\n\n\n",
                "startLine": 2925,
                "endLine": 3022,
                "introContent": null,
                "keywords": [],
                "subsections": null
              }
            ]
          },
          {
            "id": "section-3-3",
            "level": "h2",
            "number": "3.3",
            "title": "3.3. Chronic Complications of Diabetes",
            "slug": "33-chronic-complications-of-diabetes",
            "url": "/guidelines/chapter-three-management-of-complications-and-comorbidities-in-diabetes-mellitus/33-chronic-complications-of-diabetes",
            "parentId": "chapter-3",
            "breadcrumb": [
              "CHAPTER THREE: MANAGEMENT OF COMPLICATIONS AND COMORBIDITIES IN DIABETES MELLITUS",
              "3.3. Chronic Complications of Diabetes"
            ],
            "tokenCount": 6193,
            "content": "## 3.3. Chronic Complications of Diabetes\n\n\n### 3.3.1. Macrovascular Complications\n\n\nThe risk of CVD for people with type 2 diabetes is increased by two to three times for men and three to five times for women compared with people without diabetes. Outcomes following myocardial infarction, stroke or revascularization are also worse in people living with diabetes compared to individuals without diabetes. Atherosclerosis is often accelerated, severe and diffuse in diabetes. Chronic hyperglycaemia is an additional risk factor for atherosclerosis in patients with diabetes and adds to the well-known standard risk factor burden of race, gender, hypertension, dyslipidaemia, smoking, social deprivation and obesity. Table 24 summarizes the traditional modifiable risk factors for CVD and the recommended target values in diabetes.\n\n\nTable 30: CVD risk factors and targets for type 2 diabetes\n\n\n| Traditional CVD risk factors   | Targets                                                          |\n|--------------------------------|------------------------------------------------------------------|\n| Cigarette smoking              | Cessation                                                        |\n| Dyslipidaemia                  |                                                                  |\n| - Total cholesterol            | <4.5 mmol/L                                                      |\n| - LDLcholesterol               | <1.8 mmol/L                                                      |\n| - HDLcholesterol               | > 1.0 mmol/L (men) >1.2 mmol/L (women)                           |\n| - Triglycerides                | <1.7 mmol/L                                                      |\n| Obesity                        |                                                                  |\n| - Waist circumference          | <94 cm (men); <90 cm (men of South Asian descent) <80 cm (women) |\n| - Body mass index              | <25 kg/m2                                                        |\n| Hypertension                   |                                                                  |\n| - Systolic blood pressure      | <140 mmHg                                                        |\n| - Diastolic blood pressure     | <80 mmHg                                                         |\n\n\n**Two major processes lead to cardiovascular disease:**\n\n\n- Atherosclerosis,\tand\n- Hypertension\n\n\n**The clinical spectrum of cardiovascular disease is:**\n\n\n- a. Coronary artery disease\n- b. Cerebrovascular disease\n- c. Peripheral vascular disease\n\n\n**Coronary artery disease**\n\n\nCoronary artery disease (CAD) is the cause of death in more than half of all diabetic patients. Patients with diabetes but without other conventional risk factors for atherosclerosis have a risk of death from CAD 2- 4 times that of age-matched controls. Those with type 2 diabetes commonly have other associated risk factors, such as hypertension or hyperlipidemia, thus further increasing their cardiovascular risk. Women living with diabetes are at increased risk, with a risk of cardiovascular death up to 7.5 times that of women without diabetes. Individuals with diabetes and CAD fare worse than do other patients with CAD. These patients present with:\n\n\n- Chest\tpain\t(angina):\t-this\tcan\tbe\ta\tmild,\tuncomfortable\tfeeling,\tsimilar\tto\tin -digestion. However, a severe angina attack can cause a painful feeling of heaviness or tightness, usually in the centre of the chest, which may spread to the arms, neck, jaw, back or stomach. Angina is often triggered by physical activity or stressful situations.\n- Lightheadedness\n- Sweating\n- Nausea\n- Breathlessness\n\n\nThose who present with a myocardial infarction (MI) are at increased risk of dying from their event or of developing heart failure. They benefit less from therapies such as thrombolysis in the setting of an acute MI. Therefore, early detection of CAD is important to ensure that medical interventions to improve outcome are instituted.\n\n\n**The spectrum of coronary artery disease includes: -**\n\n\n- Angina\t(which\tmay\tbe\tsilent).\n- Acute\tcoronary\tsyndrome.\n- Congestive\tcardiac\tfailure.\n- Sudden\tdeath.\n\n\n**Silent ischemia**\n\n\nSilent ischemia is a particular concern in diabetic patients. Clinically, patients with diabetes are more likely to be without chest pain in the setting of unstable angina or MI, and thus late presentation contributes to a higher mortality in these patients. People with diabetes may also be less likely to experience exertional angina or chest pain with exercise testing, thus potentially increasing the difficulty of diagnosing significant CAD. This may further increase diabetic patients' risk in terms of late diagnosis and presentation.\n\n\n**Cerebrovascular disease**\n\n\nCerebrovascular complications make diabetic patients 2-6 times more susceptible to a stroke event. The risk is further increased in the DM patients who also have hyperlipidemia or hypertension. The cerebrovascular risk increases by 2-3-fold in type 2 DM patients with elevated systolic blood pressure. In addition, when patients with diabetes\n\n\nand hyperglycemia experience an acute ischemic stroke they are more likely to die or be severely disabled and less likely to benefit from the thrombolytic therapy.\n\n\n**Cerebrovascular diseases in diabetes can present either as:**\n\n\n- i. Stroke\n- ii. Transient ischaemic attack\n- iii. Cognitive impairment/dementia\n\n\n**Stroke**\n\n\nStroke refers to the partial or complete interruption of blood supply to the brain resulting in brain ischemia. The manifestations of stroke typically last longer than 24 hours. There are two main forms of stroke: -\n\n\n- a. Ischemic stroke: Occurs when there is occlusion (blockage) to the blood vessels supplying the brain by a thrombus or embolus. It is the more common form of stroke in diabetics.\n- b. hemorrhagic stroke: Occurs when a weakened blood vessel bursts or ruptures leading to an intracranial bleed. Common in individuals with uncontrolled hypertension.\n\n\n**Symptoms of stroke include:**\n\n\n- Sudden\tnumbness\tor\tweakness\tin\tthe\tface,\tarm,\tor\tleg,\tespecially\ton one side of the body\n- Sudden\tconfusion,\ttrouble\tspeaking,\tor\tdifficulty\tunderstanding\tspeech\n- Sudden\ttrouble\tseeing\tin\tone\tor\tboth\teyes\n- Sudden\ttrouble\twalking,\tdizziness,\tloss\tof\tbalance,\tor\tlack\tof coordination\n- Sudden\tsevere\theadache\twith\tno\tknown\tcause\n- c. Transient Ischaemic Attack (TIA): Transient ischaemic attack refers to temporary obstruction of blood supply to the brain. Symptoms mimic those of stroke, but typically last less than 24 hours.\n- d. Cognitive impairment: Diabetes increases the risk of developing cognitive decline and dementia, including vascular dementia and Alzheimer's disease (AD) especially in the elderly\n\n\n**Evaluation for Cerebrovascular disease will include: -**\n\n\n- Carotid\tDoppler\n- MRI\tand\n- MRI\tangiography\twhere\tindicated.\n\n\n**Treatment**\n\n\nThe treatment of the cerebrovascular disease in DM patients is divided into three levels:\n\n\n- i. First level: to prevent the brain vessels complications by adequately controlling the blood glucose when the patients are at the stage of insulin resistance or at the early stage of diabetes; to reduce the risk factors caused by the hyperglycemia\n\n\n- a. Lifestyle modification-smoking cessation, diet and physical activity\n- b. Glycemic control: OGLAs/insulin therapy\n- c. Anti-platelet therapy\n- d. Blood pressure control\n- e. Treatment of dyslipidemia: statins\n- ii. Second level: to control glucose intensively after the cerebrovascular diseases occur in DM patients. The blood pressure should be reduced to the normal range to avoid the vasculopathy-induced stroke.\n- iii. Tertiary prevention: to improve the cerebral circulation after the stroke in DM patients. The patients with ischemic stroke should be treated by thrombolytic therapy in the early phase of hyper-acute cerebral infarction\n\n\n**Peripheral vascular disease (PVD)**\n\n\nPVD is a common cardiovascular complication in persons living with diabetes. In contrast to PVD in non-diabetic individuals, it is more prevalent and, because of the involvement of the distal territory of vessels and its association with peripheral neuropathy, it is more commonly asymptomatic.\n\n\nPatients with PVD and diabetes thus may present later with more severe disease and have a greater risk of amputation. Moreover, the presence of PVD is a marker of excess cardiovascular risk.\n\n\nIt is important to diagnose PVD in patients with diabetes to elicit symptoms, prevent disability and limb loss, and identify a patient at high risk of MI, stroke, and death.\n\n\n**The clinical spectrum of PVD include: -**\n\n\n- i. Intermittent claudication-defined as pain, cramping, or aching in the calves, thighs, or buttocks that appears reproducibly with walking exercise and is relieved by rest.\n- ii. Critical Limb Ischemia-this is a triad characterized by: -\n- Rest\tpain\n- Foot\tulcers:\tthese\tischemic\tulcers\ttypically\tpresent\ton\tthe\tlateral surface of the ankle or the distal digits\n- Gangrene\n\n\n**Peripheral signs of peripheral vascular disease are the classic 'five P's,':**\n\n\n- Pulselessness\n- Paralysis\n- Paresthesia\n- Pain\n- Pallor\n\n\nThe assessment of PVD in patients with diabetes should include a thorough medical history and physical examination to identify those patients with risk factors, symptoms and signs of PVD.\n\n\n- Walking\thistory\tto\telicit\tclaudication\tsymptoms\n- Foot\tinspection-\tabsence\tof\thair\tgrowth,\tpallor\ton\televation,\tcool\tand dry\n\n\nfissured skin, fissures and ulcerations in the interdigital spaces\n\n\n- Palpation\tof\tperipheral\tpulses\t(femoral,\tpopliteal\tand\tdorsalis\tpedis pulses)\n\n\nThe diagnosis is made with a determination of the ABI. It is recommended that patients with\tdiabetes\twho\tare\t&gt;\t50\tyears\tof\tage\thave\tan\tABI\tperformed.\tAn\tABI\tis\talso\tuseful\tin patients with other PVD risk factors and in those with symptoms.\n\n\nFigure 22: How to perform an ankle-branchial index Source: National Heart Lung and Blood Institute (NIH) - National Heart Lung and Blood Institute (NIH)\n\n\n![KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS| 92](images/picture_044_page_92.png)\n\n\n**The diagnostic criteria for PVD based on the ABI are interpreted as follows:**\n\n\nTable 31: Interpretation of ankle-brachial index (ABI) values\n\n\n| ABI reading   | Interpretation       |\n|---------------|----------------------|\n| 0.91-1.30     | Normal               |\n| 0.70-0.90     | Mild obstruction     |\n| 0.40-0.69     | Moderate obstruction |\n| < 0.40        | Severe obstruction   |\n| > 1.30        | Poorly compressible  |\n\n\nAn\tABI\tvalue\t&gt;\t1.3\tsuggests\tpoorly\tcompressible\tarteries\tat\tthe\tankle\tlevel\tdue\tto\tthe presence of medial arterial calcification. This renders the diagnosis of PVD by ABI alone less reliable.\n\n\nIn addition to ABI, evaluation for peripheral vascular disease should also include Doppler and angiography of the lower limbs.\n\n\n**Treatment of the patient with diabetes and PVD should be two-fold:**\n\n\n- i. Primary and secondary risk modification\n2. -Cigarette smoking cessation,\n3. -Glycemic control\n4. -Treatment of hypertension\n5. -Treatment of dyslipidemia\n6. -Anti-platelet therapy (aspirin, clopidogrel)\n- ii. Treatment of PVD symptoms (claudication and critical limb ischemia) and limiting progression of disease\n8. -Exercise rehabilitation\n9. -Pharmacologic therapy (e.g. Pentoxifylline, cilostazol)\n10. -Wound care (debridement, offloading the ulcers, appropriate dressings, treatment of infections)\n11. -Revascularization (for patients with debilitating claudication or CLI)\n\n\n**Follow-up considerations: Cardiovascular complications in DM patients**\n\n\n- Initial\tassessment\tfor\tcardiovascular\trisk\tshould\tbe\tdone\tin\tall\tdiabetic\tpatients, and annually thereafter.\n- The\tassessment\tshould\tbe\tmore\tfrequent\tif\tthe\tpatient\thas\thad\ta cardiovascular   event (Refer to ESH/ESC CVD risk stratification tool in ANNEX I).\n- Referral\tfor\tspecialist\tcare\tis\trequired\tin\tpeople\tpresenting\twith\ttypical\tand atypical symptoms of angina, features of congestive cardiac failure, unexplained breathlessness, cardiomegaly, arrhythmias, transient ischaemic attacks or intermittent claudication of the legs.\n\n\n### 3.3.2. Chronic Microvascular Complications\n\n\nMicrovascular complications involve the kidney, eyes, lower extremities. They may be present at the time of diagnosis of diabetes as the detection of the disease is frequently delayed. Most of these complications can be prevented or their progression delayed by optimal treatment of hyperglycaemia and hypertension.\n\n\nScreening for the complications and prompt interventions reduce the risk of major outcomes such as blindness, nephropathy, and leg amputations.\n\n\n**Diabetes Nephropathy**\n\n\nDiabetes is one of the most common causes of chronic kidney disease. In Africa, there is a high morbidity and economic burden in patients with end-stage renal disease due to late presentation, delayed diagnosis and limited access to renal replacement therapy.\n\n\nDiabetes nephropathy progresses from subclinical disease to microalbuminuria. Persistent microalbuminuria is a marker for the development of overt nephropathy in diabetes as well as being a well-established marker of increased cardiovascular risk. Patients with microalbuminuria\twho\tprogress\tto\tmacro-albuminuria\t(&gt;\t300\tmg/24\th.)\tare\tlikely\tto\tprogress to end-stage renal disease. Intervention at the stage of microalbuminuria can retard the progression to end-stage renal disease.\n\n\n**Who should be screened?**\n\n\n- Patients\twith\tType\t1\tdiabetes\tfor\ta\tduration\tof\t&gt;5\tyears\n- Patients\twith\tType\t2\tdiabetes\tat\tdiagnosis\n\n\n**Detection and surveillance**\n\n\n- Check\tfor\tproteinuria\tyearly\tusing\treagent\tstrips.\n- For\tpatients\twho\ttest\tpositive,\texclude\turinary\ttract\tinfections\tby using urine strips to check for nitrites and leucocytes or urine microscopy and culture and treat infection if present.\n- During\tthe\tnext\tvisit,\tcheck\tfor\tpresence\tof\tinfection,\tif\tnone\ttest\tfor proteinuria. If proteinuria (trace or greater) is present and there is no infection, refer for renal evaluation.\n- For\tpatients\twho\ttest\tnegative\tfor\tproteinuria\tcheck\tfor\tmicroalbuminuria annually using reagent strips or the albumin-creatinine ratio.\n- If\tnegative,\trepeat\ttest\tannually.\tIf\tpositive,\ttest\tsample\tat\tleast\tone\tto\ttwo times within 3 to 6 months to confirm microalbuminuria. If confirmed, start ACEI or ARB treatment and optimize blood pressure control to less than 125/75 mmHg.\n- Measure\tserum\tcreatinine\tbi-annually,\tand\tif\traised\tor\trising,\trefer\tfor\trenal evaluation.\n\n\n**Frequency of screening**\n\n\nTable 32: Frequency of screening for diabetic nephropathy based on status of kidney\n\n\n| Status of Kidney function                                                                                 | Screening Frequency                                                                                                                       |\n|-----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|\n| Albumin-Creatinine Ratio (ACR) - normal range and the eGFR > 60 ml/minute:                                | Annually                                                                                                                                  |\n| Albumin-Creatinine Ratio (ACR) - abnormal range and the eGFR < 60 ml/minute:                              | Serum creatinine must be repeated once three months ACR must be repeated twice within the same three months:                              |\n| ACR is abnormal in two out of three tests if the eGFR < 60 ml/minute, the presence of CKD is con- firmed. | The patient must be referred for further work- up to exclude non-diabetic renal disease or to confirm Chronic Kidney Disease in diabetes. |\n\n\n**General recommendations**\n\n\n- Intensify\tmanagement\tof\tmodifiable\trisk\tfactors\n- Tobacco\tuse\tin\tany\tform\tshould\tbe\tstopped\n- Metformin\tshould\tnot\tbe\tused\tonce\teGFR\t&lt;30\tml/min/1.73\tm2\n- Between\teGFR\tof\tbetween\t30-45\tml/min/1.73\tm2\tconsider\tthe\trisks\tand benefits of metformin.\n- Treat\turinary\tinfections\taggressively.\n- Avoid\tdrugs\ttoxic\tto\tthe\tkidney\te.g.\tNon-steroidal\tanti-inflammatory\tagents (e.g. Diclofenac), Aminoglycosides (e.g. Gentamicin)\n\n\n**Principles of Treatment of Nephropathy and Chronic Kidney Disease**\n\n\n- i. Optimize glycemic control with caution in those with advanced kidney disease and those on renal replacement therapy.\n- ii. Treat blood pressure aggressively with a target of 125/75 mmHg.\n- a. Use ACE inhibitors or ARBs as first-line drug therapy unless contraindicated. These drugs should NOT be used in pregnancy.\n- iii. Diet therapy and counselling\n- iv. Psychosocial counselling\n- v. Criteria for Renal Specialist referral\n- a. Persistent micro-albuminuria\n- b. Inability to optimize blood pressure\n- c. Patients\tintolerant\tof\tACE-Inhibitors/ARBs\tor\t&gt;30%\tincrease\tin creatinine levels within 3 months of initiation of these drugs\n\n\n**When to consider other causes of CKD in Diabetes**\n\n\n- Extreme\tproteinuria\t&gt;6\tg/day\n- Persistent\thematuria\n- Rapidly\tfalling\teGFR\n- Low\tEGFR\twith\tlow\tor\tno\tproteinuria\n- Diabetes\t&lt;5\tyears\n- Family\thistory\tof\tnon-diabetic\trenal\tdisease\te.g.\tpolycystic\tkidney disease\n\n\n**Diabetes Eye Disease**\n\n\nDiabetes eye disease comprises both retinopathy and cataracts.\n\n\n**Retinopathy**\n\n\nRetinopathy is one of the major causes of blindness.\n\n\nRisk factors for retinopathy include poor glycemic control, hypertension and pregnancy, as well as a long duration of diabetes. Diabetic retinopathy is preventable, and its progression is retarded by improved blood pressure and glycemic control. Screening for retinopathy and laser therapy can prevent blindness.\n\n\n**Recommendations**\n\n\n- a. A full eye examination including visual acuity and fundoscopy (preferably after the dilatation of the pupils) should be performed at the initial contact. If no capacity for ophthalmology examination, refer as part of the initial assessment.\n- b. Examinations should be repeated annually or more frequently if retinopathy is progressing.\n- c. A comprehensive eye examination is required in women planning pregnancy, and during the first trimester. An individualized follow-up is required during pregnancy and for one year thereafter. (This does not apply to women with GDM). In women with pre-existing type 1 diabetes, fundoscopy should be performed every trimester.\n- d. If retinopathy is present, intensify the management of blood pressure, glycaemia, lipids and stop smoking.\n- e. Patients with proliferative diabetic retinopathy require guided exercises and should avoid weight-bearing exercises.\n\n\n**Who should be screened?**\n\n\n- All\tpatients\twith\tType\t2\tDiabetes\tMellitus\tat\tpresentation\n- Patients\twith\tType\t1\tDiabetes\tMellitus\tof\t&gt;\t5\tyears\tduration\tsince\tdiagnosis\t(or at presentation if uncontrolled).\n\n\n**Urgent Referral to Ophthalmologist**\n\n\n- Sudden\tdeterioration\tof\tvision\n- 'Floater'\tsensation\tin\tthe\teye\treported\tby\tpatient\n- Fundoscopy\tfindings\tof\tdot\tor\tblot\themorrhages-\t1\tdisc-width\taway\tfrom\tthe macula.\n- Cataract\tpresent,\n- Proliferative\tor\texudative\tretinopathy.\n\n\n**Diabetes Neuropathy**\n\n\nNeuropathies are common complications of diabetes. They significantly increase the risk of ulceration, infection and amputation, and other diabetes-related morbidities like postural hypotension, gastropathies and erectile dysfunction. Once present, it is difficult to reverse, but good glycemic control can reduce symptoms and slow progression.\n\n\n**There are three major categories:**\n\n\n- Motor\tneuropathy\n- Sensory\tneuropathy\n- Autonomic\tneuropathy\n\n\n**Clinical Assessment:**\n\n\n- Detailed\thistory:\tnumbness,\ttingling,\tburning\tsensation\tpain,\thistory\tof\ttrauma\n- Examination\tof\tthe\tfeet:\ttest\tfor\tsensation\tusing\t10\tg\tmonofilament, 128 Hz tuning fork or cotton wool.\n- Lying-and-standing\tblood\tpressure\tand\tpulse\trate\n- Postural/orthostatic\thypotension=Drop\tin\tsystolic\tBP\t&gt;\t20\tmmHg\tor\tdiastolic &gt;10\tmmHg\twith\tchange\tto\tstanding\tposition\n\n\n**General measures:**\n\n\n- Improve\tglycemic\tcontrol.\n- Exclude\tor\ttreat\tother\tcontributory\tfactors:\n- Excess\talcohol\tconsumption\n- Vitamin\tB12\tdeficiency\n- Chronic\trenal\tfailure\n- Poor\tnutrition\n- Smoking\n- HIV\tinfection\n\n\n**Treatment**\n\n\nTreatment of symptomatic peripheral neuropathy is extremely difficult, once diagnosed refer to secondary and/or tertiary center.\n\n\nTreatment options for neuropathy include:\n\n\n**First Line:**\n\n\n- Tricyclic\tAntidepressants\n- Pregabalin\n- Carbamazepine\n- Duloxetine\n- Tapentadol\n\n\n**Others:**\n\n\n- Tramadol\n\n\n- Topical\tcapsaicin\n\n\n**Gastroparesis**\n\n\nIt  is  a  common, but often undiagnosed complication of diabetes. Treatment includes dietary  modification  (small  frequent  meals,  reduce  dietary  fat),  withdrawal/adjusting medications that may affect motility e.g. opioids and prokinetics. Treatment is challenging. Metoclopramide may be used in severe cases judiciously due to side effects.\n\n\n**Diabetic Foot Complications**\n\n\nDiabetic foot complications comprise of peripheral neuropathy (sensory neuropathy, motor and autonomic neuropathy), ischemic and structural deformities. Neuropathy contributes to 90% of the pathophysiology of diabetic foot while ischemia contributes to 10%.\n\n\nApproximately 80% of amputations attributable to diabetes are potentially preventable through early detection, examination and simple interventions.\n\n\n**Most common predisposing factors for ulcers and amputations are:**\n\n\n- Peripheral\tneuropathy\twith\tloss\tof\tsensation\n- Peripheral\tvascular\tdisease\n- Deformities\tand\tabnormal\tbiomechanics\n- Poor\tfoot\thygiene\n- Unsuitable\tor\tno\tfootwear\n- Trauma:\tPerceived\tor\tnon-perceived\n\n\n**Cornerstone of Management of Foot Problems**\n\n\n- Identification\tof\tthe\tfoot\t'at\trisk'\n- Regular\tinspection\tand\texamination\tof\tthe\tfoot\tat\trisk\n- Education\tof\thealth\tworkers,\tpeople\tliving\twith\tdiabetes\tand\ttheir\tfamilies\n- Appropriate\tfootwear:\tThe\tshoes\tand\tsocks\tshould\talso\tbe\tinspected.\n- Early\ttreatment\tof\tnon-ulcerative\tand\tulcerative\tproblems\n\n\n**How to reduce foot ulceration and amputations**\n\n\n- Optimize\tblood\tglucose,\tblood\tpressure\tand\tlipid\tcontrol.\n- Ensure\tgood\tnutrition\tstatus\tto\tpromote\thealing\n- Encourage\tpatient\tto\tstop\ttobacco\tsmoking/use.\n- Perform\ta\tdetailed\tfoot\tevaluation\tat\tpresentation\tand\tannually.\n\n\nPeople with demonstrated risk factors should be examined more frequently. The absence of symptoms does not mean that the feet are healthy, since the patient can have neuropathy, peripheral vascular disease or even an ulcer without any complaints.\n\n\n**Full examination at presentation and annually**\n\n\n- ASK\tFOR:\tSymptoms\tof\tneuropathy\t(numbness,\ttingling\tor\tpain)\tperipheral vascular disease (pain in calves on exercise and at rest)\n- EXAMINE\tSKIN:\tInspect\tfor\tulcers,\tcallus,\tcracking,\tfragility,\tdryness,\tinter\tdigital maceration (break down of the skin between the toes) and nail pathology\n- VASCULAR:\tSkin\tcolor,\tfoot\tand\tankle\tpulses.\n- NEUROPATHY:\tcheck\tprotective\tsensation\tusing\t10\tg\tmonofilament (see figure 25)\n- BONES/JOINTS:\tdeformities,\te.g.\tclaw\ttoes\tand\thammer\ttoes.\n- FOOTWEAR:\tcheck\tfor\tappropriate\tfootwear\tand\tsocks\tboth\tinside\tand outside-ANNEX 3\n\n\nAt the examination, each person's feet must be categorized into: LOW RISK, MEDIUM RISK or HIGH RISK.\n\n\nAn example of an easy-to-use foot-screening assessment sheet for clinical examination is provided in ANNEX 2. It can be attached to the person's records.\n\n\n**FOOT CARE SCREENING FLOW CHART**\n\n\nFigure 23: Diabetic Foot Screening\n\n\n![Source: Adapted from Guidelines for the Management of People with Type 2 Diabetes in Shropshire, 2013)](images/picture_045_page_100.png)\n\n\nSource: Adapted from Guidelines for the Management of People with Type 2 Diabetes in Shropshire, 2013)\n\n\nFigure 24: Performing a monofilament test for foot sensation in diabetes\n\n\n![KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS| 100](images/picture_046_page_100.png)\n\n\n**FOOT ULCER MANAGEMENT FLOW CHART**\n\n\nFigure 25: Performing a monofilament test for foot sensation in diabetes Source: Adapted from Mahesh DM, Paul T, Thomas N. Peripheral neuropathy. A Practical Guide to Diabetes Mellitus. 7th ed. Jaypee; New Delhi. 2016. p. 171-189\n\n\n![Principle of Treatment of Diabetic Foot](images/picture_047_page_101.png)\n\n\n**Principle of Treatment of Diabetic Foot**\n\n\nThis requires interdisciplinary team approach involving:\n\n\n- Education\n- Metabolic\tcontrol\n- Microbiological\tcontrol\n- Biomechanical\tcontrol\t(footwear)\n- Vascular\tstrategies\n- Wound\tcare\n\n\n**Sexual dysfunction**\n\n\nSexual dysfunction is common in diabetes in both men and women and presents with a wide spectrum of symptoms varying from problems with libido to function and has major psychosocial impact on the individual. However, data is limited on the prevalence of  sexual  dysfunction  in  women.  In  men,  the  most  common  presentation  is  erectile dysfunction which increases in prevalence with increasing age. The common causes of erectile dysfunction are psychogenic factors, medications, glycemic control, neurological and vascular dysfunction.\n\n\n**Assessment**\n\n\n- Obtain\ta\tdetailed\tsexual\thistory\tat\tinitial\tassessment\tand\tduring\tfollow\tup.\n- Refer\tappropriately\tbased\ton\thistory\tand\tphysical\texamination.\n\n\n**Therapy**\n\n\n- Counsel\tthe\tpatient\tand\tpartner\n- Review\tmedications\tand\toptimize\ttherapy\tappropriately.\n- Phosphodiesterase-inhibitors\te.g.\tsildenafil\tand\ttadalafil\tcan\tbe\tused\twith caution in some patients with Erectile Dysfunction after cardiovascular assessment and safety is confirmed. Avoid in patients with heart failure and HIV patients on protease inhibitors.\n- Urology\treview\tmay\tbe\trequired\tif\tpoor\tresponse\tto\tpharmacologic\ttherapy.\n- Assistive\tdevices\tand\tmost\tinterventions\tdo\tnot\tchange\tthe\tnatural\thistory\tof the disease but improve the patient's quality of life.\n\n\n**TREATING ERECTILE DYSFUNCTION IN MEN WITH DIABETES**\n\n\n![Figure 25: Management of erectile dysfunction in men living with diabetes Source: Adapted from Guidelines for the Management of People with Type 2 Diabetes in Shropshire, 2013](images/picture_048_page_102.png)\n\n\nFigure 25: Management of erectile dysfunction in men living with diabetes Source: Adapted from Guidelines for the Management of People with Type 2 Diabetes in Shropshire, 2013\n\n\n**Dental Disorders in Diabetes**\n\n\nDental disorders are common in Diabetes. There is a high risk of plaque buildup leading to gingivitis and periodontitis. There is also a higher risk of infection following minor surgeries e.g. extraction\n\n\n**Recommendations**\n\n\n- Observe\tgood\toral\thygiene\tpractices\te.g.\tbrushing\tof\tthe\tteeth\tat\tleast\ttwice daily and flossing.\n- Biannual\t(6-monthly)\tdental\treviews\n\n\n",
            "startLine": 3023,
            "endLine": 3602,
            "introContent": null,
            "keywords": [],
            "subsections": [
              {
                "id": "subsection-3-3-1",
                "level": "h3",
                "number": "3.3.1",
                "title": "3.3.1. Macrovascular Complications",
                "slug": "331-macrovascular-complications",
                "url": "/guidelines/33-chronic-complications-of-diabetes/331-macrovascular-complications",
                "parentId": "section-3-3",
                "breadcrumb": [
                  "CHAPTER THREE: MANAGEMENT OF COMPLICATIONS AND COMORBIDITIES IN DIABETES MELLITUS",
                  "3.3. Chronic Complications of Diabetes",
                  "3.3.1. Macrovascular Complications"
                ],
                "tokenCount": 2680,
                "content": "### 3.3.1. Macrovascular Complications\n\n\nThe risk of CVD for people with type 2 diabetes is increased by two to three times for men and three to five times for women compared with people without diabetes. Outcomes following myocardial infarction, stroke or revascularization are also worse in people living with diabetes compared to individuals without diabetes. Atherosclerosis is often accelerated, severe and diffuse in diabetes. Chronic hyperglycaemia is an additional risk factor for atherosclerosis in patients with diabetes and adds to the well-known standard risk factor burden of race, gender, hypertension, dyslipidaemia, smoking, social deprivation and obesity. Table 24 summarizes the traditional modifiable risk factors for CVD and the recommended target values in diabetes.\n\n\nTable 30: CVD risk factors and targets for type 2 diabetes\n\n\n| Traditional CVD risk factors   | Targets                                                          |\n|--------------------------------|------------------------------------------------------------------|\n| Cigarette smoking              | Cessation                                                        |\n| Dyslipidaemia                  |                                                                  |\n| - Total cholesterol            | <4.5 mmol/L                                                      |\n| - LDLcholesterol               | <1.8 mmol/L                                                      |\n| - HDLcholesterol               | > 1.0 mmol/L (men) >1.2 mmol/L (women)                           |\n| - Triglycerides                | <1.7 mmol/L                                                      |\n| Obesity                        |                                                                  |\n| - Waist circumference          | <94 cm (men); <90 cm (men of South Asian descent) <80 cm (women) |\n| - Body mass index              | <25 kg/m2                                                        |\n| Hypertension                   |                                                                  |\n| - Systolic blood pressure      | <140 mmHg                                                        |\n| - Diastolic blood pressure     | <80 mmHg                                                         |\n\n\n**Two major processes lead to cardiovascular disease:**\n\n\n- Atherosclerosis,\tand\n- Hypertension\n\n\n**The clinical spectrum of cardiovascular disease is:**\n\n\n- a. Coronary artery disease\n- b. Cerebrovascular disease\n- c. Peripheral vascular disease\n\n\n**Coronary artery disease**\n\n\nCoronary artery disease (CAD) is the cause of death in more than half of all diabetic patients. Patients with diabetes but without other conventional risk factors for atherosclerosis have a risk of death from CAD 2- 4 times that of age-matched controls. Those with type 2 diabetes commonly have other associated risk factors, such as hypertension or hyperlipidemia, thus further increasing their cardiovascular risk. Women living with diabetes are at increased risk, with a risk of cardiovascular death up to 7.5 times that of women without diabetes. Individuals with diabetes and CAD fare worse than do other patients with CAD. These patients present with:\n\n\n- Chest\tpain\t(angina):\t-this\tcan\tbe\ta\tmild,\tuncomfortable\tfeeling,\tsimilar\tto\tin -digestion. However, a severe angina attack can cause a painful feeling of heaviness or tightness, usually in the centre of the chest, which may spread to the arms, neck, jaw, back or stomach. Angina is often triggered by physical activity or stressful situations.\n- Lightheadedness\n- Sweating\n- Nausea\n- Breathlessness\n\n\nThose who present with a myocardial infarction (MI) are at increased risk of dying from their event or of developing heart failure. They benefit less from therapies such as thrombolysis in the setting of an acute MI. Therefore, early detection of CAD is important to ensure that medical interventions to improve outcome are instituted.\n\n\n**The spectrum of coronary artery disease includes: -**\n\n\n- Angina\t(which\tmay\tbe\tsilent).\n- Acute\tcoronary\tsyndrome.\n- Congestive\tcardiac\tfailure.\n- Sudden\tdeath.\n\n\n**Silent ischemia**\n\n\nSilent ischemia is a particular concern in diabetic patients. Clinically, patients with diabetes are more likely to be without chest pain in the setting of unstable angina or MI, and thus late presentation contributes to a higher mortality in these patients. People with diabetes may also be less likely to experience exertional angina or chest pain with exercise testing, thus potentially increasing the difficulty of diagnosing significant CAD. This may further increase diabetic patients' risk in terms of late diagnosis and presentation.\n\n\n**Cerebrovascular disease**\n\n\nCerebrovascular complications make diabetic patients 2-6 times more susceptible to a stroke event. The risk is further increased in the DM patients who also have hyperlipidemia or hypertension. The cerebrovascular risk increases by 2-3-fold in type 2 DM patients with elevated systolic blood pressure. In addition, when patients with diabetes\n\n\nand hyperglycemia experience an acute ischemic stroke they are more likely to die or be severely disabled and less likely to benefit from the thrombolytic therapy.\n\n\n**Cerebrovascular diseases in diabetes can present either as:**\n\n\n- i. Stroke\n- ii. Transient ischaemic attack\n- iii. Cognitive impairment/dementia\n\n\n**Stroke**\n\n\nStroke refers to the partial or complete interruption of blood supply to the brain resulting in brain ischemia. The manifestations of stroke typically last longer than 24 hours. There are two main forms of stroke: -\n\n\n- a. Ischemic stroke: Occurs when there is occlusion (blockage) to the blood vessels supplying the brain by a thrombus or embolus. It is the more common form of stroke in diabetics.\n- b. hemorrhagic stroke: Occurs when a weakened blood vessel bursts or ruptures leading to an intracranial bleed. Common in individuals with uncontrolled hypertension.\n\n\n**Symptoms of stroke include:**\n\n\n- Sudden\tnumbness\tor\tweakness\tin\tthe\tface,\tarm,\tor\tleg,\tespecially\ton one side of the body\n- Sudden\tconfusion,\ttrouble\tspeaking,\tor\tdifficulty\tunderstanding\tspeech\n- Sudden\ttrouble\tseeing\tin\tone\tor\tboth\teyes\n- Sudden\ttrouble\twalking,\tdizziness,\tloss\tof\tbalance,\tor\tlack\tof coordination\n- Sudden\tsevere\theadache\twith\tno\tknown\tcause\n- c. Transient Ischaemic Attack (TIA): Transient ischaemic attack refers to temporary obstruction of blood supply to the brain. Symptoms mimic those of stroke, but typically last less than 24 hours.\n- d. Cognitive impairment: Diabetes increases the risk of developing cognitive decline and dementia, including vascular dementia and Alzheimer's disease (AD) especially in the elderly\n\n\n**Evaluation for Cerebrovascular disease will include: -**\n\n\n- Carotid\tDoppler\n- MRI\tand\n- MRI\tangiography\twhere\tindicated.\n\n\n**Treatment**\n\n\nThe treatment of the cerebrovascular disease in DM patients is divided into three levels:\n\n\n- i. First level: to prevent the brain vessels complications by adequately controlling the blood glucose when the patients are at the stage of insulin resistance or at the early stage of diabetes; to reduce the risk factors caused by the hyperglycemia\n\n\n- a. Lifestyle modification-smoking cessation, diet and physical activity\n- b. Glycemic control: OGLAs/insulin therapy\n- c. Anti-platelet therapy\n- d. Blood pressure control\n- e. Treatment of dyslipidemia: statins\n- ii. Second level: to control glucose intensively after the cerebrovascular diseases occur in DM patients. The blood pressure should be reduced to the normal range to avoid the vasculopathy-induced stroke.\n- iii. Tertiary prevention: to improve the cerebral circulation after the stroke in DM patients. The patients with ischemic stroke should be treated by thrombolytic therapy in the early phase of hyper-acute cerebral infarction\n\n\n**Peripheral vascular disease (PVD)**\n\n\nPVD is a common cardiovascular complication in persons living with diabetes. In contrast to PVD in non-diabetic individuals, it is more prevalent and, because of the involvement of the distal territory of vessels and its association with peripheral neuropathy, it is more commonly asymptomatic.\n\n\nPatients with PVD and diabetes thus may present later with more severe disease and have a greater risk of amputation. Moreover, the presence of PVD is a marker of excess cardiovascular risk.\n\n\nIt is important to diagnose PVD in patients with diabetes to elicit symptoms, prevent disability and limb loss, and identify a patient at high risk of MI, stroke, and death.\n\n\n**The clinical spectrum of PVD include: -**\n\n\n- i. Intermittent claudication-defined as pain, cramping, or aching in the calves, thighs, or buttocks that appears reproducibly with walking exercise and is relieved by rest.\n- ii. Critical Limb Ischemia-this is a triad characterized by: -\n- Rest\tpain\n- Foot\tulcers:\tthese\tischemic\tulcers\ttypically\tpresent\ton\tthe\tlateral surface of the ankle or the distal digits\n- Gangrene\n\n\n**Peripheral signs of peripheral vascular disease are the classic 'five P's,':**\n\n\n- Pulselessness\n- Paralysis\n- Paresthesia\n- Pain\n- Pallor\n\n\nThe assessment of PVD in patients with diabetes should include a thorough medical history and physical examination to identify those patients with risk factors, symptoms and signs of PVD.\n\n\n- Walking\thistory\tto\telicit\tclaudication\tsymptoms\n- Foot\tinspection-\tabsence\tof\thair\tgrowth,\tpallor\ton\televation,\tcool\tand dry\n\n\nfissured skin, fissures and ulcerations in the interdigital spaces\n\n\n- Palpation\tof\tperipheral\tpulses\t(femoral,\tpopliteal\tand\tdorsalis\tpedis pulses)\n\n\nThe diagnosis is made with a determination of the ABI. It is recommended that patients with\tdiabetes\twho\tare\t&gt;\t50\tyears\tof\tage\thave\tan\tABI\tperformed.\tAn\tABI\tis\talso\tuseful\tin patients with other PVD risk factors and in those with symptoms.\n\n\nFigure 22: How to perform an ankle-branchial index Source: National Heart Lung and Blood Institute (NIH) - National Heart Lung and Blood Institute (NIH)\n\n\n![KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS| 92](images/picture_044_page_92.png)\n\n\n**The diagnostic criteria for PVD based on the ABI are interpreted as follows:**\n\n\nTable 31: Interpretation of ankle-brachial index (ABI) values\n\n\n| ABI reading   | Interpretation       |\n|---------------|----------------------|\n| 0.91-1.30     | Normal               |\n| 0.70-0.90     | Mild obstruction     |\n| 0.40-0.69     | Moderate obstruction |\n| < 0.40        | Severe obstruction   |\n| > 1.30        | Poorly compressible  |\n\n\nAn\tABI\tvalue\t&gt;\t1.3\tsuggests\tpoorly\tcompressible\tarteries\tat\tthe\tankle\tlevel\tdue\tto\tthe presence of medial arterial calcification. This renders the diagnosis of PVD by ABI alone less reliable.\n\n\nIn addition to ABI, evaluation for peripheral vascular disease should also include Doppler and angiography of the lower limbs.\n\n\n**Treatment of the patient with diabetes and PVD should be two-fold:**\n\n\n- i. Primary and secondary risk modification\n2. -Cigarette smoking cessation,\n3. -Glycemic control\n4. -Treatment of hypertension\n5. -Treatment of dyslipidemia\n6. -Anti-platelet therapy (aspirin, clopidogrel)\n- ii. Treatment of PVD symptoms (claudication and critical limb ischemia) and limiting progression of disease\n8. -Exercise rehabilitation\n9. -Pharmacologic therapy (e.g. Pentoxifylline, cilostazol)\n10. -Wound care (debridement, offloading the ulcers, appropriate dressings, treatment of infections)\n11. -Revascularization (for patients with debilitating claudication or CLI)\n\n\n**Follow-up considerations: Cardiovascular complications in DM patients**\n\n\n- Initial\tassessment\tfor\tcardiovascular\trisk\tshould\tbe\tdone\tin\tall\tdiabetic\tpatients, and annually thereafter.\n- The\tassessment\tshould\tbe\tmore\tfrequent\tif\tthe\tpatient\thas\thad\ta cardiovascular   event (Refer to ESH/ESC CVD risk stratification tool in ANNEX I).\n- Referral\tfor\tspecialist\tcare\tis\trequired\tin\tpeople\tpresenting\twith\ttypical\tand atypical symptoms of angina, features of congestive cardiac failure, unexplained breathlessness, cardiomegaly, arrhythmias, transient ischaemic attacks or intermittent claudication of the legs.\n\n\n",
                "startLine": 3026,
                "endLine": 3260,
                "introContent": null,
                "keywords": [],
                "subsections": null
              },
              {
                "id": "subsection-3-3-2",
                "level": "h3",
                "number": "3.3.2",
                "title": "3.3.2. Chronic Microvascular Complications",
                "slug": "332-chronic-microvascular-complications",
                "url": "/guidelines/33-chronic-complications-of-diabetes/332-chronic-microvascular-complications",
                "parentId": "section-3-3",
                "breadcrumb": [
                  "CHAPTER THREE: MANAGEMENT OF COMPLICATIONS AND COMORBIDITIES IN DIABETES MELLITUS",
                  "3.3. Chronic Complications of Diabetes",
                  "3.3.2. Chronic Microvascular Complications"
                ],
                "tokenCount": 3501,
                "content": "### 3.3.2. Chronic Microvascular Complications\n\n\nMicrovascular complications involve the kidney, eyes, lower extremities. They may be present at the time of diagnosis of diabetes as the detection of the disease is frequently delayed. Most of these complications can be prevented or their progression delayed by optimal treatment of hyperglycaemia and hypertension.\n\n\nScreening for the complications and prompt interventions reduce the risk of major outcomes such as blindness, nephropathy, and leg amputations.\n\n\n**Diabetes Nephropathy**\n\n\nDiabetes is one of the most common causes of chronic kidney disease. In Africa, there is a high morbidity and economic burden in patients with end-stage renal disease due to late presentation, delayed diagnosis and limited access to renal replacement therapy.\n\n\nDiabetes nephropathy progresses from subclinical disease to microalbuminuria. Persistent microalbuminuria is a marker for the development of overt nephropathy in diabetes as well as being a well-established marker of increased cardiovascular risk. Patients with microalbuminuria\twho\tprogress\tto\tmacro-albuminuria\t(&gt;\t300\tmg/24\th.)\tare\tlikely\tto\tprogress to end-stage renal disease. Intervention at the stage of microalbuminuria can retard the progression to end-stage renal disease.\n\n\n**Who should be screened?**\n\n\n- Patients\twith\tType\t1\tdiabetes\tfor\ta\tduration\tof\t&gt;5\tyears\n- Patients\twith\tType\t2\tdiabetes\tat\tdiagnosis\n\n\n**Detection and surveillance**\n\n\n- Check\tfor\tproteinuria\tyearly\tusing\treagent\tstrips.\n- For\tpatients\twho\ttest\tpositive,\texclude\turinary\ttract\tinfections\tby using urine strips to check for nitrites and leucocytes or urine microscopy and culture and treat infection if present.\n- During\tthe\tnext\tvisit,\tcheck\tfor\tpresence\tof\tinfection,\tif\tnone\ttest\tfor proteinuria. If proteinuria (trace or greater) is present and there is no infection, refer for renal evaluation.\n- For\tpatients\twho\ttest\tnegative\tfor\tproteinuria\tcheck\tfor\tmicroalbuminuria annually using reagent strips or the albumin-creatinine ratio.\n- If\tnegative,\trepeat\ttest\tannually.\tIf\tpositive,\ttest\tsample\tat\tleast\tone\tto\ttwo times within 3 to 6 months to confirm microalbuminuria. If confirmed, start ACEI or ARB treatment and optimize blood pressure control to less than 125/75 mmHg.\n- Measure\tserum\tcreatinine\tbi-annually,\tand\tif\traised\tor\trising,\trefer\tfor\trenal evaluation.\n\n\n**Frequency of screening**\n\n\nTable 32: Frequency of screening for diabetic nephropathy based on status of kidney\n\n\n| Status of Kidney function                                                                                 | Screening Frequency                                                                                                                       |\n|-----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|\n| Albumin-Creatinine Ratio (ACR) - normal range and the eGFR > 60 ml/minute:                                | Annually                                                                                                                                  |\n| Albumin-Creatinine Ratio (ACR) - abnormal range and the eGFR < 60 ml/minute:                              | Serum creatinine must be repeated once three months ACR must be repeated twice within the same three months:                              |\n| ACR is abnormal in two out of three tests if the eGFR < 60 ml/minute, the presence of CKD is con- firmed. | The patient must be referred for further work- up to exclude non-diabetic renal disease or to confirm Chronic Kidney Disease in diabetes. |\n\n\n**General recommendations**\n\n\n- Intensify\tmanagement\tof\tmodifiable\trisk\tfactors\n- Tobacco\tuse\tin\tany\tform\tshould\tbe\tstopped\n- Metformin\tshould\tnot\tbe\tused\tonce\teGFR\t&lt;30\tml/min/1.73\tm2\n- Between\teGFR\tof\tbetween\t30-45\tml/min/1.73\tm2\tconsider\tthe\trisks\tand benefits of metformin.\n- Treat\turinary\tinfections\taggressively.\n- Avoid\tdrugs\ttoxic\tto\tthe\tkidney\te.g.\tNon-steroidal\tanti-inflammatory\tagents (e.g. Diclofenac), Aminoglycosides (e.g. Gentamicin)\n\n\n**Principles of Treatment of Nephropathy and Chronic Kidney Disease**\n\n\n- i. Optimize glycemic control with caution in those with advanced kidney disease and those on renal replacement therapy.\n- ii. Treat blood pressure aggressively with a target of 125/75 mmHg.\n- a. Use ACE inhibitors or ARBs as first-line drug therapy unless contraindicated. These drugs should NOT be used in pregnancy.\n- iii. Diet therapy and counselling\n- iv. Psychosocial counselling\n- v. Criteria for Renal Specialist referral\n- a. Persistent micro-albuminuria\n- b. Inability to optimize blood pressure\n- c. Patients\tintolerant\tof\tACE-Inhibitors/ARBs\tor\t&gt;30%\tincrease\tin creatinine levels within 3 months of initiation of these drugs\n\n\n**When to consider other causes of CKD in Diabetes**\n\n\n- Extreme\tproteinuria\t&gt;6\tg/day\n- Persistent\thematuria\n- Rapidly\tfalling\teGFR\n- Low\tEGFR\twith\tlow\tor\tno\tproteinuria\n- Diabetes\t&lt;5\tyears\n- Family\thistory\tof\tnon-diabetic\trenal\tdisease\te.g.\tpolycystic\tkidney disease\n\n\n**Diabetes Eye Disease**\n\n\nDiabetes eye disease comprises both retinopathy and cataracts.\n\n\n**Retinopathy**\n\n\nRetinopathy is one of the major causes of blindness.\n\n\nRisk factors for retinopathy include poor glycemic control, hypertension and pregnancy, as well as a long duration of diabetes. Diabetic retinopathy is preventable, and its progression is retarded by improved blood pressure and glycemic control. Screening for retinopathy and laser therapy can prevent blindness.\n\n\n**Recommendations**\n\n\n- a. A full eye examination including visual acuity and fundoscopy (preferably after the dilatation of the pupils) should be performed at the initial contact. If no capacity for ophthalmology examination, refer as part of the initial assessment.\n- b. Examinations should be repeated annually or more frequently if retinopathy is progressing.\n- c. A comprehensive eye examination is required in women planning pregnancy, and during the first trimester. An individualized follow-up is required during pregnancy and for one year thereafter. (This does not apply to women with GDM). In women with pre-existing type 1 diabetes, fundoscopy should be performed every trimester.\n- d. If retinopathy is present, intensify the management of blood pressure, glycaemia, lipids and stop smoking.\n- e. Patients with proliferative diabetic retinopathy require guided exercises and should avoid weight-bearing exercises.\n\n\n**Who should be screened?**\n\n\n- All\tpatients\twith\tType\t2\tDiabetes\tMellitus\tat\tpresentation\n- Patients\twith\tType\t1\tDiabetes\tMellitus\tof\t&gt;\t5\tyears\tduration\tsince\tdiagnosis\t(or at presentation if uncontrolled).\n\n\n**Urgent Referral to Ophthalmologist**\n\n\n- Sudden\tdeterioration\tof\tvision\n- 'Floater'\tsensation\tin\tthe\teye\treported\tby\tpatient\n- Fundoscopy\tfindings\tof\tdot\tor\tblot\themorrhages-\t1\tdisc-width\taway\tfrom\tthe macula.\n- Cataract\tpresent,\n- Proliferative\tor\texudative\tretinopathy.\n\n\n**Diabetes Neuropathy**\n\n\nNeuropathies are common complications of diabetes. They significantly increase the risk of ulceration, infection and amputation, and other diabetes-related morbidities like postural hypotension, gastropathies and erectile dysfunction. Once present, it is difficult to reverse, but good glycemic control can reduce symptoms and slow progression.\n\n\n**There are three major categories:**\n\n\n- Motor\tneuropathy\n- Sensory\tneuropathy\n- Autonomic\tneuropathy\n\n\n**Clinical Assessment:**\n\n\n- Detailed\thistory:\tnumbness,\ttingling,\tburning\tsensation\tpain,\thistory\tof\ttrauma\n- Examination\tof\tthe\tfeet:\ttest\tfor\tsensation\tusing\t10\tg\tmonofilament, 128 Hz tuning fork or cotton wool.\n- Lying-and-standing\tblood\tpressure\tand\tpulse\trate\n- Postural/orthostatic\thypotension=Drop\tin\tsystolic\tBP\t&gt;\t20\tmmHg\tor\tdiastolic &gt;10\tmmHg\twith\tchange\tto\tstanding\tposition\n\n\n**General measures:**\n\n\n- Improve\tglycemic\tcontrol.\n- Exclude\tor\ttreat\tother\tcontributory\tfactors:\n- Excess\talcohol\tconsumption\n- Vitamin\tB12\tdeficiency\n- Chronic\trenal\tfailure\n- Poor\tnutrition\n- Smoking\n- HIV\tinfection\n\n\n**Treatment**\n\n\nTreatment of symptomatic peripheral neuropathy is extremely difficult, once diagnosed refer to secondary and/or tertiary center.\n\n\nTreatment options for neuropathy include:\n\n\n**First Line:**\n\n\n- Tricyclic\tAntidepressants\n- Pregabalin\n- Carbamazepine\n- Duloxetine\n- Tapentadol\n\n\n**Others:**\n\n\n- Tramadol\n\n\n- Topical\tcapsaicin\n\n\n**Gastroparesis**\n\n\nIt  is  a  common, but often undiagnosed complication of diabetes. Treatment includes dietary  modification  (small  frequent  meals,  reduce  dietary  fat),  withdrawal/adjusting medications that may affect motility e.g. opioids and prokinetics. Treatment is challenging. Metoclopramide may be used in severe cases judiciously due to side effects.\n\n\n**Diabetic Foot Complications**\n\n\nDiabetic foot complications comprise of peripheral neuropathy (sensory neuropathy, motor and autonomic neuropathy), ischemic and structural deformities. Neuropathy contributes to 90% of the pathophysiology of diabetic foot while ischemia contributes to 10%.\n\n\nApproximately 80% of amputations attributable to diabetes are potentially preventable through early detection, examination and simple interventions.\n\n\n**Most common predisposing factors for ulcers and amputations are:**\n\n\n- Peripheral\tneuropathy\twith\tloss\tof\tsensation\n- Peripheral\tvascular\tdisease\n- Deformities\tand\tabnormal\tbiomechanics\n- Poor\tfoot\thygiene\n- Unsuitable\tor\tno\tfootwear\n- Trauma:\tPerceived\tor\tnon-perceived\n\n\n**Cornerstone of Management of Foot Problems**\n\n\n- Identification\tof\tthe\tfoot\t'at\trisk'\n- Regular\tinspection\tand\texamination\tof\tthe\tfoot\tat\trisk\n- Education\tof\thealth\tworkers,\tpeople\tliving\twith\tdiabetes\tand\ttheir\tfamilies\n- Appropriate\tfootwear:\tThe\tshoes\tand\tsocks\tshould\talso\tbe\tinspected.\n- Early\ttreatment\tof\tnon-ulcerative\tand\tulcerative\tproblems\n\n\n**How to reduce foot ulceration and amputations**\n\n\n- Optimize\tblood\tglucose,\tblood\tpressure\tand\tlipid\tcontrol.\n- Ensure\tgood\tnutrition\tstatus\tto\tpromote\thealing\n- Encourage\tpatient\tto\tstop\ttobacco\tsmoking/use.\n- Perform\ta\tdetailed\tfoot\tevaluation\tat\tpresentation\tand\tannually.\n\n\nPeople with demonstrated risk factors should be examined more frequently. The absence of symptoms does not mean that the feet are healthy, since the patient can have neuropathy, peripheral vascular disease or even an ulcer without any complaints.\n\n\n**Full examination at presentation and annually**\n\n\n- ASK\tFOR:\tSymptoms\tof\tneuropathy\t(numbness,\ttingling\tor\tpain)\tperipheral vascular disease (pain in calves on exercise and at rest)\n- EXAMINE\tSKIN:\tInspect\tfor\tulcers,\tcallus,\tcracking,\tfragility,\tdryness,\tinter\tdigital maceration (break down of the skin between the toes) and nail pathology\n- VASCULAR:\tSkin\tcolor,\tfoot\tand\tankle\tpulses.\n- NEUROPATHY:\tcheck\tprotective\tsensation\tusing\t10\tg\tmonofilament (see figure 25)\n- BONES/JOINTS:\tdeformities,\te.g.\tclaw\ttoes\tand\thammer\ttoes.\n- FOOTWEAR:\tcheck\tfor\tappropriate\tfootwear\tand\tsocks\tboth\tinside\tand outside-ANNEX 3\n\n\nAt the examination, each person's feet must be categorized into: LOW RISK, MEDIUM RISK or HIGH RISK.\n\n\nAn example of an easy-to-use foot-screening assessment sheet for clinical examination is provided in ANNEX 2. It can be attached to the person's records.\n\n\n**FOOT CARE SCREENING FLOW CHART**\n\n\nFigure 23: Diabetic Foot Screening\n\n\n![Source: Adapted from Guidelines for the Management of People with Type 2 Diabetes in Shropshire, 2013)](images/picture_045_page_100.png)\n\n\nSource: Adapted from Guidelines for the Management of People with Type 2 Diabetes in Shropshire, 2013)\n\n\nFigure 24: Performing a monofilament test for foot sensation in diabetes\n\n\n![KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS| 100](images/picture_046_page_100.png)\n\n\n**FOOT ULCER MANAGEMENT FLOW CHART**\n\n\nFigure 25: Performing a monofilament test for foot sensation in diabetes Source: Adapted from Mahesh DM, Paul T, Thomas N. Peripheral neuropathy. A Practical Guide to Diabetes Mellitus. 7th ed. Jaypee; New Delhi. 2016. p. 171-189\n\n\n![Principle of Treatment of Diabetic Foot](images/picture_047_page_101.png)\n\n\n**Principle of Treatment of Diabetic Foot**\n\n\nThis requires interdisciplinary team approach involving:\n\n\n- Education\n- Metabolic\tcontrol\n- Microbiological\tcontrol\n- Biomechanical\tcontrol\t(footwear)\n- Vascular\tstrategies\n- Wound\tcare\n\n\n**Sexual dysfunction**\n\n\nSexual dysfunction is common in diabetes in both men and women and presents with a wide spectrum of symptoms varying from problems with libido to function and has major psychosocial impact on the individual. However, data is limited on the prevalence of  sexual  dysfunction  in  women.  In  men,  the  most  common  presentation  is  erectile dysfunction which increases in prevalence with increasing age. The common causes of erectile dysfunction are psychogenic factors, medications, glycemic control, neurological and vascular dysfunction.\n\n\n**Assessment**\n\n\n- Obtain\ta\tdetailed\tsexual\thistory\tat\tinitial\tassessment\tand\tduring\tfollow\tup.\n- Refer\tappropriately\tbased\ton\thistory\tand\tphysical\texamination.\n\n\n**Therapy**\n\n\n- Counsel\tthe\tpatient\tand\tpartner\n- Review\tmedications\tand\toptimize\ttherapy\tappropriately.\n- Phosphodiesterase-inhibitors\te.g.\tsildenafil\tand\ttadalafil\tcan\tbe\tused\twith caution in some patients with Erectile Dysfunction after cardiovascular assessment and safety is confirmed. Avoid in patients with heart failure and HIV patients on protease inhibitors.\n- Urology\treview\tmay\tbe\trequired\tif\tpoor\tresponse\tto\tpharmacologic\ttherapy.\n- Assistive\tdevices\tand\tmost\tinterventions\tdo\tnot\tchange\tthe\tnatural\thistory\tof the disease but improve the patient's quality of life.\n\n\n**TREATING ERECTILE DYSFUNCTION IN MEN WITH DIABETES**\n\n\n![Figure 25: Management of erectile dysfunction in men living with diabetes Source: Adapted from Guidelines for the Management of People with Type 2 Diabetes in Shropshire, 2013](images/picture_048_page_102.png)\n\n\nFigure 25: Management of erectile dysfunction in men living with diabetes Source: Adapted from Guidelines for the Management of People with Type 2 Diabetes in Shropshire, 2013\n\n\n**Dental Disorders in Diabetes**\n\n\nDental disorders are common in Diabetes. There is a high risk of plaque buildup leading to gingivitis and periodontitis. There is also a higher risk of infection following minor surgeries e.g. extraction\n\n\n**Recommendations**\n\n\n- Observe\tgood\toral\thygiene\tpractices\te.g.\tbrushing\tof\tthe\tteeth\tat\tleast\ttwice daily and flossing.\n- Biannual\t(6-monthly)\tdental\treviews\n\n\n",
                "startLine": 3261,
                "endLine": 3602,
                "introContent": null,
                "keywords": [],
                "subsections": null
              }
            ]
          },
          {
            "id": "section-3-4",
            "level": "h2",
            "number": "3.4",
            "title": "3.4. Co-Morbidities in Diabetes Mellitus",
            "slug": "34-co-morbidities-in-diabetes-mellitus",
            "url": "/guidelines/chapter-three-management-of-complications-and-comorbidities-in-diabetes-mellitus/34-co-morbidities-in-diabetes-mellitus",
            "parentId": "chapter-3",
            "breadcrumb": [
              "CHAPTER THREE: MANAGEMENT OF COMPLICATIONS AND COMORBIDITIES IN DIABETES MELLITUS",
              "3.4. Co-Morbidities in Diabetes Mellitus"
            ],
            "tokenCount": 2229,
            "content": "## 3.4. Co-Morbidities in Diabetes Mellitus\n\n\nComorbidities are diseases or medical conditions that co-exist with the primary disease. There are various forms of co-morbidities that contribute to the morbidity and mortality associated with diabetes. They include hypertension, mental health, dyslipidemia among others.\n\n\n### 3.4.1. Hypertension\n\n\n**Principles of management of hypertension in diabetes mellitus**\n\n\n- Determine\tblood\tpressure\tin\tpeople\twith\tType\t2\tdiabetes\tat\tevery\tvisit,\tusing standard techniques (measure with a mercury sphygmomanometer and the right-sized cuff with the patient seated after 5 minutes).\n- Classify\tblood\tpressure\tstatus\tusing\ta\tBP\tof\t≥140/90\tmmHg\tas\thypertensive.\n- Most\tpatients\twith\tdiabetes\tand\thypertension\tshould\tbe\ttreated\tto\ta\tsystolic blood pressure goal of 140 mmHg and a diastolic blood pressure goal of 90 mmHg.\n- Lower\tsystolic\tand\tdiastolic\tblood\tpressure\ttargets,\tsuch\tas\t130/80\tmmHg, may be appropriate for individuals at high risk of cardiovascular disease, if they can be achieved without undue treatment burden.\n- In\tpregnant\tpatients\twith\tdiabetes\tand\tchronic\thypertension,\tblood\tpressure targets of SBP 130-150 and/or DBP 80-105 mmHg are suggested in the interest of optimizing long-term maternal health and minimizing impaired fetal growth.\n- If\thypertensive,\tassessment\tshould\tinclude\ta\tthorough\thistory,\tphysical examination, staging and cardiovascular risk stratification (refer to the risk stratification tool in Annex 1). Look for other components of metabolic syndrome and complications of both diabetes and hypertension.\n\n\n**Non-Pharmacologic Management**\n\n\nIntegrate management of hypertension and that of diabetes, starting with:\n\n\n- Diabetes\tEducation\n- Lifestyle\tmodifications\t(physical\texercise,\tdiet\tand\tweight\tloss)\tand\tsetting\tgoals\n\n\n- Diet\tshould\tbe\tlow\tin\tsodium,\trich\tin\tvegetables\tand\tfruits,\tand\tuse\tof\tlow-fat dairy products\n- Reduce\talcohol\tconsumption\tand\ttobacco\tcessation\n\n\n**Pharmacologic Management**\n\n\n- Pharmacologic\tmanagement\tshould\tbe\tconsidered\tin\tall\tpatients\twith diabetes and a documented sustained blood Pressure of above 140/90 mmHg despite lifestyle modification\n- Individualize\thypertensive\ttherapy\tto\tachieve\tgood\tcontrol.\n- Multiple\tagents\tare\tfrequently\trequired.\tFixed\tdose\tcombinations\tshould\tbe used when Blood pressures are stable and response to individual agents is known.\n- Monitor\tserum\tcreatinine\tand\tpotassium\tonce\ta\tyear\tand\tmore\tfrequently\tif there is evidence of renal impairment.\n- Note\tthe\tpotential\tproblems\twith\tcertain\tanti-hypertensives:\n- -Diuretics in large doses inhibit insulin release\n- -Beta blockers may blunt or mask symptoms of Hypoglycemia and exacerbate peripheral vascular disease\n- -Dyslipidaemia may be worsened by beta blockers and diuretics,\n- -Impotence and postural hypotension may be precipitated or aggravated by alpha blockers and centrally acting agents (e.g. methyldopa).\n- -Angiotensin converting enzyme (ACE) inhibitors may induce hyperkalaemia, renal failure, a persistent cough.\n\n\nTable 33: Principles of management of hypertension by level of severity\n\n\n\n\n| evel of severity                | Management                                                                                                             |\n|---------------------------------|------------------------------------------------------------------------------------------------------------------------|\n| 140/90                          | Repeat Blood pressure on different occasion and initiate lifestyle modification and pharmacologic therapy              |\n| 160/100 mmHg                    | Treat with two classes of oral Anti-Hypertensive drugs                                                                 |\n| 180/120 mmHg                    | Bring BP down to near normal below 160/100 mmHg within 48 hrs.                                                         |\n| If patient has end organ damage | Reduce blood pressure by not more than 25% in the first 1-2 hours with an agent determined by the physician/specialist |\n\n\nNOTE: Avoid sublingual antihypertensive agents that have the potential to dramatically and catastrophically reduce blood pressure.\n\n\n**Management of Hypertension**\n\n\nFigure 26: Algorithm for the management of hypertension in patients with diabetes mellitus\n\n\n![105 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS](images/picture_049_page_105.png)\n\n\n**Algorithm:  Management  of  hypertension  in  diabetes  in Primary Care**\n\n\nFigure 28: Management of hypertension in patients with diabetes in the Primary Care setting\n\n\n![Source: AMPATH](images/picture_050_page_106.png)\n\n\nSource: AMPATH\n\n\n### 3.4.2. Mental Disorders in Diabetes\n\n\nMental health is an important aspect of Diabetes management. Adolescents living with Diabetes are a particularly vulnerable population that requires psychosocial support as an integral part of their management.\n\n\nA wide spectrum of psychosocial and emotional challenges exists in people living with\n\n\n**Diabetes that include:**\n\n\n- Depressive\tdisorders\n- Disordered\teating\tbehavior\n- Anxiety\tdisorders\n\n\nHealthcare providers should be aware that psychotropic agents are known to increase the incidence of diabetes and may affect glycemic control.\n\n\n**Management**\n\n\n- All\tindividuals\tshould\tbe\tscreened\tat\tdiagnosis\tand\tduring\tfollow\tup for any mental health issues and referred appropriately for psychotherapy.\n- Counselling\tat\tdiagnosis\tis\tkey\tto\tacceptance,\tmedication\tcompliance and mitigation of mental disorders\n- Consider\tthe\teffects\ton\tglycemic\tcontrol\twhen\tpatients\tare\ton psychotropics.\n- Encourage\tpeer\tand\tsupport\tgroup\tinvolvement\tas\tpart\tof\troutine\tcare.\n\n\n### 3.4.3. Lipids disorders in Diabetes\n\n\nThe risk of coronary artery disease and other macrovascular disorders is 2 - 4 times higher in people living with diabetes than in non-diabetic subjects and increases in parallel with the degree of dyslipidaemia.\n\n\nTable 34: Desired level of lipids in patients with diabetes (LDL targets in the absence of CKD and CVD, DM in patients &lt; 40 years, duration of &lt;10 years)\n\n\n| Lipids            | Target(mmol/L)   | Target (Mg/dl   |\n|-------------------|------------------|-----------------|\n| Total cholesterol | <4.8             | <93.6           |\n| LDLcholesterol    | <2.6             | <-46.8          |\n| HDLcholesterol    | >1.2 (Female)    | >19.8           |\n| Triglycerides     | <1.7             | <30.6           |\n\n\nCKD-Chronic kidney disease, CVD- Cardiovascular disease\n\n\nTable 35: Lipid Targets for secondary prevention (people with history of cardiovascular event)\n\n\n| Lipids            | Target (mmol/L)   | Target (Mg/dL)   |\n|-------------------|-------------------|------------------|\n| Total cholesterol | <4.8              | <93.6            |\n| LDLcholesterol    | <1.8              | <32.4            |\n| HDLcholesterol    | >1.2              | >19.8            |\n| Triglycerides     | <1.7              | <30.6            |\n\n\n**Assessment**\n\n\nMeasure fasting lipids including total cholesterol, triglycerides and HDL and LDL cholesterol at initial contact.\n\n\n**How often:**\n\n\n- If\tnormal,\tdo\ta\trisk-stratification\tand\tdetermine\tappropriate\ttreatment.\n- If\tabnormal\tor\ton\ttreatment\t(but\tnot\ton\ttarget),\trepeat\tevery\t3-6\tmonths\n\n\n**What to do if results are abnormal:**\n\n\n- Use\tnon-pharmacological\tinterventions\tconcurrently\twith\tstatins\n- Improve\tblood\tglucose\tcontrol\n- Reduce\tsaturated\tfat\tintake\n- Ensure\tregular\tindividualized\texercise\n- Reduce\tweight\tif\tindicated\n- Avoid\talcohol\tintake\tif\ttriglycerides\televated\n- Referral\tto\tdietitian\n- Discourage\tsmoking\n\n\n**Pharmacologic Therapy**\n\n\n- Statin\ttherapy\tis\tthe\tmainstay\tof\tPharmacologic\ttherapy\tfor\tany\tperson\twith type\t2\tdiabetes\t&gt;40\tyears\tregardless\tof\tlipid\tlevel.\tFor\tpatients\twith type 1 diabetes, statin therapy should be started in individuals not responding to lifestyle modification.\n- Fibrates\tmay\tbe\tused\tin\taddition\tfor\tpersistent\thypertriglyceridemia.\n- Nicotinic\tacid\tmay\tbe\tconsidered\tas\tan\talternative\ttherapy\n\n\n**Management**\n\n\n- Manage\tunderlying\tassociated\tcardiovascular\trisk\tfactors.\n- Life-style\tmodification\n- Initiate\taspirin\ttherapy\tif\tindicated\n- Consider\tthe\tuse\tof\tbeta-blockers,\tAngiotensin\tConverting\tEnzyme\t(ACE) inhibitors, Angiotensin Receptor Blockers (ARBs) and good glycaemic control post myocardial infarction.\n\n\n**Recommendation for use of Aspirin**\n\n\nThe use of low dose aspirin (75 mg or 81 mg) in people with Type 2 diabetes reduces cardiovascular events, and is indicated in the following:\n\n\n- Secondary\tprevention\tfor\tcoronary\tand\tcerebrovascular\tdiseases\n- Primary\tprevention\tfor\tpeople\twith\tType\t2\tdiabetes\tover\tthe\tage\tof\t40\tyears, having:\n- Family\thistory\tof\tischaemic\theart\tdisease\t(IHD)\n- Cigarette\tsmoking\n- Hypertension\n- Obesity\n- Proteinuria\n- Dyslipidaemia\n\n\nHowever, contraindications may prevent its use, especially the presence or history of peptic ulcers, dyspepsia, heartburn or bleeding and asthma.\n\n\nAspirin should not be used in uncontrolled and malignant hypertension of more than 160/100 mmHg.\n\n\nHemorrhagic stroke must be ruled out before initiating aspirin therapy in patients with acute cerebrovascular accident. The recommended daily dose is 75 -162 mg of aspirin per day.\n\n\nCHAPTER FOUR\n\n\nKENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS| 110\n\n\n",
            "startLine": 3603,
            "endLine": 3822,
            "introContent": {
              "content": "Comorbidities are diseases or medical conditions that co-exist with the primary disease. There are various forms of co-morbidities that contribute to the morbidity and mortality associated with diabetes. They include hypertension, mental health, dyslipidemia among others.",
              "tokenCount": 54,
              "startLine": 3604,
              "endLine": 3608
            },
            "keywords": [],
            "subsections": [
              {
                "id": "subsection-3-4-1",
                "level": "h3",
                "number": "3.4.1",
                "title": "3.4.1. Hypertension",
                "slug": "341-hypertension",
                "url": "/guidelines/34-co-morbidities-in-diabetes-mellitus/341-hypertension",
                "parentId": "section-3-4",
                "breadcrumb": [
                  "CHAPTER THREE: MANAGEMENT OF COMPLICATIONS AND COMORBIDITIES IN DIABETES MELLITUS",
                  "3.4. Co-Morbidities in Diabetes Mellitus",
                  "3.4.1. Hypertension"
                ],
                "tokenCount": 963,
                "content": "### 3.4.1. Hypertension\n\n\n**Principles of management of hypertension in diabetes mellitus**\n\n\n- Determine\tblood\tpressure\tin\tpeople\twith\tType\t2\tdiabetes\tat\tevery\tvisit,\tusing standard techniques (measure with a mercury sphygmomanometer and the right-sized cuff with the patient seated after 5 minutes).\n- Classify\tblood\tpressure\tstatus\tusing\ta\tBP\tof\t≥140/90\tmmHg\tas\thypertensive.\n- Most\tpatients\twith\tdiabetes\tand\thypertension\tshould\tbe\ttreated\tto\ta\tsystolic blood pressure goal of 140 mmHg and a diastolic blood pressure goal of 90 mmHg.\n- Lower\tsystolic\tand\tdiastolic\tblood\tpressure\ttargets,\tsuch\tas\t130/80\tmmHg, may be appropriate for individuals at high risk of cardiovascular disease, if they can be achieved without undue treatment burden.\n- In\tpregnant\tpatients\twith\tdiabetes\tand\tchronic\thypertension,\tblood\tpressure targets of SBP 130-150 and/or DBP 80-105 mmHg are suggested in the interest of optimizing long-term maternal health and minimizing impaired fetal growth.\n- If\thypertensive,\tassessment\tshould\tinclude\ta\tthorough\thistory,\tphysical examination, staging and cardiovascular risk stratification (refer to the risk stratification tool in Annex 1). Look for other components of metabolic syndrome and complications of both diabetes and hypertension.\n\n\n**Non-Pharmacologic Management**\n\n\nIntegrate management of hypertension and that of diabetes, starting with:\n\n\n- Diabetes\tEducation\n- Lifestyle\tmodifications\t(physical\texercise,\tdiet\tand\tweight\tloss)\tand\tsetting\tgoals\n\n\n- Diet\tshould\tbe\tlow\tin\tsodium,\trich\tin\tvegetables\tand\tfruits,\tand\tuse\tof\tlow-fat dairy products\n- Reduce\talcohol\tconsumption\tand\ttobacco\tcessation\n\n\n**Pharmacologic Management**\n\n\n- Pharmacologic\tmanagement\tshould\tbe\tconsidered\tin\tall\tpatients\twith diabetes and a documented sustained blood Pressure of above 140/90 mmHg despite lifestyle modification\n- Individualize\thypertensive\ttherapy\tto\tachieve\tgood\tcontrol.\n- Multiple\tagents\tare\tfrequently\trequired.\tFixed\tdose\tcombinations\tshould\tbe used when Blood pressures are stable and response to individual agents is known.\n- Monitor\tserum\tcreatinine\tand\tpotassium\tonce\ta\tyear\tand\tmore\tfrequently\tif there is evidence of renal impairment.\n- Note\tthe\tpotential\tproblems\twith\tcertain\tanti-hypertensives:\n- -Diuretics in large doses inhibit insulin release\n- -Beta blockers may blunt or mask symptoms of Hypoglycemia and exacerbate peripheral vascular disease\n- -Dyslipidaemia may be worsened by beta blockers and diuretics,\n- -Impotence and postural hypotension may be precipitated or aggravated by alpha blockers and centrally acting agents (e.g. methyldopa).\n- -Angiotensin converting enzyme (ACE) inhibitors may induce hyperkalaemia, renal failure, a persistent cough.\n\n\nTable 33: Principles of management of hypertension by level of severity\n\n\n\n\n| evel of severity                | Management                                                                                                             |\n|---------------------------------|------------------------------------------------------------------------------------------------------------------------|\n| 140/90                          | Repeat Blood pressure on different occasion and initiate lifestyle modification and pharmacologic therapy              |\n| 160/100 mmHg                    | Treat with two classes of oral Anti-Hypertensive drugs                                                                 |\n| 180/120 mmHg                    | Bring BP down to near normal below 160/100 mmHg within 48 hrs.                                                         |\n| If patient has end organ damage | Reduce blood pressure by not more than 25% in the first 1-2 hours with an agent determined by the physician/specialist |\n\n\nNOTE: Avoid sublingual antihypertensive agents that have the potential to dramatically and catastrophically reduce blood pressure.\n\n\n**Management of Hypertension**\n\n\nFigure 26: Algorithm for the management of hypertension in patients with diabetes mellitus\n\n\n![105 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS](images/picture_049_page_105.png)\n\n\n**Algorithm:  Management  of  hypertension  in  diabetes  in Primary Care**\n\n\nFigure 28: Management of hypertension in patients with diabetes in the Primary Care setting\n\n\n![Source: AMPATH](images/picture_050_page_106.png)\n\n\nSource: AMPATH\n\n\n",
                "startLine": 3609,
                "endLine": 3688,
                "introContent": null,
                "keywords": [],
                "subsections": null
              },
              {
                "id": "subsection-3-4-2",
                "level": "h3",
                "number": "3.4.2",
                "title": "3.4.2. Mental Disorders in Diabetes",
                "slug": "342-mental-disorders-in-diabetes",
                "url": "/guidelines/34-co-morbidities-in-diabetes-mellitus/342-mental-disorders-in-diabetes",
                "parentId": "section-3-4",
                "breadcrumb": [
                  "CHAPTER THREE: MANAGEMENT OF COMPLICATIONS AND COMORBIDITIES IN DIABETES MELLITUS",
                  "3.4. Co-Morbidities in Diabetes Mellitus",
                  "3.4.2. Mental Disorders in Diabetes"
                ],
                "tokenCount": 219,
                "content": "### 3.4.2. Mental Disorders in Diabetes\n\n\nMental health is an important aspect of Diabetes management. Adolescents living with Diabetes are a particularly vulnerable population that requires psychosocial support as an integral part of their management.\n\n\nA wide spectrum of psychosocial and emotional challenges exists in people living with\n\n\n**Diabetes that include:**\n\n\n- Depressive\tdisorders\n- Disordered\teating\tbehavior\n- Anxiety\tdisorders\n\n\nHealthcare providers should be aware that psychotropic agents are known to increase the incidence of diabetes and may affect glycemic control.\n\n\n**Management**\n\n\n- All\tindividuals\tshould\tbe\tscreened\tat\tdiagnosis\tand\tduring\tfollow\tup for any mental health issues and referred appropriately for psychotherapy.\n- Counselling\tat\tdiagnosis\tis\tkey\tto\tacceptance,\tmedication\tcompliance and mitigation of mental disorders\n- Consider\tthe\teffects\ton\tglycemic\tcontrol\twhen\tpatients\tare\ton psychotropics.\n- Encourage\tpeer\tand\tsupport\tgroup\tinvolvement\tas\tpart\tof\troutine\tcare.\n\n\n",
                "startLine": 3689,
                "endLine": 3717,
                "introContent": null,
                "keywords": [],
                "subsections": null
              },
              {
                "id": "subsection-3-4-3",
                "level": "h3",
                "number": "3.4.3",
                "title": "3.4.3. Lipids disorders in Diabetes",
                "slug": "343-lipids-disorders-in-diabetes",
                "url": "/guidelines/34-co-morbidities-in-diabetes-mellitus/343-lipids-disorders-in-diabetes",
                "parentId": "section-3-4",
                "breadcrumb": [
                  "CHAPTER THREE: MANAGEMENT OF COMPLICATIONS AND COMORBIDITIES IN DIABETES MELLITUS",
                  "3.4. Co-Morbidities in Diabetes Mellitus",
                  "3.4.3. Lipids disorders in Diabetes"
                ],
                "tokenCount": 977,
                "content": "### 3.4.3. Lipids disorders in Diabetes\n\n\nThe risk of coronary artery disease and other macrovascular disorders is 2 - 4 times higher in people living with diabetes than in non-diabetic subjects and increases in parallel with the degree of dyslipidaemia.\n\n\nTable 34: Desired level of lipids in patients with diabetes (LDL targets in the absence of CKD and CVD, DM in patients &lt; 40 years, duration of &lt;10 years)\n\n\n| Lipids            | Target(mmol/L)   | Target (Mg/dl   |\n|-------------------|------------------|-----------------|\n| Total cholesterol | <4.8             | <93.6           |\n| LDLcholesterol    | <2.6             | <-46.8          |\n| HDLcholesterol    | >1.2 (Female)    | >19.8           |\n| Triglycerides     | <1.7             | <30.6           |\n\n\nCKD-Chronic kidney disease, CVD- Cardiovascular disease\n\n\nTable 35: Lipid Targets for secondary prevention (people with history of cardiovascular event)\n\n\n| Lipids            | Target (mmol/L)   | Target (Mg/dL)   |\n|-------------------|-------------------|------------------|\n| Total cholesterol | <4.8              | <93.6            |\n| LDLcholesterol    | <1.8              | <32.4            |\n| HDLcholesterol    | >1.2              | >19.8            |\n| Triglycerides     | <1.7              | <30.6            |\n\n\n**Assessment**\n\n\nMeasure fasting lipids including total cholesterol, triglycerides and HDL and LDL cholesterol at initial contact.\n\n\n**How often:**\n\n\n- If\tnormal,\tdo\ta\trisk-stratification\tand\tdetermine\tappropriate\ttreatment.\n- If\tabnormal\tor\ton\ttreatment\t(but\tnot\ton\ttarget),\trepeat\tevery\t3-6\tmonths\n\n\n**What to do if results are abnormal:**\n\n\n- Use\tnon-pharmacological\tinterventions\tconcurrently\twith\tstatins\n- Improve\tblood\tglucose\tcontrol\n- Reduce\tsaturated\tfat\tintake\n- Ensure\tregular\tindividualized\texercise\n- Reduce\tweight\tif\tindicated\n- Avoid\talcohol\tintake\tif\ttriglycerides\televated\n- Referral\tto\tdietitian\n- Discourage\tsmoking\n\n\n**Pharmacologic Therapy**\n\n\n- Statin\ttherapy\tis\tthe\tmainstay\tof\tPharmacologic\ttherapy\tfor\tany\tperson\twith type\t2\tdiabetes\t&gt;40\tyears\tregardless\tof\tlipid\tlevel.\tFor\tpatients\twith type 1 diabetes, statin therapy should be started in individuals not responding to lifestyle modification.\n- Fibrates\tmay\tbe\tused\tin\taddition\tfor\tpersistent\thypertriglyceridemia.\n- Nicotinic\tacid\tmay\tbe\tconsidered\tas\tan\talternative\ttherapy\n\n\n**Management**\n\n\n- Manage\tunderlying\tassociated\tcardiovascular\trisk\tfactors.\n- Life-style\tmodification\n- Initiate\taspirin\ttherapy\tif\tindicated\n- Consider\tthe\tuse\tof\tbeta-blockers,\tAngiotensin\tConverting\tEnzyme\t(ACE) inhibitors, Angiotensin Receptor Blockers (ARBs) and good glycaemic control post myocardial infarction.\n\n\n**Recommendation for use of Aspirin**\n\n\nThe use of low dose aspirin (75 mg or 81 mg) in people with Type 2 diabetes reduces cardiovascular events, and is indicated in the following:\n\n\n- Secondary\tprevention\tfor\tcoronary\tand\tcerebrovascular\tdiseases\n- Primary\tprevention\tfor\tpeople\twith\tType\t2\tdiabetes\tover\tthe\tage\tof\t40\tyears, having:\n- Family\thistory\tof\tischaemic\theart\tdisease\t(IHD)\n- Cigarette\tsmoking\n- Hypertension\n- Obesity\n- Proteinuria\n- Dyslipidaemia\n\n\nHowever, contraindications may prevent its use, especially the presence or history of peptic ulcers, dyspepsia, heartburn or bleeding and asthma.\n\n\nAspirin should not be used in uncontrolled and malignant hypertension of more than 160/100 mmHg.\n\n\nHemorrhagic stroke must be ruled out before initiating aspirin therapy in patients with acute cerebrovascular accident. The recommended daily dose is 75 -162 mg of aspirin per day.\n\n\nCHAPTER FOUR\n\n\nKENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS| 110\n\n\n",
                "startLine": 3718,
                "endLine": 3822,
                "introContent": null,
                "keywords": [],
                "subsections": null
              }
            ]
          }
        ]
      },
      {
        "id": "chapter-4",
        "level": "h1",
        "number": "4",
        "title": "CHAPTER FOUR: METABOLIC SYNDROME AND OBESITY",
        "slug": "chapter-four-metabolic-syndrome-and-obesity",
        "url": "/guidelines/chapter-four-metabolic-syndrome-and-obesity",
        "tokenCount": 1206,
        "summary": null,
        "content": "# CHAPTER FOUR: METABOLIC SYNDROME AND OBESITY\n\n\n## 4.1. Introduction\n\n\nMetabolic syndrome is a cluster of metabolic disorders. It occurs when a person has three or more of the following measurements:\n\n\n- Abdominal\tobesity\t(Waist\tcircumference\tof\tgreater\tthan\t40\tinches\tin\tmen, and greater than 35 inches in women)\n- Triglyceride\tlevel\tof\t1.69\tmmol/L\t(150\tmilligrams\tper\tdeciliter\tof\tblood\tmg/ dL) or greater\n- HDL\tcholesterol\tof\tless\tthan\t1.03\tmmol/L\t(40\tmg/dL)\tin\tmen\tor\tless\tthan 1.29 (mmol/L) 50 mg/dL in women\n- Systolic\tblood\tpressure\t(top\tnumber)\tof\t130\tmillimeters\tof\tmercury\t(mm Hg) or greater, or diastolic blood pressure (bottom number) of 85 mm Hg or greater\n- Fasting\tglucose\tof\t&gt;\t5.6\tmmol/L\t(100\tmg/dL)\n\n\n**Strong associations of the metabolic syndrome include:**\n\n\n- i. Polycystic ovary disease\n- ii. Acanthosis nigricans\n- iii. Decreased fibrinolytic activity\n- iv. Hyperuricaemia\n- v. Pro-inflammatory state (elevated CRP)\n- vi. Microalbuminuria\n\n\n## 4.2. Management of the metabolic syndrome\n\n\nTreatment  of  the  metabolic  syndrome  consists  of  managing  the  various  disease components and targeting the pathophysiological derangements of the syndrome: central obesity and insulin resistance. The first line of treatment for all components is\n\n\n- lifestyle\tchange-\tweight\tloss\tand\tincreased\tphysical\tactivity.\n- Insulin\tsensitivity\tcan\tbe\timproved\tby\tnon-pharmacological\tand pharmacological means.\n\n\n## 4.3. Obesity\n\n\nOverweight and obesity are defined as abnormal or excessive fat accumulation that presents a risk to health. For adults, WHO defines overweight and obesity as follows:\n\n\nTable 36: Definition of overweight and obesity per age category\n\n\n| Ag e categ ory         | Overw eig ht                                                                                     | Obesity                                                                                         |\n|------------------------|--------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|\n| Children under 5 years | Weight-for-height greater than 2 standard deviations above WHOChild Growth Standards median      | Weight-for-height greater than 3 standard deviations above theWHO Child Growth Standards median |\n| 5-19 years             | Overweight is BMI-for-age greater than 1 standard deviation above the WHOGrowth Reference median | Greater than 2 standard deviations above the WHOGrowth Reference median                         |\n| B                      | MI greater than or equal to 25                                                                   | BMI greater than or equal to 30                                                                 |\n\n\nBeing overweight/obese significantly increases the risk of morbidity and mortality from Type 2 diabetes and its co-morbidities. Successful weight reduction has a positive impact on these outcomes. Obesity is a major component of the metabolic syndrome. In Kenya, the WHO STEPwise Survey found the prevalence of overweight and obesity at 27.9% in adults.\n\n\n### 4.3.1. Measurements for evaluation of obesity\n\n\n**1. Calculation of overall obesity, the body mass index (BMI).**\n\n\nBMI represents overall fatness. It is derived from the patient's weight in kilograms (kg) and the height in meters (m) from the following formula: BMI= Weight (kg)/Height (m2)\n\n\nTable 37: Classification of BMI\n\n\n| Cl assification             | al ues (kg m2)   |\n|-----------------------------|------------------|\n| Underweight <               | 18.5             |\n| Normal weight               | 18.6-24.9        |\n| Overweight 2                | 5-29.9           |\n| Obesity (class 1) 3         | 0-34.9           |\n| Obesity (class 2) 3         | 5-39.9           |\n| Extreme obesity (class 3) > | 40               |\n\n\n\n\n**2. Determination of central fat distribution by measurement of waist circumference.**\n\n\nWaist circumference is an indicator of intra-abdominal fatness and is a good indicator of abdominal fat. A high waist circumference is associated with an increased risk for type 2 diabetes, high cholesterol, high blood pressure and cardiovascular disease.\n\n\nIndicators of risk\n\n\nMen: Waist Circumference greater than or equal to 102 cm\n\n\nWomen: Waist Circumference greater than or equal to 88 cm\n\n\n**3. Waist hip ratio**\n\n\nThe pattern of distribution of the fat in the body (whether mostly peripherally or centrally distributed) is assessed using the waist hip ratio (WHR):\n\n\nWHR = waist circumference (cm)/Hip circumference (cm)\n\n\nWaist circumference (WC) should be measured midway between the lower rib margin and the iliac crest\n\n\nHip circumference is taken as the largest circumference of the hip.\n\n\n**Indicators of risk**\n\n\nWomen: WHR Greater than 0.85\n\n\nMen: WHR Greater than 1.0\n\n\n### 4.3.2. General principles of the management of obesity\n\n\n- i. Assess dietary intake, level of physical activity, BMI, and waist circumference and advice accordingly\n- ii. Assess efficacy of weight loss regularly and initiate effective measures\n- iii. Maintain records of goals, instructions and weight progress chart\n\n\n![CHAPTER FIVE](images/picture_051_page_114.png)\n\n\nCHAPTER FIVE\n\n\nKENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS| 114\n\n\n",
        "startLine": 3823,
        "endLine": 3958,
        "introContent": null,
        "sections": [
          {
            "id": "section-4-1",
            "level": "h2",
            "number": "4.1",
            "title": "4.1. Introduction",
            "slug": "41-introduction",
            "url": "/guidelines/chapter-four-metabolic-syndrome-and-obesity/41-introduction",
            "parentId": "chapter-4",
            "breadcrumb": [
              "CHAPTER FOUR: METABOLIC SYNDROME AND OBESITY",
              "4.1. Introduction"
            ],
            "tokenCount": 303,
            "content": "## 4.1. Introduction\n\n\nMetabolic syndrome is a cluster of metabolic disorders. It occurs when a person has three or more of the following measurements:\n\n\n- Abdominal\tobesity\t(Waist\tcircumference\tof\tgreater\tthan\t40\tinches\tin\tmen, and greater than 35 inches in women)\n- Triglyceride\tlevel\tof\t1.69\tmmol/L\t(150\tmilligrams\tper\tdeciliter\tof\tblood\tmg/ dL) or greater\n- HDL\tcholesterol\tof\tless\tthan\t1.03\tmmol/L\t(40\tmg/dL)\tin\tmen\tor\tless\tthan 1.29 (mmol/L) 50 mg/dL in women\n- Systolic\tblood\tpressure\t(top\tnumber)\tof\t130\tmillimeters\tof\tmercury\t(mm Hg) or greater, or diastolic blood pressure (bottom number) of 85 mm Hg or greater\n- Fasting\tglucose\tof\t&gt;\t5.6\tmmol/L\t(100\tmg/dL)\n\n\n**Strong associations of the metabolic syndrome include:**\n\n\n- i. Polycystic ovary disease\n- ii. Acanthosis nigricans\n- iii. Decreased fibrinolytic activity\n- iv. Hyperuricaemia\n- v. Pro-inflammatory state (elevated CRP)\n- vi. Microalbuminuria\n\n\n",
            "startLine": 3826,
            "endLine": 3849,
            "introContent": null,
            "keywords": [],
            "subsections": null
          },
          {
            "id": "section-4-2",
            "level": "h2",
            "number": "4.2",
            "title": "4.2. Management of the metabolic syndrome",
            "slug": "42-management-of-the-metabolic-syndrome",
            "url": "/guidelines/chapter-four-metabolic-syndrome-and-obesity/42-management-of-the-metabolic-syndrome",
            "parentId": "chapter-4",
            "breadcrumb": [
              "CHAPTER FOUR: METABOLIC SYNDROME AND OBESITY",
              "4.2. Management of the metabolic syndrome"
            ],
            "tokenCount": 101,
            "content": "## 4.2. Management of the metabolic syndrome\n\n\nTreatment  of  the  metabolic  syndrome  consists  of  managing  the  various  disease components and targeting the pathophysiological derangements of the syndrome: central obesity and insulin resistance. The first line of treatment for all components is\n\n\n- lifestyle\tchange-\tweight\tloss\tand\tincreased\tphysical\tactivity.\n- Insulin\tsensitivity\tcan\tbe\timproved\tby\tnon-pharmacological\tand pharmacological means.\n\n\n",
            "startLine": 3850,
            "endLine": 3859,
            "introContent": null,
            "keywords": [],
            "subsections": null
          },
          {
            "id": "section-4-3",
            "level": "h2",
            "number": "4.3",
            "title": "4.3. Obesity",
            "slug": "43-obesity",
            "url": "/guidelines/chapter-four-metabolic-syndrome-and-obesity/43-obesity",
            "parentId": "chapter-4",
            "breadcrumb": [
              "CHAPTER FOUR: METABOLIC SYNDROME AND OBESITY",
              "4.3. Obesity"
            ],
            "tokenCount": 786,
            "content": "## 4.3. Obesity\n\n\nOverweight and obesity are defined as abnormal or excessive fat accumulation that presents a risk to health. For adults, WHO defines overweight and obesity as follows:\n\n\nTable 36: Definition of overweight and obesity per age category\n\n\n| Ag e categ ory         | Overw eig ht                                                                                     | Obesity                                                                                         |\n|------------------------|--------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|\n| Children under 5 years | Weight-for-height greater than 2 standard deviations above WHOChild Growth Standards median      | Weight-for-height greater than 3 standard deviations above theWHO Child Growth Standards median |\n| 5-19 years             | Overweight is BMI-for-age greater than 1 standard deviation above the WHOGrowth Reference median | Greater than 2 standard deviations above the WHOGrowth Reference median                         |\n| B                      | MI greater than or equal to 25                                                                   | BMI greater than or equal to 30                                                                 |\n\n\nBeing overweight/obese significantly increases the risk of morbidity and mortality from Type 2 diabetes and its co-morbidities. Successful weight reduction has a positive impact on these outcomes. Obesity is a major component of the metabolic syndrome. In Kenya, the WHO STEPwise Survey found the prevalence of overweight and obesity at 27.9% in adults.\n\n\n### 4.3.1. Measurements for evaluation of obesity\n\n\n**1. Calculation of overall obesity, the body mass index (BMI).**\n\n\nBMI represents overall fatness. It is derived from the patient's weight in kilograms (kg) and the height in meters (m) from the following formula: BMI= Weight (kg)/Height (m2)\n\n\nTable 37: Classification of BMI\n\n\n| Cl assification             | al ues (kg m2)   |\n|-----------------------------|------------------|\n| Underweight <               | 18.5             |\n| Normal weight               | 18.6-24.9        |\n| Overweight 2                | 5-29.9           |\n| Obesity (class 1) 3         | 0-34.9           |\n| Obesity (class 2) 3         | 5-39.9           |\n| Extreme obesity (class 3) > | 40               |\n\n\n\n\n**2. Determination of central fat distribution by measurement of waist circumference.**\n\n\nWaist circumference is an indicator of intra-abdominal fatness and is a good indicator of abdominal fat. A high waist circumference is associated with an increased risk for type 2 diabetes, high cholesterol, high blood pressure and cardiovascular disease.\n\n\nIndicators of risk\n\n\nMen: Waist Circumference greater than or equal to 102 cm\n\n\nWomen: Waist Circumference greater than or equal to 88 cm\n\n\n**3. Waist hip ratio**\n\n\nThe pattern of distribution of the fat in the body (whether mostly peripherally or centrally distributed) is assessed using the waist hip ratio (WHR):\n\n\nWHR = waist circumference (cm)/Hip circumference (cm)\n\n\nWaist circumference (WC) should be measured midway between the lower rib margin and the iliac crest\n\n\nHip circumference is taken as the largest circumference of the hip.\n\n\n**Indicators of risk**\n\n\nWomen: WHR Greater than 0.85\n\n\nMen: WHR Greater than 1.0\n\n\n### 4.3.2. General principles of the management of obesity\n\n\n- i. Assess dietary intake, level of physical activity, BMI, and waist circumference and advice accordingly\n- ii. Assess efficacy of weight loss regularly and initiate effective measures\n- iii. Maintain records of goals, instructions and weight progress chart\n\n\n![CHAPTER FIVE](images/picture_051_page_114.png)\n\n\nCHAPTER FIVE\n\n\nKENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS| 114\n\n\n",
            "startLine": 3860,
            "endLine": 3958,
            "introContent": {
              "content": "Overweight and obesity are defined as abnormal or excessive fat accumulation that presents a risk to health. For adults, WHO defines overweight and obesity as follows:\n\n\nTable 36: Definition of overweight and obesity per age category\n\n\n| Ag e categ ory         | Overw eig ht                                                                                     | Obesity                                                                                         |\n|------------------------|--------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|\n| Children under 5 years | Weight-for-height greater than 2 standard deviations above WHOChild Growth Standards median      | Weight-for-height greater than 3 standard deviations above theWHO Child Growth Standards median |\n| 5-19 years             | Overweight is BMI-for-age greater than 1 standard deviation above the WHOGrowth Reference median | Greater than 2 standard deviations above the WHOGrowth Reference median                         |\n| B                      | MI greater than or equal to 25                                                                   | BMI greater than or equal to 30                                                                 |\n\n\nBeing overweight/obese significantly increases the risk of morbidity and mortality from Type 2 diabetes and its co-morbidities. Successful weight reduction has a positive impact on these outcomes. Obesity is a major component of the metabolic syndrome. In Kenya, the WHO STEPwise Survey found the prevalence of overweight and obesity at 27.9% in adults.",
              "tokenCount": 254,
              "startLine": 3861,
              "endLine": 3878
            },
            "keywords": [],
            "subsections": [
              {
                "id": "subsection-4-3-1",
                "level": "h3",
                "number": "4.3.1",
                "title": "4.3.1. Measurements for evaluation of obesity",
                "slug": "431-measurements-for-evaluation-of-obesity",
                "url": "/guidelines/43-obesity/431-measurements-for-evaluation-of-obesity",
                "parentId": "section-4-3",
                "breadcrumb": [
                  "CHAPTER FOUR: METABOLIC SYNDROME AND OBESITY",
                  "4.3. Obesity",
                  "4.3.1. Measurements for evaluation of obesity"
                ],
                "tokenCount": 415,
                "content": "### 4.3.1. Measurements for evaluation of obesity\n\n\n**1. Calculation of overall obesity, the body mass index (BMI).**\n\n\nBMI represents overall fatness. It is derived from the patient's weight in kilograms (kg) and the height in meters (m) from the following formula: BMI= Weight (kg)/Height (m2)\n\n\nTable 37: Classification of BMI\n\n\n| Cl assification             | al ues (kg m2)   |\n|-----------------------------|------------------|\n| Underweight <               | 18.5             |\n| Normal weight               | 18.6-24.9        |\n| Overweight 2                | 5-29.9           |\n| Obesity (class 1) 3         | 0-34.9           |\n| Obesity (class 2) 3         | 5-39.9           |\n| Extreme obesity (class 3) > | 40               |\n\n\n\n\n**2. Determination of central fat distribution by measurement of waist circumference.**\n\n\nWaist circumference is an indicator of intra-abdominal fatness and is a good indicator of abdominal fat. A high waist circumference is associated with an increased risk for type 2 diabetes, high cholesterol, high blood pressure and cardiovascular disease.\n\n\nIndicators of risk\n\n\nMen: Waist Circumference greater than or equal to 102 cm\n\n\nWomen: Waist Circumference greater than or equal to 88 cm\n\n\n**3. Waist hip ratio**\n\n\nThe pattern of distribution of the fat in the body (whether mostly peripherally or centrally distributed) is assessed using the waist hip ratio (WHR):\n\n\nWHR = waist circumference (cm)/Hip circumference (cm)\n\n\nWaist circumference (WC) should be measured midway between the lower rib margin and the iliac crest\n\n\nHip circumference is taken as the largest circumference of the hip.\n\n\n**Indicators of risk**\n\n\nWomen: WHR Greater than 0.85\n\n\nMen: WHR Greater than 1.0\n\n\n",
                "startLine": 3879,
                "endLine": 3941,
                "introContent": null,
                "keywords": [],
                "subsections": null
              },
              {
                "id": "subsection-4-3-2",
                "level": "h3",
                "number": "4.3.2",
                "title": "4.3.2. General principles of the management of obesity",
                "slug": "432-general-principles-of-the-management-of-obesity",
                "url": "/guidelines/43-obesity/432-general-principles-of-the-management-of-obesity",
                "parentId": "section-4-3",
                "breadcrumb": [
                  "CHAPTER FOUR: METABOLIC SYNDROME AND OBESITY",
                  "4.3. Obesity",
                  "4.3.2. General principles of the management of obesity"
                ],
                "tokenCount": 109,
                "content": "### 4.3.2. General principles of the management of obesity\n\n\n- i. Assess dietary intake, level of physical activity, BMI, and waist circumference and advice accordingly\n- ii. Assess efficacy of weight loss regularly and initiate effective measures\n- iii. Maintain records of goals, instructions and weight progress chart\n\n\n![CHAPTER FIVE](images/picture_051_page_114.png)\n\n\nCHAPTER FIVE\n\n\nKENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS| 114\n\n\n",
                "startLine": 3942,
                "endLine": 3958,
                "introContent": null,
                "keywords": [],
                "subsections": null
              }
            ]
          }
        ]
      },
      {
        "id": "chapter-5",
        "level": "h1",
        "number": "5",
        "title": "CHAPTER FIVE: MANAGEMENT OF DIABETES IN SPECIAL SITUATIONS",
        "slug": "chapter-five-management-of-diabetes-in-special-situations",
        "url": "/guidelines/chapter-five-management-of-diabetes-in-special-situations",
        "tokenCount": 9796,
        "summary": null,
        "content": "# CHAPTER FIVE: MANAGEMENT OF DIABETES IN SPECIAL SITUATIONS\n\n\n## 5.1. Diabetes in Pregnancy\n\n\nHyperglycemia that is first detected during pregnancy should be classified either as Diabetes Mellitus in Pregnancy (DIP) or as Gestational Diabetes mellitus (GDM).\n\n\n**Diabetes in Preg nancy**\n\n\n- Pregnancy in a patient known to previously have Diabetes\n- Hyperglycemia diagnosed for the 1 st time during pregnancy, that meets the WHO criterion for DM in the non-pregnant state\n- May occur at any time during the pregnancy, including the 1 st trimester\n\n\n**The diagnostic criteria**\n\n\nTable 38: Diagnostic criteria for diabetes in pregnancy and gestational diabetes mellitus\n\n\n|                                                     | Diabetes in Pregnancy                                   | Gestational Diabetes mellitus   | Gestational Diabetes mellitus   |\n|-----------------------------------------------------|---------------------------------------------------------|---------------------------------|---------------------------------|\n| Fasting Blood Glucose                               | ≥ 7 mmol/L (126 mg/dL)                                  | 5.1-6.9 mmol/L                  | (92-125 mg/dL)                  |\n| 1 hour post-prandial (after 75-g oral glucose load) | Not applicable                                          | ≥ 10 mmol/L                     | (180 mg/dL)                     |\n| 2 hour post-prandial (after 75-g oral glucose load) | > 11.0 mmol/L (200 mg/dL)                               | 8.5-11.0 mmol/L                 | (153-199 mg/dL)                 |\n| Random Blood Glucose                                | ≥ 11.0 mmol/L (200 mg/dL) in the presence of DMsymptoms | Not applicable                  |                                 |\n\n\nSource:  International Federation of Gynecology and Obstetrics (FIGO) Initiative on Gestational Diabetes Mellitus 2015 (based on IADPDG 2010 and WHO 2013 recommendations)\n\n\n\n\n**estational  Diabetes Mel l itus**\n\n\n- Hyperglycemia diagnosed for the 1st time during pregnancy (in 2 nd or 3 rd trimester\n- Hyperglycemia levels do not meet WHO criterion for DM\n- May occur at any time during the pregnancy, but most likely after 24 weeks\n\n\n**Management of Diabetes during Pregnancy**\n\n\n**i. Preconception planning and care**\n\n\nThe following aspects should be discussed with women who have diabetes (and all women of reproductive age) and actioned by the attending health care provider\n\n\n- Patients\tshould\tbe\toffered\tcontraceptives\tto\tprevent\tunplanned\tpregnancy and optimize glycemic control at least 3 months before conception\n- Counsel\tpatient\ton\tthe\timportance\tof\tgood\tblood\tglucose\tcontrol\tbefore pregnancy and during pregnancy to reduce the maternal, foetal and neonatal complications\n- Optimize\tweight\n- Optimize\tblood\tglucose\tcontrol\tto\ttargets\t-\tPatients\tmay\trequire\tinsulin\tto optimize blood glucose control\n- -HbA1c 6% - 6.5%,\n- -FBS &lt; 5.3 mmol/L,\n- -One hour postprandial &lt; 7.8 mmol/l,\n- -two-hour postprandial &lt; 6.7 mmol/l\n- Should\tstop\tteratogenic\tmedications\t(ACE\tinhibitors,\tARBs,\tStatins)\tand supplements\n- Adequate\tfolate\tsupplementation\n- Stop\tsmoking\n- Good\tblood\tpressure\tcontrol\t(&lt;130/80\tmmHg)\n- Assess\tfor\tnephropathy,\tretinopathy,\tthyroid\tdysfunction,\tUTI,\tautonomic neuropathy, cardiac dysfunction and manage/ refer accordingly\n- Highlight\tthe\tneed\tfor:\t-\n- -regular visits (1st trimester: monthly visits, 2nd trimester: 2-4 weekly visits, 3rd trimester: 2-weekly visits)\n- -regular home blood glucose monitoring\n- -adjusting insulin doses depending on blood glucose levels\n- -normal routine ANC profile and need repeat screening for\n- complications in the 2nd and 3rd trimester (urinalysis, UECs, FBC, Ultrasound)\n- -an appropriate diet\n- -appropriate exercises during pregnancy\n\n\n**ii. Pregnancy care**\n\n\n- Multi-disciplinary\tcare\tis\timportant\tand\tshould\tinclude\tthe\tfollowingdiabetologists/physician, obstetrician, diabetes educator, dietitian, neonatologist/pediatrician (include the process of follow up and antenatal management). Patients should be referred to facilities offering specialized care.\n\n\n- Regular\tblood\tglucose\tmonitoring\tto\tachieve\tthe\tpreset\ttargets\tfor pregnancy.\n- -HbA1c 6.0% - 6.5%,\n- -FBS &lt; 5.3 mmol/L,\n- -One hour postprandial &lt; 7.8 mmol/l,\n- -two-hour postprandial &lt; 6.7 mmol/l\n- Nutritional\tcounseling\tshould\tbe\toffered\tduring\tpregnancy\n- Regular\texercise\ti.e.\twalking\tat\tleast\t30\tminutes\tper\tday\n- Regular\tclinic\tvisits\n- Metformin\tand\tGlibenclamide\tcan\tbe\tused\tsafely\tin\tpregnancy\tas\tlong\tas sugars   are controlled to target\n- If\tsugars\tremain\televated,\tintensification\tof\ttherapy\tmust\tbe\tconsidered, including a switch to insulin therapy\n- Patients\twith\tT1DM\tmust\tremain\ton\tinsulin\ttherapy\ttitrated\tto\ttarget\n- Due\tto\tthe\tchanges\tin\tpregnancy\tand\tincreasing\tweight\tgain,\tmost\twomen will be better controlled on insulin management.\n- Low\tdose\taspirin\t(75\tmg\tOD)\tshould\tbe\tgiven\tfor\tpre-eclampsia\tprophylaxis from 12 weeks to term.\n- First\ttrimester\tnausea\tand\tvomiting\tmay\tcause\tboth\thyper\tand\thypoglycemia that would warrant changes in therapy and dosing.\n- An\tultrasound\t(specifically\ta\tfetal\tanomaly\tscan)\tshould\tbe\tdone\tat\t18-24 weeks   to rule out congenital anomalies.\n- Monthly\tscans\tshould\tbe\tdone\tfrom\t28\tweeks\ttill\tterm\tto\tassess\tfor\tfetal growth\t\t and\tamniotic\tfluid\tindex\t(AFI).\tAn\tAFI\t&gt;25(polyhydramnios) is an indication of poor glycemic control.\n- Ensure\tnormal\troutine\tANC\tprofile\tand\tneed\trepeat\tscreening\tfor complications in the 2nd and 3rd trimester (urinalysis, UECs, FBC, Ultrasound)\n- Assess\tfor\tnephropathy,\tretinopathy,\tthyroid\tdysfunction,\tUTI,\tautonomic neuropathy, cardiac dysfunction and manage/ refer accordingly\n- Aim\tfor\tdelivery\tat\t38\tweeks,\tgiving\tsteroids\tto\tassist\tfoetal\tlung\tmaturity\tis beneficial\n- Delivery\tcan\tbe\tspontaneous,\tinduced,\telective\tor\temergency\tcaesarean\tsection\n- Delivery\tshould\tbe\tin\thospital\n\n\n**Definitive pharmacological management during pregnancy**\n\n\n- Insulin\tis\tthe\tmedication\tof\tchoice\tfor\tpregnant\tpatients\twith diabetes\n- Manage\tpatients\ton\tOGLAs\t(Metformin\tand\tGlibenclamide)\tif sugars are well-controlled\n\n\n**iii. Management during labor or caesarean section**\n\n\nGlycaemic control during labour and birth is of utmost importance to avoid adverse neonatal outcomes. It is essential that blood glucose is monitored hourly during labour and birth, ensuring that it is maintained between 4-7 mmol/l. Intravenous glucose, potassium and insulin (GKI) infusions (10% dextrose 500 mls + 10 mmol of potassium chloride + Regular insulin (10-14 units) depending on blood glucose, to run 5 hourly) should be prescribed at the onset of labour. These infusions are also useful for glycaemic control during caesarian section.\n\n\nFollowing delivery and removal of placenta insulin dose in the GKI reduces by half (GKI - 10% dextrose 500 mls + 10 mmol of potassium chloride + Regular insulin (5-7 units) to run 5 hourly) to prevent Hypoglycemia in the mother.\n\n\nOnce the mother is allowed to feed give the mother pre-pregnancy doses of insulin or oral hypoglycaemic.\n\n\n**For the neonate: -**\n\n\n- A\tblood\tglucose\tMUST\tbe\tdone\tfor\tthe\tneonate\tat\tbirth.\tIf\tbaby\tis\tstable\tand no hypoglycemia, initiate breastfeeding.\n- It's\tadvisable\tto\tadmit\tthe\tneonate\tfor\t6\t-24\thours\tin\tthe\tnew-born\tunit\tif\thypo glycemic and symptomatic.\n- Monitor\tblood\tglucose\t3\thourly\tfor\t24-48\thours\n- Aim\tat\tmaintaining\tthe\tblood\tglucose\t4\t-\t7\tmmol/L.\n- If\tblood\tglucose\tis\tless\tthan\t2.8\tmmol/L\tgive\ta\tbolus\tof\t10%\tdextrose\t2\tmls/kg and feed.\n- Monitor\tfor\tany\tneonatal\tcomplications.\n- Encourage\tbreastfeeding\n- A\tneonate\tborn\tto\ta\tmother\twho\thad\tpoor\tcontrol\tespecially\tin\tthe\tfirst trimester should be screened for congenital anomalies.\n\n\n**iv. Postpartum Care**\n\n\n- Ensure\tbreastfeeding\thas\tbeen\testablished\n- Increase\tsurveillance\tfor\tpuerperal\tinfections\tespecially\tsurgical\tincisions\tand wounds.\n- Patient\tshould\tgo\tback\tto\tpre-pregnancy\tdoses\tof\tinsulin\tor\tOGLAs\n- Maintain\tblood\tglucose\tcontrol\tbetween\t5-9\tmmol/L\n- Encourage\tcontraceptive\tuse\tat\t6\tweeks.\tAny\tpatient\twith\tvascular complications should avoid estrogen-containing contraceptives.\n\n\n**Gestational Diabetes Mellitus**\n\n\nGDM is asymptomatic and diagnosis must be sought after actively.\n\n\n**Women at high risk of GDM;**\n\n\n- BMI&gt;30kg/m2\n- Age\t&gt;\t35\tyears\n- Previous\thistory\tof\tGDM\n- Persistent\tGlycosuria\n- Previous\tlarge\tbaby\t(&gt;\t4\tkg)\n- Poor\tobstetric\thistory\t(previous\tmiscarriages,\tstill\tbirths,\tprevious\tcongenital anomalies)\n- Family\thistory\tof\tdiabetes\t(First\tdegree\trelatives)\n- Pregnancy\twith\tpolyhydramnios\n- Polycystic\tovarian\tsyndrome\n- Known\tIGT\t/\tIFG\n- Grand\tmultipara\n- Multiple\tgestation\n\n\nIf the woman has more than one risk factor, do an RBS/FBS at first contact. Screening\n\n\n- Screening\tshould\tbe\tdone\tat\t24-28\tweeks\t(or\tat\tfirst\tcontact\tif\tpatient presents late).\n- Perform\ta\t75-g\tOGTT\t-\tAdminister\t75\tg\tof\tglucose\torally\tafter\tan\t8-hr. overnight fast and do a blood glucose level after 1 hour and 2 hours (1 standard level tea spoon =5 g).\n- Diagnostic\tcriteria:\tRefer\tto\ttable\t37\tabove\n\n\n**Management**\n\n\n- Advise\tpatient\ton\thealthy\tdiet\n- Monitor\tblood\tglucose\tregularly.\tAim\tfor:\t-\n- -FBS &lt; 5.0 mmol/l\n- -Pre-meal &lt; 6.0 mmol/l\n- -1 hr. post prandial &lt; 7.8 mmol/l\n- -2 hr. post prandial &lt; 6.7 mmol/l\n- If\tblood\tglucose\tis\tnot\toptimized\twithin\t2\tweeks\tthen\tput\tthe\tpatient\ton -OGLAs (Metformin)\n- -Insulin (15 - 30% of patients will require insulin)\n- Follow-up\tsimilar\tas\tfor\tpatients\twith\tdiabetes\tin\tpregnancy\n\n\n- Delivery\tat\t38\tweeks\tis\tadvised\tif\tthe\tsugars\tare\twell\tcontrolled.\tIf\tpoorly controlled consult a specialist on timing of delivery.\n- Consider\tsteroid\tadministration\tfor\tlung\tmaturation\tif\tearly\tdelivery\tis\tindicated.\n- If\tsteroids\tare\tadministered\tat\tany\tpoint\tin\tthe\tpregnancy,\tanticipate\tdifficult glycemic control and insulin therapy is advised.\n- Aim\ttarget\tblood\tglucose\tlevel\t4-7\tmmol/L\tduring\tactive\tlabor\tand\tdelivery.\n- Anticipate\tmaternal\tand\tfetal/neonatal\tcomplications\tat\tdelivery\tand\tplan\tfor necessary interventions.\n\n\n**Postpartum Care**\n\n\n- After\tdelivery\n- -Stop OGLA and insulin\n- -Monitor the blood glucose\n- -If blood glucose goes above RBS 7.8 mmol/L or FBS 6.1 mmol/L post-delivery, manage as pre-existing diabetes\n- -If blood glucoses are normal post-delivery, repeat OGTT with 75 g Glucose at 6 weeks to exclude ongoing DM. or IGT.\n- -If OGTT at 6 weeks is normal encourage patients to do an annual fasting  blood glucose thereafter.\n- -Counsel on future risk of GDM and/or diabetes.\n- -Encourage exercise, proper diet and normal BMI\n- -Encourage contraceptive use at 6 weeks.\n\n\n**Complications of GDM and diabetes in pregnancy**\n\n\nHyperglycemia in pregnancy is associated with higher incidence of both maternal and perinatal morbidity and mortality. When glycemic control is poor in the first few weeks of life as may be seen in DIP , there may be defective organogenesis in the fetus. This results in non-chromosomal congenital malformations. Other complications are tabulated in table 39 below.\n\n\nTable 39: Effects of diabetes on the mother and fetus or newborn\n\n\n|                         | Maternal                                                    | Fetal/Neonatal                        |\n|-------------------------|-------------------------------------------------------------|---------------------------------------|\n| During Pregnancy        | Miscarriages                                                | Macrosomia > 4 kg                     |\n| During Pregnancy        | Urinary tract infections                                    | Congenital malformations              |\n| During Pregnancy        | Pre-eclampsia/Eclampsia                                     | Sudden fetal demise                   |\n| During Pregnancy        | Polyhydramnios                                              |                                       |\n| During Pregnancy        | Pre-term labour                                             |                                       |\n| Intra and Post-par- tum | Shoulder Dystocia                                           | Musculoskeletal injuries              |\n| Intra and Post-par- tum | Instrumental delivery                                       | Erb's palsy (after shoulder dystocia) |\n| Intra and Post-par- tum | Perineal tears                                              | Respiratory distress syndrome         |\n| Intra and Post-par- tum | Cesarean delivery                                           | Neonatal hypoglycemia                 |\n| Intra and Post-par- tum | Post-partum hemorrhage                                      | Neonatal polycythemia                 |\n| Intra and Post-par- tum | Thromboembolism                                             | Neonatal hyperbilirubinemia           |\n| Intra and Post-par- tum | Post-partum/post-operative infection                        | Neonatal hypomagnesemia               |\n| Intra and Post-par- tum |                                                             | Neonatal hypocalcemia                 |\n| Long term               | Cardiovascular disease                                      | Obesity                               |\n| Long term               | *GDM in subsequent pregnan- cies                            | Diabetes                              |\n| Long term               | *OvertDM                                                    | Metabolic Syndrome                    |\n| Long term               | ** Acceleration of pre-existing nephropathy and retinopathy | Hypertension                          |\n\n\n*Specific to patients with GDM\n\n\n**Specific to patients with DIP\n\n\n## 5.2. Management of diabetes during fasting\n\n\nFasting for patients with diabetes is often a personal decision.  Patients who insist on fasting should be made aware of the risks involved in fasting, and it should be in done consultation with the physician.\n\n\nRecommendation by physician in most cases, will be not to undertake fasting.\n\n\nNB:\tFor\tfasts\t&gt;12\thours,\tplease\tconsult\tthe\thealth\tcare\tpractitioner.\n\n\n**The principles of Ramadan/fasting considerations are: -**\n\n\n- Assessment\tof\tmetabolic\tcontrol\tof\tthe\tpatient\n- Adjustment\tof\tthe\tdiet\tprotocol\tfor\tRamadan/\tfasting\n- Adjustment\tof\tthe\tdrug\tregimen\n- Encouragement\tof\tcontinued\tappropriate\tphysical\tactivity\n- Education\ton\trecognition\tof\twarning\tsymptoms\tof\tdehydration, hyperglycemia and hypoglycemia\n\n\n**Patients may be classified as: -**\n\n\n- Very\thigh\trisk\n- High\trisk\n- Moderate\trisk\n- Low\trisk\t(see\ttable\t39)\n\n\n**Table 40: Risk categories of patients with diabetes with regards to fasting**\n\n\n| Risk category Religious opinion                                                                                                  | Patient characteristics                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Comments                                                                                                                                                                                                                                                                                                                                                                                                                |\n|----------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Category 1: very high risk Very high risk of hypoglycemia (poor outcome) Listen to medical advice Fasting is STRONGLYNOT advised | One or more of the following: • Severe Hypoglycemia within the three months prior to Ramadan • DKAwithin the three months prior to Ramadan • Hyperosmolar hyperglycaemic coma within the three months prior to Ramadan • History of recurrent Hypogly - cemia • History of Hypoglycemia un - awareness • Poorly controlled Type1DM • Acute illness • Pregnancy in pre-existing diabe - tes, or GDMtreated with insulin or Sulphonylureas • Chronic dialysis or CKD stage 4&5 • Advanced macrovascular com - plications • Old age with ill health | If patients insist on fasting then they should: • Receive structured education • Be followed by a qualified diabetes team • Check their blood glucose regularly (SMBG) • Adjust medication dose as per recommendations • Be prepared to break the fast in case of hypo- or hyperglycaemia • Be prepared to stop the fast in case of frequent hypo- or hyper- glycaemia or worsening of other related medical conditions |\n\n\n| Category 2: high risk Listen to medical advice Fasting NOT ad- vised   | One or more of the following: • Type 2 DMwith sustained poor glycaemic control* • Well-controlled Type1DM • Well-controlled Type 2 DMon MDI or mixed insulin • Pregnant Type 2 DMorGDM controlled by diet only or met- formin • CKD stage 3 • Stable macrovascular complica - tions • Patients with comorbid condi - tions that present additional factors • People with diabetes performing intense physical labour • Treatment with drugs that may   | If patients insist on fasting then they should: • Receive structured education • Be followed by a qualified diabetes team • Check their blood glucose regularly (SMBG) • Adjust medication dose as per recommendations • Be prepared to break the fast in case of hypo- or hyperglycaemia • Be prepared to stop the fast in case of frequent hypo- or hyper- glycaemia or worsening of other related medical conditions   |\n|------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Category 3: mod- erate/ low risk Listen to medical advice              | Well-controlled Type 2 DMtreat- ed with one or more of the follow- ing: • Lifestyle therapy • Metformin • Acarbose • Thiazolidinediones • Second-generation sulphony - lureas • Incretin-based therapy • SGLT-2 inhibitors • Basal insulin                                                                                                                                                                                                             | Patients who fast should: • Receive structured education • Check their blood glucose regularly (SMBG) • Adjust medication dose as per recommendations                                                                                                                                                                                                                                                                     |\n\n\n* treatment must be individualized\n\n\n* Analogue insulins preferable\n\n\n**General considerations**\n\n\n- Individualization\tof\tmanagement\tplans\n- Blood\tglucose\tmonitoring-\tpatients\twith\ttype\t1\tdiabetes\tand\ttype\t2\ton\tInsulin\n- Nutrition,\tencourage\tslow\tdigesting\tfoods\tincluding\tfibre\tcontaining-foods rather than refined foods.\n\n\n**Treatment Regimes**\n\n\n- Patients\ton\tinsulin:\tPatients\ton\ttwice\tdaily\tinsulin\n- Reverse\tdosages\tand\tgive\tpre-Ramadan\tmorning\tdose\twith\tthe\tevening\tmeal and give 50-80% of pre-Ramadan evening dose with dawn meal\n- Basal\tbolus\tregimes\n- Decrease\tbasal\tregime\tby\t20-30%\n- Increase\tevening\tbolus\tby\t20-30%\twhile\tdecease\tmorning\tbolus\tby\t20-50%\n\n\nTable 41: Summary of advice to Fasting patients with Type 2 diabetes\n\n\n| Treatment regimen                                          | Fasting regimen                   | When to take OGLAs/Insulin        |\n|------------------------------------------------------------|-----------------------------------|-----------------------------------|\n| Diet only                                                  | Total or partial fast             | Not applicable                    |\n| Metformin/ Thiazo- lidinediones                            | Total or partial fast             | With meals                        |\n| Insulin secretagogues sulphonylureas                       | Partial fast                      | Before meals                      |\n| Daily intermediate or long-acting insulin                  | Partial fast                      | Before first meal                 |\n| Glinides                                                   | Total or partial fast             | With meals                        |\n| Multiple insulin doses using intermediate and short acting | Avoid fasting or pleasure fasting | Not applicable                    |\n| Long-acting plus bolus fast acting insulin.                | Avoid fast or partial fast        | Lantus am and analogue with meals |\n\n\n## 5.3. Diabetes in the Older AAdults\n\n\n**Factors that affect diabetes care in the older patient**\n\n\n- Impaired\tvision\n- Impaired\tmobility\n- Hearing\timpairment\n- Poor\tnutrition\n- Impaired\tmemory/dementia\n- Other\tillnesses\tsuch\tas\thigh\tblood\tpressure,\theart\tor\trenal\timpairment, recurrent UTI and pneumonias\n- Multiple\tmedications\n- Lack\tof\tsocial\tor\tfamily\tsupport\n- Depression\n- Dental\tproblems\n- More\tprone\tto\thypoglycemia\t(due\tto\tpoor\tnutrition,\trenal\timpairment,\tuse\tof long acting hypoglycemic agents)\n\n\n**How to cope with factors that limit diabetes care**\n\n\n- Hypoglycemia\n- -encourage frequent small meals\n- -adjust medications - if on insulin reduce insulin doses\n- Use\tof\tsulfonylureas\tand\tinsulin\twith\tcaution\tdue\tto\trisk\tof\thypoglycemia,\tand dosage adjusted to individual patient situations.\n- If\ton\tlong\tacting\tOGLAs\tchange\tto\tshort\tacting\tOGLAs\n- -Assess for renal impairment\n- -Frequent blood glucose monitoring blood\n- -Adjust blood glucose targets to appropriate for the older patients. (HbA1c 8%, blood glucose 5-10 mmol/l).\n- Hearing\timpairment:\ta\thearing\taid,\ttalking\tloudly\tand\tclearly,\tor\tusing\tsign language\n- Impaired\tvision:\tannual\teye\tcheck-ups\n- Impaired\tmobility:\tAssess\tfor\tfall\trisk\tin\tall\tolder\tpatients.\tNeed\tfor\tregular\tfoot screening, use appropriate footwear and supporting aids including crutches, walking frames, and artificial limbs, skin care\n- Impaired\tmemory:\tAdditional\tcaregiver\tsupport\n- Multiple\tmedications:\teducate\tpatient\tand\tcaregiver\ton\tthe\timportance\tof adherence of pills, use of pill charts and pill containers. Use fixed dose combinations where possible to aid adherence.\n- Dental\tproblems:\tMeals\tneed\tto\tbe\tadapted\tto\tthe\tperson's\tability\tto\tchew, dental check ups\n\n\n- Lack\tof\tsocial\tand\tfamily\tsupport:\tFamily,\tphysical,\tpsychosocial\tand\temotional support is encouraged\n- Vaccines:\tAnnual\tflu\tvaccine,\tpneumococcal\tvaccine\n- Need\tfor\tregular\tclinical\tcheckup\tand\tscreening\tfor\trecurrent\tUTI,\tthyroid dysfunction, liver and renal impairment, cardiac dysfunction, anemia and malignancy\n\n\n## 5.3. Diabetes in the Older AAdults\n\n\n**Factors that affect diabetes care in the older patient**\n\n\n- Impaired\tvision\n- Impaired\tmobility\n- Hearing\timpairment\n- Poor\tnutrition\n- Impaired\tmemory/dementia\n- Other\tillnesses\tsuch\tas\thigh\tblood\tpressure,\theart\tor\trenal\timpairment, recurrent UTI and pneumonias\n- Multiple\tmedications\n- Lack\tof\tsocial\tor\tfamily\tsupport\n- Depression\n- Dental\tproblems\n- More\tprone\tto\thypoglycemia\t(due\tto\tpoor\tnutrition,\trenal\timpairment,\tuse\tof long acting hypoglycemic agents)\n\n\n**How to cope with factors that limit diabetes care**\n\n\n- Hypoglycemia\n- -encourage frequent small meals\n- -adjust medications - if on insulin reduce insulin doses\n- Use\tof\tsulfonylureas\tand\tinsulin\twith\tcaution\tdue\tto\trisk\tof\thypoglycemia,\tand dosage adjusted to individual patient situations.\n- If\ton\tlong\tacting\tOGLAs\tchange\tto\tshort\tacting\tOGLAs\n- -Assess for renal impairment\n- -Frequent blood glucose monitoring blood\n- -Adjust blood glucose targets to appropriate for the older patients. (HbA1c 8%, blood glucose 5-10 mmol/l).\n- Hearing\timpairment:\ta\thearing\taid,\ttalking\tloudly\tand\tclearly,\tor\tusing\tsign language\n- Impaired\tvision:\tannual\teye\tcheck-ups\n- Impaired\tmobility:\tAssess\tfor\tfall\trisk\tin\tall\tolder\tpatients.\tNeed\tfor\tregular\tfoot screening, use appropriate footwear and supporting aids including crutches, walking frames, and artificial limbs, skin care\n- Impaired\tmemory:\tAdditional\tcaregiver\tsupport\n\n\n- Multiple\tmedications:\teducate\tpatient\tand\tcaregiver\ton\tthe\timportance\tof adherence of pills, use of pill charts and pill containers. Use fixed dose combinations where possible to aid adherence.\n- Dental\tproblems:\tMeals\tneed\tto\tbe\tadapted\tto\tthe\tperson's\tability\tto\tchew, dental check ups\n- Lack\tof\tsocial\tand\tfamily\tsupport:\tFamily,\tphysical,\tpsychosocial\tand\temotional support is encouraged\n- Vaccines:\tAnnual\tflu\tvaccine,\tpneumococcal\tvaccine\n- Need\tfor\tregular\tclinical\tcheckup\tand\tscreening\tfor\trecurrent\tUTI,\tthyroid dysfunction, liver and renal impairment, cardiac dysfunction, anemia and malignancy\n\n\n## 5.4. Management of Diabetes during Surgery\n\n\nGood glycemic control has been shown to improve outcomes for patients undergoing surgery. As far as possible, patients with diabetes should be first on the theatre list. A patient with diabetes undergoing surgery faces potential hazards in addition to the usual operative risks in a non-diabetic patient- Hyperglycaemia and ketosis Perioperative complications - hypoglycemia, hyperglycemia and iatrogenic problems\n\n\n**i. Hyperglycaemia and Ketosis**\n\n\n- Due\tto\tthe\tmetabolic\tresponses\tto\tstress\tof\tsurgery\tespecially\tin patients with insulin deficiency (type 1 and long-standing type 2 DM)\n- Surgery\tinduces\ta\tcomplex\tseries\tof\thormonal\tand\tmetabolic\tchanges\n- Extensive\toperations\tcause\tgreater\tmetabolic\tdisruption\tand\tinsulin resistance i.e. heart surgery, laparotomies (open and laparoscopic)\n\n\n**ii. Perioperative complications**\n\n\n- a. Hypoglycemia can occur in:\n- Perioperative\tfasting\n- Delayed\teffects\tof\tlong\tacting\tinsulins\tor\tOGLAs\n- Major\thazards'\tin\tthe\tanaesthetized\tor\tsedated\tpatient\n\n\n**b. Hyperglycaemia causes**\n\n\n- Wound\tinfections\tdue\tto\timpaired\tphagocyte\tfunction\n- Delayed\twound\thealing\n- Myocardial\tinfarctions\n- Thromboembolic\tcomplications\n\n\n**c. Iatrogenic problems of diabetic control**\n\n\n- Hypoglycemia\tand\thyperglycemia\toccur\tdue\tto\n- -Inadequate B/G monitoring\n- -Poor management protocols\n\n\n### 5.4.1. Pre-Operative Management\n\n\nThe diabetic patient requires the following tests and procedures before surgery:\n\n\n- Baseline\ttests\n- -FPG, U/E/Cs, LFT profile, Urinalysis, HbA1c, Lipid profile, Serum TSH\n- -ECG\n- Ensure\tadequate\tB/G/\tcontrol\n- -FPG   4 - 7 mmol/l\n- -Pre-meal 5 -9 mmol/l\n- Patients\tfor\telective\tsurgery\tnot\twell\tcontrolled\tneed\tto\tstabilized\tprior to\tadmission\tfor\tsurgery.\tPatients\twith\tHbA1c\t&gt;9%\tshould\thave\telective surgery postponed.\n- Monitor\tblood\tpressure\n- -Aim at 140/80 mmHg\n- -Start anti-HT if elevated\n- Prepare\tpatient\tpsychologically\tfor\toperation\n- Get\twritten\tconsent\n\n\n### 5.4.2. Intraoperative management\n\n\nThe following are considerations for management of a patient with diabetes during surgical procedures\n\n\nTable 42: Management of a patient with diabetes during surgery\n\n\n| Minor Surgery, OGLAs and Good glycaemic control                                     | Major surgery or poor-gly - caemic control on OGLAs                                                                                                     | Patients on Insulin                                                                                                                                |\n|-------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|\n| Admit the patient day before sur- gery to confirm/optimize glycemic control         | Admit the patient 1 - 2 days before surgery.                                                                                                            | Admit patient 1 - 2 days be- fore surgery.                                                                                                         |\n| Stop metformin/pioglitazone day before surgery.                                     | Stop OGLAs and stabilize the blood glucose with short acting insulin.                                                                                   | Stabilize control if necessary, stop long acting insulin and put on short acting insulin.                                                          |\n| Monitor blood glucose                                                               | Operate in the morning if possible.                                                                                                                     | Operate in the morning if possible.                                                                                                                |\n| Operate in the morning if possible.                                                 | Start GKI on morning of oper- ation day                                                                                                                 | Start GKI on morning of oper- ation day                                                                                                            |\n| Omit breakfast (and no OGLAs)                                                       | Omit breakfast and morning injection.                                                                                                                   | Omit breakfast and insulin injection.                                                                                                              |\n| Pre-op, intra-op and post-op avoid glucose and lactate containing fluids.           | Monitor blood glucose 2 hourly. Maintain between 5-9 mmol/l                                                                                             | Monitor blood glucose 2 hourly Maintain between 5-9 mmol/l                                                                                         |\n| Post-op - Monitor blood glucose 2 hourly and restart OGLAs with first post-op meal. | Post-op: Monitor blood glu- cose 2 hourly. Once allowed to feed, restart previous pre-operative s.c. insulin dose. Discontinue GKI 1 hour after eating. | Post-op: Monitor blood glucose 2-hourly. Restart previous pre-operative s.c. insulin with first post-op meal. Discontinue GKI 1 hour after eating. |\n|                                                                                     | Continue with insulin regi- men until restart of regular or discharge regimen.                                                                          | Patients on long acting insulin can be converted back to their long acting insulin regimens.                                                       |\n\n\n(GKI - 10% dextrose 500 mls + 10 mmol of potassium chloride + Regular insulin (10-14 units) depending on blood glucose, to run 5- hourly\n\n\nPatients with renal impairment GKI - 10% dextrose 500 mls + Regular insulin (6-8 units) to run 12-hourly\n\n\nRecommendation: No minor or major operative surgery should be undertaken in a person with diabetes at a primary level health facility. Refer these patients, because specialist care is required\n\n\n## 5.5. Diabetes and HIV\n\n\nDiabetes as a HIV co-morbidity is increasing in both incidence and prevalence. HIV itself, and the treatment of the condition, both increase the risk for the development of diabetes. The increase in HIV testing and test to treat strategy has led to increased life expectancy of persons living with HIV(PLHIV). This has led to an increase in the chronic metabolic complications of both HIV and highly active anti-retroviral therapy (HAART) which amongst others include dyslipidaemia, accelerated atherosclerosis, osteoporosis, thyroid dysfunction, insulin resistance and diabetes mellitus.\n\n\n### 5.5.1. Classification of HIV in patients with diabetes\n\n\nThree subgroups of patients with HIV and diabetes can be identified:\n\n\n- i. Patients with pre-existing diabetes who contract HIV.\n- ii. Those who are diagnosed with both HIV and diabetes mellitus at the same time.\n- iii. Those who develop hyperglycaemia post-HAART initiation.\n\n\n### 5.5.2. Risk factors for Diabetes in HIV patients\n\n\nThere are many factors that predispose HIV positive patients on HAART to developing diabetes.\n\n\n- i. Traditional Risk Factors for developing diabetes (similar to non-HIV patients)\n- ii. HIV related risk factors\n- HIV\tvirus,\tviral\tload,\tCD4\tcount,\tduration\tof\tHIV\tinfection.\n\n\nHIV viral infection, through various inflammatory mediators and cytokines, can induce a state of insulin resistance. Most cases of HIV-associated diabetes are type 2 diabetes.\n\n\n**Auto-immune ß cell destruction has also been described.**\n\n\n- Rapid\tweight\tgain\tafter\tthe\tcatabolic\tphase\t(return\tto\thealth\tphenomenon). The rapid increase of body fat (visceral fat) instead of lean muscle mass that they would have lost during the catabolic phase of the disease. This can overwhelm the β cell secretory capacity leading to β cell failure, and induce insulin resistance.\n- Co\tinfection\twith\thepatitis\t(Hepatitis\tC\tcauses\tdysglycaemia)\n- Dyslipidaemia\twith\tlipotoxicity\n- Lipodystrophy\n- Iatrogenic\t-\tDrugs\t(NRTIs,\tNNRTIs\t&amp;\tProtease\tInhibitors)\n\n\nTable 43: Classification of drug classes by metabolic profile\n\n\n\n\n| Metabol ical y neutral NR TIs               | Metabol ical y unsafe NR TIs      | Protease inhibitors (PIs) ith potential for adverse metabol ic effects   | Metabol ical y neutral Protease inhibitors (PIs)   | Integ rase Strand Transfer Inhibitors (INSTIs) (metabol ical y neutral )   |\n|---------------------------------------------|-----------------------------------|--------------------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------------------------------|\n| Abacavir Tenofovir Emtricitabine Lamivudine | Stavudine* Didanosine* Zidovudine | Indinavir Ritonavir Saquinavir Lopinavir                                 | Darunavir Ataz anavir                              | Dolutegravir (DTG) Raltegravir                                             |\n\n\n*drugs that have been phased out\n\n\n### 5.5.3. Screening for diabetes in HIV patients\n\n\n- i. All HIV positive patients should be screened for diabetes before initiating HAART  or when changing ARVs.\n- ii. Patients with impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) should be screened every 3-6 months\n- iii. Patients with normal initial blood glucose levels should be screened annually.\n- iv. Fasting plasma glucose is preferred but standard 75 g OGTT is preferred in those with IGT or IFG with additional risk factors\n\n\n### 5.5.4. Evaluation of a patient\n\n\nInitial evaluation of a patient with both HIV and diabetes mellitus includes a detailed history which amongst others includes a detailed search for infections which are common in both conditions such as: -\n\n\n- tuberculosis\n- fungaemia\n- sexually\ttransmitted\tinfections\n- urinary\ttract\tinfections\n\n\nIn addition, the evaluation should search for other chronic conditions that need to be aggressively managed and that will also influence the choice of anti-HIV drugs and diabetic drugs: -\n\n\n- hypertension,\n- renal\timpairment\n- any\tform\tof\tdyslipidaemia\n- thyroid\tdysfunction\n- cardiac\tdysfunction\n\n\n**Initial investigations should include:**\n\n\n- i. Full blood count\n- ii. Urinalysis\n- iii. Urea and creatinine with estimated GFR\n- iv. Liver function with hepatitis screen\n- v. CD4 count\n- vi. Viral load\n- vii. Fasting blood glucose (HbA1c may be used but the readings may be low in PLHIV)\n- viii. Serum lipids\n- ix. Thyroid function test (Serum TSH)\n- x. ECG\n- xi. Serum uric acid\n\n\n### 5.5.5. Treatment of diabetes in HIV infected individuals\n\n\n**General measures**\n\n\n- i. Appropriate treatment of opportunistic infections.\n- ii. Lifestyle modification, which includes physical exercise, smoking and alcohol cessation and where available, dietary advice, taking account of BMI, desired weight and comorbidities.\n- iii. Psychosocial support and both family and community involvement where feasible.\n- iv. Reinforce compliance at every visit.\n- v. Treatment of other cardiovascular risk factors:\n6. ·Dyslipidaemia - general measures and targets apply; the only major exception is that simvastatin is contraindicated in patients using protease Inhibitors as it competes for the same Cytochrome P450 Isoenzyme. Fluvastatin and pravastatin are safer.\n7. ·Hypertension - ACE Inhibitors and ARBs (Angiotensin Receptor Blockers) need to be used with caution: captopril has been associated with the development of Kaposi's sarcoma and enalapril may cause myalgias and diarrhoea. In addition, ARBs may compete with other drugs that are metabolized by cytochrome P450 Isoenzymes.\n\n\n**Use of glucose lowering agents in people living with HIV**\n\n\n**Type 1 DM**\n\n\nAll patients with type 1 diabetes mellitus and HIV should be managed with insulin therapy.\n\n\n**Type 2 DM**\n\n\nThe following OGLAs can be used in treatment of diabetes among people living with HIV\n\n\n**i. Biguanides e.g. Metformin**\n\n\nThis is the drug of choice for most patients with HIV. It should, however, be used with caution in patients with HIV associated enteropathy as the gastrointestinal side effects of metformin will be exaggerated.\n\n\nIt is contraindicated in patients with HIV associated nephropathy (HIVAN), liver disease, cachectic patients and tuberculosis as the risk of lactic acidosis is markedly increased. It should not be used in conjunction with thymidine-based NRTIs (Stavudine, Didanosine) as the risk of lactic acidosis is increased due to mitochondrial toxicity. Extended release metformin is the preferred formulation of the drug.\n\n\n**ii.  Sulfonylureas e.g. Glibenclamide, Gliclazide, Glyburide**\n\n\nThe general principles apply as in non-HIV patients, but, caution must be exercised in patients with cachexia who might have depleted glycogen stores and who are at increased risk of Hypoglycemia.\n\n\nWhere possible, short acting or modified release formulations should be used.\n\n\n**iii. Meglitinides/Glinides**\n\n\nBecause of their short acting profile and lower risk of Hypoglycemia, they are suitable drugs but are not commonly used locally.\n\n\n**iv.  Insulin**\n\n\nInsulin remains the drug of choice for most patients with HIV and diabetes especially as both conditions are progressive. Insulin has anabolic effects, reduces inflammatory markers, has no interactions with antiretroviral drugs and can be used safely in patients with renal failure (with proper titration). It is important to note that insulin requirements might initially be high and will later fall as glucotoxicity is reversed and infections are controlled.\n\n\n**v. Other glucose lowering agents**\n\n\nThere is currently no data available regarding the newer classes of drugs in HIV patients with diabetes, including DPP-4 inhibitors, SGLT-2 inhibitors and incretin receptor analogues.\n\n\n**Changing HAART**\n\n\nA patient who develops diabetes while on HAART with drugs that are potentially diabetogenic especially the protease inhibitors should be changed to anti-retroviral agents that are metabolically neutral.\n\n\n## 5.6. Diabetes andTB\n\n\nDiabetes is associated with higher risks of TB and adverse TB treatment outcomes like treatment failure and death. TB infection may progress at a faster rate in people with diabetes than in those without diabetes. In addition, TB tends to worsen glycaemic control in patients with diabetes.\n\n\nA large proportion of people with diabetes as well as TB is not diagnosed, or is diagnosed very late. Early detection can help improve care and control of both illnesses\n\n\n### 5.6.1. Effects of diabetes onTB\n\n\n- Increases\tthe\trisk\tof\tdeveloping\tTB\tthreefold\n- Higher\trisk\tof\tlatent\tTB\tinfection\n- Faster\tprogression\tof\tTB\tinfection\tto\tTB\tdisease\n- Altered\tclinical\tpresentation\tof\tTB:\tMore\tTB\tsymptoms,\tpoor\tperformance status   (ability to perform activities of daily living without help of others) compared to patients without diabetes\n- Changes\tthe\tsensitivity\tand\tspecificity\tof\tconventional\tTB\tdiagnostic\talgorithms.\n- Adversely\taffect\tTB\ttreatment\toutcomes\tby\tdelaying\tthe\ttime\tto microbiological response/sputum culture conversion, reducing the likelihood of a favorable TB treatment outcomes, and increasing the risk of relapse or death\n- Accelerate\tthe\temergence\tof\tdrug-resistant\tTB,\tespecially\tmultidrug-resistant TB (defined as strains of TB resistant to both rifampicin and isoniazid)\n- Interference\twith\tthe\tactivity\tof\tcertain\tanti-TB\tmedications\n\n\n### 5.6.2. Effects ofTB on diabetes\n\n\n- TB\tprevalence\tand\tincidence\tare\tconsistently\thigher\tin\tpeople\twith\tdiabetes than in either the general population or in non-diabetic controls.\n- TB\tmay\ttrigger\tthe\tonset\tof\tdiabetes,\tand\tworsen\tglycaemic\tcontrol\tin\texisting diabetes\n- TB\tmedications\tmay\tinterfere\twith\tthe\ttreatment\tof\tdiabetes\tthrough\tdrug interactions\n\n\n### 5.6.3. TB screening among diabetes patients\n\n\nFigure 29: Algorithm for screening people living with diabetes for TB\n\n\n![R-Rifampicin, H-Isoniazid, Z-Pyrazinamide, Ethambutol](images/picture_052_page_135.png)\n\n\nTable 44: First line anti - TB regimen\n\n\n|                                                                        | Intensive phase   | Continuation phase   |\n|------------------------------------------------------------------------|-------------------|----------------------|\n| Adult and Pediatric TB ex- cept TB meningitis and os- teo-articular TB | 2RHZE             | 4RH                  |\n| TB meningitis and osteo-ar- ticular TB                                 | 2RHZE             | 10RH                 |\n\n\nR-Rifampicin, H-Isoniazid, Z-Pyrazinamide, Ethambutol\n\n\n- All\tTB/DM\tpatients\tshould\treceive\tpyridoxine\tfor\tthe\tduration\tof\tTB\ttreatment to prevent neuropathy from anti TB drugs.\n- Rifampicin\tmay\tcause\tnew-onset\tdysglycaemia\tor\tworsen\tglycemic\tcontrol\tin existing diabetes.\n- Rifampicin\tdecreases\tconcentrations\tof\trosiglitazone\tby\t54-65%\tand\tof\tthe related drug pioglitazone by 54%\n- Insulin\trequirements\tmight\tincrease\twhen\ton\trifampicin\n- If\tthe\tpatient\tis\ton\tDR\tTB\ttreatment\twith\taminoglycosides,\tthere\tshould\tbe close monitoring of the renal functions and liver function tests. In renal impairment, the dose of anti-TBs should be adjusted downwards according to the creatinine clearance.\n- Do\ta\trenal\tfunction\ttest\tmonthly\tfor\tDR\tTB/\tDiabetes\tpatients.\n- Glycaemic\tcontrol\tneeds\tto\tbe\tclosely\tmonitored\tin\tunderweight\tco-morbid patients who would need an increased caloric intake and dose of Oral Glucose Lowering Agents (OGLAs)/insulin adjusted accordingly.\n- OGLAs\tare\tcontraindicated\tin\tsevere\tTB\tdisease\tbut\tmay\tbe\tused\twith\tcaution once the disease has settled.\n- Insulin\tis\tthe\trecommended\ttreatment\tfor\tpatients\twith\tsevere\tTB,\trenal\tand liver impairment.\n\n\n**Recommendation**\n\n\nNeed for integrated chronic care model clinic.\n\n\n137 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS\n\n\nCHAPTER SIX\n\n\n",
        "startLine": 3959,
        "endLine": 4712,
        "introContent": null,
        "sections": [
          {
            "id": "section-5-1",
            "level": "h2",
            "number": "5.1",
            "title": "5.1. Diabetes in Pregnancy",
            "slug": "51-diabetes-in-pregnancy",
            "url": "/guidelines/chapter-five-management-of-diabetes-in-special-situations/51-diabetes-in-pregnancy",
            "parentId": "chapter-5",
            "breadcrumb": [
              "CHAPTER FIVE: MANAGEMENT OF DIABETES IN SPECIAL SITUATIONS",
              "5.1. Diabetes in Pregnancy"
            ],
            "tokenCount": 3414,
            "content": "## 5.1. Diabetes in Pregnancy\n\n\nHyperglycemia that is first detected during pregnancy should be classified either as Diabetes Mellitus in Pregnancy (DIP) or as Gestational Diabetes mellitus (GDM).\n\n\n**Diabetes in Preg nancy**\n\n\n- Pregnancy in a patient known to previously have Diabetes\n- Hyperglycemia diagnosed for the 1 st time during pregnancy, that meets the WHO criterion for DM in the non-pregnant state\n- May occur at any time during the pregnancy, including the 1 st trimester\n\n\n**The diagnostic criteria**\n\n\nTable 38: Diagnostic criteria for diabetes in pregnancy and gestational diabetes mellitus\n\n\n|                                                     | Diabetes in Pregnancy                                   | Gestational Diabetes mellitus   | Gestational Diabetes mellitus   |\n|-----------------------------------------------------|---------------------------------------------------------|---------------------------------|---------------------------------|\n| Fasting Blood Glucose                               | ≥ 7 mmol/L (126 mg/dL)                                  | 5.1-6.9 mmol/L                  | (92-125 mg/dL)                  |\n| 1 hour post-prandial (after 75-g oral glucose load) | Not applicable                                          | ≥ 10 mmol/L                     | (180 mg/dL)                     |\n| 2 hour post-prandial (after 75-g oral glucose load) | > 11.0 mmol/L (200 mg/dL)                               | 8.5-11.0 mmol/L                 | (153-199 mg/dL)                 |\n| Random Blood Glucose                                | ≥ 11.0 mmol/L (200 mg/dL) in the presence of DMsymptoms | Not applicable                  |                                 |\n\n\nSource:  International Federation of Gynecology and Obstetrics (FIGO) Initiative on Gestational Diabetes Mellitus 2015 (based on IADPDG 2010 and WHO 2013 recommendations)\n\n\n\n\n**estational  Diabetes Mel l itus**\n\n\n- Hyperglycemia diagnosed for the 1st time during pregnancy (in 2 nd or 3 rd trimester\n- Hyperglycemia levels do not meet WHO criterion for DM\n- May occur at any time during the pregnancy, but most likely after 24 weeks\n\n\n**Management of Diabetes during Pregnancy**\n\n\n**i. Preconception planning and care**\n\n\nThe following aspects should be discussed with women who have diabetes (and all women of reproductive age) and actioned by the attending health care provider\n\n\n- Patients\tshould\tbe\toffered\tcontraceptives\tto\tprevent\tunplanned\tpregnancy and optimize glycemic control at least 3 months before conception\n- Counsel\tpatient\ton\tthe\timportance\tof\tgood\tblood\tglucose\tcontrol\tbefore pregnancy and during pregnancy to reduce the maternal, foetal and neonatal complications\n- Optimize\tweight\n- Optimize\tblood\tglucose\tcontrol\tto\ttargets\t-\tPatients\tmay\trequire\tinsulin\tto optimize blood glucose control\n- -HbA1c 6% - 6.5%,\n- -FBS &lt; 5.3 mmol/L,\n- -One hour postprandial &lt; 7.8 mmol/l,\n- -two-hour postprandial &lt; 6.7 mmol/l\n- Should\tstop\tteratogenic\tmedications\t(ACE\tinhibitors,\tARBs,\tStatins)\tand supplements\n- Adequate\tfolate\tsupplementation\n- Stop\tsmoking\n- Good\tblood\tpressure\tcontrol\t(&lt;130/80\tmmHg)\n- Assess\tfor\tnephropathy,\tretinopathy,\tthyroid\tdysfunction,\tUTI,\tautonomic neuropathy, cardiac dysfunction and manage/ refer accordingly\n- Highlight\tthe\tneed\tfor:\t-\n- -regular visits (1st trimester: monthly visits, 2nd trimester: 2-4 weekly visits, 3rd trimester: 2-weekly visits)\n- -regular home blood glucose monitoring\n- -adjusting insulin doses depending on blood glucose levels\n- -normal routine ANC profile and need repeat screening for\n- complications in the 2nd and 3rd trimester (urinalysis, UECs, FBC, Ultrasound)\n- -an appropriate diet\n- -appropriate exercises during pregnancy\n\n\n**ii. Pregnancy care**\n\n\n- Multi-disciplinary\tcare\tis\timportant\tand\tshould\tinclude\tthe\tfollowingdiabetologists/physician, obstetrician, diabetes educator, dietitian, neonatologist/pediatrician (include the process of follow up and antenatal management). Patients should be referred to facilities offering specialized care.\n\n\n- Regular\tblood\tglucose\tmonitoring\tto\tachieve\tthe\tpreset\ttargets\tfor pregnancy.\n- -HbA1c 6.0% - 6.5%,\n- -FBS &lt; 5.3 mmol/L,\n- -One hour postprandial &lt; 7.8 mmol/l,\n- -two-hour postprandial &lt; 6.7 mmol/l\n- Nutritional\tcounseling\tshould\tbe\toffered\tduring\tpregnancy\n- Regular\texercise\ti.e.\twalking\tat\tleast\t30\tminutes\tper\tday\n- Regular\tclinic\tvisits\n- Metformin\tand\tGlibenclamide\tcan\tbe\tused\tsafely\tin\tpregnancy\tas\tlong\tas sugars   are controlled to target\n- If\tsugars\tremain\televated,\tintensification\tof\ttherapy\tmust\tbe\tconsidered, including a switch to insulin therapy\n- Patients\twith\tT1DM\tmust\tremain\ton\tinsulin\ttherapy\ttitrated\tto\ttarget\n- Due\tto\tthe\tchanges\tin\tpregnancy\tand\tincreasing\tweight\tgain,\tmost\twomen will be better controlled on insulin management.\n- Low\tdose\taspirin\t(75\tmg\tOD)\tshould\tbe\tgiven\tfor\tpre-eclampsia\tprophylaxis from 12 weeks to term.\n- First\ttrimester\tnausea\tand\tvomiting\tmay\tcause\tboth\thyper\tand\thypoglycemia that would warrant changes in therapy and dosing.\n- An\tultrasound\t(specifically\ta\tfetal\tanomaly\tscan)\tshould\tbe\tdone\tat\t18-24 weeks   to rule out congenital anomalies.\n- Monthly\tscans\tshould\tbe\tdone\tfrom\t28\tweeks\ttill\tterm\tto\tassess\tfor\tfetal growth\t\t and\tamniotic\tfluid\tindex\t(AFI).\tAn\tAFI\t&gt;25(polyhydramnios) is an indication of poor glycemic control.\n- Ensure\tnormal\troutine\tANC\tprofile\tand\tneed\trepeat\tscreening\tfor complications in the 2nd and 3rd trimester (urinalysis, UECs, FBC, Ultrasound)\n- Assess\tfor\tnephropathy,\tretinopathy,\tthyroid\tdysfunction,\tUTI,\tautonomic neuropathy, cardiac dysfunction and manage/ refer accordingly\n- Aim\tfor\tdelivery\tat\t38\tweeks,\tgiving\tsteroids\tto\tassist\tfoetal\tlung\tmaturity\tis beneficial\n- Delivery\tcan\tbe\tspontaneous,\tinduced,\telective\tor\temergency\tcaesarean\tsection\n- Delivery\tshould\tbe\tin\thospital\n\n\n**Definitive pharmacological management during pregnancy**\n\n\n- Insulin\tis\tthe\tmedication\tof\tchoice\tfor\tpregnant\tpatients\twith diabetes\n- Manage\tpatients\ton\tOGLAs\t(Metformin\tand\tGlibenclamide)\tif sugars are well-controlled\n\n\n**iii. Management during labor or caesarean section**\n\n\nGlycaemic control during labour and birth is of utmost importance to avoid adverse neonatal outcomes. It is essential that blood glucose is monitored hourly during labour and birth, ensuring that it is maintained between 4-7 mmol/l. Intravenous glucose, potassium and insulin (GKI) infusions (10% dextrose 500 mls + 10 mmol of potassium chloride + Regular insulin (10-14 units) depending on blood glucose, to run 5 hourly) should be prescribed at the onset of labour. These infusions are also useful for glycaemic control during caesarian section.\n\n\nFollowing delivery and removal of placenta insulin dose in the GKI reduces by half (GKI - 10% dextrose 500 mls + 10 mmol of potassium chloride + Regular insulin (5-7 units) to run 5 hourly) to prevent Hypoglycemia in the mother.\n\n\nOnce the mother is allowed to feed give the mother pre-pregnancy doses of insulin or oral hypoglycaemic.\n\n\n**For the neonate: -**\n\n\n- A\tblood\tglucose\tMUST\tbe\tdone\tfor\tthe\tneonate\tat\tbirth.\tIf\tbaby\tis\tstable\tand no hypoglycemia, initiate breastfeeding.\n- It's\tadvisable\tto\tadmit\tthe\tneonate\tfor\t6\t-24\thours\tin\tthe\tnew-born\tunit\tif\thypo glycemic and symptomatic.\n- Monitor\tblood\tglucose\t3\thourly\tfor\t24-48\thours\n- Aim\tat\tmaintaining\tthe\tblood\tglucose\t4\t-\t7\tmmol/L.\n- If\tblood\tglucose\tis\tless\tthan\t2.8\tmmol/L\tgive\ta\tbolus\tof\t10%\tdextrose\t2\tmls/kg and feed.\n- Monitor\tfor\tany\tneonatal\tcomplications.\n- Encourage\tbreastfeeding\n- A\tneonate\tborn\tto\ta\tmother\twho\thad\tpoor\tcontrol\tespecially\tin\tthe\tfirst trimester should be screened for congenital anomalies.\n\n\n**iv. Postpartum Care**\n\n\n- Ensure\tbreastfeeding\thas\tbeen\testablished\n- Increase\tsurveillance\tfor\tpuerperal\tinfections\tespecially\tsurgical\tincisions\tand wounds.\n- Patient\tshould\tgo\tback\tto\tpre-pregnancy\tdoses\tof\tinsulin\tor\tOGLAs\n- Maintain\tblood\tglucose\tcontrol\tbetween\t5-9\tmmol/L\n- Encourage\tcontraceptive\tuse\tat\t6\tweeks.\tAny\tpatient\twith\tvascular complications should avoid estrogen-containing contraceptives.\n\n\n**Gestational Diabetes Mellitus**\n\n\nGDM is asymptomatic and diagnosis must be sought after actively.\n\n\n**Women at high risk of GDM;**\n\n\n- BMI&gt;30kg/m2\n- Age\t&gt;\t35\tyears\n- Previous\thistory\tof\tGDM\n- Persistent\tGlycosuria\n- Previous\tlarge\tbaby\t(&gt;\t4\tkg)\n- Poor\tobstetric\thistory\t(previous\tmiscarriages,\tstill\tbirths,\tprevious\tcongenital anomalies)\n- Family\thistory\tof\tdiabetes\t(First\tdegree\trelatives)\n- Pregnancy\twith\tpolyhydramnios\n- Polycystic\tovarian\tsyndrome\n- Known\tIGT\t/\tIFG\n- Grand\tmultipara\n- Multiple\tgestation\n\n\nIf the woman has more than one risk factor, do an RBS/FBS at first contact. Screening\n\n\n- Screening\tshould\tbe\tdone\tat\t24-28\tweeks\t(or\tat\tfirst\tcontact\tif\tpatient presents late).\n- Perform\ta\t75-g\tOGTT\t-\tAdminister\t75\tg\tof\tglucose\torally\tafter\tan\t8-hr. overnight fast and do a blood glucose level after 1 hour and 2 hours (1 standard level tea spoon =5 g).\n- Diagnostic\tcriteria:\tRefer\tto\ttable\t37\tabove\n\n\n**Management**\n\n\n- Advise\tpatient\ton\thealthy\tdiet\n- Monitor\tblood\tglucose\tregularly.\tAim\tfor:\t-\n- -FBS &lt; 5.0 mmol/l\n- -Pre-meal &lt; 6.0 mmol/l\n- -1 hr. post prandial &lt; 7.8 mmol/l\n- -2 hr. post prandial &lt; 6.7 mmol/l\n- If\tblood\tglucose\tis\tnot\toptimized\twithin\t2\tweeks\tthen\tput\tthe\tpatient\ton -OGLAs (Metformin)\n- -Insulin (15 - 30% of patients will require insulin)\n- Follow-up\tsimilar\tas\tfor\tpatients\twith\tdiabetes\tin\tpregnancy\n\n\n- Delivery\tat\t38\tweeks\tis\tadvised\tif\tthe\tsugars\tare\twell\tcontrolled.\tIf\tpoorly controlled consult a specialist on timing of delivery.\n- Consider\tsteroid\tadministration\tfor\tlung\tmaturation\tif\tearly\tdelivery\tis\tindicated.\n- If\tsteroids\tare\tadministered\tat\tany\tpoint\tin\tthe\tpregnancy,\tanticipate\tdifficult glycemic control and insulin therapy is advised.\n- Aim\ttarget\tblood\tglucose\tlevel\t4-7\tmmol/L\tduring\tactive\tlabor\tand\tdelivery.\n- Anticipate\tmaternal\tand\tfetal/neonatal\tcomplications\tat\tdelivery\tand\tplan\tfor necessary interventions.\n\n\n**Postpartum Care**\n\n\n- After\tdelivery\n- -Stop OGLA and insulin\n- -Monitor the blood glucose\n- -If blood glucose goes above RBS 7.8 mmol/L or FBS 6.1 mmol/L post-delivery, manage as pre-existing diabetes\n- -If blood glucoses are normal post-delivery, repeat OGTT with 75 g Glucose at 6 weeks to exclude ongoing DM. or IGT.\n- -If OGTT at 6 weeks is normal encourage patients to do an annual fasting  blood glucose thereafter.\n- -Counsel on future risk of GDM and/or diabetes.\n- -Encourage exercise, proper diet and normal BMI\n- -Encourage contraceptive use at 6 weeks.\n\n\n**Complications of GDM and diabetes in pregnancy**\n\n\nHyperglycemia in pregnancy is associated with higher incidence of both maternal and perinatal morbidity and mortality. When glycemic control is poor in the first few weeks of life as may be seen in DIP , there may be defective organogenesis in the fetus. This results in non-chromosomal congenital malformations. Other complications are tabulated in table 39 below.\n\n\nTable 39: Effects of diabetes on the mother and fetus or newborn\n\n\n|                         | Maternal                                                    | Fetal/Neonatal                        |\n|-------------------------|-------------------------------------------------------------|---------------------------------------|\n| During Pregnancy        | Miscarriages                                                | Macrosomia > 4 kg                     |\n| During Pregnancy        | Urinary tract infections                                    | Congenital malformations              |\n| During Pregnancy        | Pre-eclampsia/Eclampsia                                     | Sudden fetal demise                   |\n| During Pregnancy        | Polyhydramnios                                              |                                       |\n| During Pregnancy        | Pre-term labour                                             |                                       |\n| Intra and Post-par- tum | Shoulder Dystocia                                           | Musculoskeletal injuries              |\n| Intra and Post-par- tum | Instrumental delivery                                       | Erb's palsy (after shoulder dystocia) |\n| Intra and Post-par- tum | Perineal tears                                              | Respiratory distress syndrome         |\n| Intra and Post-par- tum | Cesarean delivery                                           | Neonatal hypoglycemia                 |\n| Intra and Post-par- tum | Post-partum hemorrhage                                      | Neonatal polycythemia                 |\n| Intra and Post-par- tum | Thromboembolism                                             | Neonatal hyperbilirubinemia           |\n| Intra and Post-par- tum | Post-partum/post-operative infection                        | Neonatal hypomagnesemia               |\n| Intra and Post-par- tum |                                                             | Neonatal hypocalcemia                 |\n| Long term               | Cardiovascular disease                                      | Obesity                               |\n| Long term               | *GDM in subsequent pregnan- cies                            | Diabetes                              |\n| Long term               | *OvertDM                                                    | Metabolic Syndrome                    |\n| Long term               | ** Acceleration of pre-existing nephropathy and retinopathy | Hypertension                          |\n\n\n*Specific to patients with GDM\n\n\n**Specific to patients with DIP\n\n\n",
            "startLine": 3962,
            "endLine": 4207,
            "introContent": null,
            "keywords": [],
            "subsections": null
          },
          {
            "id": "section-5-2",
            "level": "h2",
            "number": "5.2",
            "title": "5.2. Management of diabetes during fasting",
            "slug": "52-management-of-diabetes-during-fasting",
            "url": "/guidelines/chapter-five-management-of-diabetes-in-special-situations/52-management-of-diabetes-during-fasting",
            "parentId": "chapter-5",
            "breadcrumb": [
              "CHAPTER FIVE: MANAGEMENT OF DIABETES IN SPECIAL SITUATIONS",
              "5.2. Management of diabetes during fasting"
            ],
            "tokenCount": 1274,
            "content": "## 5.2. Management of diabetes during fasting\n\n\nFasting for patients with diabetes is often a personal decision.  Patients who insist on fasting should be made aware of the risks involved in fasting, and it should be in done consultation with the physician.\n\n\nRecommendation by physician in most cases, will be not to undertake fasting.\n\n\nNB:\tFor\tfasts\t&gt;12\thours,\tplease\tconsult\tthe\thealth\tcare\tpractitioner.\n\n\n**The principles of Ramadan/fasting considerations are: -**\n\n\n- Assessment\tof\tmetabolic\tcontrol\tof\tthe\tpatient\n- Adjustment\tof\tthe\tdiet\tprotocol\tfor\tRamadan/\tfasting\n- Adjustment\tof\tthe\tdrug\tregimen\n- Encouragement\tof\tcontinued\tappropriate\tphysical\tactivity\n- Education\ton\trecognition\tof\twarning\tsymptoms\tof\tdehydration, hyperglycemia and hypoglycemia\n\n\n**Patients may be classified as: -**\n\n\n- Very\thigh\trisk\n- High\trisk\n- Moderate\trisk\n- Low\trisk\t(see\ttable\t39)\n\n\n**Table 40: Risk categories of patients with diabetes with regards to fasting**\n\n\n| Risk category Religious opinion                                                                                                  | Patient characteristics                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Comments                                                                                                                                                                                                                                                                                                                                                                                                                |\n|----------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Category 1: very high risk Very high risk of hypoglycemia (poor outcome) Listen to medical advice Fasting is STRONGLYNOT advised | One or more of the following: • Severe Hypoglycemia within the three months prior to Ramadan • DKAwithin the three months prior to Ramadan • Hyperosmolar hyperglycaemic coma within the three months prior to Ramadan • History of recurrent Hypogly - cemia • History of Hypoglycemia un - awareness • Poorly controlled Type1DM • Acute illness • Pregnancy in pre-existing diabe - tes, or GDMtreated with insulin or Sulphonylureas • Chronic dialysis or CKD stage 4&5 • Advanced macrovascular com - plications • Old age with ill health | If patients insist on fasting then they should: • Receive structured education • Be followed by a qualified diabetes team • Check their blood glucose regularly (SMBG) • Adjust medication dose as per recommendations • Be prepared to break the fast in case of hypo- or hyperglycaemia • Be prepared to stop the fast in case of frequent hypo- or hyper- glycaemia or worsening of other related medical conditions |\n\n\n| Category 2: high risk Listen to medical advice Fasting NOT ad- vised   | One or more of the following: • Type 2 DMwith sustained poor glycaemic control* • Well-controlled Type1DM • Well-controlled Type 2 DMon MDI or mixed insulin • Pregnant Type 2 DMorGDM controlled by diet only or met- formin • CKD stage 3 • Stable macrovascular complica - tions • Patients with comorbid condi - tions that present additional factors • People with diabetes performing intense physical labour • Treatment with drugs that may   | If patients insist on fasting then they should: • Receive structured education • Be followed by a qualified diabetes team • Check their blood glucose regularly (SMBG) • Adjust medication dose as per recommendations • Be prepared to break the fast in case of hypo- or hyperglycaemia • Be prepared to stop the fast in case of frequent hypo- or hyper- glycaemia or worsening of other related medical conditions   |\n|------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Category 3: mod- erate/ low risk Listen to medical advice              | Well-controlled Type 2 DMtreat- ed with one or more of the follow- ing: • Lifestyle therapy • Metformin • Acarbose • Thiazolidinediones • Second-generation sulphony - lureas • Incretin-based therapy • SGLT-2 inhibitors • Basal insulin                                                                                                                                                                                                             | Patients who fast should: • Receive structured education • Check their blood glucose regularly (SMBG) • Adjust medication dose as per recommendations                                                                                                                                                                                                                                                                     |\n\n\n* treatment must be individualized\n\n\n* Analogue insulins preferable\n\n\n**General considerations**\n\n\n- Individualization\tof\tmanagement\tplans\n- Blood\tglucose\tmonitoring-\tpatients\twith\ttype\t1\tdiabetes\tand\ttype\t2\ton\tInsulin\n- Nutrition,\tencourage\tslow\tdigesting\tfoods\tincluding\tfibre\tcontaining-foods rather than refined foods.\n\n\n**Treatment Regimes**\n\n\n- Patients\ton\tinsulin:\tPatients\ton\ttwice\tdaily\tinsulin\n- Reverse\tdosages\tand\tgive\tpre-Ramadan\tmorning\tdose\twith\tthe\tevening\tmeal and give 50-80% of pre-Ramadan evening dose with dawn meal\n- Basal\tbolus\tregimes\n- Decrease\tbasal\tregime\tby\t20-30%\n- Increase\tevening\tbolus\tby\t20-30%\twhile\tdecease\tmorning\tbolus\tby\t20-50%\n\n\nTable 41: Summary of advice to Fasting patients with Type 2 diabetes\n\n\n| Treatment regimen                                          | Fasting regimen                   | When to take OGLAs/Insulin        |\n|------------------------------------------------------------|-----------------------------------|-----------------------------------|\n| Diet only                                                  | Total or partial fast             | Not applicable                    |\n| Metformin/ Thiazo- lidinediones                            | Total or partial fast             | With meals                        |\n| Insulin secretagogues sulphonylureas                       | Partial fast                      | Before meals                      |\n| Daily intermediate or long-acting insulin                  | Partial fast                      | Before first meal                 |\n| Glinides                                                   | Total or partial fast             | With meals                        |\n| Multiple insulin doses using intermediate and short acting | Avoid fasting or pleasure fasting | Not applicable                    |\n| Long-acting plus bolus fast acting insulin.                | Avoid fast or partial fast        | Lantus am and analogue with meals |\n\n\n",
            "startLine": 4208,
            "endLine": 4289,
            "introContent": null,
            "keywords": [],
            "subsections": null
          },
          {
            "id": "section-5-3",
            "level": "h2",
            "number": "5.3",
            "title": "5.3. Diabetes in the Older AAdults",
            "slug": "53-diabetes-in-the-older-aadults",
            "url": "/guidelines/chapter-five-management-of-diabetes-in-special-situations/53-diabetes-in-the-older-aadults",
            "parentId": "chapter-5",
            "breadcrumb": [
              "CHAPTER FIVE: MANAGEMENT OF DIABETES IN SPECIAL SITUATIONS",
              "5.3. Diabetes in the Older AAdults"
            ],
            "tokenCount": 570,
            "content": "## 5.3. Diabetes in the Older AAdults\n\n\n**Factors that affect diabetes care in the older patient**\n\n\n- Impaired\tvision\n- Impaired\tmobility\n- Hearing\timpairment\n- Poor\tnutrition\n- Impaired\tmemory/dementia\n- Other\tillnesses\tsuch\tas\thigh\tblood\tpressure,\theart\tor\trenal\timpairment, recurrent UTI and pneumonias\n- Multiple\tmedications\n- Lack\tof\tsocial\tor\tfamily\tsupport\n- Depression\n- Dental\tproblems\n- More\tprone\tto\thypoglycemia\t(due\tto\tpoor\tnutrition,\trenal\timpairment,\tuse\tof long acting hypoglycemic agents)\n\n\n**How to cope with factors that limit diabetes care**\n\n\n- Hypoglycemia\n- -encourage frequent small meals\n- -adjust medications - if on insulin reduce insulin doses\n- Use\tof\tsulfonylureas\tand\tinsulin\twith\tcaution\tdue\tto\trisk\tof\thypoglycemia,\tand dosage adjusted to individual patient situations.\n- If\ton\tlong\tacting\tOGLAs\tchange\tto\tshort\tacting\tOGLAs\n- -Assess for renal impairment\n- -Frequent blood glucose monitoring blood\n- -Adjust blood glucose targets to appropriate for the older patients. (HbA1c 8%, blood glucose 5-10 mmol/l).\n- Hearing\timpairment:\ta\thearing\taid,\ttalking\tloudly\tand\tclearly,\tor\tusing\tsign language\n- Impaired\tvision:\tannual\teye\tcheck-ups\n- Impaired\tmobility:\tAssess\tfor\tfall\trisk\tin\tall\tolder\tpatients.\tNeed\tfor\tregular\tfoot screening, use appropriate footwear and supporting aids including crutches, walking frames, and artificial limbs, skin care\n- Impaired\tmemory:\tAdditional\tcaregiver\tsupport\n- Multiple\tmedications:\teducate\tpatient\tand\tcaregiver\ton\tthe\timportance\tof adherence of pills, use of pill charts and pill containers. Use fixed dose combinations where possible to aid adherence.\n- Dental\tproblems:\tMeals\tneed\tto\tbe\tadapted\tto\tthe\tperson's\tability\tto\tchew, dental check ups\n\n\n- Lack\tof\tsocial\tand\tfamily\tsupport:\tFamily,\tphysical,\tpsychosocial\tand\temotional support is encouraged\n- Vaccines:\tAnnual\tflu\tvaccine,\tpneumococcal\tvaccine\n- Need\tfor\tregular\tclinical\tcheckup\tand\tscreening\tfor\trecurrent\tUTI,\tthyroid dysfunction, liver and renal impairment, cardiac dysfunction, anemia and malignancy\n\n\n",
            "startLine": 4290,
            "endLine": 4332,
            "introContent": null,
            "keywords": [],
            "subsections": null
          },
          {
            "id": "section-5-3",
            "level": "h2",
            "number": "5.3",
            "title": "5.3. Diabetes in the Older AAdults",
            "slug": "53-diabetes-in-the-older-aadults",
            "url": "/guidelines/chapter-five-management-of-diabetes-in-special-situations/53-diabetes-in-the-older-aadults",
            "parentId": "chapter-5",
            "breadcrumb": [
              "CHAPTER FIVE: MANAGEMENT OF DIABETES IN SPECIAL SITUATIONS",
              "5.3. Diabetes in the Older AAdults"
            ],
            "tokenCount": 570,
            "content": "## 5.3. Diabetes in the Older AAdults\n\n\n**Factors that affect diabetes care in the older patient**\n\n\n- Impaired\tvision\n- Impaired\tmobility\n- Hearing\timpairment\n- Poor\tnutrition\n- Impaired\tmemory/dementia\n- Other\tillnesses\tsuch\tas\thigh\tblood\tpressure,\theart\tor\trenal\timpairment, recurrent UTI and pneumonias\n- Multiple\tmedications\n- Lack\tof\tsocial\tor\tfamily\tsupport\n- Depression\n- Dental\tproblems\n- More\tprone\tto\thypoglycemia\t(due\tto\tpoor\tnutrition,\trenal\timpairment,\tuse\tof long acting hypoglycemic agents)\n\n\n**How to cope with factors that limit diabetes care**\n\n\n- Hypoglycemia\n- -encourage frequent small meals\n- -adjust medications - if on insulin reduce insulin doses\n- Use\tof\tsulfonylureas\tand\tinsulin\twith\tcaution\tdue\tto\trisk\tof\thypoglycemia,\tand dosage adjusted to individual patient situations.\n- If\ton\tlong\tacting\tOGLAs\tchange\tto\tshort\tacting\tOGLAs\n- -Assess for renal impairment\n- -Frequent blood glucose monitoring blood\n- -Adjust blood glucose targets to appropriate for the older patients. (HbA1c 8%, blood glucose 5-10 mmol/l).\n- Hearing\timpairment:\ta\thearing\taid,\ttalking\tloudly\tand\tclearly,\tor\tusing\tsign language\n- Impaired\tvision:\tannual\teye\tcheck-ups\n- Impaired\tmobility:\tAssess\tfor\tfall\trisk\tin\tall\tolder\tpatients.\tNeed\tfor\tregular\tfoot screening, use appropriate footwear and supporting aids including crutches, walking frames, and artificial limbs, skin care\n- Impaired\tmemory:\tAdditional\tcaregiver\tsupport\n\n\n- Multiple\tmedications:\teducate\tpatient\tand\tcaregiver\ton\tthe\timportance\tof adherence of pills, use of pill charts and pill containers. Use fixed dose combinations where possible to aid adherence.\n- Dental\tproblems:\tMeals\tneed\tto\tbe\tadapted\tto\tthe\tperson's\tability\tto\tchew, dental check ups\n- Lack\tof\tsocial\tand\tfamily\tsupport:\tFamily,\tphysical,\tpsychosocial\tand\temotional support is encouraged\n- Vaccines:\tAnnual\tflu\tvaccine,\tpneumococcal\tvaccine\n- Need\tfor\tregular\tclinical\tcheckup\tand\tscreening\tfor\trecurrent\tUTI,\tthyroid dysfunction, liver and renal impairment, cardiac dysfunction, anemia and malignancy\n\n\n",
            "startLine": 4333,
            "endLine": 4375,
            "introContent": null,
            "keywords": [],
            "subsections": null
          },
          {
            "id": "section-5-4",
            "level": "h2",
            "number": "5.4",
            "title": "5.4. Management of Diabetes during Surgery",
            "slug": "54-management-of-diabetes-during-surgery",
            "url": "/guidelines/chapter-five-management-of-diabetes-in-special-situations/54-management-of-diabetes-during-surgery",
            "parentId": "chapter-5",
            "breadcrumb": [
              "CHAPTER FIVE: MANAGEMENT OF DIABETES IN SPECIAL SITUATIONS",
              "5.4. Management of Diabetes during Surgery"
            ],
            "tokenCount": 1170,
            "content": "## 5.4. Management of Diabetes during Surgery\n\n\nGood glycemic control has been shown to improve outcomes for patients undergoing surgery. As far as possible, patients with diabetes should be first on the theatre list. A patient with diabetes undergoing surgery faces potential hazards in addition to the usual operative risks in a non-diabetic patient- Hyperglycaemia and ketosis Perioperative complications - hypoglycemia, hyperglycemia and iatrogenic problems\n\n\n**i. Hyperglycaemia and Ketosis**\n\n\n- Due\tto\tthe\tmetabolic\tresponses\tto\tstress\tof\tsurgery\tespecially\tin patients with insulin deficiency (type 1 and long-standing type 2 DM)\n- Surgery\tinduces\ta\tcomplex\tseries\tof\thormonal\tand\tmetabolic\tchanges\n- Extensive\toperations\tcause\tgreater\tmetabolic\tdisruption\tand\tinsulin resistance i.e. heart surgery, laparotomies (open and laparoscopic)\n\n\n**ii. Perioperative complications**\n\n\n- a. Hypoglycemia can occur in:\n- Perioperative\tfasting\n- Delayed\teffects\tof\tlong\tacting\tinsulins\tor\tOGLAs\n- Major\thazards'\tin\tthe\tanaesthetized\tor\tsedated\tpatient\n\n\n**b. Hyperglycaemia causes**\n\n\n- Wound\tinfections\tdue\tto\timpaired\tphagocyte\tfunction\n- Delayed\twound\thealing\n- Myocardial\tinfarctions\n- Thromboembolic\tcomplications\n\n\n**c. Iatrogenic problems of diabetic control**\n\n\n- Hypoglycemia\tand\thyperglycemia\toccur\tdue\tto\n- -Inadequate B/G monitoring\n- -Poor management protocols\n\n\n### 5.4.1. Pre-Operative Management\n\n\nThe diabetic patient requires the following tests and procedures before surgery:\n\n\n- Baseline\ttests\n- -FPG, U/E/Cs, LFT profile, Urinalysis, HbA1c, Lipid profile, Serum TSH\n- -ECG\n- Ensure\tadequate\tB/G/\tcontrol\n- -FPG   4 - 7 mmol/l\n- -Pre-meal 5 -9 mmol/l\n- Patients\tfor\telective\tsurgery\tnot\twell\tcontrolled\tneed\tto\tstabilized\tprior to\tadmission\tfor\tsurgery.\tPatients\twith\tHbA1c\t&gt;9%\tshould\thave\telective surgery postponed.\n- Monitor\tblood\tpressure\n- -Aim at 140/80 mmHg\n- -Start anti-HT if elevated\n- Prepare\tpatient\tpsychologically\tfor\toperation\n- Get\twritten\tconsent\n\n\n### 5.4.2. Intraoperative management\n\n\nThe following are considerations for management of a patient with diabetes during surgical procedures\n\n\nTable 42: Management of a patient with diabetes during surgery\n\n\n| Minor Surgery, OGLAs and Good glycaemic control                                     | Major surgery or poor-gly - caemic control on OGLAs                                                                                                     | Patients on Insulin                                                                                                                                |\n|-------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|\n| Admit the patient day before sur- gery to confirm/optimize glycemic control         | Admit the patient 1 - 2 days before surgery.                                                                                                            | Admit patient 1 - 2 days be- fore surgery.                                                                                                         |\n| Stop metformin/pioglitazone day before surgery.                                     | Stop OGLAs and stabilize the blood glucose with short acting insulin.                                                                                   | Stabilize control if necessary, stop long acting insulin and put on short acting insulin.                                                          |\n| Monitor blood glucose                                                               | Operate in the morning if possible.                                                                                                                     | Operate in the morning if possible.                                                                                                                |\n| Operate in the morning if possible.                                                 | Start GKI on morning of oper- ation day                                                                                                                 | Start GKI on morning of oper- ation day                                                                                                            |\n| Omit breakfast (and no OGLAs)                                                       | Omit breakfast and morning injection.                                                                                                                   | Omit breakfast and insulin injection.                                                                                                              |\n| Pre-op, intra-op and post-op avoid glucose and lactate containing fluids.           | Monitor blood glucose 2 hourly. Maintain between 5-9 mmol/l                                                                                             | Monitor blood glucose 2 hourly Maintain between 5-9 mmol/l                                                                                         |\n| Post-op - Monitor blood glucose 2 hourly and restart OGLAs with first post-op meal. | Post-op: Monitor blood glu- cose 2 hourly. Once allowed to feed, restart previous pre-operative s.c. insulin dose. Discontinue GKI 1 hour after eating. | Post-op: Monitor blood glucose 2-hourly. Restart previous pre-operative s.c. insulin with first post-op meal. Discontinue GKI 1 hour after eating. |\n|                                                                                     | Continue with insulin regi- men until restart of regular or discharge regimen.                                                                          | Patients on long acting insulin can be converted back to their long acting insulin regimens.                                                       |\n\n\n(GKI - 10% dextrose 500 mls + 10 mmol of potassium chloride + Regular insulin (10-14 units) depending on blood glucose, to run 5- hourly\n\n\nPatients with renal impairment GKI - 10% dextrose 500 mls + Regular insulin (6-8 units) to run 12-hourly\n\n\nRecommendation: No minor or major operative surgery should be undertaken in a person with diabetes at a primary level health facility. Refer these patients, because specialist care is required\n\n\n",
            "startLine": 4376,
            "endLine": 4465,
            "introContent": {
              "content": "Good glycemic control has been shown to improve outcomes for patients undergoing surgery. As far as possible, patients with diabetes should be first on the theatre list. A patient with diabetes undergoing surgery faces potential hazards in addition to the usual operative risks in a non-diabetic patient- Hyperglycaemia and ketosis Perioperative complications - hypoglycemia, hyperglycemia and iatrogenic problems\n\n\n**i. Hyperglycaemia and Ketosis**\n\n\n- Due\tto\tthe\tmetabolic\tresponses\tto\tstress\tof\tsurgery\tespecially\tin patients with insulin deficiency (type 1 and long-standing type 2 DM)\n- Surgery\tinduces\ta\tcomplex\tseries\tof\thormonal\tand\tmetabolic\tchanges\n- Extensive\toperations\tcause\tgreater\tmetabolic\tdisruption\tand\tinsulin resistance i.e. heart surgery, laparotomies (open and laparoscopic)\n\n\n**ii. Perioperative complications**\n\n\n- a. Hypoglycemia can occur in:\n- Perioperative\tfasting\n- Delayed\teffects\tof\tlong\tacting\tinsulins\tor\tOGLAs\n- Major\thazards'\tin\tthe\tanaesthetized\tor\tsedated\tpatient\n\n\n**b. Hyperglycaemia causes**\n\n\n- Wound\tinfections\tdue\tto\timpaired\tphagocyte\tfunction\n- Delayed\twound\thealing\n- Myocardial\tinfarctions\n- Thromboembolic\tcomplications\n\n\n**c. Iatrogenic problems of diabetic control**\n\n\n- Hypoglycemia\tand\thyperglycemia\toccur\tdue\tto\n- -Inadequate B/G monitoring\n- -Poor management protocols",
              "tokenCount": 353,
              "startLine": 4377,
              "endLine": 4415
            },
            "keywords": [],
            "subsections": [
              {
                "id": "subsection-5-4-1",
                "level": "h3",
                "number": "5.4.1",
                "title": "5.4.1. Pre-Operative Management",
                "slug": "541-pre-operative-management",
                "url": "/guidelines/54-management-of-diabetes-during-surgery/541-pre-operative-management",
                "parentId": "section-5-4",
                "breadcrumb": [
                  "CHAPTER FIVE: MANAGEMENT OF DIABETES IN SPECIAL SITUATIONS",
                  "5.4. Management of Diabetes during Surgery",
                  "5.4.1. Pre-Operative Management"
                ],
                "tokenCount": 204,
                "content": "### 5.4.1. Pre-Operative Management\n\n\nThe diabetic patient requires the following tests and procedures before surgery:\n\n\n- Baseline\ttests\n- -FPG, U/E/Cs, LFT profile, Urinalysis, HbA1c, Lipid profile, Serum TSH\n- -ECG\n- Ensure\tadequate\tB/G/\tcontrol\n- -FPG   4 - 7 mmol/l\n- -Pre-meal 5 -9 mmol/l\n- Patients\tfor\telective\tsurgery\tnot\twell\tcontrolled\tneed\tto\tstabilized\tprior to\tadmission\tfor\tsurgery.\tPatients\twith\tHbA1c\t&gt;9%\tshould\thave\telective surgery postponed.\n- Monitor\tblood\tpressure\n- -Aim at 140/80 mmHg\n- -Start anti-HT if elevated\n- Prepare\tpatient\tpsychologically\tfor\toperation\n- Get\twritten\tconsent\n\n\n",
                "startLine": 4416,
                "endLine": 4435,
                "introContent": null,
                "keywords": [],
                "subsections": null
              },
              {
                "id": "subsection-5-4-2",
                "level": "h3",
                "number": "5.4.2",
                "title": "5.4.2. Intraoperative management",
                "slug": "542-intraoperative-management",
                "url": "/guidelines/54-management-of-diabetes-during-surgery/542-intraoperative-management",
                "parentId": "section-5-4",
                "breadcrumb": [
                  "CHAPTER FIVE: MANAGEMENT OF DIABETES IN SPECIAL SITUATIONS",
                  "5.4. Management of Diabetes during Surgery",
                  "5.4.2. Intraoperative management"
                ],
                "tokenCount": 600,
                "content": "### 5.4.2. Intraoperative management\n\n\nThe following are considerations for management of a patient with diabetes during surgical procedures\n\n\nTable 42: Management of a patient with diabetes during surgery\n\n\n| Minor Surgery, OGLAs and Good glycaemic control                                     | Major surgery or poor-gly - caemic control on OGLAs                                                                                                     | Patients on Insulin                                                                                                                                |\n|-------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|\n| Admit the patient day before sur- gery to confirm/optimize glycemic control         | Admit the patient 1 - 2 days before surgery.                                                                                                            | Admit patient 1 - 2 days be- fore surgery.                                                                                                         |\n| Stop metformin/pioglitazone day before surgery.                                     | Stop OGLAs and stabilize the blood glucose with short acting insulin.                                                                                   | Stabilize control if necessary, stop long acting insulin and put on short acting insulin.                                                          |\n| Monitor blood glucose                                                               | Operate in the morning if possible.                                                                                                                     | Operate in the morning if possible.                                                                                                                |\n| Operate in the morning if possible.                                                 | Start GKI on morning of oper- ation day                                                                                                                 | Start GKI on morning of oper- ation day                                                                                                            |\n| Omit breakfast (and no OGLAs)                                                       | Omit breakfast and morning injection.                                                                                                                   | Omit breakfast and insulin injection.                                                                                                              |\n| Pre-op, intra-op and post-op avoid glucose and lactate containing fluids.           | Monitor blood glucose 2 hourly. Maintain between 5-9 mmol/l                                                                                             | Monitor blood glucose 2 hourly Maintain between 5-9 mmol/l                                                                                         |\n| Post-op - Monitor blood glucose 2 hourly and restart OGLAs with first post-op meal. | Post-op: Monitor blood glu- cose 2 hourly. Once allowed to feed, restart previous pre-operative s.c. insulin dose. Discontinue GKI 1 hour after eating. | Post-op: Monitor blood glucose 2-hourly. Restart previous pre-operative s.c. insulin with first post-op meal. Discontinue GKI 1 hour after eating. |\n|                                                                                     | Continue with insulin regi- men until restart of regular or discharge regimen.                                                                          | Patients on long acting insulin can be converted back to their long acting insulin regimens.                                                       |\n\n\n(GKI - 10% dextrose 500 mls + 10 mmol of potassium chloride + Regular insulin (10-14 units) depending on blood glucose, to run 5- hourly\n\n\nPatients with renal impairment GKI - 10% dextrose 500 mls + Regular insulin (6-8 units) to run 12-hourly\n\n\nRecommendation: No minor or major operative surgery should be undertaken in a person with diabetes at a primary level health facility. Refer these patients, because specialist care is required\n\n\n",
                "startLine": 4436,
                "endLine": 4465,
                "introContent": null,
                "keywords": [],
                "subsections": null
              }
            ]
          },
          {
            "id": "section-5-5",
            "level": "h2",
            "number": "5.5",
            "title": "5.5. Diabetes and HIV",
            "slug": "55-diabetes-and-hiv",
            "url": "/guidelines/chapter-five-management-of-diabetes-in-special-situations/55-diabetes-and-hiv",
            "parentId": "chapter-5",
            "breadcrumb": [
              "CHAPTER FIVE: MANAGEMENT OF DIABETES IN SPECIAL SITUATIONS",
              "5.5. Diabetes and HIV"
            ],
            "tokenCount": 1815,
            "content": "## 5.5. Diabetes and HIV\n\n\nDiabetes as a HIV co-morbidity is increasing in both incidence and prevalence. HIV itself, and the treatment of the condition, both increase the risk for the development of diabetes. The increase in HIV testing and test to treat strategy has led to increased life expectancy of persons living with HIV(PLHIV). This has led to an increase in the chronic metabolic complications of both HIV and highly active anti-retroviral therapy (HAART) which amongst others include dyslipidaemia, accelerated atherosclerosis, osteoporosis, thyroid dysfunction, insulin resistance and diabetes mellitus.\n\n\n### 5.5.1. Classification of HIV in patients with diabetes\n\n\nThree subgroups of patients with HIV and diabetes can be identified:\n\n\n- i. Patients with pre-existing diabetes who contract HIV.\n- ii. Those who are diagnosed with both HIV and diabetes mellitus at the same time.\n- iii. Those who develop hyperglycaemia post-HAART initiation.\n\n\n### 5.5.2. Risk factors for Diabetes in HIV patients\n\n\nThere are many factors that predispose HIV positive patients on HAART to developing diabetes.\n\n\n- i. Traditional Risk Factors for developing diabetes (similar to non-HIV patients)\n- ii. HIV related risk factors\n- HIV\tvirus,\tviral\tload,\tCD4\tcount,\tduration\tof\tHIV\tinfection.\n\n\nHIV viral infection, through various inflammatory mediators and cytokines, can induce a state of insulin resistance. Most cases of HIV-associated diabetes are type 2 diabetes.\n\n\n**Auto-immune ß cell destruction has also been described.**\n\n\n- Rapid\tweight\tgain\tafter\tthe\tcatabolic\tphase\t(return\tto\thealth\tphenomenon). The rapid increase of body fat (visceral fat) instead of lean muscle mass that they would have lost during the catabolic phase of the disease. This can overwhelm the β cell secretory capacity leading to β cell failure, and induce insulin resistance.\n- Co\tinfection\twith\thepatitis\t(Hepatitis\tC\tcauses\tdysglycaemia)\n- Dyslipidaemia\twith\tlipotoxicity\n- Lipodystrophy\n- Iatrogenic\t-\tDrugs\t(NRTIs,\tNNRTIs\t&amp;\tProtease\tInhibitors)\n\n\nTable 43: Classification of drug classes by metabolic profile\n\n\n\n\n| Metabol ical y neutral NR TIs               | Metabol ical y unsafe NR TIs      | Protease inhibitors (PIs) ith potential for adverse metabol ic effects   | Metabol ical y neutral Protease inhibitors (PIs)   | Integ rase Strand Transfer Inhibitors (INSTIs) (metabol ical y neutral )   |\n|---------------------------------------------|-----------------------------------|--------------------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------------------------------|\n| Abacavir Tenofovir Emtricitabine Lamivudine | Stavudine* Didanosine* Zidovudine | Indinavir Ritonavir Saquinavir Lopinavir                                 | Darunavir Ataz anavir                              | Dolutegravir (DTG) Raltegravir                                             |\n\n\n*drugs that have been phased out\n\n\n### 5.5.3. Screening for diabetes in HIV patients\n\n\n- i. All HIV positive patients should be screened for diabetes before initiating HAART  or when changing ARVs.\n- ii. Patients with impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) should be screened every 3-6 months\n- iii. Patients with normal initial blood glucose levels should be screened annually.\n- iv. Fasting plasma glucose is preferred but standard 75 g OGTT is preferred in those with IGT or IFG with additional risk factors\n\n\n### 5.5.4. Evaluation of a patient\n\n\nInitial evaluation of a patient with both HIV and diabetes mellitus includes a detailed history which amongst others includes a detailed search for infections which are common in both conditions such as: -\n\n\n- tuberculosis\n- fungaemia\n- sexually\ttransmitted\tinfections\n- urinary\ttract\tinfections\n\n\nIn addition, the evaluation should search for other chronic conditions that need to be aggressively managed and that will also influence the choice of anti-HIV drugs and diabetic drugs: -\n\n\n- hypertension,\n- renal\timpairment\n- any\tform\tof\tdyslipidaemia\n- thyroid\tdysfunction\n- cardiac\tdysfunction\n\n\n**Initial investigations should include:**\n\n\n- i. Full blood count\n- ii. Urinalysis\n- iii. Urea and creatinine with estimated GFR\n- iv. Liver function with hepatitis screen\n- v. CD4 count\n- vi. Viral load\n- vii. Fasting blood glucose (HbA1c may be used but the readings may be low in PLHIV)\n- viii. Serum lipids\n- ix. Thyroid function test (Serum TSH)\n- x. ECG\n- xi. Serum uric acid\n\n\n### 5.5.5. Treatment of diabetes in HIV infected individuals\n\n\n**General measures**\n\n\n- i. Appropriate treatment of opportunistic infections.\n- ii. Lifestyle modification, which includes physical exercise, smoking and alcohol cessation and where available, dietary advice, taking account of BMI, desired weight and comorbidities.\n- iii. Psychosocial support and both family and community involvement where feasible.\n- iv. Reinforce compliance at every visit.\n- v. Treatment of other cardiovascular risk factors:\n6. ·Dyslipidaemia - general measures and targets apply; the only major exception is that simvastatin is contraindicated in patients using protease Inhibitors as it competes for the same Cytochrome P450 Isoenzyme. Fluvastatin and pravastatin are safer.\n7. ·Hypertension - ACE Inhibitors and ARBs (Angiotensin Receptor Blockers) need to be used with caution: captopril has been associated with the development of Kaposi's sarcoma and enalapril may cause myalgias and diarrhoea. In addition, ARBs may compete with other drugs that are metabolized by cytochrome P450 Isoenzymes.\n\n\n**Use of glucose lowering agents in people living with HIV**\n\n\n**Type 1 DM**\n\n\nAll patients with type 1 diabetes mellitus and HIV should be managed with insulin therapy.\n\n\n**Type 2 DM**\n\n\nThe following OGLAs can be used in treatment of diabetes among people living with HIV\n\n\n**i. Biguanides e.g. Metformin**\n\n\nThis is the drug of choice for most patients with HIV. It should, however, be used with caution in patients with HIV associated enteropathy as the gastrointestinal side effects of metformin will be exaggerated.\n\n\nIt is contraindicated in patients with HIV associated nephropathy (HIVAN), liver disease, cachectic patients and tuberculosis as the risk of lactic acidosis is markedly increased. It should not be used in conjunction with thymidine-based NRTIs (Stavudine, Didanosine) as the risk of lactic acidosis is increased due to mitochondrial toxicity. Extended release metformin is the preferred formulation of the drug.\n\n\n**ii.  Sulfonylureas e.g. Glibenclamide, Gliclazide, Glyburide**\n\n\nThe general principles apply as in non-HIV patients, but, caution must be exercised in patients with cachexia who might have depleted glycogen stores and who are at increased risk of Hypoglycemia.\n\n\nWhere possible, short acting or modified release formulations should be used.\n\n\n**iii. Meglitinides/Glinides**\n\n\nBecause of their short acting profile and lower risk of Hypoglycemia, they are suitable drugs but are not commonly used locally.\n\n\n**iv.  Insulin**\n\n\nInsulin remains the drug of choice for most patients with HIV and diabetes especially as both conditions are progressive. Insulin has anabolic effects, reduces inflammatory markers, has no interactions with antiretroviral drugs and can be used safely in patients with renal failure (with proper titration). It is important to note that insulin requirements might initially be high and will later fall as glucotoxicity is reversed and infections are controlled.\n\n\n**v. Other glucose lowering agents**\n\n\nThere is currently no data available regarding the newer classes of drugs in HIV patients with diabetes, including DPP-4 inhibitors, SGLT-2 inhibitors and incretin receptor analogues.\n\n\n**Changing HAART**\n\n\nA patient who develops diabetes while on HAART with drugs that are potentially diabetogenic especially the protease inhibitors should be changed to anti-retroviral agents that are metabolically neutral.\n\n\n",
            "startLine": 4466,
            "endLine": 4638,
            "introContent": {
              "content": "Diabetes as a HIV co-morbidity is increasing in both incidence and prevalence. HIV itself, and the treatment of the condition, both increase the risk for the development of diabetes. The increase in HIV testing and test to treat strategy has led to increased life expectancy of persons living with HIV(PLHIV). This has led to an increase in the chronic metabolic complications of both HIV and highly active anti-retroviral therapy (HAART) which amongst others include dyslipidaemia, accelerated atherosclerosis, osteoporosis, thyroid dysfunction, insulin resistance and diabetes mellitus.",
              "tokenCount": 117,
              "startLine": 4467,
              "endLine": 4471
            },
            "keywords": [],
            "subsections": [
              {
                "id": "subsection-5-5-1",
                "level": "h3",
                "number": "5.5.1",
                "title": "5.5.1. Classification of HIV in patients with diabetes",
                "slug": "551-classification-of-hiv-in-patients-with-diabetes",
                "url": "/guidelines/55-diabetes-and-hiv/551-classification-of-hiv-in-patients-with-diabetes",
                "parentId": "section-5-5",
                "breadcrumb": [
                  "CHAPTER FIVE: MANAGEMENT OF DIABETES IN SPECIAL SITUATIONS",
                  "5.5. Diabetes and HIV",
                  "5.5.1. Classification of HIV in patients with diabetes"
                ],
                "tokenCount": 76,
                "content": "### 5.5.1. Classification of HIV in patients with diabetes\n\n\nThree subgroups of patients with HIV and diabetes can be identified:\n\n\n- i. Patients with pre-existing diabetes who contract HIV.\n- ii. Those who are diagnosed with both HIV and diabetes mellitus at the same time.\n- iii. Those who develop hyperglycaemia post-HAART initiation.\n\n\n",
                "startLine": 4472,
                "endLine": 4482,
                "introContent": null,
                "keywords": [],
                "subsections": null
              },
              {
                "id": "subsection-5-5-2",
                "level": "h3",
                "number": "5.5.2",
                "title": "5.5.2. Risk factors for Diabetes in HIV patients",
                "slug": "552-risk-factors-for-diabetes-in-hiv-patients",
                "url": "/guidelines/55-diabetes-and-hiv/552-risk-factors-for-diabetes-in-hiv-patients",
                "parentId": "section-5-5",
                "breadcrumb": [
                  "CHAPTER FIVE: MANAGEMENT OF DIABETES IN SPECIAL SITUATIONS",
                  "5.5. Diabetes and HIV",
                  "5.5.2. Risk factors for Diabetes in HIV patients"
                ],
                "tokenCount": 467,
                "content": "### 5.5.2. Risk factors for Diabetes in HIV patients\n\n\nThere are many factors that predispose HIV positive patients on HAART to developing diabetes.\n\n\n- i. Traditional Risk Factors for developing diabetes (similar to non-HIV patients)\n- ii. HIV related risk factors\n- HIV\tvirus,\tviral\tload,\tCD4\tcount,\tduration\tof\tHIV\tinfection.\n\n\nHIV viral infection, through various inflammatory mediators and cytokines, can induce a state of insulin resistance. Most cases of HIV-associated diabetes are type 2 diabetes.\n\n\n**Auto-immune ß cell destruction has also been described.**\n\n\n- Rapid\tweight\tgain\tafter\tthe\tcatabolic\tphase\t(return\tto\thealth\tphenomenon). The rapid increase of body fat (visceral fat) instead of lean muscle mass that they would have lost during the catabolic phase of the disease. This can overwhelm the β cell secretory capacity leading to β cell failure, and induce insulin resistance.\n- Co\tinfection\twith\thepatitis\t(Hepatitis\tC\tcauses\tdysglycaemia)\n- Dyslipidaemia\twith\tlipotoxicity\n- Lipodystrophy\n- Iatrogenic\t-\tDrugs\t(NRTIs,\tNNRTIs\t&amp;\tProtease\tInhibitors)\n\n\nTable 43: Classification of drug classes by metabolic profile\n\n\n\n\n| Metabol ical y neutral NR TIs               | Metabol ical y unsafe NR TIs      | Protease inhibitors (PIs) ith potential for adverse metabol ic effects   | Metabol ical y neutral Protease inhibitors (PIs)   | Integ rase Strand Transfer Inhibitors (INSTIs) (metabol ical y neutral )   |\n|---------------------------------------------|-----------------------------------|--------------------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------------------------------|\n| Abacavir Tenofovir Emtricitabine Lamivudine | Stavudine* Didanosine* Zidovudine | Indinavir Ritonavir Saquinavir Lopinavir                                 | Darunavir Ataz anavir                              | Dolutegravir (DTG) Raltegravir                                             |\n\n\n*drugs that have been phased out\n\n\n",
                "startLine": 4483,
                "endLine": 4519,
                "introContent": null,
                "keywords": [],
                "subsections": null
              },
              {
                "id": "subsection-5-5-3",
                "level": "h3",
                "number": "5.5.3",
                "title": "5.5.3. Screening for diabetes in HIV patients",
                "slug": "553-screening-for-diabetes-in-hiv-patients",
                "url": "/guidelines/55-diabetes-and-hiv/553-screening-for-diabetes-in-hiv-patients",
                "parentId": "section-5-5",
                "breadcrumb": [
                  "CHAPTER FIVE: MANAGEMENT OF DIABETES IN SPECIAL SITUATIONS",
                  "5.5. Diabetes and HIV",
                  "5.5.3. Screening for diabetes in HIV patients"
                ],
                "tokenCount": 114,
                "content": "### 5.5.3. Screening for diabetes in HIV patients\n\n\n- i. All HIV positive patients should be screened for diabetes before initiating HAART  or when changing ARVs.\n- ii. Patients with impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) should be screened every 3-6 months\n- iii. Patients with normal initial blood glucose levels should be screened annually.\n- iv. Fasting plasma glucose is preferred but standard 75 g OGTT is preferred in those with IGT or IFG with additional risk factors\n\n\n",
                "startLine": 4520,
                "endLine": 4528,
                "introContent": null,
                "keywords": [],
                "subsections": null
              },
              {
                "id": "subsection-5-5-4",
                "level": "h3",
                "number": "5.5.4",
                "title": "5.5.4. Evaluation of a patient",
                "slug": "554-evaluation-of-a-patient",
                "url": "/guidelines/55-diabetes-and-hiv/554-evaluation-of-a-patient",
                "parentId": "section-5-5",
                "breadcrumb": [
                  "CHAPTER FIVE: MANAGEMENT OF DIABETES IN SPECIAL SITUATIONS",
                  "5.5. Diabetes and HIV",
                  "5.5.4. Evaluation of a patient"
                ],
                "tokenCount": 258,
                "content": "### 5.5.4. Evaluation of a patient\n\n\nInitial evaluation of a patient with both HIV and diabetes mellitus includes a detailed history which amongst others includes a detailed search for infections which are common in both conditions such as: -\n\n\n- tuberculosis\n- fungaemia\n- sexually\ttransmitted\tinfections\n- urinary\ttract\tinfections\n\n\nIn addition, the evaluation should search for other chronic conditions that need to be aggressively managed and that will also influence the choice of anti-HIV drugs and diabetic drugs: -\n\n\n- hypertension,\n- renal\timpairment\n- any\tform\tof\tdyslipidaemia\n- thyroid\tdysfunction\n- cardiac\tdysfunction\n\n\n**Initial investigations should include:**\n\n\n- i. Full blood count\n- ii. Urinalysis\n- iii. Urea and creatinine with estimated GFR\n- iv. Liver function with hepatitis screen\n- v. CD4 count\n- vi. Viral load\n- vii. Fasting blood glucose (HbA1c may be used but the readings may be low in PLHIV)\n- viii. Serum lipids\n- ix. Thyroid function test (Serum TSH)\n- x. ECG\n- xi. Serum uric acid\n\n\n",
                "startLine": 4529,
                "endLine": 4566,
                "introContent": null,
                "keywords": [],
                "subsections": null
              },
              {
                "id": "subsection-5-5-5",
                "level": "h3",
                "number": "5.5.5",
                "title": "5.5.5. Treatment of diabetes in HIV infected individuals",
                "slug": "555-treatment-of-diabetes-in-hiv-infected-individuals",
                "url": "/guidelines/55-diabetes-and-hiv/555-treatment-of-diabetes-in-hiv-infected-individuals",
                "parentId": "section-5-5",
                "breadcrumb": [
                  "CHAPTER FIVE: MANAGEMENT OF DIABETES IN SPECIAL SITUATIONS",
                  "5.5. Diabetes and HIV",
                  "5.5.5. Treatment of diabetes in HIV infected individuals"
                ],
                "tokenCount": 773,
                "content": "### 5.5.5. Treatment of diabetes in HIV infected individuals\n\n\n**General measures**\n\n\n- i. Appropriate treatment of opportunistic infections.\n- ii. Lifestyle modification, which includes physical exercise, smoking and alcohol cessation and where available, dietary advice, taking account of BMI, desired weight and comorbidities.\n- iii. Psychosocial support and both family and community involvement where feasible.\n- iv. Reinforce compliance at every visit.\n- v. Treatment of other cardiovascular risk factors:\n6. ·Dyslipidaemia - general measures and targets apply; the only major exception is that simvastatin is contraindicated in patients using protease Inhibitors as it competes for the same Cytochrome P450 Isoenzyme. Fluvastatin and pravastatin are safer.\n7. ·Hypertension - ACE Inhibitors and ARBs (Angiotensin Receptor Blockers) need to be used with caution: captopril has been associated with the development of Kaposi's sarcoma and enalapril may cause myalgias and diarrhoea. In addition, ARBs may compete with other drugs that are metabolized by cytochrome P450 Isoenzymes.\n\n\n**Use of glucose lowering agents in people living with HIV**\n\n\n**Type 1 DM**\n\n\nAll patients with type 1 diabetes mellitus and HIV should be managed with insulin therapy.\n\n\n**Type 2 DM**\n\n\nThe following OGLAs can be used in treatment of diabetes among people living with HIV\n\n\n**i. Biguanides e.g. Metformin**\n\n\nThis is the drug of choice for most patients with HIV. It should, however, be used with caution in patients with HIV associated enteropathy as the gastrointestinal side effects of metformin will be exaggerated.\n\n\nIt is contraindicated in patients with HIV associated nephropathy (HIVAN), liver disease, cachectic patients and tuberculosis as the risk of lactic acidosis is markedly increased. It should not be used in conjunction with thymidine-based NRTIs (Stavudine, Didanosine) as the risk of lactic acidosis is increased due to mitochondrial toxicity. Extended release metformin is the preferred formulation of the drug.\n\n\n**ii.  Sulfonylureas e.g. Glibenclamide, Gliclazide, Glyburide**\n\n\nThe general principles apply as in non-HIV patients, but, caution must be exercised in patients with cachexia who might have depleted glycogen stores and who are at increased risk of Hypoglycemia.\n\n\nWhere possible, short acting or modified release formulations should be used.\n\n\n**iii. Meglitinides/Glinides**\n\n\nBecause of their short acting profile and lower risk of Hypoglycemia, they are suitable drugs but are not commonly used locally.\n\n\n**iv.  Insulin**\n\n\nInsulin remains the drug of choice for most patients with HIV and diabetes especially as both conditions are progressive. Insulin has anabolic effects, reduces inflammatory markers, has no interactions with antiretroviral drugs and can be used safely in patients with renal failure (with proper titration). It is important to note that insulin requirements might initially be high and will later fall as glucotoxicity is reversed and infections are controlled.\n\n\n**v. Other glucose lowering agents**\n\n\nThere is currently no data available regarding the newer classes of drugs in HIV patients with diabetes, including DPP-4 inhibitors, SGLT-2 inhibitors and incretin receptor analogues.\n\n\n**Changing HAART**\n\n\nA patient who develops diabetes while on HAART with drugs that are potentially diabetogenic especially the protease inhibitors should be changed to anti-retroviral agents that are metabolically neutral.\n\n\n",
                "startLine": 4567,
                "endLine": 4638,
                "introContent": null,
                "keywords": [],
                "subsections": null
              }
            ]
          },
          {
            "id": "section-5-6",
            "level": "h2",
            "number": "5.6",
            "title": "5.6. Diabetes andTB",
            "slug": "56-diabetes-andtb",
            "url": "/guidelines/chapter-five-management-of-diabetes-in-special-situations/56-diabetes-andtb",
            "parentId": "chapter-5",
            "breadcrumb": [
              "CHAPTER FIVE: MANAGEMENT OF DIABETES IN SPECIAL SITUATIONS",
              "5.6. Diabetes andTB"
            ],
            "tokenCount": 966,
            "content": "## 5.6. Diabetes andTB\n\n\nDiabetes is associated with higher risks of TB and adverse TB treatment outcomes like treatment failure and death. TB infection may progress at a faster rate in people with diabetes than in those without diabetes. In addition, TB tends to worsen glycaemic control in patients with diabetes.\n\n\nA large proportion of people with diabetes as well as TB is not diagnosed, or is diagnosed very late. Early detection can help improve care and control of both illnesses\n\n\n### 5.6.1. Effects of diabetes onTB\n\n\n- Increases\tthe\trisk\tof\tdeveloping\tTB\tthreefold\n- Higher\trisk\tof\tlatent\tTB\tinfection\n- Faster\tprogression\tof\tTB\tinfection\tto\tTB\tdisease\n- Altered\tclinical\tpresentation\tof\tTB:\tMore\tTB\tsymptoms,\tpoor\tperformance status   (ability to perform activities of daily living without help of others) compared to patients without diabetes\n- Changes\tthe\tsensitivity\tand\tspecificity\tof\tconventional\tTB\tdiagnostic\talgorithms.\n- Adversely\taffect\tTB\ttreatment\toutcomes\tby\tdelaying\tthe\ttime\tto microbiological response/sputum culture conversion, reducing the likelihood of a favorable TB treatment outcomes, and increasing the risk of relapse or death\n- Accelerate\tthe\temergence\tof\tdrug-resistant\tTB,\tespecially\tmultidrug-resistant TB (defined as strains of TB resistant to both rifampicin and isoniazid)\n- Interference\twith\tthe\tactivity\tof\tcertain\tanti-TB\tmedications\n\n\n### 5.6.2. Effects ofTB on diabetes\n\n\n- TB\tprevalence\tand\tincidence\tare\tconsistently\thigher\tin\tpeople\twith\tdiabetes than in either the general population or in non-diabetic controls.\n- TB\tmay\ttrigger\tthe\tonset\tof\tdiabetes,\tand\tworsen\tglycaemic\tcontrol\tin\texisting diabetes\n- TB\tmedications\tmay\tinterfere\twith\tthe\ttreatment\tof\tdiabetes\tthrough\tdrug interactions\n\n\n### 5.6.3. TB screening among diabetes patients\n\n\nFigure 29: Algorithm for screening people living with diabetes for TB\n\n\n![R-Rifampicin, H-Isoniazid, Z-Pyrazinamide, Ethambutol](images/picture_052_page_135.png)\n\n\nTable 44: First line anti - TB regimen\n\n\n|                                                                        | Intensive phase   | Continuation phase   |\n|------------------------------------------------------------------------|-------------------|----------------------|\n| Adult and Pediatric TB ex- cept TB meningitis and os- teo-articular TB | 2RHZE             | 4RH                  |\n| TB meningitis and osteo-ar- ticular TB                                 | 2RHZE             | 10RH                 |\n\n\nR-Rifampicin, H-Isoniazid, Z-Pyrazinamide, Ethambutol\n\n\n- All\tTB/DM\tpatients\tshould\treceive\tpyridoxine\tfor\tthe\tduration\tof\tTB\ttreatment to prevent neuropathy from anti TB drugs.\n- Rifampicin\tmay\tcause\tnew-onset\tdysglycaemia\tor\tworsen\tglycemic\tcontrol\tin existing diabetes.\n- Rifampicin\tdecreases\tconcentrations\tof\trosiglitazone\tby\t54-65%\tand\tof\tthe related drug pioglitazone by 54%\n- Insulin\trequirements\tmight\tincrease\twhen\ton\trifampicin\n- If\tthe\tpatient\tis\ton\tDR\tTB\ttreatment\twith\taminoglycosides,\tthere\tshould\tbe close monitoring of the renal functions and liver function tests. In renal impairment, the dose of anti-TBs should be adjusted downwards according to the creatinine clearance.\n- Do\ta\trenal\tfunction\ttest\tmonthly\tfor\tDR\tTB/\tDiabetes\tpatients.\n- Glycaemic\tcontrol\tneeds\tto\tbe\tclosely\tmonitored\tin\tunderweight\tco-morbid patients who would need an increased caloric intake and dose of Oral Glucose Lowering Agents (OGLAs)/insulin adjusted accordingly.\n- OGLAs\tare\tcontraindicated\tin\tsevere\tTB\tdisease\tbut\tmay\tbe\tused\twith\tcaution once the disease has settled.\n- Insulin\tis\tthe\trecommended\ttreatment\tfor\tpatients\twith\tsevere\tTB,\trenal\tand liver impairment.\n\n\n**Recommendation**\n\n\nNeed for integrated chronic care model clinic.\n\n\n137 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS\n\n\nCHAPTER SIX\n\n\n",
            "startLine": 4639,
            "endLine": 4712,
            "introContent": {
              "content": "Diabetes is associated with higher risks of TB and adverse TB treatment outcomes like treatment failure and death. TB infection may progress at a faster rate in people with diabetes than in those without diabetes. In addition, TB tends to worsen glycaemic control in patients with diabetes.\n\n\nA large proportion of people with diabetes as well as TB is not diagnosed, or is diagnosed very late. Early detection can help improve care and control of both illnesses",
              "tokenCount": 87,
              "startLine": 4640,
              "endLine": 4647
            },
            "keywords": [],
            "subsections": [
              {
                "id": "subsection-5-6-1",
                "level": "h3",
                "number": "5.6.1",
                "title": "5.6.1. Effects of diabetes onTB",
                "slug": "561-effects-of-diabetes-ontb",
                "url": "/guidelines/56-diabetes-andtb/561-effects-of-diabetes-ontb",
                "parentId": "section-5-6",
                "breadcrumb": [
                  "CHAPTER FIVE: MANAGEMENT OF DIABETES IN SPECIAL SITUATIONS",
                  "5.6. Diabetes andTB",
                  "5.6.1. Effects of diabetes onTB"
                ],
                "tokenCount": 229,
                "content": "### 5.6.1. Effects of diabetes onTB\n\n\n- Increases\tthe\trisk\tof\tdeveloping\tTB\tthreefold\n- Higher\trisk\tof\tlatent\tTB\tinfection\n- Faster\tprogression\tof\tTB\tinfection\tto\tTB\tdisease\n- Altered\tclinical\tpresentation\tof\tTB:\tMore\tTB\tsymptoms,\tpoor\tperformance status   (ability to perform activities of daily living without help of others) compared to patients without diabetes\n- Changes\tthe\tsensitivity\tand\tspecificity\tof\tconventional\tTB\tdiagnostic\talgorithms.\n- Adversely\taffect\tTB\ttreatment\toutcomes\tby\tdelaying\tthe\ttime\tto microbiological response/sputum culture conversion, reducing the likelihood of a favorable TB treatment outcomes, and increasing the risk of relapse or death\n- Accelerate\tthe\temergence\tof\tdrug-resistant\tTB,\tespecially\tmultidrug-resistant TB (defined as strains of TB resistant to both rifampicin and isoniazid)\n- Interference\twith\tthe\tactivity\tof\tcertain\tanti-TB\tmedications\n\n\n",
                "startLine": 4648,
                "endLine": 4660,
                "introContent": null,
                "keywords": [],
                "subsections": null
              },
              {
                "id": "subsection-5-6-2",
                "level": "h3",
                "number": "5.6.2",
                "title": "5.6.2. Effects ofTB on diabetes",
                "slug": "562-effects-oftb-on-diabetes",
                "url": "/guidelines/56-diabetes-andtb/562-effects-oftb-on-diabetes",
                "parentId": "section-5-6",
                "breadcrumb": [
                  "CHAPTER FIVE: MANAGEMENT OF DIABETES IN SPECIAL SITUATIONS",
                  "5.6. Diabetes andTB",
                  "5.6.2. Effects ofTB on diabetes"
                ],
                "tokenCount": 104,
                "content": "### 5.6.2. Effects ofTB on diabetes\n\n\n- TB\tprevalence\tand\tincidence\tare\tconsistently\thigher\tin\tpeople\twith\tdiabetes than in either the general population or in non-diabetic controls.\n- TB\tmay\ttrigger\tthe\tonset\tof\tdiabetes,\tand\tworsen\tglycaemic\tcontrol\tin\texisting diabetes\n- TB\tmedications\tmay\tinterfere\twith\tthe\ttreatment\tof\tdiabetes\tthrough\tdrug interactions\n\n\n",
                "startLine": 4661,
                "endLine": 4668,
                "introContent": null,
                "keywords": [],
                "subsections": null
              },
              {
                "id": "subsection-5-6-3",
                "level": "h3",
                "number": "5.6.3",
                "title": "5.6.3. TB screening among diabetes patients",
                "slug": "563-tb-screening-among-diabetes-patients",
                "url": "/guidelines/56-diabetes-andtb/563-tb-screening-among-diabetes-patients",
                "parentId": "section-5-6",
                "breadcrumb": [
                  "CHAPTER FIVE: MANAGEMENT OF DIABETES IN SPECIAL SITUATIONS",
                  "5.6. Diabetes andTB",
                  "5.6.3. TB screening among diabetes patients"
                ],
                "tokenCount": 535,
                "content": "### 5.6.3. TB screening among diabetes patients\n\n\nFigure 29: Algorithm for screening people living with diabetes for TB\n\n\n![R-Rifampicin, H-Isoniazid, Z-Pyrazinamide, Ethambutol](images/picture_052_page_135.png)\n\n\nTable 44: First line anti - TB regimen\n\n\n|                                                                        | Intensive phase   | Continuation phase   |\n|------------------------------------------------------------------------|-------------------|----------------------|\n| Adult and Pediatric TB ex- cept TB meningitis and os- teo-articular TB | 2RHZE             | 4RH                  |\n| TB meningitis and osteo-ar- ticular TB                                 | 2RHZE             | 10RH                 |\n\n\nR-Rifampicin, H-Isoniazid, Z-Pyrazinamide, Ethambutol\n\n\n- All\tTB/DM\tpatients\tshould\treceive\tpyridoxine\tfor\tthe\tduration\tof\tTB\ttreatment to prevent neuropathy from anti TB drugs.\n- Rifampicin\tmay\tcause\tnew-onset\tdysglycaemia\tor\tworsen\tglycemic\tcontrol\tin existing diabetes.\n- Rifampicin\tdecreases\tconcentrations\tof\trosiglitazone\tby\t54-65%\tand\tof\tthe related drug pioglitazone by 54%\n- Insulin\trequirements\tmight\tincrease\twhen\ton\trifampicin\n- If\tthe\tpatient\tis\ton\tDR\tTB\ttreatment\twith\taminoglycosides,\tthere\tshould\tbe close monitoring of the renal functions and liver function tests. In renal impairment, the dose of anti-TBs should be adjusted downwards according to the creatinine clearance.\n- Do\ta\trenal\tfunction\ttest\tmonthly\tfor\tDR\tTB/\tDiabetes\tpatients.\n- Glycaemic\tcontrol\tneeds\tto\tbe\tclosely\tmonitored\tin\tunderweight\tco-morbid patients who would need an increased caloric intake and dose of Oral Glucose Lowering Agents (OGLAs)/insulin adjusted accordingly.\n- OGLAs\tare\tcontraindicated\tin\tsevere\tTB\tdisease\tbut\tmay\tbe\tused\twith\tcaution once the disease has settled.\n- Insulin\tis\tthe\trecommended\ttreatment\tfor\tpatients\twith\tsevere\tTB,\trenal\tand liver impairment.\n\n\n**Recommendation**\n\n\nNeed for integrated chronic care model clinic.\n\n\n137 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS\n\n\nCHAPTER SIX\n\n\n",
                "startLine": 4669,
                "endLine": 4712,
                "introContent": null,
                "keywords": [],
                "subsections": null
              }
            ]
          }
        ]
      },
      {
        "id": "chapter-6",
        "level": "h1",
        "number": "6",
        "title": "CHAPTER SIX: LIVING WITH DIABETES",
        "slug": "chapter-six-living-with-diabetes",
        "url": "/guidelines/chapter-six-living-with-diabetes",
        "tokenCount": 1946,
        "summary": null,
        "content": "# CHAPTER SIX: LIVING WITH DIABETES\n\n\n## 6.1. Introduction\n\n\nDiabetes mellitus is a lifelong condition, but if well controlled one can live a long healthy productive life. People living with diabetes require lifestyle adjustments in their diet, exercise and frequency of review by their medical providers. They may need to take daily medications or insulin to keep their blood glucose levels in check. Having diabetes means adjusting at work and at home. But these changes don't mean one won't be able to succeed at work or enjoy a healthy and fulfilling life. People with diabetes have equal rights with those without the condition and should be protected from all forms of discrimination.\n\n\n## 6.2. Employment\n\n\nA person with diabetes, particularly if treated with insulin, requires certain adjustments in ordinary daily life. Health-care providers require the knowledge, skills and attitudes to provide appropriate advice.\n\n\nThe commonest problem is prejudice in the workplace. Such prejudice is usually because of ignorance and misperceptions that all people with diabetes will have work performance issues.\n\n\nThis prejudice causes some people with diabetes to try and conceal their condition from their  employers  and  workmates. This  must  be  discouraged  as  concealment may result in poor adherence, lack of appropriate social support, anxiety and consequently poor performance.\n\n\nPersons living with diabetes should be encouraged to disclose their condition to the employer as they have a right to support in the workplace. Disclosure will improve capacity to perform and live positively.\n\n\nIndividuals in shift work need special attention to tailor the work conditions to support optimal performance with their conditions and prevent possible acute events during working hours.\n\n\nPatients should be encouraged to disclose to at least two colleagues and to health personnel where there are staff clinics to allow persons who can provide first aid in case of an acute diabetes emergency.\n\n\nA person living with diabetes should be eligible for any form of employment and career.\n\n\n## 6.3. Driving, Flying and Operating Machines\n\n\nThe healthcare provider should establish the profession of their patients. Individuals in the above professions should receive detailed and individually-tailored management plans to prevent catastrophic events related to diabetes emergencies.\n\n\nAll drivers, pilots and machine operators must act responsibly and schedule their medications  and  eating  pattern  to  avoid  Hypoglycemia.  Individuals  who  are  newly  diagnosed and whose sugars are not stable should avoid driving and operating machinery. In addition, it is their responsibility to disclose severe hypoglycemia, and other diabetes related complications (e.g. visual impairment from retinopathy) that may lead to adverse outcomes, and ensure appropriate measures are in place to avoid these events, even if it means changing the nature of work duties.\n\n\nIndividuals on insulin and insulin secretagogues should be advised to inform their employers and the licensing authorities.\n\n\nPilots should refer to the Kenyan Aviation Guidelines for further guidance.\n\n\n**Basic Advice:**\n\n\n- Inform\tyour\tInsurance\tCompany\tof\tyour\tcondition\n- Always\tkeep\tglucose\tor\tsweet\teatables\taccessible\tat\tall\ttimes\n- Never\tdrink\talcohol\tand\tdrive,\tfly\tor\toperate\tmachinery\n- Never\tmiss\ta\tmeal\tif\tyou\tintend\tto\tdrive,\tfly\tor\toperate\tmachinery.\n\n\n## 6.4. Insurance\n\n\nMost people with diabetes are asked to pay additional premiums for life assurance and sickness insurance. Some are denied insurance outright.\n\n\nThere should be unbiased access to insurance policies (life or sickness) at a reasonable cost.\n\n\nIndividuals should be encouraged to enroll with the National Hospital Insurance Fund (NHIF).\n\n\nInsurance providers and employers should be encouraged to invest more in screening, prevention and quality care outpatient programs to minimize overall costs incurred by managing the complications of diabetes.\n\n\n## 6.5. Sports, recreational and occupational exercise\n\n\nRegular exercise is an integral part of management of diabetes. It has many benefits including glycemic and blood pressure control as well as improvement of general wellbeing.\n\n\nTreatment with insulin  and  oral  glucose  lowering  agents  (OGLAs)  do  not  preclude vigorous sports and exercise, unless underlying ischemic heart disease or significant microvascular complications, e.g. advanced retinopathy, are present.\n\n\nThere is a possibility of Hypoglycemia as a result of exercise or vigorous sports. Hypoglycemia may occur some hours after exercise, because the liver and muscles are still replenishing glycogen stores. Exercise with poor glycemic control may predispose to DKA.\n\n\nExercise or sports may need to be accompanied by extra food or adjustment in OGLA or insulin dosage.\n\n\nIf vigorous sporting activity is being considered, the person should consult with their healthcare provider, and should have good metabolic control to reduce the risk of Hypoglycemia and DKA.\n\n\n**Principles of Exercise in the setting of Diabetes**\n\n\n1. Level of glycaemia. Test for blood glucose before and after exercise and if any symptoms of hypoglycemia\n\n\n**Avoid moderate to vigorous exercise if:**\n\n\n- FBS&gt;13.8\tor\tRBS&gt;16\tmmol/L\n- Presence\tof\tketones\n- Poor\tglycemic\ttrend\tin\tthe\tpreceding\tdays.\n2. Timing of exercise should be in relation to injection. The dose of rapid acting\n\n\nInsulin  should be reduced before the period of exercise.\n\n\n3. Exercise in relation to meals: Take a glucose rich snack before exercise e.g. a banana, fruit juice, a slice or two of bread. One can sip juice during exercise.\n4. Presence of complications: If individual with chronic complications ( Neuropathy, retinopathy, cardiovascular complications) should involve a healthcare   provider in prescription of exercise.\n\n\nTable 45: Insulin adjustment before exercise\n\n\n3\n\n\n|                               | Duration of exercise and the recommended percent reduction in bol us insul in at the meal before pl anned exercise   | Duration of exercise and the recommended percent reduction in bol us insul in at the meal before pl anned exercise   |\n|-------------------------------|----------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|\n| Intensity of aerobic exercise | minutes                                                                                                              | minutes                                                                                                              |\n| Mild                          | 25%                                                                                                                  | 50%                                                                                                                  |\n| Moderate                      | 50%                                                                                                                  | 75%                                                                                                                  |\n| Heavy                         | 75% -                                                                                                                |                                                                                                                      |\n\n\n0\n\n\n6\n\n\n0\n\n\nSource: Kelly D, Hamilton JK and Riddell M.C. Blood glucose levels and performance in a sports camp for adolescents with a basal-bolus insulin regimen (ultra-Lente-lispro) in children with type 1 diabetes mellitus: a field study. Diabetes care 2001: 24: 4: 625-630\n\n\n## 6.6. Diabetes and School\n\n\nIt is normal for parents to feel anxious about having a child with diabetes in school. With good planning and appropriate education, children can have a normal school experience and engage safely in all school activities\n\n\n- Parents\tshould\tinform\tthe\tschool\tof\ttheir\tchild's\tcondition, requirements for care and provide contacts of child's healthcare provider.\n- It\tis\timportant\tthat\tthe\tneeds\tof\teach\tstudent\twith\tdiabetes\tare recognized and accommodated according to the student's individual care plan.\n- It\tis\tessential\tthat\tschool\tpersonnel\thave\taccurate\tand\tcurrent information about diabetes and how it is managed to reduce stigma and other problems that may put the student's health and safety at risk.\n\n\n**The school environment should provide the following: -**\n\n\n- Right\tfor\tadmission\tto\tschool\tand\tright\tto\tappropriate\tcare\n- Right\tto\tintegrate\tinto\tschool\tenvironment\tand\tengage\tin\tall\tactivities\n- Right\tto\tattain\tdevelopment\tgoals,\tpeer\tacceptance\tand\tdevelopment of self-esteem.\n- Facilitate\ttimely\taccess\tto\tdiabetes\tmanagement\tsupplies\t(insulin)\tand equipment e.g. glucometers, strips and sharps containers.\n- Unrestricted\taccess\tto\thealthy\tsnacks,\twater\tand\tbathroom\tbreaks.\n- Classroom\tglucose\tmonitoring\n- Access\tto\tidentified\tand\ttrained\tpersonnel\twithin\tthe\tschool\t(school nurse,   teacher or other staff)\n\n\n## 6.7. Caregiver and Family Support\n\n\nCaregivers and family are an integral part of diabetes care. Caregivers should be trained on the basics of diabetes management including response to acute emergencies.\n\n\n**The key areas of support include:**\n\n\n- Adherence\twith\tmedication,\tfollow\tup\tand\tdiabetes\tself-management\n- Adherence\tto\thealthy\tlifestyle\n- Psychosocial\tsupport\n- They\tmay\tform\tthe\tlink\tbetween\tthe\tclient\tand\tthe\thealthcare\tworker.\n\n\nThe role of the caregiver comes with the potential for burn-out and stress due to the chronic nature of the condition.\n\n\n**Tips for caregiver:**\n\n\n- Continue\tto\ttake\tcare\tof\tyour\town\thealth\tand\twalk\tthe\ttalk.\n- Find\tsomeone\tto\ttalk\tto\twhen\tcaregiving\tbecomes\toverwhelming\tand/ or seek peer/group support.\n- Avoid\ttaking\ton\ttoo\tmuch\tand\tlearn\tto\tsay\tno\tand\tprioritize.\n- Ask\tfor\tand\taccept\thelp.\tInvolve\tfamily,\tfriends\tand\tthe\thealth\tcare provider\n\n\nCHAPTER SEVEN\n\n\nKENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS| 142\n\n\n",
        "startLine": 4713,
        "endLine": 4906,
        "introContent": null,
        "sections": [
          {
            "id": "section-6-1",
            "level": "h2",
            "number": "6.1",
            "title": "6.1. Introduction",
            "slug": "61-introduction",
            "url": "/guidelines/chapter-six-living-with-diabetes/61-introduction",
            "parentId": "chapter-6",
            "breadcrumb": [
              "CHAPTER SIX: LIVING WITH DIABETES",
              "6.1. Introduction"
            ],
            "tokenCount": 123,
            "content": "## 6.1. Introduction\n\n\nDiabetes mellitus is a lifelong condition, but if well controlled one can live a long healthy productive life. People living with diabetes require lifestyle adjustments in their diet, exercise and frequency of review by their medical providers. They may need to take daily medications or insulin to keep their blood glucose levels in check. Having diabetes means adjusting at work and at home. But these changes don't mean one won't be able to succeed at work or enjoy a healthy and fulfilling life. People with diabetes have equal rights with those without the condition and should be protected from all forms of discrimination.\n\n\n",
            "startLine": 4716,
            "endLine": 4721,
            "introContent": null,
            "keywords": [],
            "subsections": null
          },
          {
            "id": "section-6-2",
            "level": "h2",
            "number": "6.2",
            "title": "6.2. Employment",
            "slug": "62-employment",
            "url": "/guidelines/chapter-six-living-with-diabetes/62-employment",
            "parentId": "chapter-6",
            "breadcrumb": [
              "CHAPTER SIX: LIVING WITH DIABETES",
              "6.2. Employment"
            ],
            "tokenCount": 243,
            "content": "## 6.2. Employment\n\n\nA person with diabetes, particularly if treated with insulin, requires certain adjustments in ordinary daily life. Health-care providers require the knowledge, skills and attitudes to provide appropriate advice.\n\n\nThe commonest problem is prejudice in the workplace. Such prejudice is usually because of ignorance and misperceptions that all people with diabetes will have work performance issues.\n\n\nThis prejudice causes some people with diabetes to try and conceal their condition from their  employers  and  workmates. This  must  be  discouraged  as  concealment may result in poor adherence, lack of appropriate social support, anxiety and consequently poor performance.\n\n\nPersons living with diabetes should be encouraged to disclose their condition to the employer as they have a right to support in the workplace. Disclosure will improve capacity to perform and live positively.\n\n\nIndividuals in shift work need special attention to tailor the work conditions to support optimal performance with their conditions and prevent possible acute events during working hours.\n\n\nPatients should be encouraged to disclose to at least two colleagues and to health personnel where there are staff clinics to allow persons who can provide first aid in case of an acute diabetes emergency.\n\n\nA person living with diabetes should be eligible for any form of employment and career.\n\n\n",
            "startLine": 4722,
            "endLine": 4745,
            "introContent": null,
            "keywords": [],
            "subsections": null
          },
          {
            "id": "section-6-3",
            "level": "h2",
            "number": "6.3",
            "title": "6.3. Driving, Flying and Operating Machines",
            "slug": "63-driving-flying-and-operating-machines",
            "url": "/guidelines/chapter-six-living-with-diabetes/63-driving-flying-and-operating-machines",
            "parentId": "chapter-6",
            "breadcrumb": [
              "CHAPTER SIX: LIVING WITH DIABETES",
              "6.3. Driving, Flying and Operating Machines"
            ],
            "tokenCount": 279,
            "content": "## 6.3. Driving, Flying and Operating Machines\n\n\nThe healthcare provider should establish the profession of their patients. Individuals in the above professions should receive detailed and individually-tailored management plans to prevent catastrophic events related to diabetes emergencies.\n\n\nAll drivers, pilots and machine operators must act responsibly and schedule their medications  and  eating  pattern  to  avoid  Hypoglycemia.  Individuals  who  are  newly  diagnosed and whose sugars are not stable should avoid driving and operating machinery. In addition, it is their responsibility to disclose severe hypoglycemia, and other diabetes related complications (e.g. visual impairment from retinopathy) that may lead to adverse outcomes, and ensure appropriate measures are in place to avoid these events, even if it means changing the nature of work duties.\n\n\nIndividuals on insulin and insulin secretagogues should be advised to inform their employers and the licensing authorities.\n\n\nPilots should refer to the Kenyan Aviation Guidelines for further guidance.\n\n\n**Basic Advice:**\n\n\n- Inform\tyour\tInsurance\tCompany\tof\tyour\tcondition\n- Always\tkeep\tglucose\tor\tsweet\teatables\taccessible\tat\tall\ttimes\n- Never\tdrink\talcohol\tand\tdrive,\tfly\tor\toperate\tmachinery\n- Never\tmiss\ta\tmeal\tif\tyou\tintend\tto\tdrive,\tfly\tor\toperate\tmachinery.\n\n\n",
            "startLine": 4746,
            "endLine": 4769,
            "introContent": null,
            "keywords": [],
            "subsections": null
          },
          {
            "id": "section-6-4",
            "level": "h2",
            "number": "6.4",
            "title": "6.4. Insurance",
            "slug": "64-insurance",
            "url": "/guidelines/chapter-six-living-with-diabetes/64-insurance",
            "parentId": "chapter-6",
            "breadcrumb": [
              "CHAPTER SIX: LIVING WITH DIABETES",
              "6.4. Insurance"
            ],
            "tokenCount": 97,
            "content": "## 6.4. Insurance\n\n\nMost people with diabetes are asked to pay additional premiums for life assurance and sickness insurance. Some are denied insurance outright.\n\n\nThere should be unbiased access to insurance policies (life or sickness) at a reasonable cost.\n\n\nIndividuals should be encouraged to enroll with the National Hospital Insurance Fund (NHIF).\n\n\nInsurance providers and employers should be encouraged to invest more in screening, prevention and quality care outpatient programs to minimize overall costs incurred by managing the complications of diabetes.\n\n\n",
            "startLine": 4770,
            "endLine": 4784,
            "introContent": null,
            "keywords": [],
            "subsections": null
          },
          {
            "id": "section-6-5",
            "level": "h2",
            "number": "6.5",
            "title": "6.5. Sports, recreational and occupational exercise",
            "slug": "65-sports-recreational-and-occupational-exercise",
            "url": "/guidelines/chapter-six-living-with-diabetes/65-sports-recreational-and-occupational-exercise",
            "parentId": "chapter-6",
            "breadcrumb": [
              "CHAPTER SIX: LIVING WITH DIABETES",
              "6.5. Sports, recreational and occupational exercise"
            ],
            "tokenCount": 620,
            "content": "## 6.5. Sports, recreational and occupational exercise\n\n\nRegular exercise is an integral part of management of diabetes. It has many benefits including glycemic and blood pressure control as well as improvement of general wellbeing.\n\n\nTreatment with insulin  and  oral  glucose  lowering  agents  (OGLAs)  do  not  preclude vigorous sports and exercise, unless underlying ischemic heart disease or significant microvascular complications, e.g. advanced retinopathy, are present.\n\n\nThere is a possibility of Hypoglycemia as a result of exercise or vigorous sports. Hypoglycemia may occur some hours after exercise, because the liver and muscles are still replenishing glycogen stores. Exercise with poor glycemic control may predispose to DKA.\n\n\nExercise or sports may need to be accompanied by extra food or adjustment in OGLA or insulin dosage.\n\n\nIf vigorous sporting activity is being considered, the person should consult with their healthcare provider, and should have good metabolic control to reduce the risk of Hypoglycemia and DKA.\n\n\n**Principles of Exercise in the setting of Diabetes**\n\n\n1. Level of glycaemia. Test for blood glucose before and after exercise and if any symptoms of hypoglycemia\n\n\n**Avoid moderate to vigorous exercise if:**\n\n\n- FBS&gt;13.8\tor\tRBS&gt;16\tmmol/L\n- Presence\tof\tketones\n- Poor\tglycemic\ttrend\tin\tthe\tpreceding\tdays.\n2. Timing of exercise should be in relation to injection. The dose of rapid acting\n\n\nInsulin  should be reduced before the period of exercise.\n\n\n3. Exercise in relation to meals: Take a glucose rich snack before exercise e.g. a banana, fruit juice, a slice or two of bread. One can sip juice during exercise.\n4. Presence of complications: If individual with chronic complications ( Neuropathy, retinopathy, cardiovascular complications) should involve a healthcare   provider in prescription of exercise.\n\n\nTable 45: Insulin adjustment before exercise\n\n\n3\n\n\n|                               | Duration of exercise and the recommended percent reduction in bol us insul in at the meal before pl anned exercise   | Duration of exercise and the recommended percent reduction in bol us insul in at the meal before pl anned exercise   |\n|-------------------------------|----------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|\n| Intensity of aerobic exercise | minutes                                                                                                              | minutes                                                                                                              |\n| Mild                          | 25%                                                                                                                  | 50%                                                                                                                  |\n| Moderate                      | 50%                                                                                                                  | 75%                                                                                                                  |\n| Heavy                         | 75% -                                                                                                                |                                                                                                                      |\n\n\n0\n\n\n6\n\n\n0\n\n\nSource: Kelly D, Hamilton JK and Riddell M.C. Blood glucose levels and performance in a sports camp for adolescents with a basal-bolus insulin regimen (ultra-Lente-lispro) in children with type 1 diabetes mellitus: a field study. Diabetes care 2001: 24: 4: 625-630\n\n\n",
            "startLine": 4785,
            "endLine": 4850,
            "introContent": null,
            "keywords": [],
            "subsections": null
          },
          {
            "id": "section-6-6",
            "level": "h2",
            "number": "6.6",
            "title": "6.6. Diabetes and School",
            "slug": "66-diabetes-and-school",
            "url": "/guidelines/chapter-six-living-with-diabetes/66-diabetes-and-school",
            "parentId": "chapter-6",
            "breadcrumb": [
              "CHAPTER SIX: LIVING WITH DIABETES",
              "6.6. Diabetes and School"
            ],
            "tokenCount": 314,
            "content": "## 6.6. Diabetes and School\n\n\nIt is normal for parents to feel anxious about having a child with diabetes in school. With good planning and appropriate education, children can have a normal school experience and engage safely in all school activities\n\n\n- Parents\tshould\tinform\tthe\tschool\tof\ttheir\tchild's\tcondition, requirements for care and provide contacts of child's healthcare provider.\n- It\tis\timportant\tthat\tthe\tneeds\tof\teach\tstudent\twith\tdiabetes\tare recognized and accommodated according to the student's individual care plan.\n- It\tis\tessential\tthat\tschool\tpersonnel\thave\taccurate\tand\tcurrent information about diabetes and how it is managed to reduce stigma and other problems that may put the student's health and safety at risk.\n\n\n**The school environment should provide the following: -**\n\n\n- Right\tfor\tadmission\tto\tschool\tand\tright\tto\tappropriate\tcare\n- Right\tto\tintegrate\tinto\tschool\tenvironment\tand\tengage\tin\tall\tactivities\n- Right\tto\tattain\tdevelopment\tgoals,\tpeer\tacceptance\tand\tdevelopment of self-esteem.\n- Facilitate\ttimely\taccess\tto\tdiabetes\tmanagement\tsupplies\t(insulin)\tand equipment e.g. glucometers, strips and sharps containers.\n- Unrestricted\taccess\tto\thealthy\tsnacks,\twater\tand\tbathroom\tbreaks.\n- Classroom\tglucose\tmonitoring\n- Access\tto\tidentified\tand\ttrained\tpersonnel\twithin\tthe\tschool\t(school nurse,   teacher or other staff)\n\n\n",
            "startLine": 4851,
            "endLine": 4873,
            "introContent": null,
            "keywords": [],
            "subsections": null
          },
          {
            "id": "section-6-7",
            "level": "h2",
            "number": "6.7",
            "title": "6.7. Caregiver and Family Support",
            "slug": "67-caregiver-and-family-support",
            "url": "/guidelines/chapter-six-living-with-diabetes/67-caregiver-and-family-support",
            "parentId": "chapter-6",
            "breadcrumb": [
              "CHAPTER SIX: LIVING WITH DIABETES",
              "6.7. Caregiver and Family Support"
            ],
            "tokenCount": 258,
            "content": "## 6.7. Caregiver and Family Support\n\n\nCaregivers and family are an integral part of diabetes care. Caregivers should be trained on the basics of diabetes management including response to acute emergencies.\n\n\n**The key areas of support include:**\n\n\n- Adherence\twith\tmedication,\tfollow\tup\tand\tdiabetes\tself-management\n- Adherence\tto\thealthy\tlifestyle\n- Psychosocial\tsupport\n- They\tmay\tform\tthe\tlink\tbetween\tthe\tclient\tand\tthe\thealthcare\tworker.\n\n\nThe role of the caregiver comes with the potential for burn-out and stress due to the chronic nature of the condition.\n\n\n**Tips for caregiver:**\n\n\n- Continue\tto\ttake\tcare\tof\tyour\town\thealth\tand\twalk\tthe\ttalk.\n- Find\tsomeone\tto\ttalk\tto\twhen\tcaregiving\tbecomes\toverwhelming\tand/ or seek peer/group support.\n- Avoid\ttaking\ton\ttoo\tmuch\tand\tlearn\tto\tsay\tno\tand\tprioritize.\n- Ask\tfor\tand\taccept\thelp.\tInvolve\tfamily,\tfriends\tand\tthe\thealth\tcare provider\n\n\nCHAPTER SEVEN\n\n\nKENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS| 142\n\n\n",
            "startLine": 4874,
            "endLine": 4906,
            "introContent": null,
            "keywords": [],
            "subsections": null
          }
        ]
      },
      {
        "id": "chapter-7",
        "level": "h1",
        "number": "7",
        "title": "CHAPTER SEVEN: PREVENTION OF DIABETES",
        "slug": "chapter-seven-prevention-of-diabetes",
        "url": "/guidelines/chapter-seven-prevention-of-diabetes",
        "tokenCount": 803,
        "summary": null,
        "content": "# CHAPTER SEVEN: PREVENTION OF DIABETES\n\n\n## 7.1. Introduction\n\n\nPrevention refers to actions aimed at eradicating, eliminating or minimizing the impact of diabetes and disability. (Last, 2008)\n\n\nDiabetes prevention can be categorized into groups:\n\n\n- Primordial\tPrevention\n- Primary\tprevention\n- Secondary\tprevention\n- Tertiary\tprevention\n\n\n## 7.2. Primordial Prevention\n\n\nPrimordial prevention refers to prevention of adoption of risk factors which can predispose to type 2 diabetes.\n\n\nSocial and environmental conditions contribute to the emergence of risk factors for diabetes. These include eating patterns, levels of physical activity, habits such as tobacco use and alcohol consumption.\n\n\nThe  main  intervention  in  primordial  prevention  is  through  individual  and  mass health education. These include school and community-based programs that promote physical activity, improve nutrition, limit alcohol consumption and prevent smoking  and  other  tobacco  use.  Advocate  for  comprehensive Worksite Wellness Programs.\n\n\n## 7.3. Primary Prevention\n\n\nPrimary prevention can be defined as an action taken prior to the onset of diabetes, which reduces the possibility that diabetes will occur. It therefore has an impact by reducing both the need for diabetes care and the need to treat diabetes-related complications.\n\n\nPrimary prevention can be achieved by health promotion which include health education,  environmental  modification,  nutritional  intervention,  lifestyle  and  behavioral changes. This can be achieved through population (mass) strategy and high-risk individual strategy.\n\n\nWhile there is yet no conclusive evidence to suggest that type 1 diabetes can be prevented, primary prevention of type 2 diabetes is potentially possible. The components of lifestyle modification and their aims should include, but not be limited to, the following list:\n\n\n- Obese/\tOverweight\tpatients\t-\tWeight\tloss\tof\t5-10%\twith\tan\taim\tto achieving ideal sustained body weight\n- Modify\tdietary\tpatterns\tfocusing\ton\n- -Reduction in fat intake\n- -Increase in fibre, vegetables and fruits intake\n- Increase\tin\tphysical\tactivity\tlevels.\te.g.\tbrisk\twalking\t30\tminutes,\tfive times a week. Exercise should be tailored to the individual\n- Alcohol\tintake\tshould\tbe\tlimited\tto\tless\tthan\tone\tdrink\tper\tday\tof\tany type (1 standard alcoholic drink per day (7 units per week) for women, 2 standard alcoholic drinks (14 units per week) for men.\n- Screening\tof\tpeople\tat\thigh\trisk\tof\tdeveloping\tdiabetes\n- Cessation\tof\ttobacco\tuse.\n\n\n## 7.4. Secondary prevention\n\n\nThis involves action that halts the progress of diabetes at its early stage and prevent complications. Secondary prevention attempts to arrest the diabetes progression, restore health by seeking out unrecognized disease and treating it before irreversible pathological changes take place.\n\n\nThere are several landmark studies that have shown that good glycemic with HbA1c &lt; 7%, blood pressure &lt;140/80 mmHg and lipid control prevent progression of complications of diabetes.\n\n\n## 7.5. Tertiary Prevention\n\n\nActions taken when diabetes has progressed beyond its early stages. It is defined as all the measures available to reduce or limit impairments and disabilities, and to promote the patients' adjustment to irreversible conditions. This involves strict metabolic control, diabetes  education,  effective  treatment,  screening  and  monitoring  of  complications. Examples - regular assessment for foot, eye, kidney, skin and heart disease. The blood glucose, blood pressure and lipid control are important in tertiary prevention.\n\n\nCHAPTER EIGHT\n\n\nROOM28\n\n\n145 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS\n\n\nTRLNBEROOM\n\n\nROOM29\n\n\nDIABEIICCLINIC\n\n\nTRIAGE\n\n\n\n\n",
        "startLine": 4907,
        "endLine": 4996,
        "introContent": null,
        "sections": [
          {
            "id": "section-7-1",
            "level": "h2",
            "number": "7.1",
            "title": "7.1. Introduction",
            "slug": "71-introduction",
            "url": "/guidelines/chapter-seven-prevention-of-diabetes/71-introduction",
            "parentId": "chapter-7",
            "breadcrumb": [
              "CHAPTER SEVEN: PREVENTION OF DIABETES",
              "7.1. Introduction"
            ],
            "tokenCount": 68,
            "content": "## 7.1. Introduction\n\n\nPrevention refers to actions aimed at eradicating, eliminating or minimizing the impact of diabetes and disability. (Last, 2008)\n\n\nDiabetes prevention can be categorized into groups:\n\n\n- Primordial\tPrevention\n- Primary\tprevention\n- Secondary\tprevention\n- Tertiary\tprevention\n\n\n",
            "startLine": 4910,
            "endLine": 4924,
            "introContent": null,
            "keywords": [],
            "subsections": null
          },
          {
            "id": "section-7-2",
            "level": "h2",
            "number": "7.2",
            "title": "7.2. Primordial Prevention",
            "slug": "72-primordial-prevention",
            "url": "/guidelines/chapter-seven-prevention-of-diabetes/72-primordial-prevention",
            "parentId": "chapter-7",
            "breadcrumb": [
              "CHAPTER SEVEN: PREVENTION OF DIABETES",
              "7.2. Primordial Prevention"
            ],
            "tokenCount": 130,
            "content": "## 7.2. Primordial Prevention\n\n\nPrimordial prevention refers to prevention of adoption of risk factors which can predispose to type 2 diabetes.\n\n\nSocial and environmental conditions contribute to the emergence of risk factors for diabetes. These include eating patterns, levels of physical activity, habits such as tobacco use and alcohol consumption.\n\n\nThe  main  intervention  in  primordial  prevention  is  through  individual  and  mass health education. These include school and community-based programs that promote physical activity, improve nutrition, limit alcohol consumption and prevent smoking  and  other  tobacco  use.  Advocate  for  comprehensive Worksite Wellness Programs.\n\n\n",
            "startLine": 4925,
            "endLine": 4936,
            "introContent": null,
            "keywords": [],
            "subsections": null
          },
          {
            "id": "section-7-3",
            "level": "h2",
            "number": "7.3",
            "title": "7.3. Primary Prevention",
            "slug": "73-primary-prevention",
            "url": "/guidelines/chapter-seven-prevention-of-diabetes/73-primary-prevention",
            "parentId": "chapter-7",
            "breadcrumb": [
              "CHAPTER SEVEN: PREVENTION OF DIABETES",
              "7.3. Primary Prevention"
            ],
            "tokenCount": 336,
            "content": "## 7.3. Primary Prevention\n\n\nPrimary prevention can be defined as an action taken prior to the onset of diabetes, which reduces the possibility that diabetes will occur. It therefore has an impact by reducing both the need for diabetes care and the need to treat diabetes-related complications.\n\n\nPrimary prevention can be achieved by health promotion which include health education,  environmental  modification,  nutritional  intervention,  lifestyle  and  behavioral changes. This can be achieved through population (mass) strategy and high-risk individual strategy.\n\n\nWhile there is yet no conclusive evidence to suggest that type 1 diabetes can be prevented, primary prevention of type 2 diabetes is potentially possible. The components of lifestyle modification and their aims should include, but not be limited to, the following list:\n\n\n- Obese/\tOverweight\tpatients\t-\tWeight\tloss\tof\t5-10%\twith\tan\taim\tto achieving ideal sustained body weight\n- Modify\tdietary\tpatterns\tfocusing\ton\n- -Reduction in fat intake\n- -Increase in fibre, vegetables and fruits intake\n- Increase\tin\tphysical\tactivity\tlevels.\te.g.\tbrisk\twalking\t30\tminutes,\tfive times a week. Exercise should be tailored to the individual\n- Alcohol\tintake\tshould\tbe\tlimited\tto\tless\tthan\tone\tdrink\tper\tday\tof\tany type (1 standard alcoholic drink per day (7 units per week) for women, 2 standard alcoholic drinks (14 units per week) for men.\n- Screening\tof\tpeople\tat\thigh\trisk\tof\tdeveloping\tdiabetes\n- Cessation\tof\ttobacco\tuse.\n\n\n",
            "startLine": 4937,
            "endLine": 4958,
            "introContent": null,
            "keywords": [],
            "subsections": null
          },
          {
            "id": "section-7-4",
            "level": "h2",
            "number": "7.4",
            "title": "7.4. Secondary prevention",
            "slug": "74-secondary-prevention",
            "url": "/guidelines/chapter-seven-prevention-of-diabetes/74-secondary-prevention",
            "parentId": "chapter-7",
            "breadcrumb": [
              "CHAPTER SEVEN: PREVENTION OF DIABETES",
              "7.4. Secondary prevention"
            ],
            "tokenCount": 98,
            "content": "## 7.4. Secondary prevention\n\n\nThis involves action that halts the progress of diabetes at its early stage and prevent complications. Secondary prevention attempts to arrest the diabetes progression, restore health by seeking out unrecognized disease and treating it before irreversible pathological changes take place.\n\n\nThere are several landmark studies that have shown that good glycemic with HbA1c &lt; 7%, blood pressure &lt;140/80 mmHg and lipid control prevent progression of complications of diabetes.\n\n\n",
            "startLine": 4959,
            "endLine": 4967,
            "introContent": null,
            "keywords": [],
            "subsections": null
          },
          {
            "id": "section-7-5",
            "level": "h2",
            "number": "7.5",
            "title": "7.5. Tertiary Prevention",
            "slug": "75-tertiary-prevention",
            "url": "/guidelines/chapter-seven-prevention-of-diabetes/75-tertiary-prevention",
            "parentId": "chapter-7",
            "breadcrumb": [
              "CHAPTER SEVEN: PREVENTION OF DIABETES",
              "7.5. Tertiary Prevention"
            ],
            "tokenCount": 157,
            "content": "## 7.5. Tertiary Prevention\n\n\nActions taken when diabetes has progressed beyond its early stages. It is defined as all the measures available to reduce or limit impairments and disabilities, and to promote the patients' adjustment to irreversible conditions. This involves strict metabolic control, diabetes  education,  effective  treatment,  screening  and  monitoring  of  complications. Examples - regular assessment for foot, eye, kidney, skin and heart disease. The blood glucose, blood pressure and lipid control are important in tertiary prevention.\n\n\nCHAPTER EIGHT\n\n\nROOM28\n\n\n145 |KENYA NATIONAL CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS\n\n\nTRLNBEROOM\n\n\nROOM29\n\n\nDIABEIICCLINIC\n\n\nTRIAGE\n\n\n\n\n",
            "startLine": 4968,
            "endLine": 4996,
            "introContent": null,
            "keywords": [],
            "subsections": null
          }
        ]
      },
      {
        "id": "chapter-8",
        "level": "h1",
        "number": "8",
        "title": "CHAPTER EIGHT: ORGANIZATION OF DIABETES CARE",
        "slug": "chapter-eight-organization-of-diabetes-care",
        "url": "/guidelines/chapter-eight-organization-of-diabetes-care",
        "tokenCount": 1678,
        "summary": null,
        "content": "# CHAPTER EIGHT: ORGANIZATION OF DIABETES CARE\n\n\n## 8.1. Introduction\n\n\nDiabetes is a complex disorder, a systematic approach to the organization of care is essential. There are several elements to this approach. These include:\n\n\n- well\ttrained\tand\tdedicated\tpersonnel,\n- calibrated\tand\tfunctioning\tequipment,\n- management\tand\treferral\tprotocols,\n- continuous\tsupply\tof\tmedication,\n- a\tregister\tof\tall\tpatients\tto\tfacilitate\trecall\tfor\tnon-attendance\tand\tfor specific aspects of regular care,\n- legible\tpatient\trecords\n- Diabetes\tcare\tmanagement\tflow\tcharts\tand\talgorithms\n- Annual\treview\tcharts\tare\tuseful\tfor\tfollow\tup\tof\tclinical\tand\tbiochemical measurements.\n- A\thistory,\tclinical\texamination\tand\tappropriate\tbiochemical\tevaluation.\n\n\nA process of regular audit with the implementation of interventions to improve care needs to be instituted. The clinic should be a one stop care center that is multi-disciplinary and patient centered clinic.\n\n\n## 8.2. Leadership and governance\n\n\nDiabetes screening, treatment and care is complex and requires clear leadership at all levels of care. The division of Non-Communicable Diseases at the Ministry of Health provides national leadership on implementation of Diabetes prevention, care and treatment. To achieve the desired outcomes of the National NCD Strategy, the National Diabetes Program will provide technical leadership in planning for diagnosis, treatment, resource mobilization, palliation, research and data management for Diabetes.\n\n\nAt the county level, county NCD coordinators and county health management team will be responsible for the coordination of diabetes related activities. The counties will coordinate the establishment of diabetes care committees at facility level.\n\n\n**Roles and Responsibilities for each Level**\n\n\n**National level:**\n\n\n- Assess\tthe\tDiabetes\tepidemiological\tand\thealth\tdelivery\tpatterns\tin the country.\n- Develop\tnational\tlevel\tpolicies,\tstrategic\tplans\tand\tplanning\tguides\tfor lower levels.\n- Support\tresource\tmobilization.\n- Coordinate\tstakeholders\tand\tpartners\ton\tDiabetes\tmanagement\tin the health sector.\n- Consolidate,\tanalyze\tand\tdisseminate\tDiabetes\tdata.\n- Support\thuman\tresource\tdevelopment\tand\tdeployment\tfor\tDiabetes management.\n- Support\tinfrastructure\tand\tequipment\tprocurement\tfor\tDiabetes management\n\n\n**NCD County coordinators:**\n\n\n- Coordinate\tDiabetes\tmanagement\tat\tcounty\tlevel.\n- Advocate\tfor\tresource\tallocation\tfor\tcounty\thealth\tcare\tneeds.\n- Consolidate\tdata\tfrom\tthe\tcounty\tfacilities.\n- Monitor\tservice\tdelivery\tand\tensure\tquality\tand\tresponsiveness\tof Diabetes management.\n- Support\tsupervision\tand\ttraining\tcoordination.\n- Plan\tfor\tmanagement\tand\tutilization\tof\tavailable\tresources\tfor\tservice delivery.\n- Manage\tinputs\tincluding\tstaff,\tequipment\tand\tpharmaceuticals.\n- Organize\tservice\tcoverage,\tcollection\tof\tdata\tand\tappropriate\treferral management.\n\n\n**Community unit linked to health institutions:**\n\n\n- Assist\tin\testablishment\tof\tPatient\tSupport\tGroup\n- Patient\treferral\tand\tfollow-up.\n- Advocacy\tfor\tprevention\tand\tcontrol\tof\tDiabetes.\n- Provision\tof\tpalliative\tcare\tfor\tpeople\twith\tchronic\tcomplications\n- Integration\tof\tDiabetes\tissues\tinto\tother\tcommunity-based\tprograms e.g. Microfinance\n\n\nTable 46: Personnel and services offered per health-care tier\n\n\n| Health Care Tier                                    | Personnel                                                                                                  | Services offered                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |\n|-----------------------------------------------------|------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Community Services                                  | ─ Community Health Worker ─ Community Health Ex- tension Worker ─ Trained health personnel ─ Nutritionists | ─ Distribution of IEC materials ─ Health promotion and behaviour change commu- nication (BCC) ─ Community mobilization ─ Screening and outreach ─ Home based and palliative care; home blood glucose monitoring ─ Community Health Information Systems ─ Contact tracing and defaulter tracing ─ Support groups establishment                                                                                                                                                                                                 |\n| Dispensary and Health Centre (Primary Care Service) | ─ Nurse ─ Clinical Officer ─ Public Health Officer/ Public Health Technician ─ Medical Officer ─ Nutrition | ─ Referral and linkages ─ Distribution of IEC materials ─ Health promotion and behaviour change commu- nication (BCC) ─ Screening for diabetes, hypertension and TB ─ Centre for in- and outreach screening services ─ Diagnosis and management of uncomplicated diabetes and hypertension ─ Initiation of 1st line diabetes medication for uncomplicatedDM ─ Nutritional assessment and counselling ─ Referral for diabetes related complication ─ Follow-up care ─ Palliative care ─ Diabetes data collection and reporting |\n\n\nIE - Inform at ion, e duc at ion and c om unic at ion; B be hav iour c hange c om unic a\n\n\n| County Referral Service (Primary Referral Services)     | ─ Specialists ─ Public Health Officer ─ Diabetes educators ─ CHEW ─ Nurse ─ Clinicians ─ Nutritionist ─ Medical Officer ─ Pharmacist   | ─ Distribution of IEC materials ─ Health promotion and behaviour change commu- nication (BCC) ─ Screening for diabetes and TB ─ Diagnosis of diabetes and hypertension ─ Initiation of diabetes and hypertension treatment and follow-up, including second-line therapy, insulin and comorbidity management ─ Inpatient care ─ Nutritional assessment and counselling ─ Diabetic foot assessment and management ─ Referral for special conditions e.g. cardiac com- plications ─ Palliative care ─ Coordination/M&E ─ Research   |\n|---------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| National Referral Services (Tertiary Referral Services) | ─ Nurse ─ Pharmacist ─ Clinicians/specialists ─ Nutritionist ─ Counsellors/diabetes educators                                          | ─ Same as County Referral Services plus ─ Management of severe complications                                                                                                                                                                                                                                                                                                                                                                                                                                                     |\n\n\n\n\n-\n\n\n\n\n## 8.3. Requirements for a Diabetic Clinic\n\n\n- Well trained, dedicated and motivated staff\n- Adequate space:\n- -For individual consultation\n- -For group education\n- Protocols covering:\n- -Screening and diagnosis\n- -Regular care, including referrals\n- Equipment:\n- -Tape measure (waist circumference)\n- -Weighing Scale\n- -Height measure\n- -Functional and calibrated BP machines, with pediatric, normal and large cuff sizes\n- -Monofilament and 128 Hz tuning fork\n- -Glucometers in good working order\n- -HbA1c testing equipment, to enable testing on site\n- -Appropriate educational material\n- Diabetes Care Package - All new diagnosed patients should be provided with a minimum care package that should contain (a glucose testing meter, one-month supply of testing strips, medicines supply and if on insulin, provided with syringes to last for one month and educational materials\n- Regular supply of medication\n- -Supplies shall be dispensed to cover for at least 30 days. For instance, patients on insulin should be provided with a pack ('Diabetes\tCare\tPackage')\tcontaining\ta\t30-day\tsupply\tof\tinsulin,\t30 insulin syringes with the smallest available needle gauge and educational material (injection technique and rotation chart)\n- Register with recall system for non-attenders\n- Annual audits of:\n- -Numbers of patients receiving designated processes of care\n- -Numbers of patients reaching targets for glycaemia, blood pressure (BP) and lipids as per National Guidelines\n- A\tchecklist\tof\tminimum\texpected\thistory,\tclinical\texamination,\tinvestigations, treatment and the intervals for review that is initial, 3-6 months or annually. The care at each visit will depend on whether it is an initial consultation, follow-up consultation or an annual review. (Refer to Table 6 and 12)\n\n\n",
        "startLine": 4997,
        "endLine": 5119,
        "introContent": null,
        "sections": [
          {
            "id": "section-8-1",
            "level": "h2",
            "number": "8.1",
            "title": "8.1. Introduction",
            "slug": "81-introduction",
            "url": "/guidelines/chapter-eight-organization-of-diabetes-care/81-introduction",
            "parentId": "chapter-8",
            "breadcrumb": [
              "CHAPTER EIGHT: ORGANIZATION OF DIABETES CARE",
              "8.1. Introduction"
            ],
            "tokenCount": 203,
            "content": "## 8.1. Introduction\n\n\nDiabetes is a complex disorder, a systematic approach to the organization of care is essential. There are several elements to this approach. These include:\n\n\n- well\ttrained\tand\tdedicated\tpersonnel,\n- calibrated\tand\tfunctioning\tequipment,\n- management\tand\treferral\tprotocols,\n- continuous\tsupply\tof\tmedication,\n- a\tregister\tof\tall\tpatients\tto\tfacilitate\trecall\tfor\tnon-attendance\tand\tfor specific aspects of regular care,\n- legible\tpatient\trecords\n- Diabetes\tcare\tmanagement\tflow\tcharts\tand\talgorithms\n- Annual\treview\tcharts\tare\tuseful\tfor\tfollow\tup\tof\tclinical\tand\tbiochemical measurements.\n- A\thistory,\tclinical\texamination\tand\tappropriate\tbiochemical\tevaluation.\n\n\nA process of regular audit with the implementation of interventions to improve care needs to be instituted. The clinic should be a one stop care center that is multi-disciplinary and patient centered clinic.\n\n\n",
            "startLine": 5000,
            "endLine": 5019,
            "introContent": null,
            "keywords": [],
            "subsections": null
          },
          {
            "id": "section-8-2",
            "level": "h2",
            "number": "8.2",
            "title": "8.2. Leadership and governance",
            "slug": "82-leadership-and-governance",
            "url": "/guidelines/chapter-eight-organization-of-diabetes-care/82-leadership-and-governance",
            "parentId": "chapter-8",
            "breadcrumb": [
              "CHAPTER EIGHT: ORGANIZATION OF DIABETES CARE",
              "8.2. Leadership and governance"
            ],
            "tokenCount": 1055,
            "content": "## 8.2. Leadership and governance\n\n\nDiabetes screening, treatment and care is complex and requires clear leadership at all levels of care. The division of Non-Communicable Diseases at the Ministry of Health provides national leadership on implementation of Diabetes prevention, care and treatment. To achieve the desired outcomes of the National NCD Strategy, the National Diabetes Program will provide technical leadership in planning for diagnosis, treatment, resource mobilization, palliation, research and data management for Diabetes.\n\n\nAt the county level, county NCD coordinators and county health management team will be responsible for the coordination of diabetes related activities. The counties will coordinate the establishment of diabetes care committees at facility level.\n\n\n**Roles and Responsibilities for each Level**\n\n\n**National level:**\n\n\n- Assess\tthe\tDiabetes\tepidemiological\tand\thealth\tdelivery\tpatterns\tin the country.\n- Develop\tnational\tlevel\tpolicies,\tstrategic\tplans\tand\tplanning\tguides\tfor lower levels.\n- Support\tresource\tmobilization.\n- Coordinate\tstakeholders\tand\tpartners\ton\tDiabetes\tmanagement\tin the health sector.\n- Consolidate,\tanalyze\tand\tdisseminate\tDiabetes\tdata.\n- Support\thuman\tresource\tdevelopment\tand\tdeployment\tfor\tDiabetes management.\n- Support\tinfrastructure\tand\tequipment\tprocurement\tfor\tDiabetes management\n\n\n**NCD County coordinators:**\n\n\n- Coordinate\tDiabetes\tmanagement\tat\tcounty\tlevel.\n- Advocate\tfor\tresource\tallocation\tfor\tcounty\thealth\tcare\tneeds.\n- Consolidate\tdata\tfrom\tthe\tcounty\tfacilities.\n- Monitor\tservice\tdelivery\tand\tensure\tquality\tand\tresponsiveness\tof Diabetes management.\n- Support\tsupervision\tand\ttraining\tcoordination.\n- Plan\tfor\tmanagement\tand\tutilization\tof\tavailable\tresources\tfor\tservice delivery.\n- Manage\tinputs\tincluding\tstaff,\tequipment\tand\tpharmaceuticals.\n- Organize\tservice\tcoverage,\tcollection\tof\tdata\tand\tappropriate\treferral management.\n\n\n**Community unit linked to health institutions:**\n\n\n- Assist\tin\testablishment\tof\tPatient\tSupport\tGroup\n- Patient\treferral\tand\tfollow-up.\n- Advocacy\tfor\tprevention\tand\tcontrol\tof\tDiabetes.\n- Provision\tof\tpalliative\tcare\tfor\tpeople\twith\tchronic\tcomplications\n- Integration\tof\tDiabetes\tissues\tinto\tother\tcommunity-based\tprograms e.g. Microfinance\n\n\nTable 46: Personnel and services offered per health-care tier\n\n\n| Health Care Tier                                    | Personnel                                                                                                  | Services offered                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |\n|-----------------------------------------------------|------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Community Services                                  | ─ Community Health Worker ─ Community Health Ex- tension Worker ─ Trained health personnel ─ Nutritionists | ─ Distribution of IEC materials ─ Health promotion and behaviour change commu- nication (BCC) ─ Community mobilization ─ Screening and outreach ─ Home based and palliative care; home blood glucose monitoring ─ Community Health Information Systems ─ Contact tracing and defaulter tracing ─ Support groups establishment                                                                                                                                                                                                 |\n| Dispensary and Health Centre (Primary Care Service) | ─ Nurse ─ Clinical Officer ─ Public Health Officer/ Public Health Technician ─ Medical Officer ─ Nutrition | ─ Referral and linkages ─ Distribution of IEC materials ─ Health promotion and behaviour change commu- nication (BCC) ─ Screening for diabetes, hypertension and TB ─ Centre for in- and outreach screening services ─ Diagnosis and management of uncomplicated diabetes and hypertension ─ Initiation of 1st line diabetes medication for uncomplicatedDM ─ Nutritional assessment and counselling ─ Referral for diabetes related complication ─ Follow-up care ─ Palliative care ─ Diabetes data collection and reporting |\n\n\nIE - Inform at ion, e duc at ion and c om unic at ion; B be hav iour c hange c om unic a\n\n\n| County Referral Service (Primary Referral Services)     | ─ Specialists ─ Public Health Officer ─ Diabetes educators ─ CHEW ─ Nurse ─ Clinicians ─ Nutritionist ─ Medical Officer ─ Pharmacist   | ─ Distribution of IEC materials ─ Health promotion and behaviour change commu- nication (BCC) ─ Screening for diabetes and TB ─ Diagnosis of diabetes and hypertension ─ Initiation of diabetes and hypertension treatment and follow-up, including second-line therapy, insulin and comorbidity management ─ Inpatient care ─ Nutritional assessment and counselling ─ Diabetic foot assessment and management ─ Referral for special conditions e.g. cardiac com- plications ─ Palliative care ─ Coordination/M&E ─ Research   |\n|---------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| National Referral Services (Tertiary Referral Services) | ─ Nurse ─ Pharmacist ─ Clinicians/specialists ─ Nutritionist ─ Counsellors/diabetes educators                                          | ─ Same as County Referral Services plus ─ Management of severe complications                                                                                                                                                                                                                                                                                                                                                                                                                                                     |\n\n\n\n\n-\n\n\n\n\n",
            "startLine": 5020,
            "endLine": 5090,
            "introContent": null,
            "keywords": [],
            "subsections": null
          },
          {
            "id": "section-8-3",
            "level": "h2",
            "number": "8.3",
            "title": "8.3. Requirements for a Diabetic Clinic",
            "slug": "83-requirements-for-a-diabetic-clinic",
            "url": "/guidelines/chapter-eight-organization-of-diabetes-care/83-requirements-for-a-diabetic-clinic",
            "parentId": "chapter-8",
            "breadcrumb": [
              "CHAPTER EIGHT: ORGANIZATION OF DIABETES CARE",
              "8.3. Requirements for a Diabetic Clinic"
            ],
            "tokenCount": 405,
            "content": "## 8.3. Requirements for a Diabetic Clinic\n\n\n- Well trained, dedicated and motivated staff\n- Adequate space:\n- -For individual consultation\n- -For group education\n- Protocols covering:\n- -Screening and diagnosis\n- -Regular care, including referrals\n- Equipment:\n- -Tape measure (waist circumference)\n- -Weighing Scale\n- -Height measure\n- -Functional and calibrated BP machines, with pediatric, normal and large cuff sizes\n- -Monofilament and 128 Hz tuning fork\n- -Glucometers in good working order\n- -HbA1c testing equipment, to enable testing on site\n- -Appropriate educational material\n- Diabetes Care Package - All new diagnosed patients should be provided with a minimum care package that should contain (a glucose testing meter, one-month supply of testing strips, medicines supply and if on insulin, provided with syringes to last for one month and educational materials\n- Regular supply of medication\n- -Supplies shall be dispensed to cover for at least 30 days. For instance, patients on insulin should be provided with a pack ('Diabetes\tCare\tPackage')\tcontaining\ta\t30-day\tsupply\tof\tinsulin,\t30 insulin syringes with the smallest available needle gauge and educational material (injection technique and rotation chart)\n- Register with recall system for non-attenders\n- Annual audits of:\n- -Numbers of patients receiving designated processes of care\n- -Numbers of patients reaching targets for glycaemia, blood pressure (BP) and lipids as per National Guidelines\n- A\tchecklist\tof\tminimum\texpected\thistory,\tclinical\texamination,\tinvestigations, treatment and the intervals for review that is initial, 3-6 months or annually. The care at each visit will depend on whether it is an initial consultation, follow-up consultation or an annual review. (Refer to Table 6 and 12)\n\n\n",
            "startLine": 5091,
            "endLine": 5119,
            "introContent": null,
            "keywords": [],
            "subsections": null
          }
        ]
      }
    ]
  }
}